

[illegible]

The Company does not yet have a product that has been approved by the U.S. Food and Drug Administration (“FDA”) and has only generated revenues from grants, clinical trials and contract manufacturing. The Company has not yet achieved profitable operations or generated positive cash flows from operations. The Company intends to continue its efforts to raise additional funds via equity financing, develop its intellectual property, and secure regulatory approvals to commercialize its products. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. Further, the Company’s future operations are dependent on the success of the Company’s efforts to raise additional capital, its research and commercialization efforts, regulatory approval, and, ultimately, the market acceptance of the Company’s approved products, if any. These condensed financial statements do not include adjustments that might result from the outcome of these uncertainties. The Company has incurred recurring losses from operations since its inception, including a net loss of \$7.5 million and \$10.3 million for the six months ended June 30, 2024 and 2023, respectively. In addition, as of June 30, 2024, the Company had an accumulated deficit of \$101.0 million. The Company expects to continue to generate operating losses in the foreseeable future. As of June 30, 2024, the Company had cash and cash equivalents of \$12.4 million. The Company believes that its cash and cash equivalents as of June 30, 2024, together with \$15.3 million in gross cash proceeds from the July 2024 financing transactions (as described below), will enable it to fund its operating expenses and capital expenditure requirements through the fourth quarter of 2025.

9 – 2. Summary of Significant Accounting Policies

Basis of presentation: The condensed financial statements of the Company were prepared in accordance with U.S. GAAP. A Certain reclassifications have been made to prior year condensed financial statements to conform to classifications used in the current year. These reclassifications had no impact on net loss, stockholders’ equity or cash flows as previously reported.

Reverse Stock Split: On March 26, 2024, the Company effected a reverse stock split of the outstanding shares of its Class A common stock and Class B common stock on a one-for-10 (1:10) basis (the “Reverse Stock Split”). The Reverse Stock Split became effective at 11:59 p.m. Eastern Time on March 26, 2024 via a certificate of amendment to the Company’s Certificate of Incorporation filed with the Secretary of State of the State of Delaware. At the effective time of the Reverse Stock Split, every 10 shares of the Company’s Class A common stock and Class B common stock, whether issued and outstanding or held by the Company as treasury stock, were automatically combined and converted (without any further act) into one fully paid and nonassessable share of Class A common stock or Class B common stock, respectively, subject to rounding up of fractional shares to the nearest whole number of shares resulting from the Reverse Stock Split without any change in the par value per share. All share, per share, option, warrant, equity award, and other derivative security numbers and exercise prices appearing in this Quarterly Report on Form 10-Q and the accompanying condensed financial statements have been adjusted to give effect to the Reverse Stock Split for all prior periods presented. However, the Company’s annual, other periodic, and current reports, and all other information and documents incorporated by reference into this Quarterly Report on Form 10-Q that were filed prior to March 19, 2024, do not give effect to the Reverse Stock Split.

A Use of estimates: The presentation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

A Accounting Standard Updates: A variety of proposed or otherwise potential accounting standards are currently under consideration by standard-setting organizations and certain regulatory agencies. Because of the tentative and preliminary nature of such proposed standards, management has not yet determined the effect, if any, that the implementation of such proposed standards would have on the Company’s condensed financial statements.

In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09, “Improvements to Income Tax Disclosures.” The amendments in this ASU change disclosure requirements for various items, including effective tax rate reconciliations and cash taxes paid. This ASU is effective for public companies for the financial reporting periods beginning on January 1, 2025, with early adoption permitted. We have not adopted ASU 2023-09 for our financial reporting period ending December 31, 2023, and will continue to evaluate early adoption for our financial reporting period ending December 31, 2024.

Cash and cash equivalents: The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash.

Marketable securities: Marketable securities at June 30, 2024 and December 31, 2023 consisted of marketable fixed income securities, primarily corporate bonds which are categorized as available for sale securities and are thus marked to market and stated at fair value in accordance with ASC 820 Fair Value Measurement. These investments are considered Level 1 and Level 2 investments within the ASC 820 fair value hierarchy. The fair value of Level 1 investments, including cash equivalents, money funds and U.S. government securities, are substantially based on quoted market prices in active markets. The fair value of corporate bonds is determined using standard market valuation methodologies, including discounted cash flows, matrix pricing and/or other similar techniques. The inputs to these valuation techniques include but are not limited to market interest rates, credit rating of the issuer or counterparty, industry sector of the issuer, coupon rate, call provisions, maturity, estimated duration and assumptions regarding liquidity and estimated future cash flows. In addition to bond characteristics, the valuation methodologies incorporate market data, such as actual trades completed, bids and actual dealer quotes, where such information is available. Accordingly, the estimated fair values are based on available market information and judgments about financial instruments categorized within Level 1 and Level 2 of the fair value hierarchy. Interest and dividends are recorded when earned. Realized gains and losses on investments are determined by specific identification and are recognized as incurred in the condensed statement of operations. Changes in net unrealized gains and losses are reported in other comprehensive loss and represent the change in the fair value of investment holdings during the reporting period. Changes in net unrealized losses were less than \$0.1 million for the three and six months ended June 30, 2024 and 2023, respectively.

Accounts and grants receivable: Accounts and grants receivable include amounts due from customers, granting institutions and others. The amounts as of June 30, 2024, and December 31, 2023 are certain to be collected, and no amount has been recognized for expected credit losses. In addition, for the clinical trial revenue, most participants pay in advance of treatment. Advanced grant funds and prepayments for the clinical trial revenue are recorded to deferred revenue. Advance contract manufacturing payments are recorded to deferred revenue.

Accounts and grants receivable by source, as of (in thousands):

	June 30, 2024	December 31, 2023
Accounts receivable from customers	\$159A	\$A
Grants	\$15A	\$15A
National Institutes of Health	\$9A	\$9A
Total	\$218A	\$111A

Deferred offering costs: The Company recorded certain legal, professional and other third-party fees that were directly associated with in-process equity financings as deferred offering costs until the applicable equity financing was consummated. After consummation of an equity financing, these costs are recorded in stockholders’ equity as a reduction of proceeds generated as a result of the offering.

Property and equipment: Property and equipment, including improvements that extend the useful lives of related assets, are recorded at cost, while maintenance and repairs are charged to operations as incurred. Depreciation is calculated using the straight-line method based on the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the original term of the lease. Depreciation expense is recorded in the research and development line of the condensed statements of operations as the assets are primarily related to the Company’s clinical programs.

Intangible assets: Intangible assets include payments on license agreements with the Company’s co-founder and Chief Scientific Officer (see Note 9) and the University of Miami (see Note 9) and legal costs incurred related to patents and trademarks. License agreements have been recorded at the value of cash consideration, common stock and membership units transferred to the respective parties when acquired. Payments for license agreements are amortized using the straight-line method over the estimated term of the agreements, which range from 5-20 years. Patents are amortized over their estimated useful life, once issued. The Company considers trademarks to have an indefinite useful life and evaluates them for impairment on an annual basis. Amortization expense is recorded in the research and development line of the condensed statements of operations as the assets are primarily related to the Company’s clinical programs.

Impairment of Long-Lived Assets: The Company evaluates long-lived assets for impairment, including property and equipment and intangible assets, when events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. Upon the occurrence of a triggering event, the asset is reviewed to assess whether the estimated undiscounted cash flows expected from the use of the asset plus the residual value from the ultimate disposal exceeds the carrying value of the asset. If the carrying value exceeds the estimated recoverable amounts, the asset is written down to the estimated fair value. Any resulting impairment loss is reflected in the condensed statements of operations. Upon evaluation, management determined that there was no impairment of long-lived assets during the three and six months ended June 30, 2024 and 2023.

Deferred revenue: The unearned portion of advanced grant funds and prepayments for clinical trial and contract manufacturing revenues, which will be recognized as revenue when the Company meets the respective performance obligations, has been presented as deferred revenue in the accompanying condensed balance sheets. For the six months ended June 30, 2024 and 2023, the Company recognized less than \$0.1 million, respectively, of funds that were previously classified as deferred revenue. Due to the MSCRF “Technology Development Corporation” (“TEDCO”) grant Acute Respiratory Distress Syndrome (“ARDS”) program being discontinued, \$0.4 million recorded as deferred revenue was reversed when the funds were returned to TEDCO. As of June 30, 2024 and December 31, 2023, the Company had \$0.4 million and \$0.5 million, respectively, recorded in deferred revenue on the condensed balance sheets.

Revenue recognition: The Company recognizes revenue when performance obligations related to respective revenue streams are met. For grant revenue, the Company considers the performance obligation met when the grant related expenses are incurred or supplies and materials are received. The Company is paid in tranches pursuant to terms of the related grant agreements, and then applies payments based on regular expense reimbursement submissions to grantors. There are no remaining performance obligations or variable consideration once grant expense reporting to the grantor is complete. For clinical trial revenue, the Company considers the performance obligation met when the participant has received the treatment. The Company usually receives prepayment for these services or receives payment at the time the treatment is provided, and there are no remaining performance obligations or variable consideration once the participant receives the treatment. For contract manufacturing revenue, the Company considers the performance obligation met when the contractual obligation and/or statement of work has been satisfied. Payment terms may vary depending on specific contract terms. There are no significant judgments affecting the determination of the amount and timing of revenue recognition.

Revenue by source (in thousands):

	Three months ended June 30, 2024	Six months ended June 30, 2024	Three months ended June 30, 2023	Six months ended June 30, 2023
Clinical trial revenue	\$287A	\$217A	\$802A	\$455A
Contract manufacturing	\$181A	\$A	\$214A	\$A
NIH - grant	\$A	\$A	\$A	\$41A
Total	\$468A	\$217A	\$1,016A	\$496A

The Company records cost of revenues based on expenses directly related to revenue. For grants, the Company records allocated expenses for research and development costs to a grant as a cost of revenues. For the clinical trial revenue, directly related expenses for that program are expensed as incurred. These expenses are similar to those described under “Research and development expense” below. For the contract manufacturing, the Company records costs incurred under the contract as cost of revenues.

Research and development expense: Research and development costs are charged to expense when incurred in accordance with ASC 730 Research and Development. ASC 730 addresses the proper accounting and reporting for research and development costs. It identifies: 1) those activities that should be identified as research and development; 2) the elements of costs that should be identified with research and development activities, and the accounting for these costs; and 3) the financial statement disclosures related to them. Research and development costs include costs such as clinical trial expenses, contracted research and license agreement fees with no alternative future use, supplies and materials, salaries, share-based compensation, employee benefits, property and equipment depreciation and allocation of various corporate costs. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed by the third parties, patient enrollment in clinical trials, administrative costs incurred by the third parties, and other indicators of the services completed. Based on the timing of amounts invoiced by service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expense in future periods as the related services are rendered.

Concentrations of credit risk: Financial instruments which potentially subject the Company to credit risk consist principally of cash and cash equivalents, marketable securities and accounts and grants receivable. Cash and cash equivalents are held in U.S. financial institutions. At times, the Company may maintain balances in excess of the federally insured amounts.

Income taxes: The Company’s tax provision consists of taxes currently payable or receivable, plus any change during the period in deferred tax assets and liabilities. The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. In addition, a valuation allowance is established to reduce any deferred tax asset for which it is determined that it is more likely than not that some portion of the deferred tax asset will not be realized. The Company’s tax provision was \$0 for the three and six months ended June 30, 2024 and 2023 due to net operating losses. The Company has not recorded any tax benefit for the net operating losses incurred due to the offset created by the Company’s valuation allowance.

The Company recognizes the tax benefits from uncertain tax positions that the Company has taken or expects to take on a tax return. In the unlikely event an uncertain tax position exists in which the Company could incur income taxes, the Company would evaluate whether there is a probability that the uncertain tax position taken would be sustained upon examination by a taxing authority. Reserves for uncertain tax positions would then be recorded if the Company determined it is probable that either a position would not be sustained upon examination, or a payment would have to be made to a taxing authority and the amount was reasonably estimable. As of June 30, 2024 and December 31, 2023, the Company does not believe it has any uncertain tax positions that would result in the Company having a liability to a taxing authority. It is the Company’s policy to expense any interest and penalties associated with its tax obligations when they are probable and estimable.

Equity-based compensation: The Company accounts for equity-based compensation expense by the measurement and recognition of compensation expense for stock-based awards based on estimated fair values on the date of grant. The fair value of the stock options is estimated at the date of the grant using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires the input of highly subjective assumptions, the most significant of which are the expected share price volatility, the expected life of the stock option award, the risk-free rate of return, and dividends during the expected term. Because the option-pricing model is sensitive to changes in the input assumptions

amortization. As of June 30, 2024 and 2023, and \$0.4 million for the six months ended June 30, 2024 and 2023. Intangible assets, net of major components of intangible assets as of June 30, 2024, are as follows (in thousands): Useful Lives Accumulated Amortization License agreements 20 years \$2,043A \$1,020A \$1,023A Patent costs 1,123A \$1,123A Trademark costs 207A \$1,207A \$1,373A \$1,020A \$2,353A Major components of intangible assets as of December 31, 2023, are as follows (in thousands): Useful Lives Accumulated Amortization Total License agreements 20 years \$2,043A \$909A \$1,134A Patent costs 959A \$1,959A Trademark costs 194A \$1,194A \$1,94A Total \$3,196A \$909A \$2,287A Amortization expense related to intangible assets amounted to approximately \$0.1 million for each of the three- and six- month periods ended June 30, 2024 and 2023. Future amortization expense for intangible assets as of June 30, 2024 is as follows (in thousands): Years Ending December 31, 2024 (remaining six months) \$112A 2025A 2026A 2027A 2028A 2029A Thereafter 15A Total \$1,023A 15A 6 Leases The Company records a right-of-use operating lease asset and a lease liability related to its operating leases (there are no finance leases). The Company's corporate office lease expires in March 2027. As of June 30, 2024, the operating lease asset and lease liability were approximately \$1.1 million and \$1.7 million, respectively. As of December 31, 2023, the operating lease asset and lease liability were approximately \$1.2 million and \$2.0 million, respectively. Future minimum payments under the operating leases as of June 30, 2024, are as follows (in thousands): Years Ending December 31, 2024 (remaining six months) \$341A 2025A 2026A 2027A 170A Total \$1,875A Less: Interest \$127A Present value of operating lease liability \$1,748A During each of the three months ended June 30, 2024 and 2023, the Company incurred approximately \$0.2 million of total lease costs and for the six month periods ended June 30, 2024 and 2023, the Company incurred approximately \$0.3 million and \$0.2 million of total lease costs, respectively, that are included in the general and administrative expenses in the condensed statements of operations. Stockholders' Equity Class A Common Stock RSUs are taxable upon vesting based on the market value on the date of vesting. The Company is required to make mandatory tax withholding for the payment and satisfaction of income tax, social security tax, payroll tax, or payment on account of other tax related to withholding obligations that arise by reason of vesting of an RSU. The taxable income is calculated by multiplying the number of vested RSUs for each individual by the closing share price as of the vesting date and a tax liability is calculated based on each individual's tax bracket. The shares withheld are available for reissuance pursuant to the Company's Second Amended and Restated 2021 Incentive Award Plan (the "Equity Plan"). During the six months ended June 30, 2024, no stock options were exercised for Class A common stock shares. Class B Common Stock Holders of Class A common stock generally have rights identical to holders of Class B common stock, except that holders of Class A common stock are entitled to one (1) vote per share and holders of Class B common stock are entitled to five (5) votes per share. The holders of Class B common stock may convert each share of Class B common stock into one share of Class A common stock at any time at the holder's option. Class B common stock is not publicly tradable. During the six months ended June 30, 2024, stockholders converted 1,555 shares of Class B common stock into 1,555 shares of Class A common stock. During the year ended December 31, 2023, stockholders converted 3,555 shares of Class B common stock into 3,555 shares of Class A common stock. Warrants As part of the Company's initial public offering (the "IPO"), the underwriter received warrants to purchase up to 10,640 shares of Class A common stock. The warrants are exercisable at any time and from time to time, in whole or in part, during the four and a half-year period commencing August 12, 2021, at a price of \$120.00 per share and the fair value of warrants was approximately \$0.5 million. During 2021, the underwriters assigned 9,576 of the warrants to its employees. As of June 30, 2024, 5,536 warrants remain outstanding. As of June 30, 2024, As part of the Company's 2021 private placement offering, the Company issued warrants to investors to purchase up to an aggregate of 116,935 shares of Class A common stock, equal to the number of shares of Class A common stock purchased by such investor in the offering, at an exercise price of \$175.00 per share, which were immediately exercisable, expire five years from the date of issuance and had certain downward pricing adjustment mechanisms, subject to a floor, as set forth in greater detail therein (the "Purchaser Warrants"). In addition, the Company granted the underwriters warrants, under similar terms, to purchase 4,679 shares of Class A common stock, at an exercise price of \$175.00 per share. On August 16, 2023, the Company announced its Stock Rights Offering, which triggered the downward pricing mechanism on the Purchaser Warrants, at which time these warrants were adjusted downward to an exercise price of \$52.50 for the period remaining through expiration. This resulted in a deemed dividend to common stockholders of approximately \$0.8 million for the change in the fair value of the warrants using a Black-Scholes pricing model. As part of an October 2023 registered direct offering, the Company issued Series A warrants and Series B warrants to purchase up to 242,425 and 242,425, respectively, shares of Class A common stock. Each series of warrants had an exercise price of \$16.50 per share, with the Series A warrants having a term of five and one-half years from the date of issuance, and the Series B warrants having a term of eighteen months from the date of issuance. Both the Series A and Series B warrants became exercisable as of December 26, 2023, following stockholder approval. In addition, the Company granted the placement agent warrants, under similar terms, to purchase 16,971 shares of Class A common stock, at an exercise price of \$20.625 per share. In April 2024, the Series A Warrants and Series B Warrants were amended to reduce the exercise price to \$2.35 per share. The Series A Warrants and Series B Warrants were subsequently exercised in full in April 2024. As part of a December 2023 registered direct offering, the Company issued warrants to purchase an aggregate of 135,531 shares of Class A common stock. These warrants have an exercise price of \$16.20 per share, became immediately issuable upon issuance, and expire on June 30, 2029. In addition, the Company granted the placement agent warrants, under similar terms, to purchase 9,489 shares of Class A common stock, at an exercise price of \$21.813 per share. On April 8, 2024, the Company commenced a public offering of up to 661,149 shares of the Company's Class A common stock, along with pre-funded warrants to purchase up to an aggregate 1,572,894 shares of Class A common stock (the "Pre-Funded Warrants"). The shares and Pre-Funded Warrants were sold together with warrants to purchase up to an aggregate of 2,234,043 shares of Common Stock (the "Common Warrants"). The combined public offering price was \$2.35 per share and related Common Warrant and \$2.349 per Pre-Funded Warrant and related Common Warrant. Subject to certain limitations, the Pre-Funded Warrants were immediately exercisable and could be exercised at a nominal consideration of \$0.001 per share of Class A common stock at any time until all of the Pre-Funded Warrants were exercised in full. The Common Warrants were immediately exercisable and expire five years from the date of issuance. As compensation to the placement agent the Company also issued to designees of the placement agent warrants to purchase up to 154,894 shares of Class A common stock, which had substantially the same terms as the Common Warrants, and with an exercise price of \$2.9375 per share and a term of five years from the commencement of sales in the offering. In connection with the offering, the Company also entered into an agreement with a holder of existing warrants to amend the holder's existing Series A warrants and Series B warrants to reduce the exercise price to \$2.35 per share and (ii) amend the expiration date of the Series A Warrants to five and one-half (5.5) years following the closing of the public offering and the Series B warrants to eighteen (18) months following the closing of the public offering, in each case for a payment to the Company of \$0.125 per amended warrant. On April 16, 2024, the Company entered into inducement letter agreements with certain holders of its existing Series A warrants and Series B warrants, and Common Warrants issued on April 10, 2024, whereby the holders agreed to exercise the warrants for cash at the exercise price of \$2.35 per share in consideration for payment of \$0.125 per new warrant and for the Company's agreement to issue new unregistered Class A common stock warrants to purchase up to 4,799,488 shares of Class A common stock at an exercise price of \$2.35 per share, and which were immediately exercisable upon issuance. The warrants to purchase up to 2,399,744 shares of Class A common stock (the "Series C Warrants") have a term of five years from the issuance date, and the warrants to purchase up to 2,399,744 shares of Class A common stock (the "Series D Warrants") have a term of twenty-four months from the issuance date. All of the Series D Warrants were exercised in June 2024, pursuant to ordinary course exercise as well as a subsequent inducement transaction. As of June 30, 2024, 297,872 Common Warrants remain outstanding. Additionally, the Company issued to the placement agent or its designees as compensation, warrants to purchase up to 167,982 shares of Class A common stock, equal to 7.0% of the aggregate number of shares of Class A common stock issued upon exercise of the warrants pursuant to the inducement transaction, which had the same terms as the Series C Warrants, except that the placement agent warrants have an exercise price of \$3.25 per share. As of June 30, 2024, Additionally, upon exercise, if any, of the Series D Warrants for cash, the Company agreed to issue the placement agent or its designees, within five (5) business days of the Company's receipt of the exercise price, warrants to purchase the number of shares of Class A common stock equal to 7.0% of the aggregate number of shares underlying such Series D Warrants that have been exercised, with such warrants to be in the same form and terms as the prior placement agent warrants. On June 17, 2024, the Company entered into additional inducement letter agreements with the holders of its existing Series D Warrants to exercise the remaining 1,697,891 shares of Class A common stock underlying Series D Warrants that remained outstanding for cash at the exercise price of \$2.35 per share in consideration for the Company's agreement to issue new unregistered Class A common stock warrants, for payment of \$0.125 per new warrant, to purchase up to an aggregate of 3,395,782 shares of Class A common stock at an exercise price of \$2.50 per share and which were immediately exercisable upon issuance and have a term of twenty-four months from the issuance date. Additionally, the Company issued to the placement agent or its designees as compensation, (i) warrants to purchase up to 118,852 shares of Class A common stock, equal to 7.0% of the aggregate number of shares of Class A common stock issued upon exercise of the warrants pursuant to the inducement transaction and (ii) warrants to purchase up to an aggregate of 49,130 shares of Common Stock, equal to 7.0% of the aggregate number of shares of Common Stock issued upon exercise of certain Series D warrants prior to the inducement transaction, which had substantially the same terms as the new warrants, had an exercise price of \$3.25 per share and \$2.9375 per share, respectively. Additionally, upon exercise, if any, of the new warrants for cash, the Company agreed to issue within five (5) business days to the placement agent or its designees, warrants to purchase the number of shares of Class A common stock equal to 7.0% of the aggregate number of shares of Class A common stock underlying such new warrants that have been exercised, with such warrants to be in the same form and terms as the transaction placement agent warrants. The issuance under the inducement offers represented \$8.5 million in additional value provided to the investors, which was recorded as a deemed dividend to common stockholders. 8. Equity-based compensation As part of the Company's IPO, the Company adopted and approved the 2021 Incentive Award Plan, which has been subsequently amended and restated twice (as accordingly amended and restated, the "2021 Incentive Plan"). Under the 2021 Incentive Plan, the Company may grant cash and equity incentive awards to eligible service providers in order to attract, motivate and retain the talent for which the Company competes. RSUs As of June 30, 2024, and December 31, 2023, the Company had 29,725 and 11,239, respectively for RSUs outstanding (unvested). RSU activity for the six months ended June 30, 2024, was as follows: Number of RSUs Outstanding (unvested) at December 31, 2023A 11,239A RSU grantedA 30,200A RSUs vestedA (8,464) RSU expired/forfeitedA (3,250) Outstanding (unvested) at June 30, 2024A 29,725A 18A Stock Options Stock options may be granted under the 2021 Incentive Plan. The exercise price of stock options is equal to the fair market value of the Company's Class A common stock as of the grant date. Stock options historically granted have generally become exercisable over four years and expire ten years from the date of grant. The 2021 Incentive Plan provides for equity grants to be granted up to 5% of the outstanding common stock shares. As of June 30, 2024, there have been no stock options granted during 2024 under the 2021 Incentive Plan. The fair value of the options issued during 2023 were estimated using the Black-Scholes option-pricing model and had the following assumptions: a dividend yield of 0%, an expected life of 10A years; volatility ranging from 90%-95%; and risk-free interest rate based on the grant date ranging from of 3.89 % to 4.01%. Each stock option grant made during 2023 will be expensed ratably over the option vesting periods, which approximates the service period. As of June 30, 2024 and December 31, 2023, the Company has recorded issued and outstanding options to purchase a total of 36,801 and 43,786 shares of Class A common stock, respectively, pursuant to the 2021 Incentive Plan, at a weighted average exercise price of \$49.02 and \$49.60 per share, respectively. For the six months ended June 30, 2024: Number of Stock Options Stock options vested (based on ratable vesting)A 22,621A Stock options unvestedA 14,180A Total stock options outstanding at June 30, 2024A 36,801A For the year ended December 31, 2023: Number of Stock Options Stock options vested (based on ratable vesting)A 16,091A Stock options unvestedA 27,695A Total stock options outstanding at December 31, 2023A 43,786A Stock option activity for the six months ended June 30, 2024, was as follows: Number of Stock OptionsA Weighted Average Exercise PriceA Outstanding at December 31, 2023A 43,786A \$49.60A Options grantedA -A -A Options exercisedA -A -A -A Options expired/forfeitedA (6,985)A (\$52.93) Outstanding at June 30, 2024A 36,801A \$49.02A For the three months ended June 30, 2024 and 2023, the equity-based compensation expense amounted to approximately \$0.2A million and \$0.7 million, respectively, and for the six months ended June 30, 2024 and 2023, the equity-based compensation expense amounted to approximately \$0.5A million and \$1.1 million, respectively, which is included in the research and development and general and administrative expenses in the condensed statements of operations for the three and six months ended June 30, 2024 and 2023, respectively. As of June 30, 2024, the remaining unrecognized equity-based compensation (which includes RSUs and stock options) of approximately \$0.5A million will be recognized over approximately 1.5A years. Share-based payments to third-party service provider In April 2024, the Company agreed to issue stock options to a third-party service provider for future services exercisable for up to 50,000 shares of Class A common stock at an exercise price of \$2.15, the grant date fair value, with the options vesting quarterly over 36 months. The Company recorded general and administrative expenses of less than \$0.1 million for the three and six months ended June 30, 2024. 19A 9. Commitments and Contingencies Master Services Agreements As of June 30, 2024, the Company terminated its active master services agreements with third parties that were previously engaged to conduct its clinical trials and manage clinical research programs and clinical development services. This termination was due to the Company's decision to discontinue trial activities in Japan. Consulting Services Agreement: On November 20, 2014, the Company entered into a ten-year consulting services agreement with Dr. Joshua Hare, its CSO. Under the agreement, the Company has agreed to pay the CSO \$265,000 annually. The compensation payments are for scientific knowledge, medical research, technical knowledge, skills, and abilities to be provided by the CSO to further develop the intellectual property rights assigned by the CSO to the Company. This agreement requires the CSO to also assign to the Company the exclusive right, title, and interest in any work product developed from his efforts during the term of this agreement. On November 16, 2022, the Company accounted for but had not issued 4,814 RSUs convertible to unregistered shares of Class A common stock, with an aggregate value of \$0.2 million as payment for accrued expenses under the consulting agreement with the CSO. These shares were issued on May 24, 2023. As of June 30, 2024 and December 31, 2023, the Company had accrued balances due to the CSO of approximately \$0.1 million and \$0.1 million, respectively, which are included in accrued expenses and an additional \$0.1 million and \$0.1 million, respectively, which are included in accounts payable in the accompanying condensed balance sheets. The Company entered into a deferred compensation agreement with the CSO to defer payment of the consulting fees earned for services rendered during 2024. The 2024 consulting fees will be paid in the form of a lump sum distribution in February 2027. As of June 30, 2024, the Company had accrued balance of \$0.1 million which are included in other long-term liabilities in the accompanying condensed balance sheets. Technology Services Agreement: On March 27, 2015, the Company entered into a technology services agreement with Optimal Networks, Inc. (a related company owned by Dr. Joshua Hare's brother-in-law) for use of information technology services. The technology services agreement was terminated as of April 14, 2023. As of June 30, 2024 and December 31, 2023, the Company owed \$0 pursuant to this agreement. Exclusive Licensing Agreements: UM Agreement On November 20, 2014, the Company entered into an Exclusive License Agreement with UM (the "UM License") for the use of certain Aging-related Frailty Mesenchymal Stem Cell (the "MSC") technology rights developed by our CSO at UM. The UM License is a worldwide, exclusive license, with right to sublicense, with respect to any and all know-how specifically related to the development of the culture-expanded MSCs for Aging-related Frailty used at the Human-induced pluripotent stem cell-derived MSCs (the "MSCs"), all standard operating procedures used to create the IMSCs, and all data supporting isolation, culture, expansion, processing, cryopreservation and management of the IMSCs. The Company is required to pay UM (i) a license issue fee of \$5,000, (ii) a running royalty in an amount equal to three percent of annual net sales on products or services developed from the technology, payable on a country-by-country basis beginning on the date of first commercial sale through termination of the UM License Agreement, and which may be reduced to the extent we are required to pay royalties to a third party for the same product or process, (iii) escalating annual cash payments of up to \$50,000, subject to offset. The agreement extends for up to 20 years from the last date a product or process is commercialized from the technology and was amended in 2017 to modify certain milestone completion dates as detailed below. In 2021 the license fee was increased by an additional \$100,000, to defray patent costs. In addition, the Company issued 11,039 unregistered shares of Class A common stock to UM. The milestone payment amendments shifted the triggering payments to three payments of \$500,000, to be paid within six months of: (a) the completion of the first Phase 3 clinical trial of the products (based upon the final data unblinding); (b) the receipt by the Company of approval for the first new drug application (the "NDA"), biologics application (the "BLA"), or other marketing or licensing application for the product; and (c) the

The amendments also provided for the Company's license of additional technology, to the extent not previously included in the UM License and granted the Company an exclusive option to obtain an exclusive license for (a) the HLHS investigational new drug application (IND) with ckit+ cells; and (b) UMP-438 titled Method of Determining Responsiveness to Cell Therapy in Dilated Cardiomyopathy. To date, The Company has the right to terminate the UM License upon 60 days' prior written notice, and either party has the right to terminate upon a breach of the UM License. On June 30, 2024, the Company has made payments totaling \$365,000 to UM, and as of June 30, 2024 and December 31, 2023, the Company had accrued \$40,000 and \$50,000 in milestone fees payable to UM, respectively and \$15,000 for the year ended December 31, 2023 for patent related reimbursements based on the estimated progress to date. The Company also entered into an additional Exclusive License Agreement with UM, signed and effective as of July 18, 2024, for technology rights developed by our CSO at UM. This license is a worldwide, exclusive license, with right to sublicense, with respect to any and all know-how, SOPs, data and other all other rights related to UMP-144, entitled method to derive GHRHR+ cardiomyogenic cells from pluripotent stem cells (PSCs) for therapeutic and pharmacologic applications and having inventors Joshua Hare and Konstantinos Chatzistergos. UM retained a non-exclusive, royalty-free, perpetual, irrevocable, worldwide right to practice, make, and use the Patent Rights or Technology for any non-profit purposes, including educational, and research purposes. Pursuant to the terms of the license agreement, Longeveron must pay to UM: (a) \$5,000 within 30 days of the Effective Date; and (b) reimbursement of \$21,307 within 90 days of the Effective Date for previously incurred patent expenses; and (c) an annual \$10,000 fee which is both creditable against other royalty payments for the applicable license year and is waived so long as the Company is current on annual fee payments in accordance with the Exclusive License Agreement entered into November 20, 2014 between Company and UM. In addition to certain those certain other royalty payments that would be due should the Company's sublicense of the technology result in revenue, Longeveron also agreed to the following additional milestones and payments: (c) \$150,000 upon completion of the first Phase 3 Clinical Trial; and (d) \$250,000 upon issuance of a biologics license application or new drug application based on the licensed technology. The Company has the right to terminate the new UM License for convenience upon 90 days' prior written notice, and both parties have additional termination rights for material breach of the agreement. CD271 A On December 22, 2016, the Company entered into an exclusive license agreement with an affiliated entity of Dr. Joshua Hare, JMH MD Holdings, LLC (JMHMD), for the use of CD271 cellular therapy technology. The Company recorded the value of the cash consideration and membership units issued to obtain this license agreement as an intangible asset. The Company is required to pay to JMHMD a royalty 1% of the annual net sales of the licensed product(s) used, leased, or sold by or for the licensee or its sub-licensees. If the Company sublicenses the technology, it is also required to pay an amount equal to 10% of the net sales of the sub-licensees. In addition, on December 23, 2016, as required by the license agreement, the Company paid an initial fee of \$250,000 to JMHMD, and issued to it 10,000 Series C Units, valued at \$250,000. The \$0.5 million of value provided to JMHMD for the license agreement, along with professional fees of approximately \$27,000, were recorded as an intangible asset that is amortized over the life of the license agreement which was defined as 20 years. Further, expenses related to the furtherance of the CD271+ technology are being capitalized and amortized as incurred over 20 years. There were no license fees due for June 30, 2024 and December 31, 2023 pertaining to this agreement.

Other Royalty Under the grant award agreement with the Alzheimer's Association, the Company may be required to make revenue sharing or distribution of revenue payments for products or inventions generated or resulting from this clinical trial program. The potential payments, although not currently defined, could result in a maximum payment of five times (5x) the award amount of \$3.0 million. Contingencies Legal From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. As of June 30, 2024, the Company is not aware of any legal proceedings or material developments requiring disclosure.

Employee Benefits Plan The Company sponsors a defined contribution employee benefit plan (the Plan) under the provisions of Section 401(k) of the Internal Revenue Code. The Plan covers substantially all full-time employees of the Company who are eligible upon date of hire. Contributions to the Plan by the Company are at the discretion of the Board of Directors. The Company contributed approximately \$0.1 million to the Plan during both of the six months ended June 30, 2024 and 2023, and \$47,000 and \$31,000 to the Plan during the three months ended June 30, 2024 and 2023, respectively.

A Basic and diluted net loss per share have been computed using the weighted-average number of shares of common stock outstanding during the period. We have outstanding stock-based awards that are not used in the calculation of diluted net loss per share because to do so would be anti-dilutive. The following instruments (in thousands) were excluded from the calculation of diluted net loss per share because their effects would be antidilutive:

Six months ended June 30, 2024

Stock options Warrants Total

\$6,873A \$1,271A \$8,144A

Total \$6,940A \$1,895A \$8,835A

Subsequent Events July Financing Transactions

On July 10, 2024, a holder exercised Series C warrants for 50,000 shares of Class A common stock for cash (the exercise). On July 10, 2024, certain holders of warrants issued in June of 2024 exercised warrants to purchase an aggregate of 150,000 shares of Class A common stock for cash (the exercise). In addition, on July 17, 2024, we issued to the placement agent warrants to purchase up to 10,500 shares of Class A common stock, equal to 7.0% of the aggregate number of shares of Class A common stock issued in the July 10 warrant exercise (the first tranche July ordinary course placement agent warrants).

The first tranche July ordinary course placement agent warrants have substantially the same terms as the June private placement agent warrants, except that the first tranche July ordinary course placement agent warrants (i) have an exercise price of \$3.125 per share and (ii) expire July 17, 2026. On July 17, 2024, a holder of the June private placement warrants exercised the same to purchase 2,319,186 shares of Class A common stock for cash (the second tranche July ordinary course placement agent warrants).

Together with the July 10 warrant exercise, the exercise accordingly, on July 24, 2024, we issued to the placement agent warrants to purchase up to 162,344 shares of Class A common stock, equal to 7.0% of the aggregate number of shares of Class A common stock issued in the July 17 warrant exercise (the third tranche July ordinary course placement agent warrants).

We issued to the placement agent warrants, and collectively with the July transaction placement agent warrants, the second tranche July ordinary course placement agent warrants have substantially the same terms as the first tranche July ordinary course placement agent warrants, except that the second tranche July ordinary course placement agent warrants expire July 24, 2026. The gross proceeds to the Company from the July Series C warrant exercise, the July 10 warrant exercise and July 17 warrant exercise s, inclusive of the payment consideration for such Series C warrants and June private placement warrants, were approximately \$6.3 million, before deducting placement agent fees payable by the Company.

On July 18, 2024, we entered into a securities purchase agreement with institutional and accredited investors relating to the registered direct offering and sale of an aggregate of 2,336,026 shares of our Class A common stock at a purchase price of \$4.025 per share of Class A common stock and associated warrant (the registered direct offering). The securities issued in the July registered direct offering were offered pursuant to a prospectus supplement, dated July 18, 2024, and accompanying prospectus, in connection with a takedown from our shelf registration statement on Form S-3 (File No. 333-264142), which was declared effective by the SEC on April 14, 2022.

In a concurrent private placement (the private placement) and together with the July registered direct offering, the exercise, we also sold unregistered Class A common stock warrants to purchase up to an aggregate of 2,336,026 shares of our Class A common stock (the private placement warrants). The unregistered July private placement warrants have an exercise price of \$3.90 per share, became exercisable on July 19, 2024, and expire on July 20, 2026. In addition, the Company granted the placement agent warrants, under similar terms, to purchase 156,522 shares of Class A common stock, at an exercise price of \$5.0313. The gross proceeds to the Company from the Offering and the Private Placement are expected to be approximately \$9.0 million, before deducting placement agent fees and other offering expenses payable by the Company.

On August 6, 2024, the Company filed a registration statement with the SEC on Form S-1 registering the resale of an aggregate of 2,565,392 shares of Class A common stock issuable upon exercise of certain warrants, of which (i) up to 2,336,026 shares are issuable upon the exercise of the July private placement warrants issued to the purchasers upon the closing of the July private placement; (ii) 156,522 shares are issuable upon exercise of the July offering placement agent warrants issued to Wainwright, or its designees, pursuant to the terms of the current engagement Letter with Wainwright; and (iii) 172,844 shares are issuable upon exercise of the July ordinary course placement agent warrants issued to Wainwright, or its designees, pursuant to the terms of a then-applicable engagement letter with Wainwright, in connection with previously exercised June private placement warrants. The Form S-1 was declared effective by the SEC on August 12, 2024.

Item 2. Management Discussion and Analysis of Financial Condition and Results of Operations. In this document, the terms "Longeveron," "we," "our," "Company," "Registrant," "we," "they," "its," "their," and "them" refer to Longeveron Inc. We have no subsidiaries. This Quarterly Report on Form 10-Q (this "Report") contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that reflect our current expectations about our future results, performance, prospects and opportunities. This 10-Q contains forward-looking statements that can involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this 10-Q, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, future revenue, timing and likelihood of success, plans and objectives of management for future operations, future results of anticipated products and prospects, plans and objectives of management are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from what we expect, project, anticipate, believe, contemplate, continue, estimate, expect, intend, may, plan, predict, project, should, target, will, or would or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements contained in this report include, but are not limited to, statements about:

(a) — our cash position and need to raise additional capital, the difficulties we may face in obtaining access to capital, and the dilutive impact it may have on our investors;

(b) — our financial performance, and ability to continue as a going concern and ability to remain listed on the Nasdaq Capital Market;

(c) — the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements;

(d) — the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results;

(e) — the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials;

(f) — the size of the market opportunity for our product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting;

(g) — the success of competing therapies that are or may become available;

(h) — the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates;

(i) — our ability to obtain and maintain regulatory approval of our product candidates in the U.S., and other jurisdictions;

(j) — our plans relating to the further development of our product candidates, including additional disease states or indications we may pursue;

(k) — our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others;

(l) — the need to hire additional personnel and our ability to attract and retain such personnel; and

(m) — our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.

The forward-looking statements contained in this 10-Q are made on the basis of the views and assumptions of management regarding future events and business performance as of the date this 10-Q is filed with the Securities and Exchange Commission (SEC). We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements are subject to a number of risks, uncertainties and assumptions described in the section titled Risk Factors elsewhere in this 10-Q. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. We operate in a highly competitive and rapidly changing environment; therefore, new risk factors can arise, and it is not possible for management to predict all such risk factors, nor to assess the impact of all such risk factors on our business or the extent to which any individual risk factor, or combination of risk factors, may cause results to differ materially from those contained in any forward-looking statement. In addition, statements that we believe and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements. We do not undertake any obligation to update these statements to reflect events or circumstances occurring after the date this 10-Q is filed. In addition, this discussion and analysis should be read in conjunction with our unaudited condensed financial statements and notes thereto included in this 10-Q and the audited condensed financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 27, 2024, as amended on Form 10-K/A filed with the SEC on March 11, 2024 (the 2023 10-K/A). Operating results are not necessarily indicative of results that may occur in future periods.

Introduction and Overview A We are a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company's lead investigational product is Lomecel-B, an allogeneic Medicinal Signaling Cell (MSC-C) formulation sourced from the bone marrow of young, healthy adult donors. Lomecel-B, has multiple potential mechanisms of action that promote tissue repair and healing with broad potential applications across a spectrum of disease areas. The underlying mechanism(s) of action that may lead to the tissue repair programs include the stimulation of new blood vessel formation, modulation of the immune system, reduction in tissue fibrosis, and the stimulation of endogenous cells to divide and increase the numbers of certain specialized cells in the body. A We currently have three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD), and Aging-related Frail

standard-of-care HLHS surgery. HLHS is a rare and devastating congenital heart defect in which the left ventricle is severely underdeveloped. As such, babies born with this condition die shortly after birth without undergoing a complex series of reconstructive heart surgeries. Despite the availability of life-saving surgical interventions, clinical studies show that only 50 to 60 percent of affected individuals survive to adolescence. Early clinical study data shows the potential survival benefit of Lomecel-Bâ,¢ for HLHS patients and supports Longeveronâ€™s belief that this data shows the potential to alter the treatment landscape for patients with HLHS. We have completed a Phase 1 open-label study (â€œELPIS Iâ€œ)1 that supported the safety and tolerability of Lomecel-Bâ,¢ for HLHS, when directly injected into the functional right ventricle during the second-stage standard-of-care surgery (adding minimal additional time to the surgical procedure). Preliminary data revealed that several indices of right ventricular function show suggestions of either improvement or prevention of deterioration over one year following surgery. Heart transplant-free survival for patients who received Lomecel-Bâ,¢ intracardiac injection is favorable as compared to historical controls for survival. The improvement in HLHS survival following the Phase 1 ELPIS I clinical trial has resulted in acceptance by the American Heart Association (â€œAHAâ€œ) for a poster presentation at an AHA meeting in November 2023. The ELPIS I trial showed 100 percent transplant-free survival in children up to 5 years of age after receiving Lomecel-Bâ,¢,Â compared to a 20 percent mortality rate observed from historical control data. Based on these findings, the U.S. Food and Drug Administration (the â€œFDAâ€œ) granted Lomecel-Bâ,¢ both Rare Pediatric Disease (RPDâ€œ) Designation and Orphan Drug Designation (â€œODDâ€œ) for treatment of infants with HLHS. Longeveron is currently conducting a controlled Phase 2b trial (â€œELPIS IIâ€œ) to compare the effects of Lomecel-Bâ,¢ as an adjunct therapeutic versus standard-of-care (HLHS surgery alone). We hope that a positive outcome could add to the clinical data suggesting the functional and clinical benefit of Lomecel-Bâ,¢ as part of standard-of-care treatment in HLHS patients. Â Alzheimerâ€™s disease (AD) Â In September 2023, we completed our Phase 2a AD clinical trial, known as the CLEAR MIND trial. This trial enrolled patients with mild AD and was designed as a randomized, double-blind, placebo-controlled study across ten U.S. centers. Our primary objective was to assess safety, and we tested three distinct Lomecel-BTM multiple dosing regimens against placebo. Â The study demonstrated positive results. The established safety profile of Lomecel-Bâ,¢ for single and multiple dosing regimens was demonstrated in study data that showed no incidence of hypersensitivity or infusion-related reactions, there were no cases of amyloid-related imaging abnormalities (ARIA), and all Lomecel-Bâ,¢ treatment groups met the safety primary endpoint and showed slowing/prevention of disease worsening relative to placebo. There were statistically significant improvements in the secondary efficacy endpoint, composite AD score (â€œCADSâ€œ) for both the low-dose Lomecel-BTM group and the pooled treatment groups compared to placebo. Other doses also indicated promising results in slowing/prevention of disease worsening. Additionally, a statistically significant improvement versus placebo was observed in the Montreal cognitive assessment (â€œMoCAâ€œ) and in the activity of daily living observed by a caregiver and measured by Alzheimerâ€™s disease Cooperative Study Activities of Daily Living (â€œADCS-ADLâ€œ). The study indicated potential preservation of brain volumes in some but not all AD related areas of brain. Brain MRI results demonstrated a 49% reduction in brain volume loss and improvement in cerebral blood flow. Â The results of the CLEAR MIND trial were accepted for oral presentation in the Featured Research Session at the 2024 Alzheimerâ€™s Association International Conference (â€œAICAâ€œ) in July 2024. The magnetic resonance imaging (â€œMRIâ€œ) results from this trial also were accepted for poster presentation at AICA. These findings support both the safety and potential therapeutic benefit of Lomecel-BTM in managing mild AD, and we believe lays the groundwork for subsequent trials in this indication. Based on these results, the FDA granted Regenerative Medicine Advanced Therapeutics (RMAT) Designation on July 9, 2024, and Fast Track designation on July 17, 2024, to Lomecel-Bâ,¢ for the treatment of mild Alzheimerâ€™s Disease. Â Â 1Sunjay Kaushal, MD, PhD, Joshua M Hare, MD, Jessica R Hoffman, PhD, Riley M Boyd, BA, Kevin N Ramdas, MD, MPH, Nicholas Pietris, MD, Shelby Kutty, MD, PhD, MS, James S Tweddell, MD, S Adil Husain, MD, Shaji C Menon, MBBS, MD, MS, Linda M Lambert, MSN-cFNP, David A Danford, MD, Seth J Kligerman, MD, Narutoshi Hibino, MD, PhD, Laxminarayana Korutla, PhD, Prashanth Vallabhajosyula, MD, MS, Michael J Campbell, MD, Aisha Khan, PhD, Eric Naioti, MSPH, Keyvan Yousefi, PharmD, PhD, Danial Mehranfar, PharmD, MBA, Lisa McClain-Moss, Anthony A Oliva, PhD, Michael E Davis, PhD, Intramyocardial cell-based therapy with Lomecel-Bâ,¢ during bidirectional cavopulmonary anastomosis for hypoplastic left heart syndrome: The ELPIS phase I trial,Â European Heart Journal Open, 2023. Â 25 Â Â Aging-related Frailty Â Improvement of the quality of life for the aging population is one of the strategic directions of the Company. Life expectancy has substantially increased over the past century due to medical and public health advancements. However, this longevity increase has not been paralleled by health span â€œ the period of time one can expect to live in relatively good health and independence. For many developed and developing countries, health span lags life-expectancy by over a decade. This has placed tremendous strain on healthcare systems in the management of aging-related ailments and presents additional socioeconomic consequences due to a patientâ€™s decreased independence and quality-of-life. Since these strains continue to increase with demographic shifts towards an increasingly older population, improving health span has become a priority for health agencies, such as the National Institute on Aging (â€œNIAâ€œ) of the National Institutes of Health (â€œNIHâ€œ), the Japanese Pharmaceuticals and Medical Devices Agency (â€œPMDAâ€œ), and the European Medicines Agency (â€œEMAâ€œ). As we age, we experience a decline in our own stem cells, a decrease in immune system function (known as â€œimmunosenescenceâ€œ), diminished blood vessel functioning, chronic inflammation (known as â€œinflammagingâ€œ), and other aging-related alterations that affect biological functioning. Our preliminary clinical data suggest that Lomecel-Bâ,¢ may potentially address these problems through multiple potential mechanisms of action (â€œMOAsâ€œ) that simultaneously target key aging-related processes. We are using Lomecel-Bâ,¢ in registry trials in The Bahamas as part of the real-world data generation for the aging population. Â Summary of Clinical Development StrategyÂ Â Our core strategy is to become a world-leading regenerative medicine company through the development, approval, and commercialization of novel cell therapy products for unmet medical needs, with a focus on HLHS. Key elements of our current business strategy are as follows. Â Â—Execution of ELPIS II, a Phase 2b randomized controlled trial set forth in greater detail below, to measure the efficacy of Lomecel-Bâ,¢ in HLHS. This trial is ongoing and is being conducted in collaboration with the National Heart, Lung, and Blood Institute (â€œNHLBIâ€œ) through grants from the NIH. Â Â—Continue to pursue the therapeutic potential of Lomecel-Bâ,¢ in mild AD. We completed a Phase 2a trial, the (â€œCLEAR MIND Trialâ€œ), which demonstrated the potential benefits of Lomecel-Bâ,¢ over placebo to maintain cognitive function and slow deterioration of brain structure atrophy, with no safety issues observed. Specifically, the safety primary endpoint was met and the trial demonstrated a statistical significance in the secondary CADS endpoint. Overall, in Lomecel-Bâ,¢ groups, brain MRI demonstrated whole brain volume loss slowed accompanied by significant preservation of left hippocampal volume relative to placebo. We plan to continue to analyze the data in order to further develop our clinical development strategy. Our objective is to forge strategic collaborations, consider potential partnerships, or pursue other available pathways or opportunities for the advancement of Lomecel-Bâ,¢ in addressing AD. Â Â—Limited focus on our international program. In line with the Companyâ€™s strategic direction for 2024 and moving forward to focus on HLHS and AD as set forth previously, the Company has discontinued its clinical trial in Japan to evaluate Lomecel-Bâ,¢ for Aging-related Frailty. The Company will continue to enroll patients on the Frailty and Cognitive Impairment registry trials in The Bahamas and plans to also launch an Osteoarthritis registry trial. Â Â—Expand our manufacturing capabilities to commercial-scale production. We operate a current good manufacturing practice (â€œcGMPâ€œ)-compliant manufacturing facility and produce our own product candidates for testing. We continue to improve and expand our capabilities with the goal of achieving cost-effective manufacturing that may potentially satisfy future commercial demand for certain potential Lomecel-Bâ,¢ commercialization opportunities. Â Â—Collaborative arrangements and out-licensing opportunities. We will be opportunistic and consider entering into a co-development, out-licensing, or other collaboration agreements for the purpose of eventually commercializing Lomecel-Bâ,¢ and other products domestically and internationally if appropriate approvals are obtained. Â Â—Product candidate development pipeline through internal research and development, and in-licensing. Through our research and development program, and through strategic in-licensing agreements, or other business development arrangements, we intend to actively explore promising potential additions to our pipeline. Â Â—Continue to expand our intellectual property portfolio. Our intellectual property is vitally important to our business strategy, and we have taken and continue to take significant steps to develop this property and protect its value. Results from our ongoing research and development efforts are intended to add to our existing intellectual property portfolio. Â 26 Â Â Clinical Development Pipeline in 2024 Â Â We are currently in clinical development of a single product, Lomecel-Bâ,¢ for three potential indications: Â Indication Â Geography Â Phase 1 Â Phase 2 Â Phase 3 HLHS Â U.S. Â Â Â Alzheimerâ€™s disease Â U.S. Â Â Â Aging-related Frailty* Â U.S. Â Â Â Figure 1: Lomecel-Bâ,¢ clinical development pipeline Â *Not currently active for 2024 Â Hypoplastic Left Heart Syndrome (HLHS). The FDA granted Lomecel-Bâ,¢ for the treatment of HLHS a Rare Pediatric Disease (â€œRPDâ€œ) Designation (on November 8, 2021), Orphan Drug Designation (â€œODDâ€œ) (on December 2, 2021), and Fast Track Designation (on August 24, 2022). HLHS is a rare congenital heart condition affecting approximately 1,000 newborns in the US annually. HLHS is a birth defect that affects normal blood flow through the heart. As the baby develops during pregnancy, the left side of the heart does not form correctly so that babies are born with a single ventricle. It is one type of congenital heart defect present at birth. Because a baby with this defect needs surgery or other procedures soon after birth, HLHS is considered a critical congenital heart defect. To prevent certain death shortly after birth, these babies undergo a series of three heart surgeries (staged surgical palliation) that reconfigures the single right ventricle) to support systemic circulation. Despite these life-saving surgeries, HLHS patients nevertheless still have high early mortality and morbidity rates due primarily to heart failure. Â We are currently conducting a Phase 2b clinical trial (ELPIS II) under FDA IND 017677. ELPIS II is a multi-center, randomized, double-blind, controlled clinical trial designed to evaluate Lomecel-Bâ,¢ as an adjunct therapy to the standard-of-care second-stage HLHS heart reconstructive surgery which is typically performed at 4-6 months after birth. The primary objective is to evaluate change in right ventricular ejection fraction after Lomecel-Bâ,¢ treatment versus standard-of-care surgery alone (38 subjects total: 19 per arm) at 12 months. This trial is over 70% enrolled and is funded in part by the NHLBI/NIH. While we cannot predict a specific time when the trial will be fully enrolled, the current target to complete enrollment is by the end of 2024.Â Â ELPIS II is a next-step trial to our completed 10-patient open-label Phase 1 trial (ELPIS I) under the same IND. This Phase 1 trial was designed to evaluate the safety and tolerability of Lomecel-Bâ,¢ as an adjunct to the second-stage HLHS surgery, and to obtain preliminary evidence of Lomecel-Bâ€™s effect to support a next-phase trial. The primary safety endpoint was met: no major adverse cardiac events (â€œMACEâ€œ) or treatment-related infections during the first month post-treatment, and no triggering of stopping rules. Furthermore, fluid-based and imaging biomarker data supported multiple potentially relevant mechanisms-of-action of Lomecel-Bâ,¢, and the potential to improve post-surgical heart function. In addition to the 12-month follow-up evaluation on ELPIS, we continue to follow these patients on an annual basis for the survival status As of June 2024, all 10 patients have survived (100%), seven of the patients have reached the age of five and have successfully undergone the third-stage surgery, and two of them have reached the age of six years old, all without the need for a heart transplantation. Based on historical data, the incidence of interstage attrition between the Glenn operation (Stage 2) and Fontan (Stage 3) ranges from 6% to 12% with the most common cause of death being RV dysfunction. Longer-term follow-up studies showed that the transplant-free survival to age 15 is only approximately 50 % in these patients. We intended to continue to follow-up with all patients who participated in ELPIS I and ELPIS II studies for up to an additional five years, until all patients reach ten years of age to evaluate the transplant-free survival and additional data on the patients neurodevelopment, and cardiac function. Â We have filed patent applications relating to the administration of mesenchymal stem cells for treating HLHS in Australia, the Bahamas, Canada, China, the European Patent Office, Japan, South Korea, Taiwan, and the United States. Â Alzheimerâ€™s disease. AD, a devastating neurologic disease leading to cognitive decline, currently has limited therapeutic options. An estimated 6.7 million Americans aged 65 and older have AD, and this number is projected to more than double by 2060. Lomecel-Bâ,¢ treated patients showed an overall slowing/prevention of disease worsening compared to placebo in the completed Phase 2a study (CLEAR MIND Trial) as previously detailed in this report, and met its primary endpoint of safety. These results are consistent with those of our earlier Phase I study2. Based on these results, the FDA granted RMAT Designation and Fast Track designation to Lomecel-Bâ,¢ for the treatment of mild Alzheimerâ€™s Disease. As previously indicated, we intend to forge strategic collaborations, consider potential partnerships, or pursue other available pathways or opportunities for the advancement of Lomecel-Bâ,¢ in addressing AD. Â Â 2Mark Brody, Marc Agronin, Brad J. Herskowitz, Susan Y. Bookheimer, Gary W. Small, Benjamin Hitchinson, Kevin Ramdas, Tyler Wishard, Katalina Fernndez McInerney, Bruno Vellas, Felipe Sierra, Zhijie Jiang, Lisa McClain-Moss, Carmen Perez, Ana Fuquay, Savannah Rodriguez, Joshua M. Hare, Anthony A. Oliva Jr., Bernard Baumel. â€œResults and insights from a phase I clinical trial of Lomecel-Bâ,¢ for Alzheimerâ€™s diseaseâ€œ (2023) Alzheimerâ€™s & Dementia: The Journal of the Alzheimerâ€™s Association 19:261-273. Â 27 Â Â We have filed patent applications relating to the treatment of AD using mesenchymal stem cells in Australia, the Bahamas, Canada, China, the European Patent Office, Hong Kong, Israel, Japan, New Zealand, South Korea, Singapore, South Africa, and the United States. Â Aging-related Frailty. Aging-related Frailty is a life-threatening geriatric condition that disproportionately increases risks for poor clinical outcomes from disease and injury. While the definition of Aging-related Frailty lacks consensus, would be a new indication from a regulatory standpoint, and has no approved pharmaceutical or biologic treatments, there are a number of companies now working to develop potential therapeutics for this unmet medical need. Â We have previously completed two U.S. clinical trials under FDA IND 016644. One is a multicenter, randomized, placebo-controlled Phase 2b trial which showed that a single infusion of Lomecel-Bâ,¢ significantly improved 6-Minute Walk Test (â€œ6MWTâ€œ) distance 9 months after infusion (although results were inconclusive at six months after infusion), and also showed a dose-dependent increase in 6MWT distance 6 months after infusion. The second is a multicenter, randomized, placebo-controlled Phase 1/2 trial (â€œHERA Trialâ€œ) intended primarily to evaluate safety, and explore the effect Lomecel-Bâ,¢ may have on specific biomarkers of immune system function in older, frail individuals receiving the high dose influenza vaccine, as well as to evaluate the potential effects of Lomecel-Bâ,¢ on signs and symptoms of Aging Frailty. Results from this study showed that Lomecel-Bâ,¢ was generally safe and well tolerated in patients with Aging-related Frailty. Additionally, hemagglutinin inhibition (â€œHIâ€œ) assay results in the Lomecel-Bâ,¢ and placebo groups to influenza were not statistically different, indicating Lomecel-Bâ,¢ does not suppress the immune system. Â We have filed patent applications relating to the administration of MSC for Aging-related Frailty in Australia, Canada, China, the European Patent Office, Hong Kong, Israel, Japan, Singapore, South Korea, New Zealand, South Africa, Taiwan, the Bahamas and United States.Â Â Components of Our Results of Operations Â Revenue Â We have generated revenue from three sources: Â Â—Grant awards. Extramural grant award funding, which is non-dilutive, has been a core strategy for supporting our ongoing clinical research. Since 2016 our clinical programs have received over \$16.0 million in competitive extramural grant awards (\$11.5 million which has been directly awarded to us and which are recognized as revenue when the performance obligations are met) from the National Institutes of Health, Alzheimerâ€™s Association, and Maryland Stem Cell Research Fund. Â Â—The Bahamas Registry Trials. Participants in The Bahamas Registry Trials pay us a fee to receive Lomecel-Bâ,¢, imported into The Bahamas, and administered at one of two private medical clinics in Nassau. While Lomecel-Bâ,¢ is considered an investigational product in The Bahamas, under the approval terms received from the National Stem Cell Ethics Committee, we are permitted to charge a fee for participation in the Registry Trial. The fee is recognized as revenue and is used to pay for the costs associated with manufacturing and testing of Lomecel-Bâ,¢, administration, shipping and importation fees, data collection and management, biological sample collection and sample processing for biomarkers and other data, and overall management of the Registry, including personnel costs. Lomecel-Bâ,¢ is considered an investigational treatment in The Bahamas and is not licensed for commercial sale. Â Â—Contract development and manufacturing services. From time to time, we enter into fee-for-service agreements with third parties for our product development and manufacturing capabilities. In April 2024, we entered into our first manufacturing services contract with Secretome Therapeutics. Â Cost of Revenues Â We record cost of revenues based on expenses directly related to revenue. For grants we record allocated expenses for research and development costs to a grant as a cost of revenues. For the clinical trial revenue, directly related expenses for that program are allocated and accrued as incurred. These expenses are similar to those described under â€œResearch and Development Expensesâ€œ below. For the contract manufacturing, the Company records costs incurred under the contract as cost of revenues. Â 28 Â Â Â Research and Development Expenses Â Research and development costs are charged to expense when incurred in accordance with Financial Accounting Standards Board (â€œFASBâ€œ) Accounting Standards Codification (â€œASCâ€œ) 730 Research and Development. ASC 730 addresses the proper accounting and reporting for research and development costs. It identifies: Â 1.Those activities that should be identified as research and development; Â 2.The elements of costs that should be identified with research and development activities, and the accounting for these costs; and Â 3.The financial statement disclosures related to them. Â Research and development include costs such as clinical trial expenses, contracted research and license agreement fees with no alternative future use, supplies and materials, salaries, share-based compensation, employee benefits, property and equipment depreciation and allocation of various corporate costs. We accrue for costs incurred by external service providers, including contract research organizations (â€œCROsâ€œ) and clinical investigators, based on estimates of service performed and costs incurred. These estimates include the level of services performed by the third parties, subject enrollment in clinical trials, administrative costs incurred by the third parties, and other indicators of the services completed. Based on the timing of amounts invoiced by service providers, we

may also record payments made to those providers as prepaid expenses that will be recognized as expense in future periods as the related services are rendered. A We currently do not carry any inventory for our product candidates, as we have yet to launch a product for commercial distribution. Historically our operations have focused on conducting clinical trials, product research and development efforts, and improving and refining our manufacturing processes, and accordingly, manufactured clinical doses of product candidates were expensed as incurred, consistent with the accounting for all other research and development costs. Once we begin commercial distribution, all newly manufactured approved products will be allocated either for use in commercial distribution, which will be carried as inventory and not expensed, or for research and development efforts, which will continue to be expensed as incurred. A We expect that our research and development expenses will continue to be significant in the future as we increase our headcount to support increased research and development activities relating to our clinical programs, as well as incur additional expenses related to our clinical trials. A General and Administrative Expenses A General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive, finance, business development and administrative functions. General and administrative expenses also include public company related expenses; Board of Director fees; legal fees relating to corporate matters; insurance costs; professional fees for accounting, auditing, tax and consulting services; travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs. General and administrative costs also include royalty and license fees associated with our agreements with the University of Miami as well as attending and sponsoring industry, investment, organization and medical conferences and events. A 29 A Other Income A Interest income consists of interest earned on cash equivalents and marketable securities. We expect our interest income to vary in conjunction with changes in our monthly cash and marketable securities balances. Other income consists of funds earned that are not part of our normal operations. In past years they have been primarily a result of tax refunds received for social security taxes as part of a research and development tax credit program. A Income Taxes A No provision for income taxes has been recorded for the years ended December 31, 2023 and 2022. We may incur income taxes in the future if we have earnings. At this time the Company has not evaluated the impact of any future profits. A RESULTS OF OPERATIONS A COMPARISON OF THE THREE MONTHS ENDED JUNE 30, 2024 AND 2023 A The following table summarizes our results of operations for the three months ended June 30, 2024 and 2023, together with the changes in those items in dollars (in thousands): A A Three Months Ended June 30, A Increase A A 2024 A 2023 A (Decrease) A Revenues \$468A \$217A \$251A Cost of revenues A 124A A 124A A A Gross profit A 344A A 93A A 251A Expenses A A A A A A A A General and administrative A 2,122A A 3,518A A (1,396) Research and development A 1,722A A 2,287A A (565) Total operating expenses A 3,844A A 5,805A A (1,961) A A A A A A A A Loss from operations A (3,500) A (5,712) A 2,212A Other income A 87A A 80A A 7A Net loss \$ (3,413) A \$ (5,632) A \$ 2,219A Revenues, Cost of Revenues and Gross Profit: Revenues for the three months ended June 30, 2024 and 2023 were \$0.5 million and \$0.2 million, respectively. 2024 revenues increased \$0.3 million, or 116%, when compared to 2023 mainly as a result of increased participant demand for our Bahamas Registry Trial. Clinical trial revenue, which is derived from the Bahamas Registry Trial, for the three months ended June 30, 2024 and 2023 was \$0.3 million and \$0.2 million, respectively. Clinical trial revenue for the three months ended June 30, 2024 increased by \$0.1 million, or 32%, when compared to 2023 as a result of increased participant demand. Contract manufacturing revenue for the three months ended June 30, 2024 was \$0.2 million from our first manufacturing services contract with Secretome Therapeutics. A Related cost of revenues was \$0.1 million for the three-month periods ended June 30, 2024 and 2023. This resulted in a gross profit of approximately \$0.3 million for the three months ended June 30, 2024, an increase of \$0.2 million, or 270%, when compared with a gross profit of \$0.1 million for 2023. A General and Administrative Expense: General and administrative expenses for the three months ended June 30, 2024 decreased to approximately \$2.1 million, compared to \$3.5 million for the same period in 2023. The decrease of approximately \$1.4 million, or 40%, was primarily related to a decrease in personnel expenses as a result of lower severance and stock compensation costs in 2024. A 30 A Research and Development Expenses: Research and development expenses for the three months ended June 30, 2024 decreased to approximately \$1.7 million, from approximately \$2.3 million for the same period in 2023. The decrease of \$0.6 million, or 25%, was primarily due to a decrease of \$0.7 million in research and development expenses being incurred for the now-completed CLEAR MIND Alzheimer’s disease clinical trial, and reduced costs for the aging-related frailty clinical trial following our decision to discontinue trial activities in Japan, and reduced cost of supplies of \$0.2 million. These reductions were partially offset by \$0.2 million of higher compensation and benefit costs and \$0.1 million of higher equity-based compensation expenses allocated to research and development expenses. Research and development expenses consisted primarily of the following items (less those expenses allocated to the cost of revenues for the grants) (in thousands): A A Three Months Ended June 30, A 2024 A 2023 A Employee compensation and benefits A \$715A \$559A Clinical trial expenses-statistics, monitoring, labs, sites, etc. A 422A A 1,145A Depreciation A 173A A 184A Supplies and costs to manufacture Lomecel-Ba, cA 123A A 285A Equity-based compensation A 123A A 4A Amortization A 56A A 55A Travel A 47A A 55A Other activities A 63A A A A \$1,722A A 2,287A A Other Income (Expense): Other income for the three months ended June 30, 2024 was less than \$0.1 million. Other income consisted of less than \$0.1 million from interest earned on money market funds and marketable securities. Other income for the three months ended June 30, 2023 was \$0.1 million as a result of gains from marketable securities. A Net Loss: Net loss decreased to approximately \$3.4 million for the three months ended June 30, 2024 from a net loss of \$5.6 million for the same period in 2023. The decrease in the net loss of \$2.2 million, or 40%, was for the reasons outlined above. A COMPARISON OF THE SIX MONTHS ENDED JUNE 30, 2024 AND 2023 A The following table summarizes our results of operations for the six months ended June 30, 2024 and 2023, together with the changes in those items in dollars (in thousands): A A Six Months Ended June 30, A Increase A A 2024 A 2023 A (Decrease) A Revenues \$1,016A \$496A \$520A Cost of revenues A 343A A 327A A 16A Gross profit A 673A A 169A A 504A Expenses A A A A A A A A General and administrative A 4,322A A 5,530A A (1,208) Research and development A 3,941A A 5,067A A (1,126) Total operating expenses A 8,263A A 10,597A A (2,334) A A A A A A Loss from operations A (7,590) A (10,428) A 2,838A Other income A 119A A 149A A (30) Net loss \$ (7,471) A \$ (10,279) A \$ 2,808A Revenues, Cost of Revenues and Gross Profit: Revenues for the six months ended June 30, 2024 and 2023 were \$1.0 million and \$0.5 million, respectively. 2024 revenues increased \$0.5 million, or 105%, when compared to 2023 mainly as a result of increased participant demand for our Bahamas Registry Trial. Clinical trial revenue, which is derived from the Bahamas Registry Trial, for the six months ended June 30, 2024 and 2023 was \$0.8 million and \$0.5 million, respectively. Clinical trial revenue for the six months ended June 30, 2024 increased by \$0.3 million, or 76%, when compared to 2023 as a result of increased participant demand. Contract manufacturing revenue for the six months ended June 30, 2024 was \$0.2 million from our first manufacturing services contract with Secretome Therapeutics. A Related cost of revenues was \$0.3 million for the six-month periods ended June 30, 2024 and 2023. This resulted in a gross profit of approximately \$0.7 million for the six months ended June 30, 2024, an increase of \$0.5 million, or 298%, when compared with a gross profit of \$0.2 million for 2023. A 31 A A General and Administrative Expense: General and administrative expenses for the six months ended June 30, 2024 decreased to approximately \$4.3 million, compared to \$5.5 million for the same period in 2023. The decrease of approximately \$1.2 million, or 22%, was primarily related to a decrease in personnel expenses as a result of lower severance and stock compensation costs in 2024. A Research and Development Expenses: Research and development expenses for the six months ended June 30, 2024 decreased to approximately \$3.9 million, from approximately \$5.1 million for the same period in 2023. The decrease of \$1.2 million, or 22%, was primarily due to a decrease of \$1.3 million in research and development expenses being incurred for the completed CLEAR MIND Alzheimer’s disease clinical trial and reduced costs for the aging-related frailty clinical trial following our decision to discontinue trial activities in Japan, reduced cost of supplies of \$0.4 million and \$0.1 million of lower equity-based compensation expenses allocated to research and development expenses. These reductions were partially offset by \$0.6 million of higher compensation and benefit costs. Research and development expenses consisted primarily of the following items (less those expenses allocated to the cost of revenues for the grants) (in thousands): A A Six Months Ended June 30, A 2024 A 2023 A Employee compensation and benefits A \$1,678A \$1,102A Clinical trial expenses-statistics, monitoring, labs, sites, etc. A 1,230A A 2,495A Depreciation A 370A A 366A Equity-based compensation A 213A A 277A Supplies and costs to manufacture Lomecel-Ba, cA 144A A 571A Amortization A 112A A 112A Travel A 72A A 138A Other activities A 122A A 6A A 6A \$3,941A A 5,067A A Other Income (Expense): Other income for the six months ended June 30, 2024 was \$0.1 million. Other income consisted of \$0.1 million from interest earned on money market funds and marketable securities. Other income for the six months ended June 30, 2023 was \$0.1 million as result of gains from marketable securities. A Net Loss: Net loss decreased to approximately \$7.5 million for the six months ended June 30, 2024 from a net loss of \$10.3 million for the same period in 2023. The decrease in the net loss of \$2.8 million, or 27%, was for the reasons outlined above. A Cash Flows A The following table summarizes our sources and uses of cash for the period presented (in thousands): A A Six months ended June 30, A A 2024 A 2023 A Net cash used in operating activities A \$(7,652) A \$(10,449) Net cash (used in) provided by investing activities A (39) A 2,796A Net cash provided by (used in) financing activities A 15,117A A (103) Change in cash and cash equivalents A \$7,426A A \$(7,756) A Operating Activities. We have incurred losses since inception. Net cash used in operating activities for the six months ended June 30, 2024, was \$7.7 million, consisting primarily of our net loss of \$7.5 million and payments of \$0.4 million in prepaid expenses and other assets, and \$0.5 million for accrued expenses. This was partially offset by non-cash expenses of \$0.5 million for equity-based compensation and \$0.5 million for depreciation and amortization. Net cash used in operating activities for the six months ended June 30, 2023, was \$10.4 million, consisting primarily of our net loss of \$10.3 million, payments of \$1.1 million in prepaid and other assets and non-operating lawsuit of \$1.4 million. This was partially offset by non-cash expenses of \$1.1 million in equity-based compensation expenses, \$0.5 million in depreciation and amortization, and an increase in accrued expenses of \$0.7 million. A Investing Activities. Net cash used in investing activities for the six months ended June 30, 2024, was less than \$0.1 million consisting primarily of the redemption of marketable securities, which was partially offset by purchases of property and equipment and intangible assets. Net cash provided by investing activities for the six months ended June 30, 2023 was \$2.8 million, consisting primarily of proceeds from the sale of marketable securities. A Financing Activities. Net cash provided by financing activities for the six months ended June 30, 2024 was approximately \$15.1 million for proceeds from the issuance of common stock of \$4.7 million and warrants exercised of \$10.3 million. Net cash used in financing activities for the six months ended June 30, 2023 was \$0.1 million for the payment of taxes upon vesting of RSUs. A 32 A LIQUIDITY AND CAPITAL RESOURCES A A Since our inception, we have incurred significant operating losses. We expect to incur significant expenses and operating losses as we advance the preclinical and clinical development of our programs. We expect that our sales, research and development and general and administrative costs will increase in connection with conducting additional preclinical studies and clinical trials for our current and future programs and product candidates, contracting with CROs to support preclinical studies and clinical trials, expanding our intellectual property portfolio, and providing general and administrative support for our operations. As a result, we will need additional capital to fund our operations, which we may obtain from additional equity or debt financings, collaborations, licensing arrangements, or other sources. A To date, we have financed our operations primarily through our IPO, public and privately placed equity financings, grant awards, and fees generated from the Bahamas Registry Trial and contract manufacturing services. Since we were formed, we have raised approximately \$116.8 million in gross proceeds from the issuance of equity. At June 30, 2024, the Company had cash and cash equivalents of \$12.4 million and working capital of approximately \$10.2 million. A Following the capital raises in April and June 2024 as detailed below in the section entitled “LIQUIDITY AND CAPITAL RESOURCES”, and direct offering and warrant exercises in July 2024, which resulted in gross proceeds of \$32.9 million and net proceeds of \$29.4 million after deducting placement agent fees but before other deductions for offering expenses as discussed below, we believe that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements through the fourth quarter of 2025. We have based these estimates on assumptions that may prove to be imprecise, and we could utilize our available capital resources sooner than we expect. We are actively seeking financing opportunities to extend our cash runway while taking measures to reduce our cash expenditures as we focus our resources on our primary strategic program in HLHS. These cost saving measures include the discontinuation of our Aging-related Frailty clinical trial in Japan, related staff reductions, and continued prudent management of discretionary spend. A Capital Raising Efforts A On April 8, 2024, we commenced a public offering (the “Offering”) of up to 661,149 shares of our Class A common stock and pre-funded warrants to purchase up to an aggregate of 1,572,894 shares of our Class A common stock (the “Pre-funded Warrants”). The Class A common stock and Pre-funded Warrants were sold together with warrants to purchase up to an aggregate of 2,234,043 shares of Class A common stock (the “Common Warrants”). The combined public Offering price was \$2.35 per share of Class A common stock and \$2.349 per Pre-funded Warrant and related Common Warrant. The Common Warrants are immediately exercisable and expire five years from the date of issuance. As compensation to the placement agent the Company also issued to designees of the placement agent warrants to purchase up to 154,894 shares of Class A common stock, which had substantially the same terms as the Common Warrants, and with an exercise price of \$2.9375 per share and a term of five years from the commencement of sales in the Offering. A In connection with the Offering, the Company also entered into an agreement (the “Warrant Amendment Agreement”) with a holder (the “Holder”) of existing warrants to purchase shares of the Company’s Class A common stock, in consideration for the Holder’s participation in the Offering and purchase of securities in the Offering, and contingent upon the closing of the Offering and the Holder’s participation in the Offering, to amend the Holder’s existing warrants to purchase up to (a) 242,425 shares of Class A common stock at an exercise price of \$16.50 per share, issued on October 13, 2023 and expiring on April 13, 2029 (the “Series A Warrants”) and (b) 242,425 shares of Class A common stock at an exercise price of \$16.50 per share, issued on October 13, 2023 and expiring on April 14, 2025 (the “Series B Warrants”) and together with the Series A Warrants, the “Existing Warrants”) to (i) reduce the exercise price of the Existing Warrants to \$2.35 per share and (ii) amend the expiration date of the Series A Warrants to five and one-half (5.5) years following the closing of the Offering and the Series B Warrants to eighteen (18) months following the closing of the Offering, in each case for a payment to the Company of \$0.125 per amended warrant, for aggregate gross consideration of \$60,606.25, prior to deducting placement agent fees (the “Warrant Amendment”). The Offering closed on April 10, 2024 and the gross proceeds from the Offering were \$5.25 million, and net proceeds of \$4.7 million after placement agent fees but before other offering expenses payable by the Company. The Warrant Amendment was effective upon the closing of the Offering. A 33 A On April 16, 2024, we entered into an inducement letter agreement with certain holders of our existing Series A Warrants and Series B Warrants (collectively, the “October Warrants”), and certain Common Warrants pursuant to which the holders agreed to exercise for cash the October Warrants and such Common Warrants at an exercise price of \$2.35 per share in consideration for payment of \$0.125 per new warrant and our issuance of new Series C warrants to purchase 2,399,744 shares of Class A common stock, with a term of five years from the issuance date, and new Series D warrants to purchase 2,399,744 shares of Class A common stock, with a term of twenty-four months from the issuance date. Additionally, the Company agreed to issue to the placement agent or its designees as compensation, warrants to purchase up to 167,982 shares of Class A common stock, equal to 7.0% of the aggregate number of shares of Class A common stock issued upon exercise of the October Warrants and Common Warrants pursuant to the inducement transaction, which had the same terms as the Series C Warrants, except that the placement agent warrants have an exercise price of \$3.25 per share. A The inducement transaction closed on April 18, 2024, and the gross proceeds to the Company, inclusive of the payment consideration for the New Warrants, were approximately \$6.2 million, and net proceeds of \$5.6 million after deducting placement agent fees but before other offering expenses payable by the Company. A On June 17, 2024, we entered into another series of inducement letter agreements with the holders of our existing Series D warrants, pursuant to which the holders agreed to exercise their Series D warrants for cash at the exercise price of \$2.35 per share in consideration for the Company’s agreement to issue new unregistered common stock warrants, for payment of \$0.125 per new warrant, to purchase up to an aggregate of 3,395,782 shares of common stock at an exercise price of \$2.50 per share (the “June private placement warrants”), which, were immediately exercisable upon issuance and have a term of twenty-four months from the issuance date. Additionally, the Company agreed to issue to the placement agent or its designees as compensation, (i) warrants to purchase up to 118,852 shares of Class A common stock, equal to 7.0% of the aggregate number of shares of Class A common stock issued upon exercise of the warrants pursuant to the June inducement transaction and (ii) warrants to purchase up to an aggregate of 49,130 shares of Common Stock, equal to 7.0% of the aggregate number of shares of Common Stock issued upon exercise of certain Series D warrants prior to the June inducement transaction, which had substantially the same terms as the new warrants, had an exercise price of \$3.25 per share and \$2.9375 per share, respectively. A The aggregate gross proceeds to the Company from the June exercise of the remaining Series D warrants, inclusive of the payment consideration for the new warrants that were issued, were approximately \$4.4 million, before deducting placement agent fees and other offering expenses payable by the Company. All of the Series D Warrants were exercised in June 2024, pursuant to ordinary course exercise as well as the subsequent inducement transaction. As of June 30, 2024, 297,872 Common Warrants remain outstanding. A On July 10, 2024, certain holders of the June private placement warrants

we issued the same to purchase an aggregate of 250,000 shares of Class A common stock for cash (the “July 10 warrant exercise”). Accordingly, on July 17, 2024, we issued to the placement agent additional warrants to purchase up to 10,500 shares of Class A common stock, equal to 7.0% of the aggregate number of shares of Class A common stock issued in the July 10 warrant exercise (the “first tranche July ordinary course placement agent warrants”). The first tranche July ordinary course placement agent warrants have substantially the same terms as the private placement agent warrants issued in June, except that the first tranche July ordinary course placement agent warrants have an exercise price of \$3.125 per share and expire July 17, 2026. Å On July 17, 2024, holders of the June private placement warrants exercised June private placement warrants to purchase an aggregate of 2,319,186 shares of Class A common stock for cash (the “July 17 warrant exercise”) and together with the July 10 warrant exercise, the “July warrant exercises”). Accordingly, on July 24, 2024, we issued to the placement agent additional warrants to purchase up to 162,344 shares of Class A common stock, equal to 7.0% of the aggregate number of shares of Class A common stock issued in the July 17 warrant exercise (the “second tranche July ordinary course placement agent warrants”), and together with the first tranche July ordinary course placement agent warrants, the “July ordinary course placement agent warrants,” and collectively with the July transaction placement agent warrants, the “July placement agent warrants”). The second tranche July ordinary course placement agent warrants have substantially the same terms as the first tranche July ordinary course placement agent warrants, except that the second tranche July ordinary course placement agent warrants expire July 24, 2026. Å 34 Å The gross proceeds to the Company from the July 10 warrant exercise and July 17 warrant exercise of June private placement warrants, inclusive of the payment consideration for such June private placement warrants, were approximately \$6.2 million, before deducting placement agent fees payable by the Company. Å On July 18, 2024, we entered into a securities purchase agreement with institutional and accredited investors relating to the registered direct offering and sale of an aggregate of 2,236,026 shares of our Class A common stock at a purchase price of \$4.025 per share of Class A common stock and associated warrant (the “July registered direct offering”). The securities issued in the July registered direct offering were offered pursuant to a prospectus supplement, dated July 18, 2024, and accompanying prospectus, in connection with a takedown from our shelf registration statement on Form S-3 (File No. 333-264142), which was declared effective by the SEC on April 14, 2022. Å In a concurrent private placement (the “July private placement”) and together with the July registered direct offering, the “July offering”), we also sold unregistered Class A common stock warrants to purchase up to an aggregate of 2,236,026 shares of our Class A common stock (the “July private placement warrants”). The unregistered July private placement warrants have an exercise price of \$3.90 per share, became exercisable on July 19, 2024, and expire on July 20, 2026. Additionally the Company agreed to issue to the placement agent, or its designees, warrants to purchase up to an aggregate of 156,522 shares of Class A common stock (the “Placement Agent Warrants”), equal to 7.0% of the aggregate number of shares of Class A common stock sold in the offering, which have substantially the same terms as the unregistered July private placement warrants, except that the Placement Agent Warrants have an exercise price of \$5.0313 per share. Å The gross proceeds to the Company from the July registered direct offering and concurrent private placement were approximately \$9.0 million, before deducting placement agent fees and other offering expenses payable by the Company. Å Grant Awards Å From inception through December 31, 2023, we have been awarded approximately \$11.9A million in governmental and non-profit association grants, which have been used to fund our clinical trials, research and development, production and overhead. Grant awards are recognized as revenue, and depending on the funding mechanism, are deposited directly in our accounts as lump sums, which are staggered over a predetermined period or drawn down from a federal payment management system account for reimbursement of expenses incurred. Revenue recognition occurs when the grant related expenses are incurred or supplies and materials are received. As of June 30, 2024, and December 31, 2023, the amount of unused grant funds that were available for us to draw was approximately \$0.1A million. Å Terms and Conditions of Grant Awards Å Grant projects are typically divided into periods (e.g., a three-year grant may have three one-year periods), and the total amount awarded is divided according to the number of periods. At pre-specified time points, which are detailed in the grant award notifications, we are required to submit interim financial and scientific reports to the granting agency totaling funds spent, and in some cases, detailing use of proceeds and progress made during the reporting period. After funding the initial period, receipt of additional grant funds is contingent upon satisfactory submission of our interim reports to the granting agency. Å Grant awards arise from submitting detailed research proposals to granting agencies, and winning a highly competitive and rigorous application review and process that is judged on the merits of the proposal. There are typically multiple applicants applying and competing for a finite amount of funds. As such we cannot be sure that we will be awarded grant funds in the future despite our past success in receiving such awards. Å 35 Å Funding Requirements Å Our operating costs will continue to be substantial for the foreseeable future in connection with our ongoing activities. In past years we have been able to fund a large portion of our clinical programs and our administrative overhead with the use of grant funding. Å Specifically, our expenses will increase as we: Å—advance the clinical development of Lomecel-B, for the treatment of several disease states and indications; Å—pursue the preclinical and clinical development of other current and future research programs and product candidates; Å—in-license or acquire the rights to other products, product candidates or technologies; Å—maintain, expand and protect our intellectual property portfolio; Å—hire additional personnel in research, manufacturing and regulatory and clinical development as well as management personnel; Å—seek regulatory approval for any product candidates that successfully complete clinical development; and Å—expand our operational, financial and management systems and increase personnel, including personnel to support our operations as a public company. Å We believe that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements through the fourth quarter of 2025. We have based these estimates on assumptions that may prove to be imprecise, and we could utilize our available capital resources sooner than we expect. We are actively seeking financing opportunities to extend our cash runway while taking measures to reduce our cash expenditures as we focus our resources on our primary strategic program in HLHS. These cost saving measures include the discontinuation of our Aging-related Frailty clinical trial in Japan, related staff reductions, and continued prudent management of discretionary spend. Å Because of the numerous risks and uncertainties associated with research, development and commercialization of our product candidates, it is difficult to estimate with certainty the amount of our working capital requirements. Our future funding requirements will depend on many factors, including: Å—the progress, costs and results of our clinical trials for our programs for our cell-based therapies, and additional research and preclinical studies in other research programs we initiate in the future; Å—the costs and timing of process development and manufacturing scale-up activities associated with our product candidates and other programs we advance through preclinical and clinical development; Å—our ability to establish and maintain strategic collaborations, licensing or other agreements and the financial terms of such agreements; Å—the extent to which we in-license or acquire rights to other products, product candidates or technologies; and Å—the costs and timing of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against any intellectual property-related claims. Å Further, our operating results may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans. Until such time, if ever, that we can generate product revenue sufficient to achieve profitability, we expect to finance our cash needs through a combination of equity offerings, debt financings, grant awards, collaboration agreements, other third-party funding, strategic alliances, licensing arrangements and marketing and distribution arrangements. Å 36 Å We currently have no credit facility or committed sources of capital. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through other third-party funding, collaboration agreements, strategic alliances, licensing arrangements or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our biologic drug development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves. Å In order to meet our operational goals, we will need to obtain additional capital, which we will likely obtain through a variety of means, including through public or private equity, debt financings or other sources, including up-front payments and milestone payments from strategic collaborations. To the extent that we raise additional capital through the sale of convertible debt or equity securities, current stockholder ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. Such financing may result in dilution to stockholders, and may result in imposition of debt covenants, increased fixed payment obligations or other restrictions that may affect our business. If we raise additional funds through up-front payments or milestone payments pursuant to strategic collaborations with third parties, we may have to relinquish valuable rights to our product candidates, or grant licenses on terms that are not favorable to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Å Contractual Obligations and Commitments Å As of June 30, 2024, we have \$1.7 million in operating lease obligations and \$0 million in contract research organization obligations due to the termination of our active master services agreements with third parties that were previously engaged to conduct its clinical trials and manage clinical research programs and clinical development services. This termination was due to the Company’s decision to discontinue trial activities in Japan. We enter into contracts in the normal course of business with third-party contract organizations for clinical trials, preclinical studies, manufacturing and other services and products for operating purposes. These contracts generally provide for termination following a certain period after notice and therefore we believe that our non-cancelable obligations under these agreements are not material. Å We have not included milestone or royalty payments or other contractual payment obligations if the timing and amount of such obligations are unknown or uncertain. Å Critical Accounting Estimates Å For a discussion of our critical accounting estimates, refer to “Management’s Discussion and Analysis of Results of Operations and Financial Condition” in Part II, Item 7 and the notes to our financial statements in Part II, Item 8 of our 2023 Form 10-K. See also Note 1 to the condensed financial statements. There have been no material changes to our critical accounting estimates since the filing of our 2023 Form 10-K. Å 37 Å Emerging Growth Company Status Å We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act, or JOBS Act, which is a law intended to encourage funding of small businesses in the U.S. by easing many of the country’s securities regulations, and we may take advantage of reduced reporting requirements that are otherwise applicable to public companies. Section 107 of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with those standards. We have elected to take advantage of the extended transition period for complying with new or revised accounting standards; and as a result of this election, our condensed financial statements may not be comparable to companies that comply with public company effective dates. The JOBS Act also exempts us from having to provide an auditor attestation of internal control over financial reporting under Sarbanes-Oxley Act Section 404(b). Å We will remain an “emerging growth company” until the earliest of (1) the last day of the fiscal year in which we have total annual gross revenues of \$1.07 billion or more, (2) the last day of the fiscal year following the fifth anniversary of the completion of our IPO, (3) the date on which we have issued more than \$1.0 billion in nonconvertible debt during the previous three years or (4) the date on which we are deemed to be a large accelerated filer under the rules of the SEC, which generally is when a company has more than \$700 million in market value of its reported class of stock held by non-affiliates and has been a public company for at least 12 months and have filed at least one Annual Report on Form 10-K. Å Recent Accounting Pronouncements Å A description of recent accounting pronouncements that may potentially impact our financial position, results of operations or cash flows is disclosed in Note Å 2 to our unaudited condensed financial statements included in Item 1 of this 10-Q. Å Item Å 3. Quantitative and Qualitative Disclosures About Market Risk Å There were no material changes in our exposure to market risk since the disclosure included in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our 2023 10-K. Å Item Å 4. Controls and Procedures Å Disclosure controls and procedures Å Our management, under the supervision of and with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were effective. Å Changes in internal control over financial reporting Å There were no changes in our internal control over financial reporting that occurred during the fiscal quarter ended June 30, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Å 38 Å PART II. OTHER INFORMATION Å Item 1. Legal Proceedings Å From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. As of June 30, 2024, the Company is not aware of any legal proceedings or material developments requiring disclosure. Å Item 1A. Risk Factors. Å There have been no material changes to the risk factors affecting the Company from those disclosed in the 2023 10-K. Å Item Å 2. Unregistered Sales of Equity Securities and Use of Proceeds. Å ISSUER PURCHASES OF EQUITY SECURITIES Å Period Å Total Number of Shares Å Purchased (a) Å Average Price Paid per Share (or Unit) (b) Å Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (c) Å Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (d) Å April 1-30, 2024 Å 1,145A Å \$2.89A Å Å Å Å Å Å Å Å Å Å Å Å Å Å Å May 1-31, 2024 Å 287A Å 1.34A Å Å Å Å Å June 1-30, 2024 Å 325A Å 1.04A Å Å Å Å Å Total Å 1,757A Å \$2.29A Å Å Å Å (a) Includes shares withheld from employees to satisfy minimum tax withholding obligations associated with the vesting of restricted stock and performance stock units during the period. Å Item 3. Defaults Upon Senior Securities Å None. Å Item 4. Mine Safety Disclosures Å Not applicable. Å Item 5. Other Information Å Trading Arrangements Å None of the Company’s directors or officers, as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), adopted, modified, or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K, during the Company’s fiscal quarter ended June 30, 2024. Å 39 Å Å Item Å 6. Exhibits. Å Exhibit Å No. Å Description Å 3.1 Certificate of Incorporation of Longeveron Inc., incorporated by reference to Exhibit 3.1 to the Registrant’s Annual Report on Form 10-K filed on March 30, 2021 Å 3.2 Certificate of Amendment to Certificate of Incorporation of Longeveron Inc., incorporated by reference to Exhibit 3.1(a) to the Registrant’s Current Report on Form 8-K filed March 19, 2024 Å 4.1 Form of Pre-Funded Warrant, incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed April 11, 2024 Å 4.2 Form of Common Warrant, incorporated by reference to Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed April 11, 2024 Å 4.3 Form of Placement Agent Warrant, incorporated by reference to Exhibit 4.3 to the Registrant’s Current Report on Form 8-K filed April 11,

Sarbanes-Oxley Act of 2002. Â Â 32.1 Â Certification of principal executive officer, and principal financial officer, pursuant to 18 U.S.C. SectionÂ 1350, adopted pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002. Â Â 101.INS Â Inline XBRL Instance Document Â Â 101.SCH Â Inline XBRL Taxonomy Extension Schema Document Â Â 101.CAL Â Inline XBRL Taxonomy Extension Calculation Linkbase Document Â Â 101.DEF Â Inline XBRL Taxonomy Extension Definition Linkbase Document Â Â 101.LAB Â Inline XBRL Taxonomy Extension Label Linkbase Document Â Â 101.PRE Â Inline XBRL Taxonomy Extension Presentation Linkbase Document Â Â 104 Â Inline Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) * Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish copies of any of the omitted schedules upon request by the SEC. Â 41 Â Â SIGNATURES Â Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Â Â LONGEVERON INC. Â Â Date: August 14, 2024 /s/ Waâ€™el Hashad Â Mohamed Waâ€™el Ahmed Hashad Â Chief Executive Officer Â (principal executive officer) Â Date: August 14, 2024 /s/ Lisa A. Locklear Â Lisa A. Locklear Â Executive Vice President and Chief Financial Officer Â (principal financial and accounting officer) Â 42 Â Â 1.83 2.67 3.54 4.88 2106973 2110544 4511734 6509881 P24Y fllse --12-31 Q2 0001721484 0001721484 2024-01-01 2024-06-30 0001721484 us-gaap:CommonClassAMember 2024-08-14 0001721484 us-gaap:CommonClassBMember 2024-08-14 0001721484 2024-06-30 0001721484 us-gaap:CommonClassAMember 2023-12-31 0001721484 us-gaap:CommonClassAMember 2024-06-30 0001721484 us-gaap:CommonClassAMember 2023-12-31 0001721484 us-gaap:CommonClassBMember 2023-12-31 0001721484 us-gaap:CommonClassBMember 2024-06-30 0001721484 us-gaap:CommonClassBMember 2023-12-31 0001721484 lgvn:ClinicalTrialRevenueMember 2024-04-01 2024-06-30 0001721484 lgvn:ClinicalTrialRevenueMember 2023-04-01 2023-06-30 0001721484 lgvn:ClinicalTrialRevenueMember 2024-01-01 2024-06-30 0001721484 lgvn:ClinicalTrialRevenueMember 2023-01-01 2023-06-30 0001721484 lgvn:ContractManufacturingRevenueMember 2024-04-01 2024-06-30 0001721484 lgvn:ContractManufacturingRevenueMember 2023-04-01 2023-06-30 0001721484 lgvn:ContractManufacturingRevenueMember 2024-01-01 2024-06-30 0001721484 lgvn:ContractManufacturingRevenueMember 2023-01-01 2023-06-30 0001721484 lgvn:GrantRevenueMember 2024-01-01 2024-06-30 0001721484 lgvn:GrantRevenueMember 2023-01-01 2023-06-30 0001721484 2024-04-01 2024-06-30 0001721484 2023-04-01 2023-06-30 0001721484 2023-01-01 2023-06-30 0001721484 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-12-31 0001721484 us-gaap:CommonStockMember 2023-12-31 0001721484 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001721484 us-gaap:RetainedEarningsMember 2023-12-31 0001721484 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001721484 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001721484 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001721484 us-gaap:ReceivablesFromStockholderMember 2024-01-01 2024-06-30 0001721484 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001721484 us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0001721484 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-06-30 0001721484 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001721484 us-gaap:RetainedEarningsMember 2024-06-30 0001721484 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001721484 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-12-31 0001721484 us-gaap:ReceivablesFromStockholderMember 2022-12-31 0001721484 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001721484 us-gaap:RetainedEarningsMember 2022-12-31 0001721484 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001721484 2022-12-31 0001721484 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001721484 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001721484 us-gaap:ReceivablesFromStockholderMember 2023-01-01 2023-06-30 0001721484 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001721484 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-06-30 0001721484 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-06-30 0001721484 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-06-30 0001721484 us-gaap:ReceivablesFromStockholderMember 2023-06-30 0001721484 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001721484 us-gaap:RetainedEarningsMember 2023-06-30 0001721484 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001721484 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-03-31 0001721484 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2024-03-31 0001721484 us-gaap:ReceivablesFromStockholderMember 2024-03-31 0001721484 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001721484 us-gaap:RetainedEarningsMember 2024-03-31 0001721484 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001721484 2024-03-31 0001721484 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001721484 us-gaap:ReceivablesFromStockholderMember 2024-04-01 2024-06-30 0001721484 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001721484 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001721484 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001721484 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-03-31 0001721484 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-03-31 0001721484 us-gaap:ReceivablesFromStockholderMember 2023-03-31 0001721484 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001721484 us-gaap:RetainedEarningsMember 2023-03-31 0001721484 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001721484 2023-03-31 0001721484 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001721484 us-gaap:ReceivablesFromStockholderMember 2023-04-01 2023-06-30 0001721484 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001721484 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001721484 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001721484 srt:MinimumMember us-gaap:FiniteLivedIntangibleAssetsMember 2024-06-30 0001721484 srt:MaximumMember us-gaap:FiniteLivedIntangibleAssetsMember 2024-06-30 0001721484 srt:MinimumMember us-gaap:FiniteLivedIntangibleAssetsMember 2024-06-30 0001721484 us-gaap:FiniteLivedIntangibleAssetsMember 2024-06-30 0001721484 lgvn:AccountsReceivableFromCustomersMember 2024-06-30 0001721484 lgvn:AccountsReceivableFromCustomersMember 2023-12-31 0001721484 lgvn:NationalInstitutesOfHealthGrantMember 2024-06-30 0001721484 lgvn:NationalInstitutesOfHealthGrantMember 2023-12-31 0001721484 lgvn:ContractManufacturingMember 2024-04-01 2024-06-30 0001721484 lgvn:ContractManufacturingMember 2023-01-01 2023-06-30 0001721484 lgvn:ContractManufacturingMember 2023-01-01 2023-06-30 0001721484 lgvn:NationalInstitutesOfHealthGrantMember 2024-04-01 2024-06-30 0001721484 lgvn:NationalInstitutesOfHealthGrantMember 2023-04-01 2023-06-30 0001721484 lgvn:NationalInstitutesOfHealthGrantMember 2024-01-01 2024-06-30 0001721484 lgvn:NationalInstitutesOfHealthGrantMember 2023-01-01 2023-06-30 0001721484 us-gaap:AllOtherCorporateBondsMember us-gaap:FairValueInputsLevel1Member 2024-06-30 0001721484 us-gaap:AllOtherCorporateBondsMember us-gaap:FairValueInputsLevel2Member 2024-06-30 0001721484 us-gaap:AllOtherCorporateBondsMember us-gaap:FairValueInputsLevel3Member 2024-06-30 0001721484 us-gaap:AllOtherCorporateBondsMember 2024-06-30 0001721484 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2024-06-30 0001721484 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2024-06-30 0001721484 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2024-06-30 0001721484 us-gaap:MoneyMarketFundsMember 2024-06-30 0001721484 us-gaap:AccruedIncomeReceivableMember us-gaap:FairValueInputsLevel1Member 2024-06-30 0001721484 us-gaap:AccruedIncomeReceivableMember us-gaap:FairValueInputsLevel2Member 2024-06-30 0001721484 us-gaap:AccruedIncomeReceivableMember us-gaap:FairValueInputsLevel3Member 2024-06-30 0001721484 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001721484 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001721484 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001721484 us-gaap:LeaseholdImprovementsMember 2024-06-30 0001721484 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001721484 us-gaap:FurnitureAndFixturesMember 2024-06-30 0001721484 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001721484 us-gaap:ComputerEquipmentMember 2024-06-30 0001721484 us-gaap:ComputerEquipmentMember 2023-12-31 0001721484 us-gaap:SoftwareDevelopmentMember 2024-06-30 0001721484 us-gaap:SoftwareDevelopmentMember 2023-12-31 0001721484 us-gaap:LicensingAgreementsMember 2024-06-30 0001721484 us-gaap:PatentsMember 2024-06-30 0001721484 us-gaap:TrademarksMember 2024-06-30 0001721484 us-gaap:LicensingAgreementsMember 2023-12-31 0001721484 us-gaap:PatentsMember 2023-12-31 0001721484 us-gaap:TrademarksMember 2023-12-31 0001721484 srt:MaximumMember 2023-12-31 0001721484 us-gaap:CommonClassAMember 2024-01-01 2024-06-30 0001721484 us-gaap:CommonClassBMember 2024-01-01 2024-06-30 0001721484 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001721484 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001721484 us-gaap:WarrantMember us-gaap:CommonClassAMember 2024-06-30 0001721484 us-gaap:CommonClassAMember us-gaap:IPOMember 2024-06-30 0001721484 us-gaap:WarrantMember lgvn:UnderwritersMember 2021-12-31 0001721484 us-gaap:WarrantMember 2024-06-30 0001721484 us-gaap:WarrantMember lgvn:TwoThousandTwentyOnePIPEOfferingMember 2024-06-30 0001721484 lgvn:TwoThousandTwentyOnePIPEOfferingMember 2024-06-30 0001721484 us-gaap:CommonClassAMember lgvn:TwoThousandTwentyOnePIPEOfferingMember 2024-06-30 0001721484 us-gaap:ValuationTechniqueConsensusPricingModelMember 2023-08-16 0001721484 us-gaap:ValuationTechniqueConsensusPricingModelMember 2023-08-16 2023-08-16 0001721484 us-gaap:SeriesAMember lgvn:October2023RegisteredDirectOfferingMember 2024-06-30 0001721484 us-gaap:SeriesBMember lgvn:October2023RegisteredDirectOfferingMember 2024-06-30 0001721484 us-gaap:SeriesAMember lgvn:October2023RegisteredDirectOfferingMember 2024-06-30 0001721484 us-gaap:SeriesBMember lgvn:October2023RegisteredDirectOfferingMember 2024-06-30 0001721484 us-gaap:CommonClassAMember 2024-06-30 0001721484 lgvn:PlacementAgentWarrantsMember us-gaap:CommonClassAMember 2024-06-30 0001721484 lgvn:SeriesAAndSeriesBWarrantsMember 2024-04-30 0001721484 us-gaap:CommonClassAMember lgvn:December2023OfferingMember 2024-06-30 0001721484 lgvn:UnderwritersWarrantsMember lgvn:December2023OfferingMember 2024-06-30 0001721484 us-gaap:CommonClassAMember us-gaap:IPOMember 2024-04-08 0001721484 lgvn:PreFundedWarrantMember us-gaap:CommonClassAMember 2024-04-08 0001721484 lgvn:CommonWarrantsMember us-gaap:CommonStockMember 2024-04-08 0001721484 lgvn:CommonWarrantsMember 2024-04-08 0001721484 lgvn:PreFundedWarrantMember 2024-04-08 0001721484 lgvn:CommonWarrantsMember 2024-06-30 0001721484 lgvn:SeriesAAndSeriesBWarrantsMember 2024-06-30 0001721484 us-gaap:SeriesAMember 2024-06-30 0001721484 us-gaap:SeriesBMember 2024-06-30 0001721484 us-gaap:WarrantMember 2024-01-01 2024-06-30 0001721484 us-gaap:WarrantMember 2024-04-16 0001721484 us-gaap:WarrantMember us-gaap:CommonClassAMember 2024-04-16 2024-04-16 0001721484 lgvn:ClassACommonStockWarrantsMember us-gaap:CommonClassAMember 2024-04-16 0001721484 lgvn:SeriesCWarrantsMember us-gaap:CommonClassAMember 2024-04-16 0001721484 lgvn:SeriesCWarrantsMember 2024-04-16 0001721484 lgvn:SeriesDWarrantsMember us-gaap:CommonClassAMember 2024-04-16 0001721484 lgvn:SeriesDWarrantsMember 2024-04-16 0001721484 lgvn:SeriesDWarrantsMember 2024-06-30 0001721484 lgvn:SeriesDWarrantsMember us-gaap:CommonClassAMember 2024-01-01 2024-06-30 0001721484 lgvn:SeriesDWarrantsMember us-gaap:CommonClassAMember 2024-06-17 0001721484 us-gaap:CommonClassAMember 2024-06-17 0001721484 lgvn:PlacementAgentWarrantsMember us-gaap:CommonClassAMember 2024-01-01 2024-06-30 0001721484 us-gaap:CommonStockMember 2024-06-30 0001721484 lgvn:SeriesDWarrantsMember us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001721484 us-gaap:CommonClassAMember 2024-01-01 2024-06-30 0001721484 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0001721484 srt:MinimumMember 2024-01-01 2024-06-30 0001721484 srt:MaximumMember 2024-01-01 2024-06-30 0001721484 srt:MaximumMember 2024-01-01 2024-06-30 0001721484 srt:MinimumMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001721484 srt:MaximumMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001721484 us-gaap:StockOptionMember 2024-04-01 2024-06-30 0001721484 us-gaap:StockOptionMember 2023-04-01 2023-06-30 0001721484 us-gaap:StockOptionMember us-gaap:CommonClassAMember 2024-04-30 0001721484 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonClassAMember 2024-04-30 0001721484 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001721484 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001721484 us-gaap:StockOptionMember 2024-06-30 0001721484 us-gaap:StockOptionMember 2023-12-31 0001721484 us-gaap:StockOptionMember 2024-01-01 2024-06-30 0001721484 2014-11-20 2014-11-20 0001721484 2022-11-16 2022-11-16 2022-11-16 0001721484 2022-11-16 0001721484 lgvn:ChiefScienceOfficerMember 2024-06-30 0001721484 lgvn:ChiefScienceOfficerMember 2023-12-31 0001721484 lgvn:TechnologyServicesAgreementMember 2024-06-30 0001721484 lgvn:TechnologyServicesAgreementMember 2023-12-31 0001721484 2014-11-20 0001721484 us-gaap:LicenseMember 2021-01-01 2021-12-31 0001721484 us-gaap:CommonClassAMember 2014-11-20 0001721484 us-gaap:LicenseMember 2024-01-01 2024-06-30 0001721484 lgvn:UMAgreementsMember 2024-01-01 2023-12-31 0001721484 lgvn:LongeveronMember 2024-01-01 2024-06-30 0001721484 lgvn:FirstPhase3ClinicalTrialMember 2014-11-20 2014-11-20 0001721484 lgvn:BiologicsLicenseMember 2014-11-20 2014-11-20 0001721484 2016-12-16 2016-12-22 0001721484 2016-12-23 0001721484 lgvn:SeriesCUnitsMember 2016-12-23 2016-12-23 2016-12-23 0001721484 2016-12-23 0001721484 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001721484 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001721484 us-gaap:PhantomShareUnitsPSUMember 2024-01-01 2024-06-30 0001721484 us-gaap:PhantomShareUnitsPSUMember 2024-01-01 2024-06-30 0001721484 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001721484 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001721484 us-gaap:WarrantMember 2024-01-01 2024-06-30 0001721484 us-gaap:WarrantMember 2023-01-01 2023-06-30 0001721484 lgvn:SeriesCWarrantsMember us-gaap:SubsequentEventMember 2024-07-10 0001721484 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2024-07-10 0001721484 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2024-07-17 2024-07-17 0001721484 us-gaap:SubsequentEventMember 2024-07-17 2024-07-17 0001721484 us-gaap:SubsequentEventMember 2024-07-17 0001721484 us-gaap:SubsequentEventMember 2024-07-10 0001721484 us-gaap:SubsequentEventMember us-gaap:NoteWarrantMember 2024-07-17 2024-07-17 0001721484 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2024-07-24 2024-07-24 0001721484 us-gaap:WarrantMember us-gaap:NoteWarrantMember 2024-01-01 2024-06-30 0001721484 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2024-07-18 2024-07-18 0001721484 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2024-07-18 0001721484 us-gaap:SubsequentEventMember 2024-07-19 2024-07-19 0001721484 lgvn:SeriesBWarrantsMember 2024-01-01 2024-06-30 0001721484 2024-08-06 0001721484 lgvn:JulyPrivatePlacementMember 2024-08-06 2024-08-06 0001721484 lgvn:JulyOfferingPlacementMember 2024-08-06 2024-08-06 0001721484 lgvn:JulyOrdinaryCoursePlacementAgentMember 2024-08-06 2024-08-06 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure EX-31.1 2 ea0211041ex31-1 longeveron.htm CERTIFICATION Exhibit 31.1 Â Rule 13a-14(a)(15)(d)-14(a) Certifications Â I, Mohamed Waâ€™el Ahmed Hashad, certify that: Â 1.I have reviewed this quarterly report on Form 10-Q of Longeveron Inc.; Â 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4.The registrantâ€™s other certifying officer and I are responsible for establishing and

maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting. 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. 6. /s/ Waaf el Hashad A Mohamed Waaf el Ahmed Hashad A Chief Executive Officer Date: August 14, 2024 7. EX-31.2 3 ea0211041ex31-2_longeveron.htm CERTIFICATION Exhibit 31.2 Rule 13a-14(a)(15)(d)-14(a) Certifications A I, Lisa A. Locklear, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Longeveron Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. 7. /s/ Lisa A. Locklear A Lisa A. Locklear A Executive Vice President and Chief Financial Officer Date: August 14, 2024 8. EX-32.1 4 ea0211041ex32-1_longeveron.htm CERTIFICATION Exhibit 32.1 A SECTION 1350 CERTIFICATION A Pursuant to the requirement set forth in Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934, as amended, and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Mohamed Waaf el Ahmed Hashad, Chief Executive Officer (principal executive officer) of Longeveron Inc. (the "Company"), and Lisa A. Locklear, the Chief Financial Officer (principal financial officer) of the Company, each hereby certifies that, to his knowledge on the date hereof: (a) The Quarterly Report on Form 10-Q of the Company for the period ended June 30, 2024 filed on the date hereof with the Securities and Exchange Commission (the "Quarterly Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and (b) The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the period covered by the Quarterly Report. A This certification shall not be deemed to be filed with the Securities and Exchange Commission and shall not be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Quarterly Report), irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained and furnished to the Securities and Exchange Commission or its staff upon request. 8. /s/ Waaf el Hashad A Mohamed Waaf el Ahmed Hashad A Chief Executive Officer A (Principal Executive Officer) A August 14, 2024 9. /s/ Lisa A. Locklear A Lisa A. Locklear A Executive Vice President and Chief Financial Officer A (Principal Financial Officer) A August 14, 2024 10. EX-101.SCH 5 lgvn-20240630.xsd XBRL SCHEMA FILE 995301 - Statement - Condensed Balance Sheets link:presentationLink link:definitionLink link:calculationLink 995302 - Statement - Condensed Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 995303 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 995304 - Statement - Condensed Statements of Operations (Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 995305 - Statement - Condensed Statements of Comprehensive Loss (Unaudited) link:presentationLink link:definitionLink link:calculationLink 995306 - Statement - Condensed Statements of Stockholders' Equity (Unaudited) link:presentationLink link:definitionLink link:calculationLink 995307 - Statement - Condensed Statements of Stockholders' Equity (Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 995308 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 995309 - Disclosure - Nature of Business, Basis of Presentation, and Liquidity link:presentationLink link:definitionLink link:calculationLink 995310 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 995311 - Disclosure - Marketable Securities link:presentationLink link:definitionLink link:calculationLink 995312 - Disclosure - Property and Equipment, Net link:presentationLink link:definitionLink link:calculationLink 995313 - Disclosure - Intangible Assets, Net link:presentationLink link:definitionLink link:calculationLink 995314 - Disclosure - Leases link:presentationLink link:definitionLink link:calculationLink 995315 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 995316 - Disclosure - Equity-Based Compensation link:presentationLink link:definitionLink link:calculationLink 995317 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 995318 - Disclosure - Employee Benefits Plan link:presentationLink link:definitionLink link:calculationLink 995319 - Disclosure - Loss Per Share link:presentationLink link:definitionLink link:calculationLink 995320 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 996000 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 996001 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 996002 - Disclosure - Marketable Securities (Tables) link:presentationLink link:definitionLink link:calculationLink 996003 - Disclosure - Property and Equipment, Net (Tables) link:presentationLink link:definitionLink link:calculationLink 996004 - Disclosure - Intangible Assets, Net (Tables) link:presentationLink link:definitionLink link:calculationLink 996005 - Disclosure - Leases (Tables) link:presentationLink link:definitionLink link:calculationLink 996006 - Disclosure - Equity-Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 996007 - Disclosure - Loss Per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 996008 - Disclosure - Nature of Business, Basis of Presentation, and Liquidity (Details) link:presentationLink link:definitionLink link:calculationLink 996009 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 996010 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 996011 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 996012 - Disclosure - Marketable Securities (Details) link:presentationLink link:definitionLink link:calculationLink 996013 - Disclosure - Marketable Securities (Details) link:presentationLink link:definitionLink link:calculationLink 996014 - Disclosure - Property and Equipment, Net (Details) link:presentationLink link:definitionLink link:calculationLink 996015 - Disclosure - Property and Equipment, Net (Details) link:presentationLink link:definitionLink link:calculationLink 996016 - Disclosure - Intangible Assets, Net (Details) link:presentationLink link:definitionLink link:calculationLink 996017 - Disclosure - Intangible Assets, Net (Details) link:presentationLink link:definitionLink link:calculationLink 996018 - Disclosure - Intangible Assets, Net (Details) link:presentationLink link:definitionLink link:calculationLink 996019 - Disclosure - Leases (Details) link:presentationLink link:definitionLink link:calculationLink 996020 - Disclosure - Leases (Details) link:presentationLink link:definitionLink link:calculationLink 996021 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:definitionLink link:calculationLink 996022 - Disclosure - Equity-Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 996023 - Disclosure - Equity-Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 996024 - Disclosure - Equity-Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 996025 - Disclosure - Equity-Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 996026 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 996027 - Disclosure - Employee Benefits Plan (Details) link:presentationLink link:definitionLink link:calculationLink 996028 - Disclosure - Loss Per Share (Details) link:presentationLink link:definitionLink link:calculationLink 996029 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 6 lgvn-20240630_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 lgvn-20240630_def.xml XBRL DEFINITION FILE EX-101.LAB 8 lgvn-20240630_lab.xml XBRL LABEL FILE Rule 10b51 ArrModified Flag Non-Rule 10b51 ArrModified Flag Class of Stock [Axis] Total current assets Total assets Total current liabilities Total long-term liabilities Total liabilities Total stockholders' equity Balance Balance Total liabilities and stockholders' equity Product and Service [Axis] Gross profit Total operating expenses Loss from operations Total other income, net Net loss Net loss Net loss attributable to common stockholders Total comprehensive loss Balance (in Shares) Balance (in Shares) Equity Components [Axis] Net cash used in operating activities Net cash (used in) provided by investing activities Net cash provided by (used in) financing activities Change in cash and cash equivalents Cash and cash equivalents at beginning of the period Cash and cash equivalents at end of the period Nature of Business, Basis of Presentation, and Liquidity [Abstract] Summary of Significant Accounting Policies [Abstract] Receivable Type [Axis] Marketable Securities [Abstract] Cash and Cash Equivalents [Axis] Fair Value Hierarchy and NAV [Axis] Property and Equipment, Net [Abstract] Long-Lived Tangible Asset [Axis] Property and equipment, net Property and equipment, net Intangible Assets, Net [Abstract] Finite-Lived Intangible Assets by Major Class [Axis] Schedule of Future Amortization Expense for Intangible Assets [Abstract] Total Leases [Abstract] Schedule of Future Minimum Payments Under the Operating Leases [Abstract] Total Stockholders' Equity [Abstract] Equity-Based Compensation [Abstract] Outstanding (unvested) at December 31, 2023 Outstanding (unvested) at June 30, 2024 Unvested shares (in Shares) Total stock options outstanding Number of Stock Options, Outstanding at Beginning Number of Stock Options, Outstanding at ending Stock option issued and outstanding (in Shares) Derivative Instrument [Axis] Weighted Average Exercise Price, Outstanding at Beginning Weighted Average Exercise Price, Outstanding at ending Exercise price (in Dollars per share) Commitments and Contingencies [Abstract] Employee Benefits Plan [Abstract] Loss Per Share [Abstract] Antidilutive Securities [Axis] Subsequent Events [Abstract] Assets Current assets: Cash and cash equivalents Marketable securities Prepaid expenses and other current assets Accounts and grants receivable Intangible assets, net Total Operating lease asset Other assets Liabilities and stockholders' equity Current liabilities: Accounts payable Accrued expenses Current portion of lease liability Deferred revenue Long-term liabilities: Lease liability Other liabilities Commitments and contingencies (Note 9) Stockholders' equity: Preferred stock, \$0.001 par value per share, 5,000,000 shares authorized, no shares issued and outstanding at June 30, 2024, and December 31, 2023. Preferred stock, par value (in Dollars per share) Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock value Common stock, par value (in Dollars per share) Price per share (in Dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Additional paid-in capital Accumulated deficit Accumulated other comprehensive loss Revenues Total revenues Total revenue Cost of revenues Operating expenses General and administrative Research and development Other income and (expenses) Other income, net Basic net loss per share (in Dollars per share) Diluted net loss per share Basic weighted average common shares outstanding (in Shares) Diluted weighted average common shares outstanding Other comprehensive loss: Net unrealized (loss) gain on available-for-sale securities Conversion of Class B common stock for Class A common stock (in Shares) Stockholders shares converted Class A common stock, issued for RSUs vested Class A common stock, issued for RSUs vested (in Shares) Class A common stock, held for taxes on RSUs vested Class A common stock, held for taxes on PSUs vested (in Shares) Class A common stock, issued for PSUs vested (in Shares) Class A common stock, held for taxes on PSUs vested Class A common stock, held for taxes on PSUs vested (in Shares) Collection of stock subscription receivable Equity-based compensation Unrealized gain attributable to change in market value of available for sale investments Class A common stock issued in public offering, net of issuance cost of \$1.145 Class A common stock issued in public offering, net of issuance costs Class A common stock issue for warrants exercised, net of issuance cost of \$1,359 Class A common stock issue for warrants exercised, net of issuance cost of \$1,359 (in Shares) Number of Stock Options, Options exercised Class A common stock issued for warrants exercised, net of issuance costs Deemed dividend â€" warrant inducement offers Reverse stock split rounding adjustment Reverse stock split rounding adjustment (in Shares) Reverse stock split Conversion of Units into Class A and B common stock Conversion of Units into Class A and B common stock (in Shares) Cash flows from operating activities Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Equity-based compensation Changes in operating assets and liabilities: Accounts payable Deferred revenue Nonoperating lawsuit liability Accrued expenses Other liabilities Cash flows from investing activities Proceeds from the sale of marketable securities Cash flows from financing activities Proceeds from the issuance of common stock, net of issuance cost Proceeds from warrants exercised, net of issuance cost Proceeds from stock subscription receivable Supplement Disclosure of Non-cash Investing and Financing Activities: Vesting of RSUs and PSUs into Class A common stock Deemed dividend â€" warrant inducement offers Deemed dividend â€" warrant inducement offers Offering costs in accrued expenses Stock subscription receivable Conversion of Class B common stock for Class A common stock Interest earned on marketable securities Accounts and grants receivable Prepaid expenses and other current assets Other assets Operating lease asset and lease liability Acquisition of property and equipment Acquisition of intangible assets Payments for taxes on RSUs vested Class A Common Stock Class A Class A Common Stock [Member] Class A Common Stock [Member] Class B Common Stock Class B common stock Class B Class B Common Stock [Member] Clinical trial revenue Clinical trial revenue [Member] Contract manufacturing revenue Grant revenue Common Stock Common Stock [Member] Subscription Receivable Additional Paid-In Capital Accumulated Deficit Accumulated Other Comprehensive Gain (Loss) Nature of Business, Basis of Presentation, and Liquidity Summary of Significant Accounting Policies Schedule of Accounts and Grants Receivable Schedule of Revenue Marketable securities Schedule of Marketable Securities Marketable Securities Property and equipment, net Schedule of Major Components of Property and Equipment Property and Equipment, Useful Lives Total Property and Equipment Less accumulated depreciation and amortization Intangible assets, net Schedule of Major Components of Intangible Assets Useful Lives Intangible assets estimated useful life Cost Schedule of Future Amortization Expense for Intangible Assets 2024 (remaining six months) 2025 2026 2027 2028 Thereafter Leases Schedule of Future Minimum Payments Under the Operating Leases 2024 (remaining six months) 2025 2026 2027 Less: Interest

Present value of operating lease liability Operating lease liability Stockholders' Equity Equity-based compensation Schedule of RSU Activity RSU granted Schedule of Issued and Outstanding Options Stock options vested (based on ratable vesting) Stock options unvested Schedule of Stock Option Activity Number of Stock Options, Options granted Weighted Average Exercise Price, Options granted Weighted Average Exercise Price, Options exercised Commitments and Contingencies Employee Benefits Plan Loss Per Share Schedule of Diluted Net Loss per Share Total Subsequent Events Accumulated Amortization RSUs vested RSU expired/forfeited Number of Stock Options, Options expired/forfeited Weighted Average Exercise Price, Options expired/forfeited Accounts receivable from customers [Member] National Institutes of Health &c Grant [Member] NIH - grant [Member] Contract manufacturing [Member] Corporate bonds [Member] Money market funds [Member] Accrued income [Member] Level 1 [Member] Level 2 [Member] Level 3 [Member] Leasehold Improvements [Member] Furniture Lab Equipment [Member] Computer Equipment [Member] Software Website [Member] License agreements [Member] Patent costs [Member] Trademark costs [Member] Restricted Stock Units (RSUs) [Member] RSUs [Member] Stock Option [Member] PSUs [Member] Stock options [Member] Warrants [Member] Warrant [Member] Statistical Measurement [Axis] Asset Class [Axis] Class of Warrant or Right [Axis] Sale of Stock [Axis] Valuation Approach and Technique [Axis] Related Party Transaction [Axis] Title and Position [Axis] Related and Nonrelated Parties [Axis] Subsequent Event Type [Axis] Gross cash proceeds Net unrealized losses Deferred revenue Tax provision Options granted maximum term Accrued interest receivable related to marketable securities Depreciation and amortization expense Amortization expense related to intangible assets Lease costs Common stock voting rights Warrants to purchase Warrant purchase shares Number of warrants outstanding Warrant shares Warrants exercise price per share (in Dollars per share) Exercise price (in Dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) Warrant term Fair value of warrants (in Dollars) Payment per warrant (in Dollars per share) Percentage of aggregate number of shares Exercise of remaining shares Deemed dividend to common stockholders (in Dollars) Stock options exercisable term Stock option expiration term Share percentage Dividend yield Expected life Risk-free interest rate Equity-based compensation expense Unrecognized equity-based compensation Unrecognized equity-based compensation term General and administrative expenses Expenditures amount Issued RSUs shares (in Shares) Aggregate value Accrued expenses Accounts payable License fee Cash payment Agreement term Unregistered shares (in Shares) Milestone payment Payments to UM Milestone fees payable Reimbursement Annual royalty fee Completion of trial Annual net sales percentage Net sales of sub licensees percentage Initial fee paid Shares issued (in Shares) Company value amount License agreement amount Professional fees License agreement term Incurred term Award amount Company contributed amount Exercise price (in Dollars per share) Expire date Net proceeds (in Dollars) Public offering shares Aggregate shares Share issued Aggregate gross (in Dollars) Shares issuable (in Dollars) Basis of presentation Reverse Stock Split Use of estimates Accounting Standard Updates Cash and cash equivalents Marketable securities Accounts and grants receivable Deferred offering costs Property and equipment Intangible assets Impairment of Long-Lived Assets Deferred revenue Revenue recognition Research and development expense Concentrations of credit risk Income taxes Equity-based compensation Minimum [Member] Intangible Assets [Member] Finite-Lived Intangible Assets [Member] Maximum [Member] Public offering [Member] Underwriters [Member] 2021 private placement offering [Member] 2021 PIPE Offering [Member] Black-Scholes pricing model [Member] Series A warrants [Member] October 2023 registered direct offering [Member] Series B warrants [Member] Series B [Member] Placement agent warrants [Member] Series A and Series B Warrants [Member] December 2023 registered direct offering [Member] Underwriters Warrants [Member] Pre Funded Warrant [Member] Common Warrants [Member] Class A common stock warrants [Member] Series C warrants [Member] Series D Warrants [Member] Chief Science Officer [Member] Technology Services Agreement [Member] License [Member] UM License [Member] UM Agreements [Member] Longeveron [Member] First Phase 3 Clinical Trial [Member] Biologics license [Member] Series C Units [Member] Subsequent Event [Member] New Warrant Shares [Member] Series B Warrants [Member] July Private Placement [Member] July Offering Placement [Member] July Ordinary Course Placement Agent [Member] Class of Stock [Domain] Statement [Table] Statement [Line Items] Product and Service [Domain] Equity Component [Domain] Receivable [Domain] Accounts and Financing Receivables [Table] Schedule of Accounts and Grants Receivable [Line Items] Disaggregation of Revenue [Table] Schedule of Revenue [Line Items] Cash and Cash Equivalents [Domain] Fair Value Hierarchy and NAV [Domain] Marketable Securities [Table] Schedule of Marketable Securities [Line Items] Long-Lived Tangible Asset [Domain] Property, Plant and Equipment [Table] Schedule of Major Components of Property and Equipment [Line Items] Finite-Lived Intangible Assets, Major Class Name [Domain] Intangible Asset, Finite-Lived [Table] Schedule of Major Components of Intangible Assets [Line items] Award Type [Domain] Equity-Based Compensation (Details) - Schedule of RSU Activity [Table] Schedule of RSU Activity [Line Items] Derivative Contract [Domain] Equity-Based Compensation (Details) - Schedule of Issued and Outstanding Options [Table] Schedule of Issued and Outstanding Options [Line Items] Equity-Based Compensation (Details) - Schedule of Stock Option Activity [Table] Schedule of Stock Option Activity [Line Items] Antidilutive Securities, Name [Domain] Antidilutive Security, Excluded EPS Calculation [Table] Schedule of Diluted Net Loss per Share [Line Items] Asset Class [Domain] Statistical Measurement [Domain] Summary of Significant Accounting Policies (Details) [Table] Summary of Significant Accounting Policies [Line Items] Marketable Securities (Details) [Table] Marketable Securities [Line Items] Leases (Details) [Table] Leases [Line Items] Sale of Stock [Domain] Valuation Approach and Technique [Domain] Class of Warrant or Right [Domain] Stockholders' Equity (Details) [Table] Stockholders' Equity [Line Items] Related Party Transaction [Domain] Equity-Based Compensation (Details) [Table] Equity-Based Compensation [Line Items] Title and Position [Domain] Related and Nonrelated Parties [Domain] Commitments and Contingencies (Details) [Table] Commitments and Contingencies [Line Items] Subsequent Event Type [Domain] Subsequent Events (Details) [Table] Subsequent Events [Line Items] Annual net sales percentage, Class A common stock, issued for RSUs vested, Represent the amount of deemed dividend warrant inducement offers, Number of shares exercised, Incurred terms, Milestone fees Payable, Amount of milestone of triggering payments, Net sales of sub licensees, Amount of offering costs in a accrued expenses, Payment per warrant, Payments for taxes on RSUs vested, Percentage of aggregate number of shares, Amount of proceeds from stock subscription receivable, Disclosure of Reverse Stock Split, Period of expiration of stock options, Number of option right of use vested, Class A common stock, held for taxes on RSUs vested, Represent the amount of unrealized loss attributable to change in market value of available-for-sale securities, Amount of common stock issued for warrants exercised, net of issuance costs, Class A common stock, held for taxes on RSUs vested shares, Number of shares of stock issued for PSUs vested, Class A common stock, issued for RSUs vested shares, Terms of agreement, Amount of vesting of RSU and PSUs into class A common stock, Warrants to purchase, license agreement term, Assets [Abstract] July Offering Placement Member Other Comprehensive Loss Abstract Earnings Per Share, Diluted Liabilities, Noncurrent [Abstract] Stock Issued During Period Unrealized Loss Attributable To Change In Market Value Of Available For Sale Securities Underwriters Warrants Member Retained Earnings [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Weighted Average Number of Shares Outstanding, Basic Finite-Lived Intangible Assets, Net Reverse Stock Split Policy Text Block Warrants To Purchase Share Based Compensation Arrangement By Share Based Payment Stock Option Expiration Term Other Nonoperating Income (Expense) Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Accrued Income Receivable [Member] Valuation Technique, Consensus Pricing Model [Member] Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Finite-Lived Intangible Asset, Expected Amortization, after Year Five Deemed Dividend Warrant Inducement Offers Finite-Lived Intangible Asset, Expected Amortization, Year Two Stock Issued During Period, Shares, New Issues Goodwill and Intangible Assets, Policy [Policy Text Block] Other Assets, Noncurrent Additional Paid in Capital Operating Expenses [Abstract] Common Warrants Member UM Agreements Member Stock Issued During Period, Shares, Conversion of Units Net Cash Provided by (Used in) Operating Activities [Abstract] Royalty Expense Equity, Attributable to Parent [Abstract] Preferred Stock, Shares Issued Adjustments to Additional Paid in Capital, Stock Split Technology Services Agreement Member Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block] Minimum [Member] Common Stock, Shares, Outstanding Retained Earnings (Accumulated Deficit) Shares, Issued Lessee, Operating Lease, Liability, to be Paid, Year Three Net Cash Provided by (Used in) Investing Activities Payments for Other Fees Payments to Acquire Property, Plant, and Equipment Business Description and Basis of Presentation [Text Block] Stock Issues During Period Shares For PSUs Vested Marketable Securities Net Sales Of Sub Licensees Share-Based Payment Arrangement [Policy Text Block] Preferred Stock, Shares Authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Preferred Stock, Shares Outstanding Fair Value, Inputs, Level 2 [Member] Property, Plant and Equipment, Net Prepaid Expense and Other Assets, Current Increase (Decrease) in Accrued Liabilities Income Tax, Policy [Policy Text Block] Maximum [Member] Pre Funded Warrant Member Proceeds from License Fees Received Common Stock, Shares Authorized Operating Lease, Liability, Noncurrent Lease, Cost Concentration Risk, Credit Risk, Policy [Policy Text Block] Stock Issued During Period Class A Common Stock Held For Taxes On RSUs Vested December 2023 Offering Member Share-Based Payment Arrangement, Expense Increase (Decrease) in Operating Capital [Abstract] Net Cash Provided by (Used in) Financing Activities [Abstract] Additional Paid-in Capital [Member] Class of Warrant or Right, Number of Securities Called by Warrants or Rights Accounts Payable, Other Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Net Cash Provided by (Used in) Investing Activities [Abstract] Finite-Lived Intangible Asset, Expected Amortization, Year One Stockholders' Equity Note, Subscriptions Receivable Intangible Assets Disclosure [Text Block] Contract Manufacturing Member Proceeds from Issuance of Debt Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Depreciation, Depletion and Amortization, Nonproduction Increase (Decrease) in Other Operating Assets Significant Accounting Policies [Text Block] Milestone Fees Payable Conversion of Stock, Amount Converted Stock Issued During Period, Shares, Reverse Stock Splits AOCI Attributable to Parent [Member] Schedule of Finite-Lived Intangible Assets [Table Text Block] Property, Plant and Equipment, Useful Life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Lessee, Operating Lease, Liability, to be Paid, Year Two Comprehensive Income (Loss), Net of Tax, Attributable to Parent Property, Plant and Equipment, Other, Accumulated Depreciation Fair Value, Inputs, Level 3 [Member] Non Rule 10b51 Arr Modified Flag Percentage Of Aggregate Number Of Shares Net Cash Provided by (Used in) Operating Activities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Trademarks [Member] Finite-Lived Intangible Assets [Member] Incurred Terms Receivable [Policy Text Block] Warrant, Exercise Price, Increase Patents [Member] Equity Option [Member] Stock Issued During Period, Shares, Other Payments of Stock Issuance Costs Other Accrued Liabilities, Noncurrent Fair Value, Inputs, Level 1 [Member] Sharebased Compensation Arrangement By Share Based Payment Award Options RSUs Vested Series B [Member] Finite-Lived Intangible Assets, Gross Equity, Attributable to Parent Accumulated Other Comprehensive Income (Loss), Net of Tax Computer Equipment [Member] Other Expenses Property, Plant and Equipment, Policy [Policy Text Block] Furniture and Fixtures [Member] Schedule Of Accounts And Grants Receivable Abstract Series A [Member] Cash and Cash Equivalents, Policy [Policy Text Block] Fair Value Adjustment of Warrants Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Unlabeled Abstract Marketable Security, Unrealized Gain (Loss) Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Investment Company, Reimbursable Excess Expense Net Income (Loss) Available to Common Stockholders, Basic Accrued Investment Income Receivable Proceeds from Issuance of Common Stock, Dividend Reinvestment Plan Series DWarrants Member Property, Plant and Equipment Disclosure [Text Block] Payment Per Warrant Lessee, Operating Lease, Liability, to be Paid Offering Costs In Accrued Expenses Share-Based Payment Arrangement, Option, Activity [Table Text Block] Marketable Securities, Current Equity [Text Block] Sale of Stock, Number of Shares Issued in Transaction Proceeds from Warrant Exercises Increase (Decrease) in Other Deferred Liability Property, Plant and Equipment [Table Text Block] Accounts Receivable From Customers Member Series C Units Member Operating Expenses Defined Contribution Plan, Cost Statement of Financial Position [Abstract] Cash and Cash Equivalents, at Carrying Value Series A And Series BWarrants Member Schedule Of Diluted Net Loss Per Share Abstract Research and Development Expense, Policy [Policy Text Block] license Agreement Term Lessee, Operating Lease, Liability, to be Paid, Year One Series BWarrants Member Adjustments to Additional Paid in Capital, Other OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Proceeds from Issuance of Common Stock Schedule Of Revenue Abstract Stock Issued During Period Value For Warrants Exercised Net Of Issuance Costs Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Lessee, Operating Lease, Liability, Undiscounted Excess Amount Marketable Securities, Policy [Policy Text Block] Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Share-Based Payment Arrangement, Noncash Expense Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Series CWarrants Member July Ordinary Course Placement Agent Member Stock Issued During Period, Value, Other National Institutes Of Health Grant Member Increase (Decrease) in Other Operating Assets and Liabilities, Net Use of Estimates, Policy [Policy Text Block] Commitments and Contingencies Clinical Trial Revenue Member Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Common Stock, Value, Issued Proceeds from Issuance of Warrants Underwriters Member Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Increase (Decrease) in Deferred Revenue Other Corporate Bonds [Member] Exercise Of Remaining Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Increase (Decrease) in Prepaid Expense and Other Assets Rule 10b51 Arr Modified Flag IPO [Member] Payments For Taxes On RSUs Vested Stock Issued During Period, Value, New Issues Statement of Stockholders' Equity [Abstract] Basis of Accounting, Policy [Policy Text Block] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Schedule Of Stock Option Activity Abstract Income Tax Expense (Benefit) Amortization of Intangible Assets Income Statement [Abstract] Lessee, Operating Leases [Text Block] Milestone Of Triggering Payments New Accounting Pronouncements, Policy [Policy Text Block] Equity Securities, Restricted [Abstract] Phantom Share Units (PSUs) [Member] Earnings Per Share, Basic Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Liabilities, Noncurrent Revenues [Abstract] Assets Liabilities Common Stock, Voting Rights Research and Development Expense Terms Of Agreement Temporary Equity, Accretion to Redemption Value, Adjustment Contract Manufacturing Revenue Member Subsequent Events [Text Block] Debt Instrument, Fee Amount Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Finite-Lived Intangible Asset, Useful Life Conversion of Stock, Shares Converted Warrants and Rights Outstanding, Term Professional Fees Share-Based Payment Arrangement, Expensed and Capitalized, Amount Software Development [Member] Net Cash Provided by (Used in) Financing Activities Accounts Payable, Current Property, Plant and Equipment, Gross Subsequent Event [Member] Warrant [Member] Revenue from Contract with Customer, Excluding Assessed Tax Unrealized Gain (Loss) on Investments Other General and Administrative Expense Contract with Customer, Liability Sale of Stock, Consideration Received on Transaction Leasehold Improvements [Member] Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year License [Member] Operating Income (Loss) Class A Common Stock Warrants Member Note Warrant [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Operating Lease, Liability Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Class A Common Stock Issued For RSUs Vested During Period Other Income and Expenses [Abstract] Indefinite-Lived License Agreements Annual Net Sales Percentage Revenue from Contract with Customer [Policy Text Block] Common Stock [Member] Other Cash Equivalents, at Carrying Value Loan Restructuring, Trial Modifications, Amount Statement of Cash Flows [Abstract] Stock Issues Suring Period Class A Common Stock Issued For RSUs Vestedin Shares Class of Warrant or Right, Outstanding Operating Lease, Liability, Current Other Liabilities, Noncurrent Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Vesting Of RSUs And PSUs Into Class A Common Stock Compensation and Employee Benefit Plans [Text Block] Money Market Funds [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Liabilities, Current [Abstract] Stock Issued During Period, Value, Conversion of Units APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Placement Agent Warrants Member Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Increase (Decrease) in Other Operating Liabilities Share-Based Payment Arrangement [Text Block] Earnings Per Share [Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Biologics License Member Statement of Comprehensive Income [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares Common Stock, Other Shares, Outstanding Stock Issued During Period, Value, Stock Options Exercised Two Thousand Twenty One PIPE Offering Member Restricted Stock Units (RSUs) [Member] Partners' Capital Account, Units, Sold in Public Offering Proceeds From Stock Subscription Receivable Chief Science Officer Member General and Administrative Expense Marketable Securities [Table Text Block] Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted

verage Exercise Price Longeveron Member Reuse [Policy Text Block] Depreciation, Depletion and Amortization Schedule Of Major Components Of Intangible Assets Abstract Contract With Customer, Liability, Current Common Stock, Par or Stated Value Per Share Deferred Offering Costs Policy Text Block Common Stock, Shares, Issued Proceeds from Sale and Maturity of Marketable Securities Share-Based Compensation Arrangements by Share-Deferred Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price first Phase3 Clinical Trial Member Weighted Average Number of Shares Outstanding, Diluted Gross Profit Intangible Assets, Net (Excluding Goodwill) Schedule Of Marketable Securities Abstract Schedule Of Rsu Activity Abstract Stock Issued During Perios Shares Class ACommon Stock Held For Taxes On RSUs Nested Accounts Receivable, after Allowance for Credit Loss, Current Finite-Lived Intangible Assets, Accumulated Amortization Grant Revenue Member Cash, Cash Equivalents, and Marketable Securities [Text Block] July Private Placement Member Licensing Agreements [Member] Disaggregation of Revenue [Table Text Block] Increase (Decrease) in Accounts and Other Receivables Assets, Current [Abstract] Cash Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Liabilities, Current Finite-Lived Intangible Asset, Expected Amortization, Year Four Increase (Decrease) in Accounts Payable Proceeds from Debt, Net of Issuance Costs Accrued Liabilities, Current Liabilities and Equity [Abstract] Shares, Outstanding Finite-Lived Intangible Asset, Expected Amortization, Year Three Payments to Acquire Intangible Assets Commitments and Contingencies Disclosure [Text Block] Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Cost of Revenue Receivables from Stockholder [Member] Class of Warrant or Right, Exercise Price of Warrants or Rights Preferred Stock, Value, Issued Schedule Of Issued And Outstanding Options Abstract Liabilities and Equity Nonoperating Income (Expense) Debt Conversion, Converted Instrument, Expiration or Due Date October2023 Registered Direct Offering Member Preferred Stock, Par or Stated Value Per Share Schedule Of Major Components Of Property And Equipment Abstract Operating Lease, Right-of-use Asset Excess Stock, Shares Issued Assets, Current Accrued Liabilities, Fair Value Disclosure EX-101.PRE 9 lgvn-20240630 pre.xml XBRL PRESENTATION FILE GRAPHIC 10 image_001.jpg GRAPHIC begin 644 image_001.jpg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~v+16IRZ?JV=<C K/JEC ~> UZ~84 MV25(8VED<B#@8G&T!5)1E=%1FTSZ5HKAO?UJXPFT?SDET~\$LR9VJ5UEVY M.W.< "<"/O,KSFBO5Y_(JGE'M&Y37M17?RM3;>2#9< C J5 P#P7S? M_1-%5%)7JIA?SB'F7A?Z P#?1: 31YES T~7 %W_ 31117J]/[MG\$/N? HA O P'''^: XFCS+G H\$:O '<'; P')HHH'K?P>SB'F7/_# M~7 !?Z -/31YES T~7 _/?Z -/A \$T44Y5Z28/90+S+G H\$:O X-YOI XFCS M+G H\$:O _": XFBBCCZO3J!(->9< C J5 !?Z P#?T-9< P#0(U?<.% MW QO-%%U<-GV#V<O!RY Z!&K_/OF _B;/N? H\$:O P'''^: XFBBCCZO3J MI!(->9< C J5 P#P7S? !-F7/_# M~7 !?Z -/31117J]/[G\$/N?>@1 MJ _X+YO B;/N?>@1J _OF_P#B:**J/L LXB^9<_] C5_P#P7S? !-MF7/_# M~7 !?Z -/3113<KT>P>SB>ON?<@1JW _OF _?KT3P-X%>:67->M FW3:0JGR8+>@TD< O-B PJ3SC:44Z+=;9?0BKGU`U%=9L?]D! end GRAPHIC 11 image_002.jpg GRAPHIC begin 644 image_002.jpg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~v+16IRZ?JV=<C K/JEC ~> UZ~84 MV25(8VED<B#@8G&T!5)1E=%1FTSZ5HKAO?UJXPFT?SDET~\$LR9VJ5UEVY M.W.< "<"/O,KSFBO5Y_(JGE'M&Y37M17?RM3;>2#9< C J5 P#P7S? M_1-%5%)7JIA?SB'F7A?Z P#?1: 31YES T~7 %W_ 31117J]/[MG\$/N? HA O P'''^: XFCS+G H\$:O '<'; P')HHH'K?P>SB'F7/_# M~7 !?Z -/31YES T~7 _/?Z -/A \$T44Y5Z28/90+S+G H\$:O X-YOI XFCS M+G H\$:O _": XFBBCCZO3J!(->9< C J5 !?Z P#?T-9< P#0(U?<.% MW QO-%%U<-GV#V<O!RY Z!&K_/OF _B;/N? H\$:O P'''^: XFBBCCZO3J MI!(->9< C J5 P#P7S? !-F7/_# M~7 !?Z -/31117J]/[G\$/N?>@1 MJ _X+YO B;/N?>@1J _OF_P#B:**J/L LXB^9<_] C5_P#P7S? !-MF7/_# M~7 !?Z -/3113<KT>P>SB>ON?<@1JW _OF _?KT3P-X%>:67->M FW3:0JGR8+>@TD< O-B PJ3SC:44Z+=;9?0BKGU`U%=9L?]D! end GRAPHIC 11 image_003.jpg GRAPHIC begin 644 image_003.jpg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~v+16IRZ?JV=<C K/JEC ~> UZ~84 MV25(8VED<B#@8G&T!5)1E=%1FTSZ5HKAO?UJXPFT?SDET~\$LR9VJ5UEVY M.W.< "<"/O,KSFBO5Y_(JGE'M&Y37M17?RM3;>2#9< C J5 P#P7S? M_1-%5%)7JIA?SB'F7A?Z P#?1: 31YES T~7 %W_ 31117J]/[MG\$/N? HA O P'''^: XFCS+G H\$:O '<'; P')HHH'K?P>SB'F7/_# M~7 !?Z -/31YES T~7 _/?Z -/A \$T44Y5Z28/90+S+G H\$:O X-YOI XFCS M+G H\$:O _": XFBBCCZO3J!(->9< C J5 !?Z P#?T-9< P#0(U?<.% MW QO-%%U<-GV#V<O!RY Z!&K_/OF _B;/N? H\$:O P'''^: XFBBCCZO3J MI!(->9< C J5 P#P7S? !-F7/_# M~7 !?Z -/31117J]/[G\$/N?>@1 MJ _X+YO B;/N?>@1J _OF_P#B:**J/L LXB^9<_] C5_P#P7S? !-MF7/_# M~7 !?Z -/3113<KT>P>SB>ON?<@1JW _OF _?KT3P-X%>:67->M FW3:0JGR8+>@TD< O-B PJ3SC:44Z+=;9?0BKGU`U%=9L?]D! end GRAPHIC 11 image_004.jpg GRAPHIC begin 644 image_004.jpg M JC X 02D9J1 / 0 \$8 !0 # ^ VP1# &@!<&!0/I?P<^0*#10 L + M#I2D\$P41H?AT:'IP@'XG'(L(P<#7J#A(6&AXB)B1F3C6EYB9JF?C16FZBJK?SM+6VMJBYNL+<Q,7& MQ(CRM+3U-76UJC9VN'BX<3EYNZHZ>KQ/O/T)?W/GZ _0 P'S P\$! O\$! 0 " P0%!(("<"OH+ _0 M1\$ @\$/1 #! <%! 0 0W \$ " M Q\$S!2\$Q!A!)40=A<1,B,H\$(%'1H;'!2,S4O 58G+1"A8D-\$E!1<8&1HF MJR@!C4V-S@Y.D-\$149'2\$E*4U155E=8651C9&5F9VAIG:T=79W>EZ@H.\$ MA8:B(F*DI.E9:7F)F:HJ.DI:-GJ*FJLK.TM:WN+FZPL/SQ<;R,G*TM/4 MU=:7V-G.XN/DY>.GZ.GJO/T)?W/G

DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1:

diffication -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19:
http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap AssetsCurrentNamespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap AssetsCurrentAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap CommitmentsAndContingencies Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap CommonStockValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap ContractWithCustomerLiabilityCurrentNamespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-45-1 + Details Name: us-gaap IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic

1-Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/214747802/946-310-45-1>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/214748112/505-10-45-2> + Details Name: us-gaap StockholdersEquityNotesSubscriptionsReceivable Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - Details Name: us-gaap StatementClassOfStockAxis=us-gaap CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementClassOfStockAxis=us-gaap CommonClassBMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 16 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Balance Sheets (Parentheticals) - \$ / shares Jun. 30, 2024 Dec. 31, 2023 Preferred stock, par value (in Dollars per share) \$ 0.001 \$ 0.001 Preferred stock, shares authorized 5,000,000 5,000,000 Preferred stock, shares issued Preferred stock, shares outstanding Class A Common Stock A Common stock, par value (in Dollars per share) \$ 0.001 \$ 0.001 Common stock, shares authorized 84,295,000 84,295,000 Common stock, shares issued 8,116,909 1,025,183 Common stock, shares outstanding 8,116,909 1,025,183 Class B common stock A Common stock, par value (in Dollars per share) \$ 0.001 \$ 0.001 Common stock, shares authorized 15,705,000 15,705,000 Common stock, shares issued 1,484,005 1,485,560 Common stock, shares outstanding 1,484,005 1,485,560 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1> + Details Name: us-gaap CommonStockSharesAuthorized Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap CommonStockSharesIssued Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/214748112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 6: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3> + Details Name: us-gaap CommonStockSharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/214748112/505-10-50-13> + Details Name: us-gaap PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1> + Details Name: us-gaap PreferredStockSharesAuthorized Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI

gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 -Details Name: us-gaap GeneralAndAdministrativeExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 -Details Name: us-gaap GrossProfit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478667/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274

FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference> 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-31> + Details Name: us-gaap OperatingIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap OtherIncomeAndExpensesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-50-32> + Details Name: us-gaap OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writedoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference> 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference> 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479532/912-730-25-1> + Details Name: us-gaap ResearchAndDevelopmentExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference> 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference> 4: <http://fasb.org/us-gaap/role/ref/otherTransitionRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference> 5: <http://fasb.org/us-gaap/role/ref/otherTransitionRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference> 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479941/924-10-50-1Reference> 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference> 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference> 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference> 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference> 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference> 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference> 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479806/606-10-50-4> + Details Name: us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap RevenuesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference> 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-10> + Details Name: us-gaap WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt ProductOrServiceAxis=lgvn_ClinicalTrialRevenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt ProductOrServiceAxis=lgvn_ContractManufacturingRevenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt ProductOrServiceAxis=lgvn_GrantRevenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 18 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Statements of Operations (Unaudited) (Parentheticals) - \$ / shares 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2024 Jun. 30, 2024 Jun. 30, 2023 Income Statement [Abstract] Á Á Á Diluted net loss per share \$ (1.83) \$ (2.67) \$ (3.54) \$ (4.88) Diluted weighted average common shares outstanding 6,509,883 2,110,544 4,511,734 2,106,973 X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference> 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference> 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference> 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference> 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference> 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference> 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference> 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference> 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference> 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference> 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference> 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference> 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference> 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference> 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-50-2Reference> 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-50-2Reference> 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-50-2Reference> 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-7> + Details Name: us-gaap EarningsPerShareDiluted Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap IncomeStatementAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference> 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-16> + Details Name: us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 19 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Statements of Comprehensive Loss (Unaudited) - USD (\$) in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Statement of Comprehensive Income [Abstract] Á Á Á Net loss \$ (3,413) \$ (5,668) \$ (6,323) \$ (7,471) (10,279) Other comprehensive loss: Á Á Á Net unrealized (loss) gain on available-for-sale securities (2) (36) (1) 22 Total comprehensive loss \$ (3,415) \$ (5,668) \$ (6,323) \$ (7,471) X - ReferencesNo definition available. + Details Name: lgvn OtherComprehensiveLossAbstract Namespace Prefix: lgvn Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-50-2Reference> 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-50-2Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-50-2Reference> 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1Reference> 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1Reference> 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-50-2Reference> 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-5> + Details Name: us-gaap ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference> 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference> 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference> 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference> 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference> 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference> 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference> 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference> 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference> 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference> 17: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference> 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference> 19:

[http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21:](#)

[http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23:](#)

[http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25:](#)

[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27:](#)

[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29:](#)

[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31:](#)

[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34:](#)

[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/230-10-45-28Reference 35:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37:](#)

[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and adjustment, of unrealized gain \(loss\) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income \(available-for-sale\) and unrealized gain \(loss\) on investment in debt security measured at amortized cost \(held-to-maturity\) from transfer to available-for-sale. + ReferencesReference 1:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3:](#)

[http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 4:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 20 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Statements of Stockholders' Equity \(Unaudited\) - USD \(\\$\) \\$ in Thousands Common Stock Class A Common Stock Class B Subscription Receivable Additional Paid-In Capital Accumulated Deficit Accumulated Other Comprehensive Gain \(Loss\) Total Balance at Dec. 31, 2022 \\$ 1 \\$ 1 \(100\) \\$ 83,731 \\$ \(62,773\) \\$ \(357\) \\$ 20,503 Balance \(in Shares\) at Dec. 31, 2022 612,732 1,489,109 \\$ \\$ \\$ \\$ Conversion of Class B common stock for Class A common stock Conversion of Class B common stock for Class A common stock \(in Shares\) 3,555 \(3,555\) \\$ \\$ \\$ \\$ Class A common stock, issued for RSUs vested Class A common stock, issued for RSUs vested \(in Shares\) 17,972 \\$ \\$ \\$ \\$ Class A common stock, held for taxes on RSUs vested \(103\) \(103\) Class A common stock, held for taxes on RSUs vested \(in Shares\) \(2,836\) \\$ \\$ \\$ \\$ Equity-based compensation 1,120 1,120 Unrealized gain attributable to change in market value of available for sale investments 22 Reverse stock split rounding adjustment Reverse stock split rounding adjustment \(in Shares\) 6 \\$ \\$ \\$ \\$ Net loss \(10,279\) \(10,279\) Balance at Jun. 30, 2023 \\$ 1 \(100\) 84,748 \(73,052\) \(335\) 11,263 Balance \(in Shares\) at Jun. 30, 2023 631,423 1,485,560 \\$ \\$ \\$ \\$ Balance at Dec. 31, 2022 \\$ 1 \(100\) 83,731 \(62,773\) \(357\) 20,503 Balance \(in Shares\) at Dec. 31, 2022 612,732 1,489,109 \\$ \\$ \\$ \\$ Conversion of Class B common stock for Class A common stock \(in Shares\) 3,555 3,555 \\$ \\$ \\$ \\$ Balance at Dec. 31, 2023 \\$ 1 \(100\) 91,823 \(84,984\) 6,741 Balance \(in Shares\) at Dec. 31, 2023 1,025,183 1,485,560 \\$ \\$ \\$ \\$ Balance at Mar. 31, 2023 \\$ 1 \(100\) 84,135 \(67,420\) \(299\) 16,318 Balance \(in Shares\) at Mar. 31, 2023 616,305 1,487,109 \\$ \\$ \\$ \\$ Conversion of Units into Class A and B common stock Conversion of Units into Class A and B common stock \(in Shares\) 1,555 \(1,555\) \\$ \\$ \\$ \\$ Class A common stock, issued for RSUs vested Class A common stock, issued for RSUs vested \(in Shares\) 15,955 \\$ \\$ \\$ \\$ Class A common stock, held for taxes on RSUs vested \(86\) \(86\) Class A common stock, held for taxes on RSUs vested \(in Shares\) \(2,392\) \\$ \\$ \\$ \\$ Equity-based compensation 699 699 Unrealized gain attributable to change in market value of available for sale investments \(36\) \(36\) Reverse stock split rounding adjustment Reverse stock split rounding adjustment \(in Shares\) 6 \\$ \\$ \\$ \\$ Net loss \(5,632\) \(5,632\) Balance at Jun. 30, 2023 \\$ 1 \(100\) 84,748 \(73,052\) \(335\) 11,263 Balance \(in Shares\) at Jun. 30, 2023 631,423 1,485,560 \\$ \\$ \\$ \\$ Balance at Dec. 31, 2023 \\$ 1 \(100\) 91,823 \(84,984\) 6,741 Balance \(in Shares\) at Dec. 31, 2023 1,025,183 1,485,560 \\$ \\$ \\$ \\$ Conversion of Class B common stock for Class A common stock Conversion of Class B common stock for Class A common stock \(in Shares\) 1,555 \(1,555\) \\$ \\$ \\$ \\$ Class A common stock, issued for RSUs vested Class A common stock, issued for RSUs vested \(in Shares\) 9,714 \\$ \\$ \\$ \\$ Class A common stock, held for taxes on RSUs vested \(26\) \(26\) Class A common stock,](#)

Paragraph 1 - Subparagraph (b)(2) - Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12:

[Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12:](#) [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13:](#) [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14:](#) [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SAB Topic 4.E\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders. + ReferencesNo definition available. + Details Name: us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 21 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Statements of Stockholders' Equity \(Unaudited\) \(Parentheticals\) - USD \(\\$\) \\$ in Thousands 3 Months Ended Jun. 30, 2024 Jun. 30, 2024 Statement of Stockholders' Equity \[Abstract\] A A Class A common stock issued in public offering, net of issuance costs \\$ 1,145 \\$ 1,145 Class A common stock issued for warrants exercised, net of issuance costs \\$ 1,359 \\$ 1,359 X - DefinitionAmount of common stock issued for warrants exercised, net of issuance costs. + ReferencesNo definition available. + Details Name: lgvn_StockIssuedDuringPeriodValueForWarrantsExercisedNetOfIssuanceCosts Namespace Prefix: lgvn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: \[http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfStockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 22 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Statements of Cash Flows \\(Unaudited\\) - USD \\(\\\$\\) \\\$ in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Cash flows from operating activities A A Net loss \\\$ \\(7,471\\) \\\$ \\(10,279\\) Adjustments to reconcile net loss to net cash used in operating activities: A A Depreciation and amortization 481 478 Interest earned on marketable securities 60 151 Equity-based compensation 525 1,120 Changes in operating assets and liabilities: A A Accounts and grants receivable \\(107\\) 122 Prepaid expenses and other current assets \\(441\\) \\(1,136\\) Other assets \\(11\\) 23 Accounts payable \\(38\\) \\(51\\) Deferred revenue \\(109\\) \\(10\\) Nonoperating liability \\(1,398\\) Accrued expenses \\(547\\) 658 Operating lease asset and lease liability \\(127\\) \\(127\\) Other liabilities 133 Net cash used in operating activities \\(7,652\\) \\(10,449\\) Cash flows from investing activities A A Proceeds from the sale of marketable securities 350 3,116 Acquisition of property and equipment \\(212\\) \\(134\\) Acquisition of intangible assets \\(177\\) \\(186\\) Net cash \\(used in\\) provided by investing activities \\(39\\) 2,796 Cash flows from financing activities A A Proceeds from the issuance of common stock, net of issuance cost 4,722 Proceeds from warrants exercised net of issuance cost 10,338 Proceeds from stock subscription receivable 100 Payments for taxes on RSUs vested \\(43\\) \\(103\\) Net cash provided by \\(used in\\) financing activities 15,117 \\(103\\) Change in cash and cash equivalents 7,426 \\(7,756\\) Cash and cash equivalents at beginning of the period 4,949 10,503 Cash and cash equivalents at end of the period 12,375 2,747 Supplement Disclosure of Non-cash Investing and Financing Activities: A A Vesting of RSUs and PSUs into Class A common stock \\(108\\) \\(575\\) Deemed dividend â€” warrant inducement offers 8,501 Offering costs in accrued expenses \\\$ 86 X - DefinitionRepresent the amount of deemed dividend warrant inducement offers. + ReferencesNo definition available. + Details Name: lgvn_DeemedDividendWarrantInducementOffers Namespace Prefix: lgvn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of offering costs in an accrued expense. + ReferencesNo definition available. + Details Name: lgvn_OfferingCostsInAccruedExpenses Namespace Prefix: lgvn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPayments for taxes on RSUs vested. + ReferencesNo definition available. + Details Name: lgvn_PaymentsForTaxesOnRSUVested Namespace Prefix: lgvn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of proceeds from stock subscription receivable. + ReferencesNo definition available. + Details Name: lgvn_ProceedsFromStockSubscriptionReceivable Namespace Prefix: lgvn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of vesting of RSU and PSUs into class A common stock. + ReferencesNo definition available. + Details Name: lgvn_VestingOfRSUsAndPSUsIntoClassACommonStock Namespace Prefix: lgvn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2:\\]\\(#\\) \\[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3:\\]\\(#\\) \\[http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase \\\(decrease\\\) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: \\\[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2:\\\]\\\(#\\\) \\\[http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: \\\\[http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \\\\\(b\\\\\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2:\\\\]\\\\(#\\\\) \\\\[http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph \\\\\(a\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase \\\\\(decrease\\\\\) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables. + ReferencesReference 1: \\\\\[http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \\\\\\(a\\\\\\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase \\\\\\(decrease\\\\\\) during the reporting period in the aggregate amount of liabilities incurred \\\\\\(and for which invoices have typically been received\\\\\\) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: \\\\\\[http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \\\\\\\(a\\\\\\\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase \\\\\\\(decrease\\\\\\\) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: \\\\\\\[http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \\\\\\\\(a\\\\\\\\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase \\\\\\\\(decrease\\\\\\\\) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: \\\\\\\\[http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \\\\\\\\\(a\\\\\\\\\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInDeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase \\\\\\\\\(decrease\\\\\\\\\) in deferred obligations classified as other. + ReferencesReference 1: \\\\\\\\\[http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \\\\\\\\\\(a\\\\\\\\\\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherDeferredLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase \\\\\\\\\\(decrease\\\\\\\\\\) in operating assets classified as other. + ReferencesReference 1: \\\\\\\\\\[http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph\\\\\\\\\\]\\\\\\\\\\(#\\\\\\\\\\)\\\\\\\\\]\\\\\\\\\(#\\\\\\\\\)\\\\\\\\]\\\\\\\\(#\\\\\\\\)\\\\\\\]\\\\\\\(#\\\\\\\)\\\\\\]\\\\\\(#\\\\\\)\\\\\]\\\\\(#\\\\\)\\\\]\\\\(#\\\\)\\\]\\\(#\\\)\\]\\(#\\)\]\(#\)](#)

https://asc.fasb.org/1943274/2147483443/250-10-50-Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section 59 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-599-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 59 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 59 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 59 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 59 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 59 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 59 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 59 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 59 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 59 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 59 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 59 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 59 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section 59 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-599-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period. + ReferencesNo definition available. + Details Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 23.R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Nature of Business, Basis of Presentation, and Liquidity 6 Months Ended Jun. 30, 2024 Nature of Business, Basis of Presentation, and Liquidity [Abstract] Å Nature of Business, Basis of Presentation, and Liquidity 1. Nature of Business, Basis of Presentation, and Liquidity Å Nature of business: Å Longeveron was formed as a Delaware limited liability company on October 9, 2014, and was authorized to transact business in Florida on December 15, 2014. On February 12, 2021, Longeveron, LLC converted

Interest income and dividends are recorded when earned. Realized gains and losses on investments are determined by specific identification and are recognized as incurred in the condensed statement of operations. Changes in net unrealized gains and losses are reported in other comprehensive loss and represent the change in the fair value of investment holdings during the reporting period. Changes in net unrealized losses were less than \$0.1 million for the three and six months ended June 30, 2024 and 2023, respectively. Accounts and grants receivable: Accounts and grants receivable include amounts due from customers, granting institutions and others. The amounts as of June 30, 2024, and December 31, 2023 are certain to be collected, and no amount has been recognized for expected credit losses. In addition, for the clinical trial revenue, most participants pay in advance of treatment. Advanced grant funds and prepayments for the clinical trial revenue are recorded to deferred revenue. Advance contract manufacturing payments are recorded to deferred revenue. Accounts and grants receivable by source, as of (in thousands): June 30, 2024 December 31, 2023 Accounts receivable from customers \$159A \$A National Institutes of Health Grant A 59A A 96A TotalA \$218A \$111A A Deferred offering costs: The Company recorded certain legal, professional and other third-party fees that were directly associated with its process equity financings as deferred offering costs until the applicable equity financing was consummated. After consummation of an equity financing, these costs are recorded in stockholders' equity as a reduction of proceeds generated as a result of the offering. Property and equipment: Property and equipment, including improvements that extend the useful lives of related assets, are recorded at cost, while maintenance and repairs are charged to operations as incurred. Depreciation is calculated using the straight-line method based on the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the original term of the lease. Depreciation expense is recorded in the research and development line of the condensed statements of operations as the assets are primarily related to the Company's clinical programs. Intangible assets: Intangible assets include payments on license agreements with the Company's co-founder and Chief Scientific Officer (CSO) and the University of Miami (UM) (see Note 9) and legal costs incurred related to patents and trademarks. License agreements have been recorded at the value of cash consideration, common stock and membership units transferred to the respective parties when acquired. Payments for license agreements are amortized using the straight-line method over the estimated term of the agreements, which range from 5-20 years. Patents are amortized over their estimated useful life, once issued. The Company considers trademarks to have an indefinite useful life and evaluates them for impairment on an annual basis. Amortization expense is recorded in the research and development line of the condensed statements of operations as the assets are primarily related to the Company's clinical programs. Impairment of Long-Lived Assets: The Company evaluates long-lived assets for impairment, including property and equipment and intangible assets, when events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. Upon the occurrence of a triggering event, the asset is reviewed to assess whether the estimated undiscounted cash flows expected from the use of the asset plus the residual value from the ultimate disposal exceeds the carrying value of the asset. If the carrying value exceeds the estimated recoverable amounts, the asset is written down to the estimated fair value. Any resulting impairment loss is reflected in the condensed statements of operations. Upon evaluation, management determined that there was no impairment of long-lived assets during the three and six months ended June 30, 2024 and 2023. Deferred revenue: The unearned portion of advanced grant funds and prepayments for clinical trial and contract manufacturing revenues, which will be recognized as revenue when the Company meets the respective performance obligations, has been presented as deferred revenue in the accompanying condensed balance sheets. For the six months ended June 30, 2024 and 2023, the Company recognized less than \$0.1 million, respectively, of funds that were previously classified as deferred revenue. Due to the MSCRF Technology Development Corporation (TDCO) grant Acute Respiratory Distress Syndrome (ARDS) program being discontinued, \$0.4 million recorded as deferred revenue was reversed when the funds were returned to MSCRF TEDCO. As of June 30, 2024 and December 31, 2023, the Company had \$0.4 million and \$0.5 million, respectively, recorded in deferred revenue on the condensed balance sheets. Revenue recognition: The Company recognizes revenue when performance obligations related to respective revenue streams are met. For grant revenue, the Company considers the performance obligation met when the grant related expenses are incurred or supplies and materials are received. The Company is paid in tranches pursuant to terms of the related grant agreements, and then applies payments based on regular expense reimbursement submissions to grantors. There are no remaining performance obligations or variable consideration once grant expense reporting to the grantor is complete. For clinical trial revenue, the Company considers the performance obligation met when the participant has received the treatment. The Company usually receives prepayment for these services or receives payment at the time the treatment is provided, and there are no remaining performance obligations or variable consideration once the participant receives the treatment. For contract manufacturing revenue, the Company considers the performance obligation met when the contractual obligation and/or statement of work has been satisfied. Payment terms may vary depending on specific contract terms. There are no significant payments affecting the determination of the amount and timing of revenue recognition. Revenue by source (in thousands): Three months ended June 30, 2024 Six months ended June 30, 2024 2023A 2024A 2023A Clinical trial revenueA \$287A \$217A \$802A \$455A Contract manufacturingA \$181A \$A \$A \$A NIH - grantA \$A \$A \$A \$A 41A TotalA \$468A \$217A \$1,016A \$496A The Company records cost of revenues based on expenses directly related to revenue. For grants, the Company records allocated expenses for research and development costs to a grant as a cost of revenues. For the clinical trial revenue, directly related expenses for that program are expensed as incurred. These expenses are similar to those described under Research and development expense below. For the contract manufacturing, the Company records costs incurred under the contract as cost of revenues. Research and development expense: Research and development costs are charged to expense when incurred in accordance with ASC 730 Research and Development. ASC 730 addresses the proper accounting and reporting for research and development costs. It identifies: 1) those activities that should be identified as research and development; 2) the elements of costs that should be identified with research and development activities, and the accounting for these costs; and 3) the financial statement disclosures related to them. Research and development costs include costs such as clinical trial expenses, contracted research and license agreement fees with no alternative future use, supplies and materials, salaries, share-based compensation, employee benefits, property and equipment depreciation and allocation of various corporate costs. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed by the third parties, patient enrollment in clinical trials, administrative costs incurred by the third parties, and other indicators of the services completed. Based on the timing of amounts invoiced by service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expense in future periods as the related services are rendered. Concentrations of credit risk: Financial instruments which potentially subject the Company to credit risk consist principally of cash and cash equivalents, marketable securities and accounts and grants receivable. Cash and cash equivalents are held in U.S. financial institutions. At times, the Company may maintain balances in excess of the federally insured amounts. Income taxes: The Company's tax provision consists of taxes currently payable or receivable, plus any change during the period in deferred tax assets and liabilities. The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. In addition, a valuation allowance is established to reduce any deferred tax asset for which it is determined that it is more likely than not that some portion of the deferred tax asset will not be realized. The Company's tax provision was \$0 for the three and six months ended June 30, 2024 and 2023 due to net operating losses. The Company has not recorded any tax benefit for the net operating losses incurred due to the offset created by the Company's valuation allowance. The Company recognizes the tax benefits from uncertain tax positions that the Company has taken or expects to take on a tax return. In the unlikely event an uncertain tax position exists in which the Company could incur income taxes, the Company would evaluate whether there is a probability that the uncertain tax position taken would be sustained upon examination by a taxing authority. Reserves for uncertain tax positions would then be recorded if the Company determined it is probable that either a position would not be sustained upon examination, or a payment would have to be made to a taxing authority and the amount was reasonably estimable. As of June 30, 2024 and December 31, 2023, the Company does not believe it has any uncertain tax positions that would result in the Company having a liability to a taxing authority. It is the Company's policy to expense any interest and penalties associated with its tax obligations when they are probable and estimable. Equity-based compensation: The Company accounts for equity-based compensation expense by the measurement and recognition of compensation expense for stock-based awards based on estimated fair values on the date of grant. The fair value of the stock options is estimated at the date of the grant using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires the input of highly subjective assumptions, the most significant of which are the expected share price volatility, the expected life of the stock option award, the risk-free rate of return, and dividends during the expected term. Because the option-pricing model is sensitive to changes in the input assumptions, different determinations of the required inputs may result in different fair value estimates of the stock options. Neither the Company's stock options nor its restricted stock units (RSUs) trade on an active market. Volatility is a measure of the amount by which a financial variable, such as a stock price, has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. Given the Company's limited historical data, the Company utilizes the average historical volatility of similar publicly traded companies that are in the same industry. The risk-free interest rate is the average U.S. treasury rate (having a term that most closely approximates the expected life of the option) for the period in which the stock option was granted. The expected life is the period of time that the stock options granted are expected to remain outstanding. Stock options granted have a maximum term of ten years. The Company has insufficient historical data to utilize in determining its expected life assumptions and, therefore, uses the simplified method for determining expected life. The Company accounts for the cost of services performed by vendors in exchange for an award of stock options based on the grant-date fair value of the award. The Company recognizes the expense consistent with the contractual vesting period and in the same manner as if the Company had paid cash for the services. X - ReferencesNo definition available. + Details Name: us-gaap AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Marketable Securities 6 Months Ended Jun. 30, 2024 Marketable Securities [Abstract] A Marketable securities 3. Marketable securities A The following is summary of marketable securities that the Company measures at fair value (in thousands): A Fair Value at June 30, 2024A Level 1A Level 2A Level 3A TotalA Corporate bondsA \$A \$A \$A \$A Money market funds(1)A \$6,716A \$A \$A \$6,716A Accrued incomeA \$28A \$A \$A \$A \$28A Total marketable securitiesA \$6,744A \$A \$A \$6,744A (1)Money market funds are included in cash and cash equivalents in the condensed balance sheets. A Fair Value at December 31, 2023A Level 1A Level 2A Level 3A TotalA Corporate bondsA \$A \$412A \$A \$A \$412A Money market funds(1)A \$3,948A \$A \$A \$A \$3,948A Accrued incomeA \$16A \$A \$A \$A \$16A Total marketable securitiesA \$3,964A \$412A \$A \$4,376A (1)Money market funds are included in cash and cash equivalents in the condensed balance sheets. A As of June 30, 2024 and December 31, 2023, the Company reported accrued interest receivable related to marketable securities of less than \$0.1 million. These amounts are recorded in other assets on the condensed balance sheets and are not included in the carrying value of the marketable securities. X - DefinitionThe entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContent + Details Name: us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_MarketableSecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 26 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property and Equipment, Net 6 Months Ended Jun. 30, 2024 Property and Equipment, Net [Abstract] A Property and equipment, net A Major components of property and equipment are as follows (in thousands): A Useful LivesA June 30, 2024A December 31, 2023A Leasehold improvementsA 10 yearsA \$4,328A \$4,328A Furniture/Lab equipmentA 7 yearsA \$2,695A \$2,483A Computer equipmentA 5 yearsA \$120A \$120A Software/WebsiteA 3 yearsA \$38A \$38A Total property and equipmentA \$7,181A \$6,969A A Less accumulated depreciation and amortizationA \$A \$4,810A \$4,440A Property and equipment, netA \$2,371A \$2,529A A Depreciation and amortization expense amounted to approximately \$0.2 million for the three-month periods ended June 30, 2024 and 2023, and \$0.4 million for the six months ended June 30, 2024 and 2023. X - DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/214747798/958-360-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/214747798/958-360-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 7 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/214747798/95

its operating leases (there are no finance leases). The Company’s corporate office lease expires in March 2027. As of June 30, 2024, the operating lease asset and lease liability were approximately \$1.1 million and \$1.7 million, respectively. As of December 31, 2023, the operating lease asset and lease liability were approximately \$1.2 million and \$2.0 million, respectively. A Future minimum payments under the operating leases as of June 30, 2024, are as follows (in thousands): A Years Ending December 31, A AmountA 2024 (remaining six months)A \$341A 2025A \$682A 2026A \$682A 2027A \$170A TotalA \$1,875A Less: InterestA \$127A Present value of operating lease liabilityA \$1,748A A During each of the three months ended June 30, 2024 and 2023, the Company incurred approximately \$0.2 million of total lease costs and for the six month periods ended June 30, 2024 and 2023, the Company incurred approximately \$0.3 million and \$0.2 million of total lease costs, respectively, that are included in the general and administrative expenses in the condensed statements of operations. X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1:

ReferencesReference 1:

to 2,236,026 shares are issuable upon the exercise of the July private placement warrants issued to the purchasers upon the closing of the July private placement; (ii) 156,522 shares are issuable upon exercise of the July offering placement agent warrants issued to Wainwright, or its designees, pursuant to the terms of the current engagement Letter with Wainwright; and (iii) 172,844 shares are issuable upon exercise of the July ordinary course placement agent warrants issued to Wainwright, or its designees, pursuant to the terms of a then-applicable engagement letter with Wainwright, in connection with previously exercised June private placement warrants. The Form S-1 was declared effective by the SEC on August 12, 2024. X - ReferencesNo definition available. + Details Name: us-gaap. SubsequentEventsAbstract Namespace Prefix: us-gaap. Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1:

the research and development line of the condensed statements of operations as the assets are primarily related to the Company’s clinical programs. Intangible assets include payments on license agreements with the Company’s co-founder and Chief Scientific Officer (CSO) and the University of Miami (UM) (see Note 9) and legal costs incurred related to patents and trademarks. License agreements have been recorded at the value of cash consideration, common stock and membership units transferred to the respective parties when acquired. Payments for license agreements are amortized using the straight-line method over the estimated term of the agreements, which range from 5-20 years. Patents are amortized over their estimated useful life, once issued. The Company considers trademarks to have an indefinite useful life and evaluates them for impairment on an annual basis. Amortization expense is recorded in the research and development line of the condensed statements of operations as the assets are primarily related to the Company’s clinical programs. Impairment of Long-Lived Assets: The Company evaluates long-lived assets for impairment, including property and equipment and intangible assets, when events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. Upon the occurrence of a triggering event, the asset is reviewed to assess whether the estimated undiscounted cash flows expected from the use of the asset plus the residual value from the ultimate disposal exceeds the carrying value of the asset. If the carrying value exceeds the estimated recoverable amounts, the asset is written down to the estimated fair value. Any resulting impairment loss is reflected in the condensed statements of operations. Upon evaluation, management determined that there was no impairment of long-lived assets during the three and six months ended June 30, 2024 and 2023. Deferred revenue: The unearned portion of advanced grant funds and prepayments for clinical trial and contract manufacturing revenues, which will be recognized as revenue when the Company meets the respective performance obligations, has been presented as deferred revenue in the accompanying condensed balance sheets. For the six months ended June 30, 2024 and 2023, the Company recognized less than \$0.1 million, respectively, of funds that were previously classified as deferred revenue. Due to the MSCRF Technology Development Corporation (TEDCO) grant Acute Respiratory Distress Syndrome (ARDS) program being discontinued, \$0.4 million recorded as deferred revenue was reversed when the funds were returned to MSCRF TEDCO. As of June 30, 2024 and December 31, 2023, the Company had \$0.4 million and \$0.5 million, respectively, recorded in deferred revenue on the condensed balance sheets. Revenue recognition: The Company recognizes revenue when performance obligations related to respective revenue streams are met. For grant revenue, the Company considers the performance obligation met when the grant related expenses are incurred or supplies and materials are received. The Company is paid in tranches pursuant to terms of the related grant agreements, and then applies payments based on regular expense reimbursement submissions to grantors. There are no remaining performance obligations or variable consideration once grant expense reporting to the grantor is complete. For clinical trial revenue, the Company considers the performance obligation met when the participant has received the treatment. The Company usually receives prepayment for these services or receives payment at the time the treatment is provided, and there are no remaining performance obligations or variable consideration once the participant receives the treatment. For contract manufacturing revenue, the Company considers the performance obligation met when the contractual obligation and/or statement of work has been satisfied. Payment terms may vary depending on specific contract terms. There are no significant judgments affecting the determination of the amount and timing of revenue recognition. Revenue by source (in thousands): Three months ended June 30, Six months ended June 30, 2024 2023A 2024A 2023A Clinical trial revenue \$287A \$217A \$802A \$455A Contract manufacturing 181A 214A 214A 41A Total \$468A \$217A \$1,016A \$496A The Company records cost of revenues based on expenses directly related to revenue. For grants, the Company records allocated expenses for research and development costs to a grant as a cost of revenues. For the clinical trial revenue, directly related expenses for that program are expensed as incurred. These expenses are similar to those described under Research and development expense below. For the contract manufacturing, the Company records costs incurred under the contract as cost of revenues. Research and development expense: Research and development costs are charged to expense when incurred in accordance with ASC 730 Research and Development. ASC 730 addresses the proper accounting and reporting for research and development costs. It identifies: 1) those activities that should be identified as research and development; 2) the elements of costs that should be identified with research and development activities, and the accounting for these costs; and 3) the financial statement disclosures related to them. Research and development costs include costs such as clinical trial expenses, contracted research and license agreement fees with no alternative future use, supplies and materials, salaries, share-based compensation, employee benefits, property and equipment depreciation and allocation of various corporate costs. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed by the third parties, patient enrollment in clinical trials, administrative costs incurred by the third parties, and other indicators of the services completed. Based on the timing of amounts invoiced by service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expense in future periods as the related services are rendered. Concentrations of credit risk: Financial instruments which potentially subject the Company to credit risk consist principally of cash and cash equivalents, marketable securities and accounts and grants receivable. Cash and cash equivalents are held in U.S. financial institutions. At times, the Company may maintain balances in excess of the federally insured amounts. Income taxes: The Company’s tax provision consists of taxes currently payable or receivable, plus any change during the period in deferred tax assets and liabilities. The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. In addition, a valuation allowance is established to reduce any deferred tax asset for which it is determined that it is more likely than not that some portion of the deferred tax asset will not be realized. The Company’s tax provision was \$0 for the three and six months ended June 30, 2024 and 2023 due to net operating losses. The Company has not recorded any tax benefit for the net operating losses incurred due to the offset created by the Company’s valuation allowance. The Company recognizes the tax benefits from uncertain tax positions that the Company has taken or expects to take on a tax return. In the unlikely event an uncertain tax position exists in which the Company could incur income taxes, the Company would evaluate whether there is a probability that the uncertain tax position taken would be sustained upon examination by a taxing authority. Reserves for uncertain tax positions would then be recorded if the Company determined it is probable that either a position would not be sustained upon examination, or a payment would have to be made to a taxing authority and the amount was reasonably estimable. As of June 30, 2024 and December 31, 2023, the Company does not believe it has any uncertain tax positions that would result in the Company having a liability to a taxing authority. It is the Company’s policy to expense any interest and penalties associated with its tax obligations when they are probable and estimable. Equity-based compensation: The Company accounts for equity-based compensation expense by the measurement and recognition of compensation expense for stock-based awards based on estimated fair values on the date of grant. The fair value of the stock options is estimated at the date of the grant using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires the input of highly subjective assumptions, the most significant of which are the expected share price volatility, the expected life of the stock option award, the risk-free rate of return, and dividends during the expected term. Because the option-pricing model is sensitive to changes in the input assumptions, different determinations of the required inputs may result in different fair value estimates of the stock options. Neither the Company’s stock options nor its restricted stock units (RSUs) trade on an active market. Volatility is a measure of the amount by which a financial variable, such as a stock price, has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. Given the Company’s limited historical data, the Company utilizes the average historical volatility of similar publicly traded companies that are in the same industry. The risk-free interest rate is the average U.S. treasury rate (having a term that most closely approximates the expected life of the option) for the period in which the stock option was granted. The expected life is the period of time that the stock options granted are expected to remain outstanding. Stock options granted have a maximum term of ten years. The Company has insufficient historical data to utilize in determining its expected life assumptions and, therefore, uses the simplified method for determining expected life. The Company accounts for the cost of services performed by vendors in exchange for an award of stock options based on the grant-date fair value of the award. The Company recognizes the expense consistent with the contractual vesting period and in the same manner as if the Company had paid cash for the services. X - ReferencesNo definition available. + Details Name: lgvn_DeferredOfferingCostsPolicyTextBlock Namespace Prefix: lgvn_ Data Type: dtr:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of Reverse Stock Split. + ReferencesNo definition available. + Details Name: lgvn_ReverseStockSplitPolicyTextBlock Namespace Prefix: lgvn_ Data Type: dtr:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity’s use of its cash and cash equivalents, (2) whether the entity’s cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for credit risk. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_ConcentrationRiskCreditRisk Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.CC) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 05 -Paragraph 4 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4 + Details Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(h)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1 + Details Name: us-gaap_IncomeTaxPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for investment classified as marketable security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 320 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5 + Details Name: us-gaap_MarketableSecuritiesPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity’s financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2 + Details Name: us-gaap_ReceivablesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type:

Period Type: duration X - DefinitionDisclosure of accounting policy for costs it has incurred (a) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 730-SubTopic 10-Name Accounting Standards Codification-Section 05-Paragraph 1-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483044/730-10-05-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 730-SubTopic 10-Name Accounting Standards Codification-Section 05-Paragraph 1-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483044/730-10-05-1) + Details Name: us-gaap ResearchAndDevelopmentExpensePolicy Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue from contract with customer. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 17-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-17>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 19-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-19>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-18)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-18)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 20-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-20](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 20-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-20)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 20-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-20](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 20-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-20)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 20-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-20](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 20-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-20)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 20-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-20](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 20-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-20)Reference 9: [http://www.xbrl.org/2003/role/exampleRef-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(e\)-SubTopic 10-Topic 235-Publisher FASB-URI https://asc.fasb.org/1943274/2147483426/235-10-50-4](http://www.xbrl.org/2003/role/exampleRef-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (e)-SubTopic 10-Topic 235-Publisher FASB-URI https://asc.fasb.org/1943274/2147483426/235-10-50-4)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-07\(1\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Topic 606-Publisher FASB-URI https://asc.fasb.org/606/tableOfContent+Details Name: us-gaap RevenueFromContractWithCustomerPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources. + ReferencesReference 1: <a href=)Reference 2: [http://www.xbrl.org/2003/role/exampleRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483426/235-10-50-4](http://www.xbrl.org/2003/role/exampleRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483426/235-10-50-4)Reference 3: [http://www.xbrl.org/2003/role/exampleRef-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(e\)-SubTopic 10-Topic 235-Publisher FASB-URI https://asc.fasb.org/1943274/2147483426/235-10-50-4](http://www.xbrl.org/2003/role/exampleRef-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (e)-SubTopic 10-Topic 235-Publisher FASB-URI https://asc.fasb.org/1943274/2147483426/235-10-50-4) + Details Name: us-gaap RevenueRecognitionPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(f\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(f\)\(2\)\(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f)(2)(i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(f\)\(2\)\(ii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f)(2)(ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(f\)\(2\)\(v\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f)(2)(v)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SAB Topic 14.C.Q3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB Topic 14.C.Q3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1)Reference 6:

Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year. + ReferencesNo definition available. + Details Name: us-gaap ScheduleOfShareBasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 44 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Loss Per Share (Tables) 6 Months Ended Jun. 30, 2024 Loss Per Share [Abstract] A Schedule of Diluted Net Loss per Share The following instruments (in thousands) were excluded from the calculation of diluted net loss per share because their effects would be antidilutive: A A Six months ended June 30, A A A 2024A A 2023A RSUsA A 30A A A 98A PSUsA A-A A A 125A Stock optionsA A 37A A A 401A WarrantsA A 6,873A A A 1,271A TotalA A 6,940A A A 1,895A X - ReferencesNo definition available. + Details Name: us-gaap EarningsPerShareAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 45 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Nature of Business, Basis of Presentation, and Liquidity (Details) - USD (\$) in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Nature of Business, Basis of Presentation, and Liquidity [Abstract] A A A A Net loss \$(3,413) \$(5,632) \$(7,471) \$(10,279) A Accumulated deficit (100,956) A (100,956) A \$(84,984) Cash and cash equivalents 12,375 A 12,375 A \$ 4,949 Gross cash proceeds \$ 15,300 A \$ 15,300 A A X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 210 -Topic 946 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20 + Details Name: us-gaap Cash Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference

receivable. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479837/606-10-45-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479806/606-10-50-8>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479837/606-10-45-2> + Details Name: us-gaap ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionUseful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482685/740-10-50-12>Reference 4: <http://www.xbrl.org/2003/role/exampleRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482663/740-10-55-231>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SAB Topic 6.1.7) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479360/740-10-599-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482685/740-10-50-10>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-599-1>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482659/740-20-45-2>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-599-1> + Details Name: us-gaap IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_UnrealizedGainLossOnInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies (Details) - Schedule of Accounts and Grants Receivable - USD (\$) \$ in Thousands Jun. 30, 2024 Dec. 31, 2023 Schedule of Accounts and Grants Receivable [Line Items] Á Á Accounts and grants receivable \$ 218 \$ 111 Accounts receivable from customers [Member] Á Á Schedule of Accounts and Grants Receivable [Line Items] Á Á Accounts and grants receivable 159 15 National Institutes of Health æ Grant [Member] Á Á Schedule of Accounts and Grants Receivable [Line Items] Á Á Accounts and grants receivable \$ 59 \$ 96 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 40 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481628/310-20-40-7>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481990/310-10-45-2> + Details Name: us-gaap_AccountsNotesAndLoansReceivableLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481990/310-10-45-2> + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=lgvn_AccountsReceivableFromCustomersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=lgvn_NationalInstitutesOfHealthGrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies (Details) - Schedule of Revenue - USD (\$) \$ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Schedule of Revenue [Line Items] Á Á Á Total revenue \$ 468 \$ 217 \$ 1,016 \$ 496 Clinical trial revenue [Member] Á Á Á Schedule of Revenue [Line Items] Á Á Á Total revenue 287 217 802 455 Contract manufacturing [Member] Á Á Á Schedule of Revenue [Line Items] Á Á Á Total revenue 181 214 NIH - grant [Member] Á Á Á Schedule of Revenue [Line Items] Á Á Á Total revenue \$ 41 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_DeferredRevenueArrangementLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-41>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 4: <http://fasb.org/us-gaap/role/ref/otherTransitionRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 5: <http://fasb.org/us-gaap/role/ref/otherTransitionRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479941/924-10-599-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479806/606-10-50-5>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-30>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-42>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-40>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479806/606-10-50-4> + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=lgvn_ClinicalTrialRevenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=lgvn_ContractManufacturingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=lgvn_NationalInstitutesOfHealthGrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Marketable Securities (Details) - USD (\$) \$ in Millions Jun. 30, 2024 Dec. 31, 2023 Marketable Securities [Line Items] Á Á Accrued interest receivable related to marketable securities \$ 0.1 \$ 0.1 X - DefinitionInterest, dividends, rents, ancillary and other revenues earned but not yet received by the entity on its investments. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.9-03(10)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-599-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-599-1>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-599-1> + Details Name: us-gaap_AccruedInvestmentIncomeReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_MarketableSecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 50 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Marketable Securities (Details) - Schedule of Marketable Securities - USD (\$) \$ in Thousands Jun. 30, 2024 Dec. 31, 2023 Schedule of Marketable Securities [Line Items] Á Á Marketable Securities \$ 6,744 \$ 4,376 Level 1 [Member] Á Á Schedule of Marketable Securities [Line Items] Á Á Marketable Securities 6,744 3,964 Level 2 [Member] Á Á Schedule of Marketable Securities [Line Items] Á Á Marketable Securities 412 Level 3 [Member] Á Á Schedule of Marketable Securities [Line Items] Á Á Marketable Securities Corporate bonds [Member] Á Á Schedule of Marketable Securities [Line Items] Á Á Marketable Securities 412 Corporate bonds [Member] | Level 1 [Member] Á Á Schedule of Marketable Securities [Line Items] Á Á Marketable Securities Corporate bonds [Member] | Level 2 [Member] Á Á Schedule of Marketable Securities [Line Items] Á Á Marketable Securities 412 Corporate bonds [Member] | Level 3 [Member] Á Á Schedule of Marketable Securities [Line Items] Á Á Marketable Securities Money market funds [Member] Á Á Schedule of Marketable Securities [Line Items] Á Á Marketable Securities [1] 6,716 3,948 Money market funds [Member] | Level 1 [Member] Á Á Schedule of Marketable Securities [Line Items] Á Á Marketable Securities [1] 6,716 3,948 Money market funds [Member] | Level 2 [Member] Á Á Schedule of Marketable Securities [Line Items] Á Á Marketable Securities [1] Money market funds [Member] | Level 3 [Member] Á Á Schedule of Marketable Securities [Line Items] Á Á Marketable Securities [1] Accrued income [Member] Á Á Schedule of Marketable Securities [Line Items] Á Á Marketable Securities 28 16 Accrued income [Member] | Level 1 [Member] Á Á Schedule of Marketable Securities [Line Items] Á Á Marketable Securities 28 16 Accrued income [Member] | Level 2 [Member] Á Á Schedule of Marketable Securities [Line Items] Á Á Marketable Securities Accrued income [Member] | Level 3 [Member] Á Á Schedule of Marketable Securities [Line Items] Á Á Marketable Securities [1] Money market funds are included in cash and cash equivalents in the condensed balance sheets. X - DefinitionAmount of investment in marketable security. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-599-1>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-599-1> + Details Name: us-gaap_MarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_MarketableSecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_AllOtherCorporateBondsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_AccruedIncomeReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property and Equipment, Net (Details) - USD (\$) \$ in Millions 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2024 Jun. 30, 2024 Jun. 30, 2023 Property and Equipment, Net [Abstract] Á Á Á Depreciation and amortization expense \$ 0.2 \$ 0.2 \$ 0.4 \$ 6.0 X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 770 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

[page 22](#) Subparagraph (e) - Publisher FASB - URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gAAP DepreciationDepletionAndAmortization Namespace Prefix: us-gAAP Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gAAP PropertyPlantAndEquipmentNetAbstract Namespace Prefix: us-gAAP Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 52 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property and Equipment, Net (Details) - Schedule of Major Components of Property and Equipment - USD (\$) \$ in Thousands Jun. 30, 2024 Dec. 31, 2023 Schedule of Major Components of Property and Equipment [Line Items] A Total Property and Equipment \$ 7,181 \$ 6,969 Less accumulated depreciation and amortization 4,810 4,440 Property and equipment, net \$ 2,371 2,529 Leasehold Improvements [Member] A Schedule of Major Components of Property and Equipment [Line Items] A Property and Equipment, Useful Lives 10 years A Total Property and Equipment \$ 4,328 4,328 Furniture Lab Equipment [Member] A Schedule of Major Components of Property and Equipment [Line Items] A Property and Equipment, Useful Lives 7 years A Total Property and Equipment \$ 2,695 2,483 Computer Equipment [Member] A Schedule of Major Components of Property and Equipment [Line Items] A Property and Equipment, Useful Lives 5 years A Total Property and Equipment \$ 120 120 Software Website [Member] A Schedule of Major Components of Property and Equipment [Line Items] A Property and Equipment, Useful Lives 3 years A Total Property and Equipment \$ 38 \$ 38 X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/214748777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gAAP PropertyPlantAndEquipmentGross Namespace Prefix: us-gAAP Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gAAP PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gAAP Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gAAP PropertyPlantAndEquipmentNet Namespace Prefix: us-gAAP Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other. + ReferencesNo definition available. + Details Name: us-gAAP PropertyPlantAndEquipmentOtherAccumulatedDepreciation Namespace Prefix: us-gAAP Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYmMnDTnHnMns' format, for example, 'PY5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + ReferencesNo definition available. + Details Name: us-gAAP PropertyPlantAndEquipmentUsefulLife Namespace Prefix: us-gAAP Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gAAP PropertyPlantAndEquipmentByTypeAxis=us-gAAP LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gAAP PropertyPlantAndEquipmentByTypeAxis=us-gAAP FurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gAAP PropertyPlantAndEquipmentByTypeAxis=us-gAAP ComputerEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gAAP PropertyPlantAndEquipmentByTypeAxis=us-gAAP SoftwareDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Intangible Assets, Net (Details) - USD (\$) \$ in Millions 3 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Intangible Assets, Net [Abstract] A A Amortization expense related to intangible assets \$ 0.1 \$ 0.1 \$ 0.1 \$ 0.1 X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gAAP AmortizationOfIntangibleAssets Namespace Prefix: us-gAAP Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gAAP FiniteLivedIntangibleAssetsNetAbstract Namespace Prefix: us-gAAP Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 54 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Intangible Assets, Net (Details) - Schedule of Major Components of Intangible Assets - USD (\$) \$ in Thousands Jun. 30, 2024 Dec. 31, 2023 Schedule of Major Components of Intangible Assets [Line items] A Cost \$ 3,373 \$ 3,196 Accumulated Amortization (1,020) (909) Total 2,353 \$ 2,287 License agreements [Member] A Schedule of Major Components of Intangible Assets [Line items] A Useful Lives 20 years 20 years Cost \$ 2,043 \$ 2,043 Accumulated Amortization (1,020) (909) Total 1,023 1,134 Patent costs [Member] A Schedule of Major Components of Intangible Assets [Line items] A Cost 1,23 959 Accumulated Amortization Total 1,123 959 Trademark costs [Member] A Schedule of Major Components of Intangible Assets [Line items] A Cost 207 194 Accumulated Amortization Total \$ 207 \$ 194 X - DefinitionUseful life of finite-lived intangible assets, in 'PnYmMnDTnHnMns' format, for example, 'PY5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gAAP FiniteLivedIntangibleAssetUsefulLife Namespace Prefix: us-gAAP Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-55-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gAAP FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gAAP Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-55-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1 + Details Name: us-gAAP FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gAAP Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used

Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2>Reference 3: [http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40](http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: <a href=)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: <a href=)Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53](http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X.htm IDEA: XBRL DOCUMENT v3.24.2.1 Leases (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Leases [Line Items] Á Á Á Á Operating lease asset $ 1,055 Á $ 1,055 Á $ 1,221 Operating lease liability 1,748 Á 1,748 Á Á Lease costs 200 $ 200 300 $ 200 Á Minimum [Member] Á Á Á Á Leases [Line Items] Á Á Á Á Operating lease asset 1,100 Á 1,100 Á Á Operating lease liability 1,700 Á $ 1,700 Á Á Maximum [Member] Á Á Á Á Leases [Line Items] Á Á Á Á Operating lease asset Á Á Á Á 1,200 Operating lease liability Á Á Á Á $ 2,000 X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: <a href=)Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 2: <http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3>Reference 3:

http://www.xbrl.org/2003/role/disclosureRef -Topic 272- SubTopic 10 -Name Accounting Standards Codification -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1-Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-13-Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-13-Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-13-Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-13-Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-14-Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-18-Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-2-Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockInItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionDescription of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_CommonStockVotingRights Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4-Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3-Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_ConversionOfStockSharesConverted1 Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from capital contributions to an entity associated with a dividend reinvestment plan. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDtHnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2-Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2-Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_Data Type: xbrli:durationItem Type Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_SeriesBMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_SeriesAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=lgvn_SeriesAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=lgvn_CommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=lgvn_ClassACommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=lgvn_SeriesCWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=lgvn_SeriesDWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueConsensusPricingModelMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=lgvn_October2023

Balance Type: na Period Type: instant X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4:](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4:) [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5:](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5:) [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6:](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6:) [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7:](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7:) [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8:](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8:) [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9:](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9:) [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10:](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10:) [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11:](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11:) [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12:](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12:) [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13:](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13:) [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14:](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14:) [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15:](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15:) [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16:](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16:) [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17:](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17:) [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18:](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18:) [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19:](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19:) [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20:](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20:) [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21:](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21:) [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22:](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22:) [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23:](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23:) [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24:](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24:) [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25:](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25:) [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26:](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26:) [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27:](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27:) [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28:](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28:) [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(v\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_Data Type: dtr-types:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2:](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2:) [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2:](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2:) [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionMaximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYmMnDtnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYmMnDtnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details> Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: XML 60 R47.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity-Based Compensation (Details) - Schedule of RSU Activity - Restricted Stock Units (RSUs) [Member] 6 Months Ended Jun. 30, 2024 shares Schedule of RSU Activity [Line Items] A Outstanding (unvested) at December 31, 2023 11,239 RSU granted 30,200 RSUs vested (8,464) RSU expired/forfeited (3,250) Outstanding (unvested) at June 30, 2024 29,725 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details) Name: us-gaap_RestrictedCashAndCashEquivalentsItemsLineltms Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2:](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2:) [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R48.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity-Based Compensation (Details) - Schedule of Issued and Outstanding Options - Stock Option [Member] - shares Jun. 30, 2024 Dec. 31, 2023 Schedule of Issued and Outstanding Options [Line Items] A Stock options vested (based on ratable vesting) 22,621 16,091 Stock options unvested 14,180 27,695 Total stock options outstanding 36,801 43,786 X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2:](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2:) [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineltms Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of non-vested options outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedNumberOfShares Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R49.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity-Based Compensation (Details) - Schedule of Stock Option Activity - Stock Option [Member] 6 Months Ended Jun. 30, 2024 \$ / shares shares Schedule of Stock Option Activity [Line Items] A Number of Stock Options, Outstanding at Beginning | shares 43,786 Weighted Average Exercise Price, Outstanding at Beginning | \$ / shares \$ 49.6 Number of Stock Options, Options granted | shares Weighted Average Exercise Price, Options granted | \$ / shares Number of Stock Options, Options exercised | shares Weighted Average Exercise Price, Options exercised | \$ / shares Number of Stock Options, Options expired/forfeited | shares (6,985) Weighted Average Exercise Price, Options expired/forfeited | \$ / shares \$ (52.93) Number of Stock Options, Outstanding at ending | shares 36,801 Weighted Average Exercise Price, Outstanding at ending | \$ / shares \$ 49.02 X - ReferencesNo definition available. + Details Name: lgvn_EquityBasedCompensationDetailsScheduleOfStockOptionActivityLineltms Namespace Prefix: lgvn_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event

specified in contractual agreements pertaining to the stock option plan or that expired. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(iv\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2+Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iv)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2+Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod) Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1:

expensed and capitalized for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationCost1 Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: dei_LegalEntityAxis=lgvn_LongeveronMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=lgvn_UMAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_LicenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=lgvn_TechnologyServicesAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=lgvn_firPhase3ClinicalTrialMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=lgvn_BiologicsLicenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=lgvn_ChiefScienceOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=lgvn_SeriesCUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R51.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Employee Benefits Plan (Details) - USD (\$) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Employee Benefits Plan [Abstract] A A A Company contributed amount \$ 47,000 \$ 31,000 \$ 100,000 \$ 100,000 - ReferencesNo definition available. + Details Name: us-gaap_CompensationAndRetirementDisclosureAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost for defined contribution plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 70 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1 + Details Name: us-gaap_DefinedContributionPlanCostRecognized Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 65 R52.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Loss Per Share (Details) - Schedule of Diluted Net Loss per Share - shares shares in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Schedule of Diluted Net Loss per Share [Line Items] A A Total 6,940 1,895 RSUs [Member] A A Schedule of Diluted Net Loss per Share [Line Items] A A Total 30 98 PSUs [Member] A A Schedule of Diluted Net Loss per Share [Line Items] A A Total 125 Stock options [Member] A A Schedule of Diluted Net Loss per Share [Line Items] A A Total 37 401 Warrants [Member] A A Schedule of Diluted Net Loss per Share [Line Items] A A Total 6,873 1,271 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemBalance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_EarningsPerShareBasicLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PhantomShareUnitsPSUsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R53.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Subsequent Events (Details) - USD (\$) 6 Months Ended Aug. 06, 2024 Jul. 24, 2024 Jul. 19, 2024 Jul. 18, 2024 Jul. 17, 2024 Jul. 10, 2024 Jun. 30, 2024 Jun. 17, 2024 Apr. 16, 2024 Dec. 31, 2023 Subsequent Events [Line Items] A A A A A A A A Exercise price (in Dollars per share) A A A A A A \$ 49.02 A A \$ 49.6 Warrant shares 2,565,392 A A A A A A Series C warrants [Member] A A A A A A A A Subsequent Events [Line Items] A A A A A A Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) A A A A A A 3.25 A A A A Warrant [Member] A A A A A A A A Subsequent Events [Line Items] A A A A A A Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) A A A A A A \$ 2.9375 A A \$ 2.35 A A Warrant shares A A A A A A 5,536 A A A Series B Warrants [Member] A A A A A A A A Subsequent Events [Line Items] A A A A A A Aggregate gross (in Dollars) A A A A A A \$ 9,000,000 A A A A July Private Placement [Member] A A A A A A A A Subsequent Events [Line Items] A A A A A A Shares issuable (in Dollars) \$ 2,236,026 A A A A A A A A A A July Offering Placement [Member] A A A A A A A A Subsequent Events [Line Items] A A A A A A Shares issuable (in Dollars) 156,522 A A A A A A A A A A July Ordinary Course Placement Agent [Member] A A A A A A A A Subsequent Events [Line Items] A A A A A A Shares issuable (in Dollars) \$ 172,844 A A A A A A A A A A Subsequent Event [Member] A A A A A A A A Subsequent Events [Line Items] A A A A A A Exercise price (in Dollars per share) A A A A A A \$ 3.9 A A A A A A Percentage of aggregate number of shares A A A A 7.00% A A A A Exercise price (in Dollars per share) A A A A A A \$ 3.125 A A A A Expire date A A A A Jul. 20, 2026 A A Jul. 24, 2026 Jul. 17, 2026 A A A A Subsequent Event [Member] | Series C warrants [Member] A A A A A A A A Subsequent Events [Line Items] A A A A A A A A Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) A A A A A A \$ 50,000 A A A A Class A Common Stock [Member] A A A A A A A A Subsequent Events [Line Items] A A A A A A Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) A A A A A A \$ 2.5 A A A A Exercise price (in Dollars per share) A A A A A A \$ 5.0313 A A A A Percentage of aggregate number of shares A A A A 7.00% A A A A Warrant shares A A A A A A 2,236,026 A A A A Share issued A A A A 156,522 A A A A Class A Common Stock [Member] | Warrant [Member] A A A A A A A A Subsequent Events [Line Items] A A A A A A Percentage of aggregate number of shares A A A A 7.00% A A A A Class A Common Stock [Member] | Subsequent Event [Member] A A A A A A A A Subsequent Events [Line Items] A A A A A A Exercise price (in Dollars per share) A A A A A A \$ 150,000 A A A A Reverse stock split 162,344 A A A A 10,500 A A A A Percentage of aggregate number of shares A A A A 7.00% A A A A Public offering shares A A A A 2,236,026 A A A A Aggregate shares A A A A 4,025 A A A A New Warrant Shares [Member] | Warrant [Member] A A A A A A A A Subsequent Events [Line Items] A A A A A A A A Net proceeds (in Dollars) A A A A A A \$ 6,300,000 A A A A New Warrant Shares [Member] | Subsequent Event [Member] A A A A A A A A Subsequent Events [Line Items] A A A A A A A A Exercise price (in Dollars per share) A A A A A A \$ 2,319,186 A A A A X - DefinitionPercentage of aggregate number of shares. + ReferencesNo definition available. + Details Name: lgvn_PercentageOfAggregateNumberOfShares Namespace Prefix: lgvn_Data Type: dt:percentItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_Data Type: dt:types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - DefinitionNumber of shares of other common stock instruments held by shareholder, including, but not limited to, exchangeable shares. + ReferencesNo definition available. + Details Name: us-gaap_CommonStockOtherSharesOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - DefinitionExpiration, mandatory redemption, or due date, in YYYY-MM-DD format, of the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_DebtConversionConvertedInstrumentExpirationDueDateDayMonthAndYear Namespace Prefix: us-gaap_Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionThe number of units sold in a public offering of each class of partners' capital account. Units represent shares of ownership of the general, limited, and preferred partners. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 4.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-5Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemBalance Type: na Period Type: duration X - DefinitionThe cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/194

[illegible]

WEIK7LILF'G&.%9%48.7%6;(IC-E5Q1>9V)G]/P M6.FSHJ3ZV"FI9=UPB&KJRR01[O G. &1&0VY/%V0%>^T@ V9LX-D*U2%8-?B1 MAT-O+J]73R34"(CZWGRIP+S) 7H(R01P)k&ZU M.OJ3J.9J [HB*Q *L\$+&6X(A)LA0BM7DGB*QO]"F@O80(4VR)="I Q MA4P7TGD X=-{(K0,S; RP@%\$SFR.:21K\$%;?LERA(EZ8>G1ZZ2Q)>M#ND M NO 99V[IFZ55QI]>: 51J;GTX2(-P#5U0J[69X]>=<8Y1J,K8,D+<G;0# MN(MD)7B,P%>WJY@<P(,**)J?TG2N;7./A+<6JYD#\$%>SMD68J,RO[W2.D.HID M(5-&LONIS)&]S%<1>:4TL1QI>@/(JT-1W@<FJ:3B GMH[KHL9G6C0 M)+S600(O)<M*?MQ4+GITB-N+1; 2/(G[K875&DHP+=+< QHBTJYRRXK- M.L.S: FXLA<+!%CB JY'J9@< ; 4244*CS;<EK J6G=<XCE2Z=VF=)T)D7%> M)+S5XSV17&TCT9<1ENK >KYOI@/3TJ56HU.ULBVP+=<FDJ+P(CFO-D01 M1)MSJG(A3CC")<M+2 MI(^(6*H+<4 X2ZKH9L"\$<1<,<V MA'E*V4*<%)>FDWX=<B)P JO*=<W*#<T.~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i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

0?OEV@?2MH MEAD?J?O33C033? KKLK! XBjY?Y<+TS!>=!E5K15SFLXKQWIE M&63FK HKG>KZ539,WQTO.M0,1Q1QB?&7.(A GEV6!)&3F#&K?&OY< MR-
BAIT6&+WU00T\$%17?&F&1?&L36B04?ER\$L Y7?DQ1JGWSBUJ9?& MNNS50XFKU5U/7T04N(HH. Y< MH@?71M?J29[EQ0A&ZE8E+W6(W6H2DNK4UD+ZEPRI?&?AD2_JNX=
W7.2Q<+=[I:W&A]#%>17, /J8LXD6W?DW M7@AMG(@S):9@SSM0R1J=JR([RTRRUZHY)6CD;+!0R.CN!IRYULQJ.LR1ZJ H;WAG?>3,K.EB06!|T|9V>Q& Z\$&TF3C?N?>.
MD0V&8&47?30<@/9+K<UVM&AL F33/U+ P04 " L@ Y9YH&S;TH!+ M&& &O?AL+W=0=78J2 M\$P\$D&E=7>,(2/39)K&Z\$27-;10GDZN@BSO/VHBS.9&63%!(.S!JLJW?<
AS!6&8;|AN>@WA(QVW)K1<1!&#&G&IV M+<4/IGX? TI!9%;T9&R8+W.U.R0JF:*K4 IMAF6J1&4#TB8R.R.34&L2.A M 4/91Q.D =>CT10@36F(C)5.OU+~.R571.JQ?Y?K?M6&HSC?2,EUBAB
MRT?7-SF<@U+YBPYU,?JPSD0&U?<4EBJN"AS5ICH9?2>3\$VOR(8U8M"X M G-JFX+?IJM@!+>3HD8H@E@!>=,=N@;USZ.K;|QOCZ22R|CVBA Q+|=|A:|)M|MW:L\$1=&9#=&CZ
M1,W|J0:|Q JEWNL626W9J?V? ?Q6X4?&#FCQBE=M R+1+ !1\$10>.;HDW05=-65H4 (U1|X|Y!=PDEL1014X0|,|5RS2)RRQ1|G MFER3654@<3|J\$C4G?WF&C?Q?D29-VNP3
084#ZP?WB~X#+=|I(F MR1R2E!| \$8 FVJB@S!|,|R|XRTYH?<5A>?>@<QSRU2|HS7N1|J?<Q&W59 MEJ58&GK/H|,|<C C|PD|P41 T201PU2B?=&62P?B3/?#&N?>HCG0@R,~F
M0HJ|QK9W~,"QJ@<SHZBP~>?#YMOQT (FV)/TV\$J @<S&L&A&V~.M:KG M<NVR|3WN%K,4Y>.&ZN+&+5%P&A @C|CUCV?O?>?OF?QWAFY9?~BH>~.V:1 M#V@NV52J%~%HF"C%
SZQ?IZ,"9Q?5R62 _B3 5QDZ.V6X~=.U MP&L62HSM2R!;QM#MR1DED6U?=&DUXG4VB>@T,UABG+|Q9\$8FEDH#23,FOL4A7%70MDXRFCV2A9-JD
M|<?<Y=&3043WOMU@/0Y%KP\$156!EIG\$DZ QYH 5(+|BNEG&=QOX|3U) R M|Y=&D2>0A#P|W?&0&1|J|.AF.8UH6#P7|.8 L&9X4H|J|C|+49SP6#>.<X M J4,~S!>H6K0JN&+F\$&
~="L6~&Y&EF,1@R,M,@X|1, 05W%W@U|JPR|("8IQ0Q2U-189 R+JNMG@&E2?IF?Y@<#C|>M21?A1?W1R? M C-8SUQ OXNX M.WJD|SFEF=|Y|H|D @<UD9|U1FL9,44!>?&V2V =C
M|NXC%<SYH4?>:SQ<~&P BOX(S"~"IB18P3L10M|(B18Y92XC?>K&A59?>0 M,4|HOSA|<+&H|(052VXW,M;5&F;TF?>?>SOSR5AXX~L10G6GT4&D\$3D< M T3UO*NB#F|!BX|X1~?W2?
C|N1VW\$0(SVLF?>)=@<PZ QY338L\$5?>:17K|UYUMVJ2 1&-PFMHQ2K&G@<SZFF@|<4E77|7G0V LCY 5IKVZ.U?>N?F?>=<X|H3J6*4XJ|TL(Y&9|.IYZ MS|N)JVTV*Y|O=>
(Y|<Y<9DFOFCQ%<Q&S~"3FFGUA@<Y\$3,06>?>F-R+<31,NF|A1J|WMMW&H~8*4"|1~MX>4C15D1|T~R-5?F~"W|KONKA~F*0+>|>J|E2U|O.M F#&5~1;|Y/M|DIHD> M@?TM4V~V*H=
<~>.,6TU|J@:8YF.JXW K6~&+|LHB;M?<Y3U>Q>JEC +0B06.(H~<Z3C&HHJXZ+>|R,Q~<Q?>3*Q7V@<91Q Q?2&FJ M|JR@<U?>Q|7Q2P.S@<K|.6<44OCZ?>P<|D |X;|JW;WJ
M&UL55M;|HP\$<XK5E9K;225V!C\$?D0IG5J|U36 M|,~.1J8F>V0|J /L|&S105H8XOB7V~YWEYU|=&N&+<2>0 %C&WG&143*Y6R M&~FVB%<|L>BQ |JZG63>8ZVF?
&V@&@<~"~C/|,|Q|G:~.7!L~M~&AF!&|629J&+7~>P M6J|VD|NZNM<Q?3.PJEDF&R?|J7X3J.EE<K&DQ|PLEP@<5 01J %<S~ M-84\$1%G3|0V@<4>|HX3?2M|N@00,|>8X7?>C=QK<@|PKG
M_J3G;U;?2X;?5H60@/RWS\$78)=T03=>[F|TCA>8] 8I9J?@<XJ|SP 3MWX\$SN MROOYR?|SDLW|+>|WJ|D|L\$Q|O?&A*W&-8YH,O0K(BBK3?H*0>@<H37CM MI2|B?P.KR&P=&#>|Y|W>+F-
_S&NM7|VCLM0*>@<H-K H)B5 9U-9UV5K;?>0-CNNPK?>J=O=S=P>Z3&AS&U. M7L~&T+&S4&S&E..@Z@J G M1;V1K~>1%<9%>U5|..E4C&KAV4.V ~V G V Q R8P5 M=N(X|O)=|..E6R&=&5
6CT4C.N9E&=&7,3QR|OH,J2C3 S9~"RIK,Y5EK|H MF+BDLFD15HS&E>95.WMI+95+240KXB1;UUB~>+H|?2S|J2N%|U16VB|M\$V.3|3K?P M&L|J|G&GD|H\$501P9&S&A>S>+B8UW
3L~7!&E~UD|VGF2 M\$+&?%<@|L~E~N J~7&+AH _X@?<E33P<@|<EWKG93RQKHN1|76R&ZF7D C M\$|SH<.<OT@<JA~A5T|J|O|<4>I5|N\$V\$V|XDXDGFKM&AWR<@<|K\$|QB?|&P&D&|Q
MA12D&F&K0.B~G1|EKGSVEV?|IHPW~ERI+M0(46Y _E\$|>G>L3|OT(H5+4F&A;T\$|(Y5W4&QZV M0;E1#6 >HEZ~>?>E[U|.S8EH|J|.M|G3&P<S|O&H|Q1;|C|G?>|J|AUP8>DYN9.5&
|~K:~TC\$9&N\$3.F.F;=<K|W;| M|L%<+<M+>A8&GQ>?# MT|O&6.H|O2&K&L5K5Q|4W BM>SLPZGS J
)&A#&O?>#SF|K|Y%&M;K+N|J\$P,3M =7),\$WC\$G|9U 5G~<N5M|>+&F9D21W\$1+C?>P|FTIOE4<~<N"|L0U;6+Z5YV56NK M7|PES:WQDW4 %9&N5/PH6>?>|LA?>?>#&|<U|K|J|E5, 584I
M&O,|VXU|PUYQ?VE53|>AXHDZ.3T|WT L\$5 (Z3W0>|>|>?>5W5E MEY5~>?>Q7K1IAB?|?B|EK&XC0 X|Q0987\$&~&K|<7.1N7AQ<~Q9IKLWIRW ~N54,~>|JASB-
ASC=1 WE*~<V|LHR,|P-K5),QCF P,2N|X|J|HO,|J556E!EA@<|RMCRCGQ;Q><+<KW1U.VZ.8TA(OA=8|M, @<UJ>+7F&8&AVNU*2E=3 M|J?>P?>Q?>NINC1~>|J|.M5|SKNPF12F.J6S.C.ZET)5M.(X7|X|J6
?>QK~L10M ZMIE 7M5E81K\$SWV9D|>3\$S ~EL~Z?>K5|J07LEG;84~N~>YAA9K;JH M-5T5 VQ2L VWMQ?M?Q?>B|BK.MJCE;<=N YN|JG~L *O5..E~G3P6E9L
M+MHL~K?>L8&.>60ZLT,YFN|J|H.CP.5416F36T\$F6G LKNF5V~PN~<?>K-9@J M0H _WLQX?>Z M.C1.Y9 D+>=<KX&X+>?>ZTJV:~S|<G-3=J5V|K6F|>1~>|YR MZM|J."Z' M,
(O4&HBZ4~>4)20)<8-(W+4RNNQR?>UM132 6+300!<~>97V&AN5B M@BRKL8M|J0?>QV\$C+! 3C\$|U|ON4.6\$U>26|L|Z&8;U,4N. PS&PD5 MJMW .P73=>1~>8&R7V+|/A*B9BR|Q6V&Q|K5G
G\$E|).G.W~<| MRGP036X~<0?>XQ2L\$ZL\$1?>#C.MOSJ&VBP1 80|J\$=2|J|>| MBVGOWLE ML&A@&

[illegible]

(=A3XS1[37@6H9]@E4DZBF45VCFD5UGV>P63>=#@8IJW%A*EA OC5 M38[9D7N(\\&L]A ?IG2ZTU8%J] M4DJBE4TZAFA,VBFJ,T/X)U1V1VLEN[S- ^ M**IEJ*903*:0C6- :@;5+*HY20-S5 ,=I9D=N[P?/[?<9IGL*#RV\$HJ]HMZ? MT73W0&:1C6#&:A;5*5Y 8L~?<C] 6KSDRR&5K(ZE+9,J,[KN#&,%CSLX,WS^N,(S0[3-P7*GY15&M3P;F;P0@7.GX M>- /+;*+5 M\$);+6\$ZP&GQY07*:Y0S+699S&-?*>+21P1?[(CVZCD+G H IE+>R\$1) 9<K0F_ 6Q>B>6&6ZSG&5Y>+@A'H C_#>AKM1FQ<5LYF3S&FYU +@JWZ6~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~^W#U>+ MYI- R=K10/GGGJ?K80^>W0!7UJMY?W;I_?SL#110 (*R #E@C[\\C# M2 D 1N 9 &P=VJR:W-H965T3C&@!#7< _.:IELHV\$2YJDK*=P?S2X6515 \$M5IVC/045? O=HGA<53R7R?5KDGJ?7R,LSL4QGN5[5GUE?]?C9_EI&G25+& M&:O?7^9IY.?J8_K4O=VJR:W-H965T3C&@!#7< _.:IELHV\$2YJDK*=P?S2X6515 \$M5IVC/045? _DM=\$YVT^/S598G41VL6A %SO MW1/[U_=.L1H3X1;[I^C9AC6 <C T9UP.C8@=\$,%XV8%(^3JC6QV,EAZ M?NY/+|/DE:3%UHI6+)^2**/5(OSBOKMW>:I^&ZBX?&K_6@7YCR_7ZO OR^R; M+;|SY1|?^N3W) _|1#^YXN01[+|IE_U01[|GV;]^RHP\$;^F|@SS15:U4RS1= M&^JH|^+?J?U8J1[Z(L1%U010]3PL<L^Q_DKL MJZ_DVC8? [F^SX&0^?78]MM; <L^H^?7<+>COJN>SELB^KO#<[X- 7;= MQ@MSN^?G^M@QJ(VVUN)V2YV0WJY_4IN2WVW(99J1DIVS)=>NYQ7ARD2W]MN;SJJ0&C^F^+|S+W C=K-/A^FUZO,)HT@80(X\$B9 ,5A#^|EJ^KHD^0?M9) M8K= 7^YJB2V5=Z5BY_A&>5=14>#N8A810)8T@10]1N16L&(^6^3^U+LY MO^R^M^AJN^6;4T^*BHNSR92R?)LNC,B+? 9#H/,OAE^27=0?B^OJZB0, ^| MIRIY(2VT;4YID:U@21A^P@O(INELM_-9Z&B+^9DM@|0L_>=I&S^KC(DS-0)O MIS^78+S,D,Q@2QIS^P,4L,AN0938RZP28#_E2]6(RSM7I\$5\$6PI^YF- (&\$?^? BF^>A^K;|SHX+HVU+>BYEZ&^RVJ)D+&|^X^ M0L(\\XZ9|CAD,Q@2QIS^P 8)INK(&C<E:9P9T|^+|@!^J51*(U1:1Q*SRB;+L;&K&=&)ZHL6U^?; \$KSH^0^I3\$H MC4-I D73Q>@82,90>J88JYIFU5^? WQL[YP0(WRXY)2%(&I7\$H3;1(8;_LM-78X);9I]>=D&G60NBJE6LLJ\$7^T\$1=-@4QVFN;^,H_8-14 SIN^84F M95 :A|(\$B|;KJ^#^+> 17.GHWY6.C+>KJ^T^17E0&H72&3&H32IHNG7759^ MN3TXX?>S^1AJ_R_K@|(HE;@- ZE^11-V-3UW!^?C^~.4-G54(+ %:A=(8E;A M-. LWNYN|C3:2H7Sj&^~^SP8DPSM|^/H^4,*^U^~:RF;5Z-&|_XH^%4PH4 M37^>:/U#<,TU#;,4IZ=<%W/BKAJ\$TCPHC4)I#&KC4)I T72Q-14|U25#0?; M^#82^|B^0FD,2N-0FD^1=#\$VEUO_W1^=F+&F=MOBM@T1U\$IC4I1V=V1=<L^L MK%;>H^+J&FO^*^ZY#^JH=#|ZOE95GLZ>@Y9 H^03\$5HC4-I D73M;GQ^H^I3 ME4!<; D\$20_@_JE_2B-OVD^1(=V^Y) W_-?2^!81^1_7BL_07,BTV4^1_3)+_4.18|BVG_5 1+P4^>^L^ Y91H+E M-L^ #V!@< @_AL+W=OJ\$D|/W-J=CD>IPEQ(N_ /,5&7I]>L\$UOQLS_VBNSM^A^?^ M2KZ >+>I>=IYCQ>=||GOQK GP69FO,^?;2CW9R47ZT M|@C^0)(T#P)^BSA\$O><SIE+YS6GUTA:X/9XP_[%Y4ZY^(#ERK_)5+>QMJO M8RG,>97C5^+PCJ7GPN5+5&I<+UNMBR,9515\$YI^*OLOJREW4 M=|A9P|01_?^Y[\\6D/909;MH5A,X^KD2^HRH<12 M=JD^FS#7;V.K@>YR,TQ.V\$S^B^D50Y,S=ET=LIN;^T)1UM3,%A%@@@2?H4J> MV+T4;-@1A1^TX1:*1J^_1S22620D)VMCDJ|I8N,-8G|TJB9EAUS%*|%^~3TDV MF8;3"? A0<=>OE3QE4^?A4^892;C&P|V|V@J^B18.IHHSVT>TOS|)TBV0U^85K3 MKVFI|^3V+I2;DB RC0H>HVGW0M^/MG@+ MS26^>/U:L|^C&074=>H0^H^XUF_S_ P^KLVS3^|YHGVPZ_VXZY;0^|B^>270 MD/K45.<@|@|=M6CL+JGV1?%N.SZ(1A.H^=9WM4 M2W#23-ZF\$#;_J^?X6;B15HGKKX^U1+ P04^>^L^ Y92D.33Y@>^# M!@&0 ^AL+W=O>MFM7J75BVBWJ?Q DK\$^ISDDS;,%JD,C^#^UNS^W<Z5-6Q-3R5I2^U>=<9&^;L2 M0Z1-IQ|O4R BS1\$IEGV39^H.G.26NE1=&^D^4R1RN9-GUH=U@|^I^ H@;^'IOP^A^ M^M^A=0AMFJ^MPSJ72D1\$SDTGAC+>PVE@T5L^1^Q5OM<13ACB>?^VLF7X^.\$4E M,C(117;H^@Q3O;E^>P3P|^+39/5G;@8DN8E^K1EY8RN;JUTKA@Y9Q<5O;E MC+>6Z4-KD|M+*8@|W^?Y52^BEV-M\$UR-VTIGC84@U_0XNX^8LF^AD+=|J7=)(KZ\$YGI M>Z(JFL+8PONJ0^I_23Y^\\(?>YSX5_E.P#4W^3I/PK>A)|E%6_8^E\$95J|:V MJDTAT6BGQ>9=&5%F0%J2.6^<X>,<=<=A50;0SSX30^*,LNZ_E7P^%4K^110 (L^R #E&F;2&Q^&I,^<M+9>+>P=O^VJR:W-H965T18=>M9Y,9Y8J|9N^|T^Z-4\$4Y M@>=>=>=>HX)>=1^F9OR>_1^F1\$4^@Y>=>7^P@8BNQXSOKBOLR7T|JX<C^L M #FN3/8LKS^RV^U1^0?>@BCB_<L|ISZ|Q_1^9FQ21^?|J|TWEAK^6/3A-QXZ M-\$5&B=0NL&J6< 191CTI^>^U4Z^>J0W;^7W+X;|(G.#11RQ|JDDH^?6TOXIEPGS1|JF.K2@I6EY;P0Y(16+>ZOA6@9&^&_Z V M^ SN^I1^>8PECD>U>1:Q&@&X:3P.KP6TD| M^*3V4.%7?0>N4@L_ =1-18(8-:A^*8;R(\\U@=V^3B7BDJLDE?>N O Z M8I2(B.B^EDJBA,K1 MEFV^HEFX=O@5G&^;C#5@ZT48,V^D|J|PZ;^~^UF2@|(A115) <8,R/|GHH|60F^VH^&@M.W^\\JUGT^IKR9^_ MM4M?1QZT(??>"SC#<@3G88 I>Y.;&JF>5-7@B.Q@-/?^Q,W+Z%N^?KA??W W4 M9R0-GTB|JFTO> 37;=5%."YJ^X\$2EA)954B;-> A7E8U56;Y55>H>Y>E, \$ MRF^F3+U.7TG%|XJ0&DA6F^KKADE5LYGN0E^T^J_7^&F^P|^="(F^FH|_E1+ M P04^>^L^ ?0Y(UL)P^*;&P @0^'AL+W=OXPS|RR>A>Z.K MS7T^>J^J60^JCVZ_VXZY;0^|B^>270 MD/K45.<@|@|=M6CL+JGV1?%N.SZ(1A.H^=9WM4 M2W#23-ZF\$#;_J^?X6;B15HGKKX^U1+ P04^>^L^ Y92D.33Y@>^# M!@&0 ^AL+W=O>MFM7J75BVBWJ?Q DK\$^ISDDS;,%JD,C^#^UNS^W<Z5-6Q-3R5I2^U>=<9&^;L2 M0Z1-IQ|O4R BS1\$IEGV39^H.G.26NE1=&^D^4R1RN9-GUH=U@|^I^ H@;^'IOP^A^ M^M^A=0AMFJ^MPSJ72D1\$SDTGAC+>PVE@T5L^1^Q5OM<13ACB>?^VLF7X^.\$4E M,C(117;H^@Q3O;E^>P3P|^+39/5G;@8DN8E^K1EY8RN;JUTKA@Y9Q<5O;E MC+>6Z4-KD|M+*8@|W^?Y52^BEV-M\$UR-VTIGC84@U_0XNX^8LF^AD+=|J7=)(KZ\$YGI M>Z(JFL+8PONJ0^I_23Y^\\(?>YSX5_E.P#4W^3I/PK>A)|E%6_8^E\$95J|:V MJDTAT6BGQ>9=&5%F0%J2.6^<X>,<=<=A50;0SSX30^*,LNZ_E7P^%4K^110 (L^R #E&F;2&Q^&I,^<M+9>+>P=O^VJR:W-H965T18=>M9Y,9Y8J|9N^|T^Z-4\$4Y M@>=>=>=>HX)>=1^F9OR>_1^F1\$4^@Y>=>7^P@8BNQXSOKBOLR7T|JX<C^L M #FN3/8LKS^RV^U1^0?>@BCB_<L|ISZ|Q_1^9FQ21^?|J|TWEAK^6/3A-QXZ M-\$5&B=0NL&J6< 191CTI^>^U4Z^>J0W;^7W+X;|(G.#11RQ|JDDH^?6TOXIEPGS1|JF.K2@I6EY;P0Y(16+>ZOA6@9&^&_Z V M^ SN^I1^>8PECD>U>1:Q&@&X:3P.KP6TD| M^*3V4.%7?0>N4@L_ =1-18(8-:A^*8;R(\\U@=V^3B7BDJLDE?>N O Z M8I2(B.B^EDJBA,K1 MEFV^HEFX=O@5G&^;C#5@ZT48,V^D|J|PZ;^~^UF2@|(A115) <8,R/|GHH|60F^VH^&@M.W^\\JUGT^IKR9^_ MM4M?1QZT(??>"SC#<@3G88 I>Y.;&JF>5-7@B.Q@-/?^Q,W+Z%N^?KA??W W4 M9R0-GTB|JFTO> 37;=5%."YJ^X\$2EA)954B;-> A7E8U56;Y55>H>Y>E, \$ MRF^F3+U.7TG%|XJ0&DA6F^KKADE5LYGN0E^T^J_7^&F^P|^="(F^FH|_E1+ M P04^>^L^ ?0Y(UL)P^*;&P @0^'AL+W=OXPS|RR>A>Z.K MS7T^>J^J60^JCVZ_VXZY;0^|B^>270 MD/K45.<@|@|=M6CL+JGV1?%N.SZ(1A.H^=9WM4 M2W#23-ZF\$#;_J^?X6;B15HGKKX^U1+ P04^>^L^ Y92D.33Y@>^# M!@&0 ^AL+W=O>MFM7J75BVBWJ?Q DK\$^ISDDS;,%JD,C^#^UNS^W<Z5-6Q-3R5I2^U>=<9&^;L2 M0Z1-IQ|O4R BS1\$IEGV39^H.G.26NE1=&^D^4R1RN9-GUH=U@|^I^ H@;^'IOP^A^ M^M^A=0AMFJ^MPSJ72D1\$SDTGAC+>PVE@T5L^1^Q5OM<13ACB>?^VLF7X^.\$4E M,C(117;H^@Q3O;E^>P3P|^+39/5G;@8DN8E^K1EY8RN;JUTKA@Y9Q<5O;E MC+>6Z4-KD|M+*8@|W^?Y52^BEV-M\$UR-VTIGC84@U_0XNX^8LF^AD+=|J7=)(KZ\$YGI M>Z(JFL+8PONJ0^I_23Y^\\(?>YSX5_E.P#4W^3I/PK>A)|E%6_8^E\$95J|:V MJDTAT6BGQ>9=&5%F0%J2.6^<X>,<=<=A50;0SSX30^*,LNZ_E7P^%4K^110 (L^R #E&F;2&Q^&I,^<M+9>+>P=O^VJR:W-H965T18=>M9Y,9Y8J|9N^|T^Z-4\$4Y M@>=>=>=>HX)>=1^F9OR>_1^F1\$4^@Y>=>7^P@8BNQXSOKBOLR7T|JX<C^L M #FN3/8LKS^RV^U1^0?>@BCB_<L|ISZ|Q_1^9FQ21^?|J|TWEAK^6/3A-QXZ M-\$5&B=0NL&J6< 191CTI^>^U4Z^>J0W;^7W+X;|(G.#11RQ|JDDH^?6TOXIEPGS1|JF.K2@I6EY;P0Y(16+>ZOA6@9&^&_Z V M^ SN^I1^>8PECD>U>1:Q&@&X:3P.KP6TD| M^*3V4.%7?0>N4@L_ =1-18(8-:A^*8;R(\\U@=V^3B7BDJLDE?>N O Z M8I2(B.B^EDJBA,K1 MEFV^HEFX=O@5G&^;C#5@ZT48,V^D|J|PZ;^~^UF2@|(A115) <8,R/|GHH|60F^VH^&@M.W^\\JUGT^IKR9^_ MM4M?1QZT(??>"SC#<@3G88 I>Y.;&JF>5-7@B.Q@-/?^Q,W+Z%N^?KA??W W4 M9R0-GTB|JFTO> 37;=5%."YJ^X\$2EA)954B;-> A7E8U56;Y55>H>Y>E, \$ MRF^F3+U.7TG%|XJ0&DA6F^KKADE5LYGN0E^T^J_7^&F^P|^="(F^FH|_E1+ M P04^>^L^ ?0Y(UL)P^*;&P @0^'AL+W=OXPS|RR>A>Z.K MS7T^>J^J60^JCVZ_VXZY;0^|B^>270 MD/K45.<@|@|=M6CL+JGV1?%N.SZ(1A.H^=9WM4 M2W#23-ZF\$#;_J^?X6;B15HGKKX^U1+ P04^>^L^ Y92D.33Y@>^# M!@&0 ^AL+W=O>MFM7J75BVBWJ?Q DK\$^ISDDS;,%JD,C^#^UNS^W<Z5-6Q-3R5I2^U>=<9&^;L2 M0Z1-IQ|O4R BS1\$IEGV39^H.G.26NE1=&^D^4R1RN9-GUH=U@|^I^ H@;^'IOP^A^ M^M^A=0AMFJ^MPSJ72D1\$SDTGAC+>PVE@T5L^1^Q5OM<13ACB>?^VLF7X^.\$4E M,C(117;H^@Q3O;E^>P3P|^+39/5G;@8DN8E^K1EY8RN;JUTKA@Y9Q<5O;E MC+>6Z4-KD|M+*8@|W^?Y52^BEV-M\$UR-VTIGC84@U_0XNX^8LF^AD+=|J7=)(KZ\$YGI M>Z(JFL+8PONJ0^I_23Y^\\(?>YSX5_E.P#4W^3I/PK>A)|E%6_8^E\$95J|:V MJDTAT6BGQ>9=&5%F0%J2.6^<X>,<=<=A50;0SSX30^*,LNZ_E7P^%4K^110 (L^R #E&F;2&Q^&I,^<M+9>+>P=O^VJR:W-H965T18=>M9Y,9Y8J|9N^|T^Z-4\$4Y M@>=>=>=>HX)>=1^F9OR>_1^F1\$4^@Y>=>7^P@8BNQXSOKBOLR7T|JX<C^L M #FN3/8LKS^RV^U1^0?>@BCB_<L|ISZ|Q_1^9FQ21^?|J|TWEAK^6/3A-QXZ M-\$5&B=0NL&J6< 191CTI^>^U4Z^>J0W;^7W+X;|(G.#11RQ|JDDH^?6TOXIEPGS1|JF.K2@I6EY;P0Y(16+>ZOA6@9&^&_Z V M^ SN^I1^>8PECD>U>1:Q&@&X:3P.KP6TD| M^*3V4.%7?0>N4@L_ =1-18(8-:A^*8;R(\\U@=V^3B7BDJLDE?>N O Z M8I2(B.B^EDJBA,K1 MEFV^HEFX=O@5G&^;C#5@ZT48,V^D|J|PZ;^~^UF2@|(A115) <8,R/|GHH|60F^VH^&@M.W^\\JUGT^IKR9^_ MM4M?1QZT(??>"SC#<@3G88 I>Y.;&JF>5-7@B.Q@-/?^Q,W+Z%N^?KA??W W4 M9R0-GTB|JFTO> 37;=5%."YJ^X\$2EA)954B;-> A7E8U56;Y55>H>Y>E, \$ MRF^F3+U.7TG%|XJ0&DA6F^KKADE5LYGN0E^T^J_7^&F^P|^="(F^FH|_E1+ M P04^>^L^ ?0Y(UL)P^*;&P @0^'AL+W=OXPS|RR>A>Z.K MS7T^>J^J60^JCVZ_VXZY;0^|B^>270 MD/K45.<@|@|=M6CL+JGV1?%N.SZ(1A.H^=9WM4 M2W#23-ZF\$#;_J^?X6;B15HGKKX^U1+ P04^>^L^ Y92D.33Y@>^# M!@&0 ^AL+W=O>MFM7J75BVBWJ?Q DK\$^ISDDS;,%JD,C^#^UNS^W<Z5-6Q-3R5I2^U>=<9&^;L2 M0Z1-IQ|O4R BS1\$IEGV39^H.G.26NE1=&^D^4R1RN9-GUH=U@|^I^ H@;^'IOP^A^ M^M^A=0AMFJ^MPSJ72D1\$SDTGAC+>PVE@T5L^1^Q5OM<13ACB>?^VLF7X^.\$4E M,C(117;H^@Q3O;E^>P3P|^+39/5G;@8DN8E^K1EY8RN;JUTKA@Y9Q<5O;E MC+>6Z4-KD|M+*8@|W^?Y52^BEV-M\$UR-VTIGC84@U_0XNX^8LF^AD+=|J7=)(KZ\$YGI M>Z(JFL+8PONJ0^I_23Y^\\(?>YSX5_E.P#4W^3I/PK>A)|E%6_8^E\$95J|:V MJDTAT6BGQ>9=&5%F0%J2.6^<X>,<=<=A50;0SSX30^*,LNZ_E7P^%4K^110 (L^R #E&F;2&Q^&I,^<M+9>+>P=O^VJR:W-H965T18=>M9Y,9Y8J|9N^|T^Z-4\$4Y M@>=>=>=>HX)>=1^F9OR>_1^F1\$4^@Y>=>7^P@8BNQXSOKBOLR7T|JX<C^L M #FN3/8LKS^RV^U1^0?>@BCB_<L|ISZ|Q_1^9FQ21^?|J|TWEAK^6/3A-QXZ M-\$5&B=0NL&J6< 191CTI^>^U4Z^>J0W;^7W+X;|(G.#11RQ|JDDH^?6TOXIEPGS1|JF.K2@I6EY;P0Y(16+>ZOA6@9&^&_Z V M^ SN^I1^>8PECD>U>1:Q&@&X:3P.KP6TD| M^*3V4.%7?0>N4@L_ =1-18(8-:A^*8;R(\\U@=V^3B7BDJLDE?>N O Z M8I2(B.B^EDJBA,K1 MEFV^HEFX=O@5G&^;C#5@ZT48,V^D|J|PZ;^~^UF2@|(A115) <8,R/|GHH|60F^VH^&@M.W^\\JUGT^IKR9^_ MM4M?1QZT(??>"SC#<@3G88 I>Y.;&JF>5-7@B.Q@-/?^Q,W+Z%N^?KA??W W4 M9R0-GTB|JFTO> 37;=5%."YJ^X\$2EA)954B;-> A7E8U56;Y55>H>Y>E, \$ MRF^F3+U.7TG%|XJ0&DA6F^KKADE5LYGN0E^T^J_7^&F^P|^="(F^FH|_E1+ M P04^>^L^ ?0Y(UL)P^*;&P @0^'AL+W=OXPS|RR>A>Z.K MS7T^>J^J60^JCVZ_VXZY;0^|B^>270 MD/K45.<@|@|=M6CL+JGV1?%N.SZ(1A.H^=9WM4 M2W#23-ZF\$#;_J^?X6;B15HGKKX^U1+ P04^>^L^ Y92D.33Y@>^# M!@&0 ^AL+W=O>MFM7J75BVBWJ?Q DK\$^ISDDS;,%JD,C^#^UNS^W<Z5-6Q-3R5I2^U>=<9&^;L2 M0Z1-IQ|O4R BS1\$IEGV39^H.G.26NE1=&^D^4R1RN9-GUH=U@|^I^ H@;^'IOP^A^ M^M^A=0AMFJ^MPSJ72D1\$SDTGAC+>PVE@T5L^1^Q5OM<13ACB>?^VLF7X^.\$4E M,C(117;H^@Q3O;E^>P3P|^+39/5G;@8DN8E^K1EY8RN;JUTKA@Y9Q<5O;E MC+>6Z4-KD|M+*8@|W^?Y52^BEV-M\$UR-VTIGC84@U_0XNX^8LF^AD+=|J7=)(KZ\$YGI M>Z(JFL+8PONJ0^I_23Y^\\(?>YSX5_E.P#4W^3I/PK>A)|E%6_8^E\$95J|:V MJDTAT6BGQ>9=&5%F0%J2.6^<X>,<=<=A50;0SSX30^*,LNZ_E7P^%4K^110 (L^R #E&F;2&Q^&I,^<M+9>+>P=O^VJR:W-H965T18=>M9Y,9Y8J|9N^|T^Z-4\$4Y M@>=>=>=>HX)>=1^F9OR>_1^F1\$4^@Y>=>7^P@8BNQXSOKBOLR7T|JX<C^L M #FN3/8LKS^RV^U1^0?>@BCB_<L|ISZ|Q_1^9FQ21^?|J|TWEAK^6/3A-QXZ M-\$5&B=0NL&J6< 191CTI^>^U4Z^>J0W;^7W+X;|(G.#11RQ|JDDH^?6TOXIEPGS1|JF.K2@I6EY;P0Y(16+>ZOA6@9&^&_Z V M^ SN^I1^>8PECD>U>1:Q&@&X:3P.KP6TD| M^*3V4.%7?0>N4@L_ =1-18(8-:A^*8;R(\\U@=V^3B7BDJLDE?>N O Z M8I2(B.B^EDJBA,K1 MEFV^HEFX=O@5G&^;C#5@ZT48,V^D|J|PZ;^~^UF2@|(A115) <8,R/|GHH|60F^VH^&@M.W^\\JUGT^IKR9^_ MM4M?1QZT(??>"SC#<@3G88 I>Y.;&JF>5-7@B.Q@-/?^Q,W+Z%N^?KA??W W4 M9R0-GTB|JFTO> 37;=5%."YJ^X\$2EA)954B;-> A7E8U56;Y55>H>Y>E, \$ MRF^F3+U.7TG%|XJ0&DA6F^KKADE5LYGN0E^T^J_7^&F^P|^="(F^FH|_E1+ M P04^>^L^ ?0Y(UL)P^*;&P @0^'AL+W=OXPS|RR>A>Z.K MS7T^>J^J60^JCVZ_VXZY;0^|B^>270 MD/K45.<@|@|=M6CL+JGV1?%N.SZ(1A.H^=9WM4 M2W#23-ZF\$#;_J^?X6;B15HGKKX^U1+ P04^>^L^ Y92D.33Y@>^# M!@&0 ^AL+W=O>MFM7J75BVBWJ?Q DK\$^ISDDS;,%JD,C^#^UNS^W<Z5-6Q-3R5I2^U>=<9&^;L2 M0Z1-IQ|O4R BS1\$IEGV39^H.G.26NE1=&^D^4R1RN9-GUH=U@|^I^ H@;^'IOP^A^ M^M^A=0AMFJ^MPSJ72D1\$SDTGAC+>PVE@T5L^1^Q5OM<13ACB>?^VLF7X^.\$4E M,C(117;H^@Q3O;E^>P3P|^+39/5G;@8DN8E^K1EY8RN;JUTKA@Y9Q<5O;E MC+>6Z4-KD|M+*8@|W^?Y52^BEV-M\$UR-VTIGC84@U_0XNX^8LF^AD+=|J7=)(KZ\$YGI M>Z(JFL+8PONJ0^I_23Y^\\(?>YSX5_E.P#4W^3I/PK>A)|E%6_8^E\$95J|:V MJDTAT6BGQ>9=&5%F0%J2.6^<X>,<=<=A50;0SSX30^*,LNZ_E7P^%4K^110 (L^R #E&F;2&Q^&I,^<M+9>+>P=O^VJR:W-H965T18=>M9Y,9Y8J|9N^|T^Z-4\$4Y M@>=>=>=>HX)>=1^F9OR>_1^F1\$4^@Y>=>7^P@8BNQXSOKBOLR7T|JX<C^L M #FN3/8LKS^RV^U1^0?>@BCB_<L|ISZ|Q_1^9FQ21^?|J|TWEAK^6/3A-QXZ M-\$5&B=0NL&J6< 191CTI^>^U4Z^>J0W;^7W+X;|(G.#11RQ|JDDH^?6TOXIEPGS1|JF.K2@I6EY;P0Y(16+>ZOA6@9&^&_Z V M^ SN^I1^>8PECD>U>1:Q&@&X:3P.KP6TD| M^*3V4.%7?0>N4@L_ =1-18(8-:A^*8;R(\\U@=V^3B7BDJLDE?>N O Z M8I2(B.B^EDJBA,K1 MEFV^HEFX=O@5G&^;C#5@ZT48,V^D|J|PZ;^~^UF2@|(A115) <8,R/|GHH|60F^VH^&@M.W^\\JUGT^IKR9^_ MM4M?1QZT(??>"SC#<@3G88 I>Y.;&JF>5-7@B.Q@-/?^Q,W+Z%N^?KA??W W4 M9R0-GTB|JFTO> 37;=5%."YJ^X\$2EA)954B;-> A7E8U56;Y55>H>Y>E, \$ MRF^F3+U.7TG%|XJ0&DA6F^KKADE5LYGN0E^T^J_7^&F^P|^="(F^FH|_E1+ M P04^>^L^ ?0Y(UL)P^*;&P @0^'AL+W=OXPS|RR>A>Z.K MS7T^>J^J60^JCVZ_VXZY;0^|B^>270 MD/K45.<@|@|=M6CL+JGV1?%N.SZ(1A.H^=9WM4 M2W#23-ZF\$#;_J^?X6;B15HGKKX^U1+ P04^>^L^ Y92D.33Y@>^# M!@&0 ^AL+W=O>MFM7J75BVBWJ?Q DK\$^ISDDS;,%JD,C^#^UNS^W<Z5-6Q-3R5I2^U>=<9&^;L2 M0Z1-IQ|O4R BS1\$IEGV39^H.G.26NE1=&^D^4R1RN9-GUH=U@|^I^ H@;^'IOP^A^ M^M^A=0AMFJ^MPSJ72D1\$SDTGAC+>PVE@T5L^1^Q5OM<13ACB>?^VLF7X^.\$4E M,C(117;H^@Q3O;E^>P3P|^+39/5G;@8DN8E^K1EY8RN;JUTKA@Y9Q<5O;E MC+>6Z4-KD|M+*8@|W^?Y52^BEV-M\$UR-VTIGC84@U_0XNX^8LF^AD+=|J7=)(KZ\$YGI M>Z(JFL+8PONJ0^I_23Y^\\(?>YSX5_E.P#4W^3I/PK>A)|E%6_8^E\$95J|:V MJDTAT6BGQ>9=&5%F0%J2.6^<X>,<=<=A50;0SSX30^*,LNZ_E7P^%4K^110 (L^R #E&F;2&Q^&I,^<M+9>+>P=O^VJR:W-H965T18=>M9Y,9Y8J|9N^|T^Z-4\$4Y M@>=>=>=>HX)>=1^F9OR>_1^F1\$4^@Y>=>7^P@8BNQXSOKBOLR7T|JX<C^L M #FN3/8LKS^RV^U1^0?>@BCB_<L|ISZ|Q_1^9FQ21^?|J|TWEAK^6/3A-QXZ M-\$5&B=0NL&J6< 191CTI^>^U4Z^>J0W;^7W+X;|(G.#11RQ|JDDH^?6TOXIEPGS1|JF.K2@I6EY;P0Y(16+>ZOA6@9&^&_Z V M^ SN^I1^>8PECD>U>1:Q&@&X:3P.KP6TD| M^*3V4.%7?0>N4@L_ =1-18(8-:A^*8;R(\\U@=V^3B7BDJLDE?>N O Z M8I2(B.B^EDJBA,K1 MEFV^HEFX=O@5G&^;C#5@ZT48,V^D|J|PZ;^~^UF2@|(A115) <8,R/|GHH|60F^VH^&@M.W^\\JUGT^IKR9^_ MM4M?1QZT(??>"SC#<@3G88 I>Y.;&JF>5-7@B.Q@-/?^Q,W+Z%N^?KA??W W4 M9R0-GTB|JFTO> 37;=5%."YJ^X\$2EA)954B;-> A7E8U56;Y55>H>Y>E, \$ MRF^F3+U.7TG%|XJ0&DA6F^KKADE5LYGN0E^T^J_7^&F^P|^="(F^FH|_E1+ M P04^>^L^ ?0Y(UL)P^*;&P @0^'AL+W=OXPS|RR>A>Z.K MS7T^>J^J60^JCVZ_VXZY;0^|B^>270 MD/K45.<@|@|=M6CL+JGV1?%N.SZ(1A.H^=9WM4 M2W#23-ZF\$#;_J^?X6;B15HGKKX^U1+ P04^>^L^ Y92D.33Y@>^# M!@&0 ^AL+W=O>MFM7

< IXS26%G*!T!O!O!\$NTDDY52!F\$G\$7Y-J|ZW,LL:|J|@#42*!- .+.#.'!3@*42#19^ M9ZFD8DXVXV!|GL!R\$+R,X|62!%SYH:3,A|ANH|UEC|6%\$AA>^>C"IV| V:~N|W?A7A, M/G=0?2#FBG, 7H=SGNM@O4G\$(RPII..C\$!M<?7DOYRPU, UQ,R&A3Y<I<.,|R<|PY/G\$?F|T+M %079,NM|VULDI\$(K\$N~" & !,M|@%*H| Q|Q|?5>^VQQX M G=I?N2W6YYQ PXA:(6P2+<.,B,I7|L| WBC|B*02E). C\$|1100^R3N|G\$A MBQ0^ Y3W:)\$(BPN\$)

[illegible]

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š^X4E4^@O1^1X(^C6#MJ-DCE^H#4Y HW^M^(*P\$P. P^ZA31565ME&R^ 71A D=4ZC41VW^V676.QC:J5H5U\$^VE-O^M M(CP^W^R03^>D<8QV2UXJ6+>NM:~)C1@1X^9VQEZBA12F2W^Q.%19^*A-D@ M1J1E4A46^C M^1228B4+1+1M172.XH&@^E^T5.C1>6)F:P./T:11A1!_1 MOD8=3^3XFH9^5.8\$1^V^D5B>N 978^7^74N1(E78F:0BH2>IS&=5(^>=>10^-C^7.M C D8^3AL5DM+9-UMSHH0A1^1>@B1H(PM46Z7I7I#^1N^F81M15MH5K+ M5\$1DP215^6\$S1BM3TA6^?J1^ 223.A^5VOILLNND^W^93^21 3AZU&M^7J: MMH^@UO1UL3ZM(C@/Y)-B4Q^I?> B^VG^6>0^F)IJSQ(4 F4:@V4=%RSU)5Z M4GP^0(T9MS:Y2FVE[3JO^1H9E7(SV+>L.O.9R? ME09FHVUO.^NPET:>:SIV0>P2IXDDHFQ4Y9BH.A;B9PB^BA3.AKQAJ84-&9G MTX^F1P HF5^<=m@5)DSW>Q1WJ1HDM>@F(L:"BUI=>B&EQ192^R176)> 4P0D M&K10K^""T^3&GN1X5DC=(105^+1 160F^<8F+>X^R^3A15&69NELLE^G-);I MR42Z=EMPZY=XNBV1^3JR^2^7R^H^ZD+X6HMMa)<6^7L1.OCD^N^UDD^NNBLUMM^F1J7^P^Y:K1@B^A@O1ALIG@T^KO>CZK MY.6J(Y<^1.J+>L^T^1Z SLO^6^>:P^VJ^7(5@<0=8^L?7^SOOG6=>5%>N^C3^ M M L)?^7^>SOHXFZ %>#I^E<?Z^>KOJF1^>I^D1T34^.@6@6<^B^U^T^?#31^FV^M^ MH^B8E^11.8QB6=FV^+>(H1DR4N5K0L1T^*E/|B-OL<06VWLR^&?&UR^\$B120ZGRJ)U|B|29:UW9^L13^T+PT9^>A=O6C3R^M^C&=7SV^>6H>@>I6734^YR|O8^GV^UE85HFV>S2>+ 815VVEB2M5FIKN5(M^:S^XQ<0JLA0Y@T0J8EURUG_9%FGZ.I;K/5-MH^ESZ4RI9;HJ>?F6XJB^<NH MV5K1XM+6R# 4^K6T W227UF1+S;7_7%1>IUS8=S-K>=\$PYI\$ <^GA(I!)^*V M\$2^QB39A\$<="D^TGL V-1^H^KURKW^I@/O^" I;T^&I1JDO2^H18=2^0L MO(I8N&10C1A^I^SJD1;I\$<:=6@P\$>X9P P5&:4+>VXY10> 8 K2I^CZ"? OTYE1M3G&1=&I@BDO Q(C^XPB^A). \$#7^CE>Q^?#2?TJA(H^1J1.8T2.^\$6YQ J^/3^I B^>A@I1 MVUTA. =^T\$B8(MATW7B+&O<@<X;9PWU>Q^O9&3LGD0C:06+>|M1 8_sMTY8 MT.<@PVP&G4^2^K.2HTUJ14>?>F7;R|OXIOOHLK^ 718C-B^P^:1I2H72 M.M4J)O187^QABET /+>AXIL&A.4.WIRKPS;BTIO^&#s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~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~%G.M>P#<1<^8X.D1DRJQYW5#0.M158V.+/61=YZUUL.+-1.H% M=2H:~^FRD^U4:58V1%-! (5OH158VZE~(5OH358NXO)/X:F5N15&AGBN>C M39>CF1 =. @S.Z:NPIAM:XJNW ~^WU:HX.U?/IKFO#(I7N0US(H* MYA =AV2*3-C2)U=; (A12PB(12V251339V5812J8EN21TV72.1J70E@YV1YV:~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~#YFLDMK15CNMFH5CS: MQ^>1RT>=KT%B5#>8^=9=FICC^X^=S<%N196.45:JA+UK>.#N8YKX@6Y1:1=YY92.51=WY.M@0AMH.1K9K8J&W~< @HUOTU^@.J1L.+-4.D^ISE^KJ1B61^1^P^Y1Y1^M3-O^#P.~D^TA^OK-CE^ZELC>66ML.V8WUO.D&X&B^0R1P.FCV^P(KERU)^&MMW8.J+D75M1^ ML(>A- 9%KM^1H.KH9V.02TV^1^ QM1P^YF:54IE(155NK51S9U.BFSR).RS.M^YQ=^Z8N1QV^1JMF5@C.3V>=>10^DOKE^ V1P^X^C2%N-S^ST1^J. MH+ UF=^N8V>=1.B- M^KM(PDL6.4JC4KZTIV/U10+&M6LOS&X. X2^X1+@6 M68L17T04P2YQ^>X29F/QV.O.F#P0.WEJXJ5(=R+T^CXQLSP.N.MJBV2M\$FME/JK.FM9UN3^26^R1? &16VIC.V+1BWLV1X9<4.4#E>~5J1G9E>VA>~(FLZ.872Z5C=ELA7RH.M2^@s1A2 @.1S=2+M=OB#)9.IE0VQO>2.9.4J6XD.1ND.ML5=1. 1KHYWRR9W=>A)MA7.V1(NJZW)^F4IV^KVGE^M^1EDYE.Y^IG@X7WOGD MWR= ID# 4^VD#U@5TU^1 O/C&+^RSJ5^R1KL^YPR@GK=ADVLFMV.O0:594 M53:D71-^9 M2DKZ21(05OVQC.O:H+D1SNRL M07#QES9+<16. >YPZ5S1%NYOL?>RH:~^F67Y2>KJ.~XLAN.I&GVN^R^ON M192547>061WH^W2S1 MC6^#767^DL1M(^=P.K1^S123=K<~M76:~Y1>. N40:9~^#Q00S^IEZ.1/V1AG MG/2671^U5J:JF>O>O:M^43QO TIGR2?>^P.69J?>Z=NK^2ADH.8B&B&R.^SS&198K40S^CDMP/U- 11@6^TAD Q 2K.&1H^ID55D Q=<= MU:76+1A1>~# O1CB&#.AL.D&1E>~X-XH#1275J88^T1%<E>~M^30> MK1^YI&S-L=ZFOMWJ.02O1YI23T^1^YE- JO>VIN+^NUINMNYQJ.C1:090>M.2>R211^G21J.O8^>V.W.CT.DI92WCH6.IE0G+VWHQO^Z.SGC=#.M0Y1%\$8F#0S&T^1^721.FX&CIGU7X@CEOIPZXD@.T&3E(7>.R? 77904JE M7SKVHG78:AI=>SW7A1^/GC?X8J2WPXGOJ.6A4^C70#^UND>WS1JG+W M^&H&1+&R41&WSF=V>9K5O#3E17-XTV1N^IDSS^1^?^HI&?^GTA^N.DNU^? MYY3^37BG:4Z821D1W7EHS1J:YNN^Q51.V>2?Z^N.MKSAWCAO~.1JSIOI M^31T^N^TTFN>?2UIF1%.NIH^~%A97% %1N.M2&LW>N>B0- 11>G.F02B^OGS1A1(I)U2.O0QJ4ASU(1^5Y/Q+D.51.MKPO4+A^O3N&P=MH.(^%R-Q.O.1W15K1X(9.9)BC&31R1:3LA\$>EFE-TF14 MQC&=LU^TR3+HX^>F\$W.K1X^34? 131X=FE28^1U61P&X.^55N^Y^ G.KY>S^ ML.S1@Y^?C2K79.FG5YQ^?Z#2F53+A=KL=>O(1#IEY9FK183+7CD4S67.M=>EYAI+Y.(9AUW)1Z^S^E^<#0P9+KX^C^)(S09IC- PGI.A0M^753^6EXFU^7C.M.2>R>RVR.(I)9FB(I)(DMT48M.QYHDSM^Q2GLU1Q1>1.B1PEW2?Q.M^12KVA^E^~+5^FEL<64(FE=Y&XB.F<9E4IDNP3LX>47CB-5Q&:(^F2 MT4W 41+C#.\$S C&16ZD2DMV(B#+N6V1+\$DRTW4B@#=#4PH\$0>SZ@^1) M4J1I21W1@RD=8#;#Z7&S^C^%1#@9Z1+1^C11^ AGG1E MX+2^J(DX)O>~^T^GP^G^B85SB1U081ON>=<8370A1="IE>[X# MZK.==LX19V 1!>1^PNQ1>1[7T93T2HASOP^ILS2&D^1T BN2HVT^P.#MH^F1M) 1T1ODD9(C<DKLY<5)UPC=>A^E5FD1C^U^Y1-13M<+RR Z.9JC043U M^#BM@1(I)Q71^#GE4S:3>B1J9.FO84@0PU41CZ^H^X)50&@0174I.E/MAR^ 6S61=<CVOP&XKLU- 2ZA=<G176.B1@PGO(Q2K)K65.2<YQ.11J2@.1E.M/47H^OY7RKL1G5.FE<OCT6.LH^A:Z4R1K3A1RH7AL69@B46Z HTB: MVS>@B12R^&K<~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~#B44R&OZS MS^C2&AD.Y.U^21&2&9/M^P1^T29G4Q70A>OET6414OCV&8.N6.OP#R.R.M6LE&S^OS1X.11^9WWA@120V3\$M.M6TGCZ5D.VAIXO>2^&X.C.TQ151D MK^LOHH^VB- B1HJY.YG0W6@C73MGG6A^F^MTR81.3XY750\$GOH.Y1JBB01.MI@W2XDG?=>(>O.E1+14\$1L^110 (^F^#EDSKARJ4<=N^> M96\$P.C0097@S.2TR7VQO.FE=F5R:VXN:1MI91O1I1S.12(=5DA7 M9(4^1V^M1^?728R:21%)2G8:1B+175W:OCWZ>^970.1 WD:7TS^H1.MI/TS81OGFYUVO 1? 1.J17VOVIG#1. K71Y.U>1Z3=<=)XVRA.M1J GWUE M7 1?>1UWM5 EV3KJ1<921M8&9)3-BEBGBBN0>~>R^T#&OHB^X7^~W78C^7 M0YD< VJZWV^9N. 1V>2^*3361353

[illegible]

[illegible]

2:2BF6=8U>*ZAR*IN6<VR9:D:OQ<BANX# ETD042-GS/TF2\$7!= MABD.WJZK,#*I+R+E6D(MF177TJ;>|JBX3AD;IL<=5WC+>@Q O M(C'AX,3(7IZB?I.#'=P3F:WV.2A'X2 4W=FD>?J?I?9>YGL\$XNCS/ #># MD&I,3/9>?2/ITKLR#GC45H/IB1R#<#HY 8,I'IS/N #<0<2.I,LIAB8?7>*&M'KP7@5Y?Q'CV72>^Q'Q'3- COP0=5WHS698K!>|S2EOY?C6#0->BPQ\$M/7T M2TG3ZON8;?D:Q=,O03?I,*?A*2BWC=>?7,7UK1Z,1VJ8I0'=O,W#D'TNEI@ MD'SU /S2BXLU^6^1AO'3@ TO&VIYFTM \$88,LA'HTOI'16IIL N8VH946\$> MPC.XBB+JHCA!TFU+!|MG.O15I,8 U O6I'M8H,(*\$SE9-B1 C6I:DSN=> M%W05WL9Y3Y=|C'>?77OH+SL^#>N>1(LIC@I'@<^ (+)H1^3@PB^1NN"+SO.Q\$?. MM+;@2! V#2CR ,0 9ZA/=-U& 9IG /&N93! 2 :.V'I' 2BD@Q9R^NBPL^A M'!\$?T?I "I,? H/U/;>PMIN?P'>#H:1J9QDIWDH#FY&I!A47K3'KB6A(N@B+4 M?P.MR/CO-?>|SIGVG37I;>I->EYORCI-!A M/!>7+>WOATQ'> '20POL0I\$|I'V35Z88WH6Z9+M?>E1 :68J6& C:Q08B 33I|U1+91D6#>AO5;4P?>6Q0>24XB4I^VLTS#H CDIJZ R+2T6<6 MR-1!005\$'SL HR9&EYRIS-K7Y)ELVS'CS2KN' +>6' 1IRK73?'7RXRH9I?Z, 11/ M\$<IE37?2=? |I2, \$IW#?12,(C7L=2%>DH0&C&21D1!<A\$ 9F', ^K=2C'2>?YTG M=BG6QMW'0Q_61@ K9I2/=)'%S1=MZ\$3;B:8A^C'Y%72IX.OY'2>1TU2QT MJ?S<>E/L M=V4I4UW' U!*,?H- IZL=51'SERMM8>@C9P9?W=;>@_ /IJO M'>W81R R!""*?DTR""|U\$OL:7VIN'6<1?OI.U'P+&P'P' T-K'7LY^E9,3CJ1'6'1(MFZJIOU@=Q2D=5.38AT'Y|JRLM;PI.X:O/W^C\$W!> 7BYMF+V1# WVIG-V0 MG3,^BA9R,Z02* 1*8U+ E(CTV-,1'178&@I5?>JFE-%O,ITEJC&C20\$1ZLA MPD+L#270.@6I|I;B;J(C >J DHT'JTR'3G=F&(-B OI:~P;Y9SKG!9TI;\$E8N MVHWW#.#I@= 5'RU^AQ/6D'XEN9_ OX7IG=5KJ-6<@ QH1Z:RKV8G<=>|Y2/M,SM,+>@2K1TS+@I0RITB3VH,LD>Y?>L,LIW#>3!PMX?2>9&S?>+E9Q\$ M7L;'**FP!&M471I)BNB8G@>?Y*54, :3SBCW+BX M42&84A'HLIC>|H5V2IYO-HIVR GD:85&S@ M'696_282X!>?PMM962 S=>6F5P7FE TS+M=#!1^7' M@>S(<=<6' GFAI2\$6P2+L+IUX;ZIJX=8YD0T&WUZR9&M9\$5I!) (70U8R3XZ M1+7&K>X?YVNO'0\$3FX? _E'53M^X'<~^P!M^7,'B!:(SB,0=>\$X\$D5G M!JIT@G?7I/E/L'E KGA8-HVD:G,)&#>?TOXIV&N 1=>DPOOX24<,&IRX%,MXRC\$+<K08>OAL:LY?C'1'>TRNO=DR\$QI65I2!<6 @S-XL@ (MOE^_I1@F1!<=>AXXB=SR!JGMLARGMMY!A|PIX35M, (I|I@ (B&I&,<9&YI M+VB=|SM"H<1&9D/Y/CTHO W"SGA3'T<+B.SVG?9QKF-S&O5:O9#M!2P' I M2H-S5-0C442&8;?5TS6YV!8>=3'Y"6PEFA @ AOES52OI(O0>PRC,=U,?(-U M?21D1H CD\$A0,9I2FOI0>2L+IQW3I#B75=>#087BT#,'Y+>?>2L?7?>7: M:F0\$QIWBXLU Q (O)TO>=X:9Z?3'/M2,5C&H+C S#<8V=175I1V'E02OBSS+ MB541QDI 1%0108:IYMW4RO+<C'PU?4+I?P/O:/7TIEMO=>P MAYP006&S@.|L|H2Y3Y1' M,W2YU 9?>F09+>QCE6OY21XE@HJ90D_L@09 MVB/H6?E9JOLES1 F15- GMON?VY^5RWMBW<>?244Y?,"<8"E'F:~G40EDS MKW5IOEY:5\$>9>2Y-MIM, 5.JGO&S&L'>R'>T'9!<C|DT >=>AOE,1TE6.51 MSOD>+,*\$?1KE-%PGI?Z/4KI,2.R MV148085C\$C'>,"B1 \$5&3ZZ)?FTTS+&8I+7U0L8E1T,|EZXSROFX,PIUXA MX>|X5ZU?2F@E'0_ \$X.FWS\$PRT6\$DN4=>=&N20630IR@#44=>O?QOE+=YR M?I?B0I?9RIJ,952 I6V5IJK IOIIFTO/I'G#D^50KA/A8E-<(U<)1VP9.E+>P>+ M(O5F)GX<3GOA=1H.U7^LSYDC&T>|S\$H:7&XJ2?%?%IYZ:6UA KOE9PD550IY M&?/3)(I- &M^<42154I)1RK45+5%ZF2QM#RSJ0/78XK'?R DLV^4IKKP6DYDG+>13_*K@.8I M4P=652^4HIS<X-KQI+XMKOLF ^6Y<32?XUDF!>#VY&O2(IY MBM&V9\$4(BD)I1.128RD58C_X2?2P^R\$9|>M%G^43^6I^9@B.#>XLIJ\$TFF&?T|IM&G6!P2>84&V IE:10=S, MVS-^A6@ZAS^'650M2Z|ACYRT N50G^LQI6GRK0_>UVV8EE4ZIEUS OUI MVA4M6V^3?I^Q2R1&L1QRM\$5LZVB\$>SJMUTU/U\$Q<~> T W<-E'F:7C0?Z?7+ M/9GCIIP+5=5M6=>S1I3;Z&BMAZ_@>R0F4SDO=U?2>QNJDI7(V D:C1F^I" MW6M^H1\$C9@+>LO1X\$3@ARV!>2+3(FI+9M1AEP MB\$C-UQ8!2A;@>SANAIXI/U?D80K<=5.1F1XTZ:U>9G4^0%VS#IY2\$%>+S, M UWZ? NIAO:O0%VY9@SC=2< 4IXEQ MKD+=2 6G+Z&/^2M=)20A 0=T>V3W2>Y%|I#N,%5DO15YI?83YYB^*8UL>C, MIZ?U:), 94!^L#BCP57V^L&BK,VNF%T^N;V#9J" %B:(#>X#L@K,D+71% MWTUM1%&D&WH#A9I?>49MY 56+>W BSE7TNY>|IR7=~/^7.T.Q\$CUN@!\$>P'P,R MR^&9X@/7HPMJ+6FI/HP_4@)BK6P4^PW3&5@>95=0>0>3.1R # MZ&K! ST^I9, SIUG.FM8^>~>81 +&G^TRI1+>B2A?>Q>S\$W4=Q3RT=5W?VZ MDHXHC<^%OU5\$;D.ST9RY@*6KN7L419!A!V=HW-/XVLSI MW=U^WT=>FIFT?|R1,>UD?U? |T81+^IV.MX9I4V?R M0.ING6W2\$W^U9-O1Z1?>S7B;|I SCCI52G=PKK^K-MOVJ@=\$.4)IIB=:8I.VI MR3M1,IL(8F6&30W@>O>HE\$>29,3W3PIPTW87Q\$|V5Y|@N%2LZ,^TPI+5^C3)=M.YCZLZFU>E|I;A?P-PHH|UB+3+&4PQ-3FTC-C<(%N'#=UH3)>_MUQI+B(MPK49R,7' #7\$U<=91@+>F>G.IJIGSH\$JIC0I 6P2\$X/GLC0A@>F9_!T9,! MG'I=WIX\$;3-7V&48X2Q/8GRIOD_#IR>DS_ MOK!^:FAOHSY\$U-B:ZR\$5-<=)IK-U KLWNP.= (L1\$OE)FAVX>VQ>@>@<=> MQ92\$EDP,4.163\$;3.L,= 9 YVG /?^?^4YV 8(7UCU^4AP?I?>_ O8VCHHM& M4@>I2VHVMV^H'ITUMN<AY+>LAOXQ Q:VIOQC6IT8IJ|=I@O=SN6 M#;%%;?H9:=>%>6Z>Q_ ~IR^P' M?97I9D<50X\$4K9MIZI(WR&=>HULL\$;S0UV MD7CQ+1&TM?>S A0:HMXIT642A.O0IXIEV8H^54IL& KVKVO:N4,FIIL=0 M-! MJCBY#^9I\$@>EPI,ER3GG?I2Z?W=>N\$5\$N1<=>S\$0, 764 IJV|7|=5CZ>C5K&E&JY&, ^?DE9I9YI(A6 M^H8H 3I=)N'(>=>082C\$?>2I?X,3^X7R?>C^F^>W6 M>%.E%0Y9VKH&/ Q2636^4(=4L=>KUFY,EP3GG?RIH:29DSYE:MSZ(NA\$S)G6J MAQK,PJL+>3(A \$IT:EBEY6^IY-VGQNHM,M\$JD&-PBO_XP.NOW'GX M B8NK_?ZM6QI= |I.R1>>)>SE(BI@>KWX(W9.IVXG/69VG4T:Z)O7.EWC+>,R MZD5SO&WL3^I@>J<#>AIH,49I7IT+Q:>YV\$T2,T3+MH3>WB?>R!MAIX M>\$!H'PD.NS H25 :<4C,32FDA,HIR5!&I M^<~(N\$1+&?>I<~(C<16I4I)O3?TM^I9<@>O.K.CGAO!6X!I4FV M6V^SSIU6D:IQ\$5Y^IJSZB,17UWE(NB,90,|JHMHLC2M0CJ5O\$>1%6I M-Z'CKTLA)IAIDMIEI?5^@<~ W^44 JN- F\$BT-1=U(6I2H G\$C0&,&RUP\$>SUN53J!>|IRDDIOT:KX!F M=->AB/6@HP=KIJH3CX \$Z#W (I@#M.LI|JIR:VIG|KKBZH- ML^1N/K,M0?>SYV^>I<~>X0\$7&/K9,H36+R4H' MFO<68.7-WV%50527I,+ M\$Y=W8.S^4_0+>H&E'UPE^05LNC:ADK&I!N9U\$;Q5V9E76/76M:1T+Q+5GL) MZE'I -NACO- 8QW\$W8YI29I4A@Z2R,|I=>@I=QAOTIA6RV<3^>EGL:ML1 M#(HJ3,1^7UW<~>169;6X4H^O!&5C9P4PIU\$E6H36;T?E,|I,|I=:IY MG^AL+IUR' M' MOI' I^% GA_YR=O.OIS|Y2I M?S_IXE L?BGV|_OQ_>A/X<7 MP8_!L.OGN(/ W6T/O9S/SO=WOPE_L_+Q_IZ^GIUK^G1'UJN'IWC|W|^I@> M2_W7OZ?> WX|U|OCK^I90D?>NPR^W90=>1=D/HUYGQ KJFW?O3RX,|^I M W=YC4|SF OC_ZIB:O+>|RI0I:GOT GVWV^G/V_#177%ZIO?TOKY8U| M'NT>HZ>3+=? ^I|YZF7M^~>I 7 WXU^R# ^U.WG^>8V?70ZU|RI\$-V?S2 M7U |\$I| XYLXCN^ NGILZO31~BP!^ADIO:~V, U820DB3X&\$>09,4)B;D M4T@NEU66X;DMGPs+VS=J (53YF94HY^ASGV+OIGL_?P_SVLCR9?>I0\$>VTO80:MIJ&@?2 M55_VELX^4>@>I|IU|V|DROF%>VLUU:BCY+U7-C&E5U7O_0)JOV Y+U?>@&N MU|S M&WU^A~6^J?> H,85WIS\$2&C(I A^902465-3^|IWI,Z<>1>C7YIX2 M^K42EWW-FIL^1XXV6I|CQ\$1M=>@7W\$ZESS GT,@IC TE?IOZU_+8=FAI_MVNNTOWIG/MO?WWMQ8031ZW\$? 0IOQZ^_AIRX_!YGI68I29UIZU4BVME53- M8;@+8V6?S1WKI62_MIL=#^#T8QH^7E%T3M<(99KW?7AT8RJ_YLJ9 MV\$SY8HK7\$3@>S,P=WY, I^3(C/OBX/XCL05VUS^<_>Y4\$7W\$K^ZYE36I4\$! M+H%P\$32/HIS2^R2F,B/Q8I+3P(O4&,&I&^I^F^E9IG<A TG@9F0?>MH^O 77PZ^!A@;@ U#EPC_WG_RUJ\$P0&=>9D4?+5?F7 TRIT_>T^K^RZ# M!3EAY+8XY4?7 MYOF8@ M_6W=B@>U3I<~& MNHO^>9C\$;7I\$HA,|I|I^C\$1I@>4TBT&-LWXV|NUJ- C^I^9E^R48GLYX&S M|S|C=8YN0WS68<I|9&L7U(W4U\$|JLX^*7_ M0\$94 DORR^B|B_!IWI+>PZG! MGGW^P\$> V\$X&B|I|I^59_>@G&S^I^I2:KDS!>1^85XHI|NSK2C=C=1%26K5IU? DWR MKIC_ZA6@ \$8D?3***)>_>DXB,3^>C0I6Y\$4^2XYG!&I\$JY@>NNEFLB!A2IU^?2R2 M1J=I7N,7HX+I6GWI\$>=PYCIV-0>#^>I W65\$O L^>6X^H^>6X^>FL8I\$52@ MN^@2#V|P,IY5M7M,==&I6^~V_*?R%\$SSE(N4F7I|J#M.LOWGV.OS^A/POI+WH M@T|F.A@&,**6PKVG)P|/RG@Q=A=ZC:ARB U?E0/X5\$N(IA%,%#C\$#2S MT,LD>I1 2@1#>+>O4^>5^>0D2KCU&TD&M=PPFU^!A0-7?EPK=VN5ON,5M5PHY|NP8824WWT?I?G7;_&8X5I+J^WRK^MOT?9<=>P7K: Ix5I M,NIO\$2UX&6\$4E9U0L,F)H7&KM^? NOI5+>,(Y4=>=>NQJ-5ALZ<1).U%Q|E(I\$1L-03I3>?>ZL1I:AB\$4+S^50:RIK5X)U MP1^YB4#P5COB,|IWI(&A^XN2^U15>@># MSHVSSH-B#2_NJN>9^R^39VU|UC2I87I\$W> (L3T_OI&E)T\$>?>@&O_0 M7@2QO?2\$S2A^6.OH4V\$>@>B:SKYEMD|I(26I.68,N,E9^:KUS@>FHKFI^F M4,42Z2I0U(G6PU|_OIOIXOQ|SIM9I,UA|L|5ZD&P^:08D?7?>UO'H0Q|IMJ|I @Q-B<Q^YWF^H49^THEUIZ^YI|JC^I2&6>8BS,71+3IIV15 (AL QO,4I M^:TC6I8G8I275NDY(A^3YSJ)9RM6P^6DHAT5 (I=I)E MVAY:~>I^Z^W6\$N|IBK:7_V756,BQ!>@TQ (DB)4IB.XI^B86H04-8&I: MY^O1M|I+5YI5G^W8EE7#FXY6.(IG6CKH_~%A5%<KIRI.F.W:KIW6H,XIO@ MG^JN^U=C09NWKAH,13N/MUZ-LN=>|V-MZ/51^I^~*# M#ZPSHH^ 7C^> >IOP/PA7S,T4L\$Z&6&DULXZT?E ME^<@-ZC\$G^ W@>I9,4I^402U1=)OIZR(IQOQFIGZ97>+I,0,7MZC,&K_ MPBE(I?X)X0@N0N3SV3 DI9Y#?>=YA33?^B-IDT^9VZ GOQ|^E\$? 926 I 1MMH2IAIJ\$>**RXY UZ4I|N\$CI |I|S|I<|U<7I^YIO3T(RZKK?P^< 7 M,1).SRYFO.P^KZ2VYR8K62595XQ5=N-DW#^L^ZQIE^O F<~>U2XB W,RR2038GWL:(7: 69:<K<6TDE M-8(OIRG-18N_X+Z92@MTI@P,L)DO M+M<80YI=WP\$3_X4PAI|PWRGRJ\$ (MHP+GR9>S9WO^YI^>?>FAS?>0+6L^8YH^XZ=U0I,F9\$MYQ^H\$&?>VZSE E MPZL? %0\$S,@6L|>^O\$OX^>E=\$3QLONB|8%J^I^13 VZ:RGT JI^>X^T MN=&F\$MXTD\$>5\$3QJG?2%Z\$2K3T5I8T_IJ3D7@GINQOQA06|V8U+EP&@H M?J^ "+>55A^TF6H2U.60EDYIK_,YVRL2HJ3(ZK:T.O6+92<=>U? N2#14V M8;L(4X>_YS2+>CSF @^3I/(O^N@N=W0XC&&-P-N:C MG_IX\$2\$ZVZE2 M (L67\$8HP- SROLVYF8I87>J^C/PU:4=>M9LE:=Y5E4+>|QRVK6FE>+ H.M.II5P@>9I9M^L?D:UYHO-QDMWQ+>G^Y?P32@OYV51\$A:G\$2A#PU)F3FHVDS MF-;>O6TG^?I9V(A:~)J5 %ZHE:SG8G+ GFA|J8I0I|9I278,IQF=ME> M8#XQ|NJ;I5 KSZ:2>HD3QFV3I!ZAR\$SGOQY2I0I6M2M3Q?ZFRZA,EK0H MX:~IUK3+8E0I=+P=5>#I\$OBATUOT031^@>R&W,6&SX:2_0^>YFVXWHV9G6MZ&8 MY\$T,3SY^IGZ^ZM?>@ZZ+>S|O|DNBL7LNK&DP,B9&D&GAIX#V!>#N+>BZL> M#>IXQDI8ERUOI,OSCR?0K^DFZB7M|JH@2I>6&KZ78Y<O@>G/RHYH7H M(X+6P%\$>3_3WWV^>PU^>+IY.AIZG3KBL?I0Q_5\$V JB;5B2D&HJ\$4<4IHL MY#0&\$DOY^6ID^XYB0)BIK^8DN\$<0_D4-OV#>4DB\$N|F.T,|I=WIU_ "97- M'L2IM76GBA:>8N>)FA^\$0I GMYE1S:=G|2P&C/!&^X^2ZK^N6J|O86+=: MDX15>3GDP,^YFZ6K6Z3>5^HFFPAO@=>=>@>U|UJD^>5+4YV4^41@>GY7FI MX^+K=V0&@>I^>?>Z B<R^F^T!HIXOT^AO8TPG/ MH|I(3>C0>?FEA@)JFC^Y#P.PIO MH20:N-@X!+>9V^<@>CNDBP4W>268UO.V5\$5LQ9D11BS:1FEUQ=I,SUX= MH272003)G:>4!OHA(N^R^F^T^B=3#T0GTY^# KPL,T?>@ K M24P?<5@1G:DO:U|RI^ &3&W3@Q(22+0ADD@>I0Q5I0.5IAGI\$5,ICJ (6L(I: MGM)=B%SO>ERY#>HOCW+>~*#DI^G&P^0^>YPI^I1_>Q4(CA^WBI M7N,4IOEPCKL M@2X""\$XIH|L(C:0PIQ\$4\$=> (4E+ BCY6<3C^Z|I?>B9WR6_O M'E,\$>QB89F2EU4U|N.C_>YH@>52Y6Q4FT^!2I<~>C#F7I,X3&P^0^>Y7Z00C?X# MCASA|94(0)>8I.C O_5I3L16I|MI\$>+O>G_Z #KPIZG^PL7^78D(I LR3&A) M8P5^>B-?D8E5|I3_I_ZAQA3A:E^%>(&A1#9^>+>VAVS.O4^?7 MI<=&_I3E_ I^7\$ZIM.8/>8T6^FI@G8D^X4,OI|I2?I23,3TBY HAAF6G_>U|@Q' M?&@ (HFK\$ETYM63X6|I(D+>5I)M|IG8C 29+EV7FIOU4J^?7N\$5!>068&9YISU3G1#BIKU7LC^QOIAIT^ICJCYT.HO^Q_1VGB/^C&I0@XNZL,I^YI?P6OT 2-H M&X4Y1RPN!>O^0^7%\$> B=BX6F8^5\$ M^I65HIPPV2YG=IN=ON=>4,6XIS<YU>428I,ZJPII66^"MSRL2C>2HS, N A MKK^GR:ER,(JB7_1I|C2AKTWY:FIJ 3(7DT^|(L|B2KM9I&LY:4IS+>#R/_ M+L.B. IRD^3B1D\$>+>PQ6^>VKHXWUL_>I^/ONZ3_ QYPI!>F^|W^4QFET=>G+>2 MC^I?750F@>N^!|(A3K870?<~>YRQ,T^?OHR9^IY.09I^X9F5<~>S HI^ M>=&\$S?>R H6N6CJ4PB\$A\$TMI+XTB^3J|MI9>10)NCSX&384 /O^%\$>I-0X& M+M9&Y->OED-AL+>W82ZKCY&RU;O8^?>P\$BI+>I+>O&XPODUI:SCS291 MGX!>FD?> 8NTGW,JCTGL_!I0I6I.6^I|O&I.C9(O)^51%4&GSZ&SEI@>F8O MNICW^LZ^OYQPT^4@XN6N P^R\$|I89M.IF SFAZ0G%VH%I(5- M537=I8F L+^I^&I SAYT>|)JH|WCW\$""_6I|I=? %S=DIE:H>~>L^N^J M,.-B\$5\$?T^ 5I1YS:|I@MSFI RK^P4~^I 4L1I;@B90&B&3.E^G^EA M^>K&H^H08J^>^AL2;L^H2K<3<=>#NJE+MMBI^|>M2/70?^ (2PXUBU4M8F<@>V@I:3V5I^X8CQ352C/TUX@?I619DI4055 HMRHG0>4LJ^G M8I.AUDP,B|EMJ3H+IYK^I-ZM5R^I^F%Q0I2X^XB \$6:~1I@>#HXK+3A MV>@>W=IAJOBS^I^ZSKHTNI(1=BDOP9I:2P^P C|H7^@X3CSZQ\$>KTF\$53&NTJB9,|I~YI^>~7^8UCVOTI6&C4?>NCR =>FUR9^6I7GT9+>?>FI?FI69?Y^R>~LPJZ^6 M/UYOQK\$S^T1I9E8\$T?>OSGO 6H_9AR&:G9\$U_>?3Z8+HJSV!>2W^K79@) MEH>=>?7F2:2UCE_XI|I@>?>M^CWWJLVK-2X I&K|W @F=WP3I:1-3>>1C/IJ-= V%KQC/HF8R9Z:I\$>?EWMF/HJH2^>C(C3 <=<D MVCU+=>RN9=:>N23\$9Q9,1^CTMUF:FOUHS#_@5_LABVX75<~>H@/RS0^S1_9 M^XBX H^ARGTR&D EN_S1+D^CV\$4K<=>I>H&F6JZAFH^EG->~>MD7Y14|5I;3 MJ3I?>X,I9K-MSS\$2H?>~IPI>D K I8I;IWI@>3;1T^H^<@>C:MMIP<=>MQ:~> MR#9Q?<0\$S_>M^<+> <?>I056D9Y,ANI=>K1@CBSYW(OP@>IAZOHVIOCR2E MV.B%>=>?000%>#IY>,>#W=&@QCM9Q,3UAN|RIH^>D">0.M(87Z|I|OBYCPM).OP?>+>A=I/B-89J_ "RHBAZI|I@>6 M&BFLI^K|>D>IR^FNI|>I&D>I)U2H6I<(<5I>~>3.9&I:=>?7QOLP0\$>I6;4H M9I-K^U23+>D:7?TYO?YI>I3^?>F^C^HGIHJR07)5H!5V3\$80^>PN< M91C7^L@>I@C M+KT<~>I%VM&,&T^I JICHZ?72MT@-M\$T<~>#BOXQW8H|J|I M|I_>I_>7OZR?><3A+>MCF2FK.6\$|IY OD\$|S<=&~>I\$3^KJ|L\$|X|H!^I2M4^ MZ| <3>I\$VPH^BOO7X^U|(OOSYHYU=I=)~>8N6,.55\$S&8V^ M 9M6G<~>I|LPK^C2%1GXSE1 UPY|LBDD/V#;7O&8M^=>8I2V3T^V=L>VLA?P W M@>@PCWHVY14|M98@-FLC3YIN4B%- RJI|OI4P^GHDZ(I5ZR)K8\$>W IG!~>I|BL MSY|I?:"3"RKYW%9SZIOK1ZI^N96NYIOR>=>LX^G-G^BMG23GR=M+E@L^>I^>IWR6>?>Y\$C>?>?E8- PI^>V3E_UY^2980+8WYER<0>@>P&S^2M5M|@>M|H^M^V\$5I96F^AI\$SIJ2X6RB9304Y+>E6N-5D7%:"MPMYF\$F-L|N|N|WRM@>H@/I\$J&6^I|I2A+LAI%=>?>T^ M|Y>T^I.S^WLY71?232 MM2(AEQTOW^7V\$G9I^F9WT^/33-65I0I@>OELJL 61CB23Z|I)=<+>XJWS8 M^>DAW^Y|L|R)62,3BA(OU@>O:0I=PG2ODORO.(?>T^QO)12W^J2T^ZL MM%+>*I0_2INC^\$5\$A@>4.LLX:28I\$5A@G\$>S^RR*214UWC\$4MTP2WE&4N! MENI|GC.LI= 6I6&@>C^W^O+^>C^>= 7VZ90XP^BHPX0^8?>+>60A00K^4 M1+>?>I^Q4Y12J3@I|I? V47=>@>LH.MHL8ISX.15% IMOOF3G:KTI\$3Q\$S M1?>IS&K8^IT^O^EKNME/WNICX^,Q6^@>A-CRY6U79BVJ?PLG:>^V7_XI^< M^>NBOHA=U5CT>37Z^PAWK4HNM69P2,3I^ECF3YQ+>I\$K/C30?>JF7I M3 M|IROS208B3N@>#2 "TH:38R05^>MB|D|VH#VR:I^I-16/I7A6Q O M MJ3|Q4F^I^N\$SSNE, K4F^3CTW^4R\$V^>E(F<9^=>\$0I^RVU|I^3BLB^>6<4>30J9 \$LX+XIAI^T L G+GUB-9PRNXA M835JFKINL^+I.TB.K)5I^>XA.G-80V^24I^/?>^CHFSI.(B&J_+>O1EK M%24\$;2 N#>L|P|A6MOYNR7RX(I|I>I&G<@>IVS M^|B(V+=+3)HDC&,06UF M^|I(3E3I3P?O|I>Z=IUZ?>ICFIZQI^1X|I)EOMGL+K2)RODS(^Y05^ M0/GXPZEYX^I\$S6 M0WEDZA^OY&=>=WML3I3GK^I?>^I^>4@>~>I^R^>FOJZXS M^>L\$35^>+>H^G/P|PMC+>G+IUS3_@EBZL4^9U:6BY3SJT^H^>G^T^W2!8I MTLI\$E6M3E3I)7P U(60:>? I7I+5I>U@>M.W.V.K>~W5HYHD712I9\$YVIDA MDP:32I-UFXCRB@=<=<N9%>C|C/L^K0G^5^>E,D>2B&NQ3\$>URWJ3I T P M2D^T^HC:9-W-R_I-<~>IVM53C43G! 7LQ=>^>TH:6+>MWWJ-6 MLXIXPNEG_>P/E&S^U|T^Z^F+L&OEDHRO_QO?EH52CDUPI^JGR=REJWP2 M^>QO^92T?>+>DBOIFMI_O+>ODS^FH6HSH:~>RI& (X^F%&8&L16^WGW MROO@>3F^>O^I&K+LZ98&+0E;3O|IYMD?T|L+HBS?)I9I6-S^W-6^U>=>=> M|I-J9SE|2M IV^FITE6I,K3UFIZ@9+,>@E=>?>42+>I^I|H1TSFB?&87@>N7 M7ERLR7+M2.Z&8H(Z8SB?2.KC0M0Q23FCE7@|BO^>HVH5<K^Q_ QHR3PLAW<43=M (6I8TC%7L\$>7&55(IPIU|I\$>1>)&A(N^M^>D.Q_2Q2I_1_ OY^>+>KN+U|? MLC>G26? KAUC^>@>3,1^G7IULOQA_4A&B5:E>F>~>M^Z0I0L\$JBG^T!>XO MNR^M^>P&L^POL4I(P5&\$&F^K-OE 16#9%IWEI,5N|IKIBVD@I)DOS^>VMR M|S^J1 EZI:G?6? B^>6>I.XGG<~>C^N1229I=RL^W^>?E9NIB,V>~>I V;EL%O=YMTR^ MXTK?>~>I5DK:8#>S^EAOKG^TF624&K<=<20/I6^>8J@6V,B^W2#% 09Q\$E4U@Y MBG8K@L9\$>7CWDI9+>=O0\$KQ8:D6&0?>?FIUVIFU>XYUI|I+>W2ZY^I^Y8 M1+>WMJL7L>?I270+>#(CPI>OCICE?ID\$X3K\$P5GD^AOOI>=>Y@IJ8%=CS7:%>E /@>^G2^%A4>=>O1POR>VOP<=<8<4,I9E\$1^>I^> M1?>?> MRHNI^>|>SCNN9JA^HO/QNHCFI3B+>6M#VIN^!>@8I5CV@0P M9YVI^YH1BRMD(C:>@>HJHU^T?I76X8=7HF^&^>YQOJ743 Q14I|RR5>BZ>YXJXM^U@>G0^?YGIH^5@T^I^YI67D|9, M.6&2+H; /2^%POAI^TGL HCBC@73IKMHX@AZ683+RUBA\$>(W.SBD112:OGE M^T49B2UO^YTLI.W6WO2HJIE,~>S3X>YI2V3JM#I.LM^>I^>C3 LB)TUXW:UT^J1I|D>I> M010> 50R&5R+>457Z&M\$&+>I+MIDY,I9DU-SPG:0^>F<~>78L=I:PC|@>G(O:G M^8BY&D73/1NS ME,%>3I<=>4AR12~2L2+HHT(KI2)I5V:>^UDE5\$ LLIWM^ACIUS^+PG.U M&M_>FW>&I? SOIP.OU>L>U^SX<~>C&U^>I^>A^>I^>59TE5B4@OKU45C^33#9JY 3 MIEF9R6<I>A+>F-93R87C9I/M5.C<272 Z7>NUJ\$M^I6&S&WKMO

W- (RUS)=S-..2HAX51YLB\$WU+;140W4H-;16-7X22-B;..M+;XO/R<PQI/G(99-7ZIG2;(<S-MX+9U4.KJKSHY%JCU//>>BVD2-Z1 M0-<J5+J4P/O,X9CF11-V#
Q#<VY2/4O1N0%1X2.N1W11(8X)HDXDRI+ M6JCOV#>B6:26Z->5EV.6\$EQ&..G139P->B\$F+((%D/22)UFEUV2&E2 M5O=6XBCB/JM.O;1B:3-H290/4AKPB#>
J#<ESQXV&6C<95/G9C=>ESN M6MR1R<E#<4L81/RVR8Z<BU2 MPX-BQFF#<#<1%<E<TL>U-P.OQ;1)XJ M59R;R2/D3D-.05-%<SLZ/>B:5 D50H;73+ (63R&T'P=7.
<C/H3J1WROA M43&9D000.4P:8KE1+22 D51UPL/83J5 M#<54'N1V5+99EIBX4'P-2H LUNJ'N5Y7'IT&RKRS6YM2IHYRR9P1- HIQ9BY M1(=*Z &W'1.5/12R4XK)/
/IVT<.8Y+;..5U143-B.7U.O;V&A9:H44'Q MZIAO+T'3*HPIC'13U+<4DLUVB54A-XJOG0GJ&GFWFAV)FOVGZR'>IHT MQO+OAN<
/VO&V8>Y%TN*VKOE0/(S533)T\$<PKE&+U/L:AVY(+01YFVB=>2R..X1 MJQI51B2)D1->80<@U/LN).PIDOWU&S. 62?H&YCYHYSH26W<
M1!/>2=0W1'=KDJ30/K;=<Q&GY8+EKGS0Q>US,N.U..*W30Q?E**=>4(5< MZG&A:JGNCW9BBN3IH6%IEB.XAJ9#2U'>'XYIRA9VA170.(Z16B1LZ72+*H(C MA8 >*KUBX-
QZLJR164MҒ&D\$N=>@<3'5>57R>B3Y Q\$Y<UN?TJ[XKMS#<(<=719:48P<CVLJ8M>.D>W&P NFL M#<MVR10L:3)Q=>D\$1-D\$Q;1J7N A14U.QC M'W>=>&..
/DB<K/47/1N G188<9-M+7<GYT6<KUMD L5NNJ)VM>M Q MD+VFO2PMT2>1)'.<#8+172:PUA TUJNE QI<#E 1JFMZ0Q2D=9Z=>FLIR2G+66N1(M500WRK)%<\$.J M S150AW<
C/L8B 1H:60?>J)D5-PYOC VG<=>QFOD'3ET&+J'1 O0SIC1 MFGY1F2 27R<K&Q<(<+Y1482<572%<A1V2ZG88W^T)PQ OBI2&A9Q M\$S.(3XCMT1500W)<?>
<2OWD19J9TE. @J<QKS<\$.Q?Y#61** Z=SE&S MZD\$5&+<A.M1.V:VSVBZ1>=>O:19NMRC'2XIVJB91.YT:105UNJLR M&K(K>=ICI
M.O&X)<+IHD(UO&EDH0)WY2K.P.91>DTM4(#Y1<50 MZ.8=>YK<NM T6NR3/F>STVE@<3740F=LIH9VW7FIJUY2Y=3 M5I\$N(U(G)
/IASVG60+SP(>M>VCEMOQ>?<P&S< GSDZHC(F42A.L01V>1IR3. MK'Z<CM AR(32.0M+<P'BU'HW7R&U-LPXOIF6ZU2D XXYV6)35JIRYR+AN\$5 M'ADO<>Z15YQ=QI=W#V7C'45-
8PFE9M1Z1&H<.<Y'LK'<OM@28HR160>QO.72D1F40.DG<I<M1=<= /19J1D2'G1?>.EUPJ2'J=<'D9H\$M%'197623/>@<JQ.1U'CFXU
M#4Q1O.MQI#E>VW22R7UMKHQW18S1Q2A.FJ+UJ'567QV?FXULJS8) L M5 LCW#IUC<MR-N'>'MIW#HWH#SD2P'7J3&+>LJI=Z)X)77F:;@C'HOJZ M,UU?'@<G:2#<
<C4 C@<E=M04702U-PUHFIQ056H063U5H\$5'MWL(L-;..< MB0(ZI&A46I2L.AO>+>17U:A'XJT>9P3A:0(5460LUI@<#%<+4E>ZABQSC=2@+> MJ(5<3J1V7V>3GD?'< < SX>
D'9&67+SV'>).W#W@<=;T'CW.Z. OPG2' M9W14-;..OY7T5:F10KFN8(AW:)<@<27YONS9@<K0.1LXV<1L 3G;F= M&T.46PL(X886Z)'<'GDYR&4\$S
M1\$EBI'<3\$<U16#DU119A0BTDB98I>..F75'16T#PWT+1J35. ACRI&O M'C'DY'Q98I.>..T29'W9F6Z19BCOO?YD1<@<IMJIRC+KKAFAH=CVS7>J/K B+>+?<KI(HUBO=
M5/EK6.9LD19:ZYGDAX@MA3I&*>5&V&A08JF(IW713DY:RS5+5BM+&F)H.R3LO M.U=JZ1<E+YA<+<BFC1A9RV00 I:5IN7'ITC1OEOWIT'<V'P#BUI&53%<V'VW?<
MM<?<'M29VW>VJIRJ ONIL&0<=<SE&C1F/ETIU&'E&..820:9<0E@<IAU6& &Y&7CGX' M'KKZ2W?=>..9AICGB'<C9%<?<IO<(<H1071F?YHUNIOJ:G& <6H1RX20&Q<^<
(M4+>)<J>Q5@<.'CY6S03P94(W68P)~..13Y7H<=>Q01H2L#U MYZQ P.J:V\$C4&2HN/V*..H02M<1'<T'Z6&:5>1..SPKPAW&8U%U&X&5U&15W1AC<+<4@J5.<%1%N.8B:TKJO#1<
(S.SB&AT2-8S7JXUSP<1F52C'7#4 M<=<J&KJ2P&S&SB8U<C1&9Y'2H<+<LQG M.4=5102K.O'<+H9.N(5966276F#I.YZ B>7+P9@576Z1=>W0\$E104:\$W6/N6 <5B4C?21OY<
MEH&5X4+..51Jk=>=<BPH9T5.002YIPGVK0OU?MX96C<L&Y'UO+<LQG M.4=5102K.O'<+H9.N(5966276F#I.YZ B>7+P9@576Z1=>W0\$E104:\$W6/N6 <5B4C?21OY<
MS25N.FAP31I2X5I@A@B\$33OT>.<@<D\$@<#%<..3SGEK ^\$<ISR4F5LIX^U/I M=5NCI'>'N6I4@<(UNSF&)HW:2&/%>..5.9.Q&L1=P<1:GJN5+ P)JD/B1#E'<
M1./@Q\$<65+T5A+>T.DS80=CJ(M'QUNV3F4DS2(>51'1*=>=<IC:21(IXB9P+1V 25V1:MHC9<K0:2GOF M=633R
M'ZC'D=OZE>99VQI#E'019.V1Y9KU(<O>6FYH16BYCCO3(<C&C3H'<W8. M1A=>61..2-6#19'>'#1HU:4&S1JDI<#<'BJ6E1|@GH'1|@<+D0B9'T@<O/RF7 MOIPIEM-7'E \$S\$U12V0'<J
M00YQK604GQ'<2H%12>..SE0L@<6.2 K1>A/<6&+<Z.H0A20I:RV4A9B(=<=<1#<2>V1AANE<17 MXR(9< <L.G1>+<.&WISOYHVAIK'RKVY CBR#<+<Z11SPH&5'550 M9->* D'<
<UWW+>#<J>..<NHY218D+6>=<2.9(1%0)H=V8'ZS<=<ZWZD M68IKWU(L'<K21=9\$1'<T'>'#N'YK.HG-60X.BA1&A57Y-C2Y.NMVMZN P.M)<=<E'F4\$=<
C)8LND<@FV<)<I&L PX6.Y<UDX&2VB&.\$M.R513#U&TT IG4+<2\$S\$W.3TU-GSX517IH?WVN#X\$T M+<..STD8I3I?OJ4AAA0:YI(E.FFPT-#3I'GLCM*>L-9.HGN+@<P8/VA68--T=Y
M1'5D1X'1LT84#=<1D'<'<SPR=T-P>7X>+<157H13&S'<CW.'F0V>2B'1 M'N.3C'Q1+<2N&31>SP>CU20I/CJB#<Q'<'<WA44'>+<A25/>+<6J'NP&E1I(L'5 M2 J
|KJ19Q'<9IGM548GD+2V.NIK979JMS10>..5R.0'DJ.9.20EF<R>B1 M'N.3C'Q1+<2N&31>SP>CU20I/CJB#<Q'<'<WA44'>+<A25/>+<6J'NP&E1I(L'5 M2 J
M4B.4.Y1+<SZ9P/B.A.NJ1SIA8NOMC'K'<Y.OPK.523MISOCVNA&1<+<3 M)JLM6F8X2U19:<NG'N'<T1=<V19.C-72?T13U?M%W760L D12:V6LJ1'S M.O4 3?F%=<(J10)1I'<
<+84>NJO+2.012TG?1&80H.GJZ 1T SHKU1+5 M2E'1B&48Y4..1U3U1=5796H36TJ(GATSW '71.36U<C&G?CL15E1054#<
M70LM06=OJ+Y3I=>73U2+<CON\$M<C%>)<Y+HA91Y/A00I'D>=<6K3I.R**E MP.MP9XC=<4S>..NE-5.O;X&=<..V4>TU V7Z..D'NEYH

[illegible]

lgvn:ContractManufacturingMember 2024-01-012024-06-30 0001721484 lgvn:ContractManufacturingMember 2023-01-012023-06-30 0001721484
lgvn:NationalInstitutesOfHealthGrantMember 2024-04-012024-06-30 0001721484 lgvn:NationalInstitutesOfHealthGrantMember 2023-04-012023-06-30 0001721484
lgvn:NationalInstitutesOfHealthGrantMember 2024-01-012024-06-30 0001721484 lgvn:NationalInstitutesOfHealthGrantMember 2023-01-012023-06-30 0001721484 us-
gaap:AllOtherCorporateBondsMemberus-gaap:FairValueInputsLevel1Member 2024-06-30 0001721484 us-gaap:AllOtherCorporateBondsMemberus-
gaap:FairValueInputsLevel2Member 2024-06-30 0001721484 us-gaap:AllOtherCorporateBondsMemberus-gaap:FairValueInputsLevel3Member 2024-06-30 0001721484 us-
gaap:AllOtherCorporateBondsMember 2024-06-30 0001721484 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member 2024-06-30 0001721484 us-
gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member 2024-06-30 0001721484 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member
2024-06-30 0001721484 us-gaap:MoneyMarketFundsMember 2024-06-30 0001721484 us-gaap:AccruedIncomeReceivableMemberus-gaap:FairValueInputsLevel1Member
2024-06-30 0001721484 us-gaap:AccruedIncomeReceivableMemberus-gaap:FairValueInputsLevel2Member 2024-06-30 0001721484 us-
gaap:AccruedIncomeReceivableMemberus-gaap:FairValueInputsLevel3Member 2024-06-30 0001721484 us-gaap:AccruedIncomeReceivableMember 2024-06-30 0001721484
us-gaap:FairValueInputsLevel1Member 2024-06-30 0001721484 us-gaap:FairValueInputsLevel2Member 2024-06-30 0001721484 us-gaap:FairValueInputsLevel3Member
2024-06-30 0001721484 us-gaap:AllOtherCorporateBondsMemberus-gaap:FairValueInputsLevel1Member 2023-12-31 0001721484 us-
gaap:AllOtherCorporateBondsMemberus-gaap:FairValueInputsLevel2Member 2023-12-31 0001721484 us-gaap:AllOtherCorporateBondsMemberus-
gaap:FairValueInputsLevel3Member 2023-12-31 0001721484 us-gaap:AllOtherCorporateBondsMember 2023-12-31 0001721484 us-gaap:MoneyMarketFundsMemberus-
gaap:FairValueInputsLevel1Member 2023-12-31 0001721484 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member 2023-12-31 0001721484 us-
gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member 2023-12-31 0001721484 us-gaap:MoneyMarketFundsMember 2023-12-31 0001721484 us-
gaap:AccruedIncomeReceivableMemberus-gaap:FairValueInputsLevel1Member 2023-12-31 0001721484 us-gaap:AccruedIncomeReceivableMemberus-
gaap:FairValueInputsLevel2Member 2023-12-31 0001721484 us-gaap:AccruedIncomeReceivableMemberus-gaap:FairValueInputsLevel3Member 2023-12-31 0001721484 us-
gaap:AccruedIncomeReceivableMember 2023-12-31 0001721484 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001721484 us-gaap:FairValueInputsLevel2Member
2023-12-31 0001721484 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001721484 us-gaap:LeaseholdImprovementsMember 2024-06-30 0001721484 us-
gaap:LeaseholdImprovementsMember 2023-12-31 0001721484 us-gaap:FurnitureAndFixturesMember 2024-06-30 0001721484 us-gaap:FurnitureAndFixturesMember 2023-
12-31 0001721484 us-gaap:ComputerEquipmentMember 2024-06-30 0001721484 us-gaap:ComputerEquipmentMember 2023-12-31 0001721484 us-
gaap:SoftwareDevelopmentMember 2024-06-30 0001721484 us-gaap:SoftwareDevelopmentMember 2023-12-31 0001721484 us-gaap:LicensingAgreementsMember 2024-06-
30 0001721484 us-gaap:PatentsMember 2024-06-30 0001721484 us-gaap:TrademarksMember 2024-06-30 0001721484 us-gaap:LicensingAgreementsMember 2023-12-31
0001721484 us-gaap:PatentsMember 2023-12-31 0001721484 us-gaap:TrademarksMember 2023-12-31 0001721484 srt:MaximumMember 2023-12-31 0001721484 us-
gaap:CommonClassAMember 2024-01-012024-06-30 0001721484 us-gaap:CommonClassBMember 2024-01-012024-06-30 0001721484 us-gaap:CommonClassBMemberus-
gaap:CommonStockMember 2023-01-012023-12-31 0001721484 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2023-01-012023-12-31 0001721484 us-
gaap:WarrantMemberus-gaap:CommonClassAMember 2024-06-30 0001721484 us-gaap:CommonClassAMemberus-gaap:IPOMember 2024-06-30 0001721484 us-
gaap:WarrantMemberlgvn:UnderwritersMember 2021-12-31 0001721484 us-gaap:WarrantMember 2024-06-30 0001721484 us-
gaap:WarrantMemberlgvn:TwoThousandTwentyOnePIPEOfferingMember 2024-06-30 0001721484 lgvn:TwoThousandTwentyOnePIPEOfferingMember 2024-06-30 0001721484
us-gaap:CommonClassAMemberlgvn:TwoThousandTwentyOnePIPEOfferingMember 2024-06-30 0001721484 us-gaap:ValuationTechniqueConsensusPricingModelMember
2023-08-16 0001721484 us-gaap:ValuationTechniqueConsensusPricingModelMember 2023-08-162023-08-16 0001721484 us-
gaap:SeriesAMemberlgvn:October2023RegisteredDirectOfferingMember 2024-06-30 0001721484 us-gaap:SeriesBMemberlgvn:October2023RegisteredDirectOfferingMember
2024-06-30 0001721484 us-gaap:SeriesAMemberlgvn:October2023RegisteredDirectOfferingMember 2024-06-30 0001721484
lgvn:October2023RegisteredDirectOfferingMemberus-gaap:CommonClassAMember 2024-06-30 0001721484 lgvn:PlacementAgentWarrantsMemberus-
gaap:CommonClassAMember 2024-06-30 0001721484 lgvn:SeriesAAndSeriesBWarrantsMember 2024-04-30 0001721484 us-
gaap:CommonClassAMemberlgvn:December2023OfferingMember 2024-06-30 0001721484 lgvn:UnderwritersWarrantsMemberlgvn:December2023OfferingMember 2024-06-
30 0001721484 us-gaap:CommonClassAMemberus-gaap:IPOMember 2024-04-08 0001721484 lgvn:PreFundedWarrantMemberus-gaap:CommonClassAMember 2024-04-08
0001721484 lgvn:CommonWarrantsMemberus-gaap:CommonStockMember 2024-04-08 0001721484 lgvn:CommonWarrantsMember 2024-04-08 0001721484
lgvn:PreFundedWarrantMember 2024-04-08 0001721484 lgvn:CommonWarrantsMember 2024-06-30 0001721484 lgvn:SeriesAAndSeriesBWarrantsMember 2024-06-30
0001721484 us-gaap:SeriesAMember 2024-06-30 0001721484 us-gaap:SeriesBMember 2024-06-30 0001721484 us-gaap:WarrantMember 2024-01-012024-06-30 0001721484
us-gaap:WarrantMember 2024-04-16 0001721484 us-gaap:WarrantMemberus-gaap:CommonClassAMember 2024-04-162024-04-16 0001721484
lgvn:ClassAMemberStockWarrantsMemberus-gaap:CommonClassAMember 2024-04-16 0001721484 lgvn:SeriesCWarrantsMemberus-gaap:CommonClassAMember 2024-04-
16 0001721484 lgvn:SeriesCWarrantsMember 2024-04-16 0001721484 lgvn:SeriesDWarrantsMemberus-gaap:CommonClassAMember 2024-04-16 0001721484
lgvn:SeriesDWarrantsMember 2024-04-16 0001721484 lgvn:SeriesCWarrantsMember 2024-06-30 0001721484 lgvn:SeriesDWarrantsMemberus-gaap:CommonClassAMember
2024-01-012024-06-30 0001721484 lgvn:SeriesDWarrantsMemberus-gaap:CommonClassAMember 2024-06-172024-06-17 0001721484 lgvn:SeriesDWarrantsMemberus-
gaap:CommonClassAMember 2024-06-17 0001721484 lgvn:ClassAMemberCommonStockWarrantsMember 2024-06-172024-06-17 0001721484 us-gaap:CommonClassAMember 2024-
06-17 0001721484 lgvn:PlacementAgentWarrantsMemberus-gaap:CommonClassAMember 2024-01-012024-06-30 0001721484 us-gaap:CommonStockMember 2024-06-30
0001721484 lgvn:SeriesDWarrantsMemberus-gaap:CommonStockMember 2024-01-012024-06-30 0001721484 lgvn:SeriesDWarrantsMember 2024-06-30 0001721484 us-
gaap:WarrantMemberus-gaap:CommonClassAMember 2024-01-012024-06-30 0001721484 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0001721484
srt:MinimumMember 2024-01-012024-06-30 0001721484 srt:MaximumMember 2024-01-012024-06-30 0001721484 srt:MinimumMemberus-
gaap:RestrictedStockUnitsRSUMember 2024-01-012024-06-30 0001721484 srt:MaximumMemberus-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-06-30
0001721484 us-gaap:StockOptionMember 2024-04-012024-06-30 0001721484 us-gaap:StockOptionMember 2023-04-012023-06-30 0001721484 us-
gaap:StockOptionMemberus-gaap:CommonClassAMember 2024-04-30 0001721484 us-gaap:RestrictedStockUnitsRSUMemberus-gaap:CommonClassAMember 2024-04-30
0001721484 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001721484 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-06-30 0001721484 us-
gaap:StockOptionMember 2024-06-30 0001721484 us-gaap:StockOptionMember 2023-12-31 0001721484 us-gaap:StockOptionMember 2024-01-012024-06-30 0001721484
2014-11-202014-11-20 0001721484 2022-11-162022-11-16 0001721484 2022-11-16 0001721484 lgvn:ChiefScienceOfficerMember 2024-06-30 0001721484
lgvn:ChiefScienceOfficerMember 2023-12-31 0001721484 lgvn:TechnologyServicesAgreementMember 2024-06-30 0001721484 lgvn:TechnologyServicesAgreementMember
2023-12-31 0001721484 2014-11-20 0001721484 us-gaap:LicenseMember 2021-01-012021-12-31 0001721484 us-gaap:CommonClassAMember 2014-11-20 0001721484 us-
gaap:LicenseMember 2024-01-012024-06-30 0001721484 lgvn:UMAgreementsMember 2024-01-012024-06-30 0001721484 2023-01-012023-12-31 0001721484
lgvn:UMAgreementsMember 2023-01-012023-12-31 0001721484 lgvn:LongeveronMember 2024-01-012024-06-30 0001721484 lgvn:firstPhase3ClinicalTrialMember 2014-11-
202014-11-20 0001721484 lgvn:BiologicsLicenseMember 2014-11-202014-11-20 0001721484 2016-12-162016-12-22 0001721484 2016-12-23 0001721484
lgvn:SeriesCUnitsMember 2016-12-232016-12-23 0001721484 2016-12-232016-12-23 0001721484 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-06-30
0001721484 us-gaap:RestrictedStockUnitsRSUMember 2023-01-012023-06-30 0001721484 us-gaap:PhantomShareUnitsPSUsMember 2024-01-012024-06-30 0001721484 us-
gaap:PhantomShareUnitsPSUsMember 2023-01-012023-06-30 0001721484 us-gaap:EmployeeStockOptionMember 2024-01-012024-06-30 0001721484 us-
gaap:EmployeeStockOptionMember 2023-01-012023-06-30 0001721484 us-gaap:WarrantMember 2024-01-012024-06-30 0001721484 us-gaap:WarrantMember 2023-01-
012023-06-30 0001721484 lgvn:SeriesCWarrantsMemberus-gaap:SubsequentEventMember 2024-07-10 0001721484 us-gaap:CommonClassAMemberus-
gaap:SubsequentEventMember 2024-07-102024-07-10 0001721484 us-gaap:CommonClassAMemberus-gaap:SubsequentEventMember 2024-07-172024-07-17 0001721484 us-
gaap:SubsequentEventMember 2024-07-172024-07-17 0001721484 us-gaap:SubsequentEventMember 2024-07-17 0001721484 us-gaap:SubsequentEventMember 2024-07-
102024-07-10 0001721484 us-gaap:SubsequentEventMemberus-gaap:NoteWarrantMember 2024-07-172024-07-17 0001721484 us-gaap:CommonClassAMemberus-
gaap:SubsequentEventMember 2024-07-242024-07-24 0001721484 us-gaap:WarrantMemberus-gaap:NoteWarrantMember 2024-01-012024-06-30 0001721484 us-
gaap:CommonClassAMemberus-gaap:SubsequentEventMember 2024-07-182024-07-18 0001721484 us-gaap:CommonClassAMemberus-gaap:SubsequentEventMember 2024-
07-18 0001721484 us-gaap:SubsequentEventMember 2024-07-192024-07-19 0001721484 lgvn:SeriesBWarrantsMember 2024-01-012024-06-30 0001721484 2024-08-06
0001721484 lgvn:JulyPrivatePlacementMember 2024-08-062024-08-06 0001721484 lgvn:JulyOfferingPlacementMember 2024-08-062024-08-06 0001721484
lgvn:JulyOrdinaryCoursePlacementAgentMember 2024-08-062024-08-06 shares iso4217:USD iso4217:USD shares pure10-Qtrue2024-06-30false001-40060Longeveron
Inc.DE47-21741461951 NW 7th AvenueSuite 520MiamiFL33136(305)909-0840Class A common stock, par value \$0.001 per shareLGVNNASDAQYESNoNon-accelerated
Filertruefalsefalse12875413148400512375000494900041200081700037600021800011100013410000584800023710002529000235300022870001055000112210002040001
100956000-84984000-
10001491100067410001939300012078000287000217000802000455000181000214000410004680002170001016000496000124000124000343000327000344000930006730001
3500000-5712000-7590000-1042800087000800001190001490008700080000119000149000-3413000-5632000-7471000-1027900085010008501000-11914000-5632000-
15972000-10279000-1.83-2.67-3.54-4.88650988121105445117342106973-3413000-5632000-7471000-10279000-2000-36000-100022000-341500-5668000-7472000-
102570001025183100014855601000-1000091823300-8498400067410001555-15559714-3501-26000-260008002-3268-17000-170001000010000525000525000-1000-
10001145000221276620004720000472000013590004799488500010333000103380008501000-850100066970-7471000-747100081699800014840051000115859000-
100956000-100014911000612732100014891091000-10000083731000-62773000-357000205030003555-355517972-2836-103000-1030001120000112000022000220006-
10279000-10279000631423100014855601000-10000084748000-73052000-33500011263000103428310001484005100092080000-89042000100030410005158-1756-5000-
5000230000230000-2000-2000114500022127662000472000047200013590004799488500010333000103380008501000-850100066970-3413000-
3413000811690980014840051000115859000-100956000-100014911000616305100014871091000-10000084135000-6742000-299000163180001555-155515955-2392-
86000-86000699000699000-36000-360006-5632000-5632000631423100014855601000-10000084748000-73052000-33500011263000-7471000-10279000481000478000-
60000-1510005250001120000107000-122000441000113600011000-23000-38000-51000-109000-10000-1398000-547000658000127000127000133000-7652000-
1044900035000033116000212000134000177000186000-3900027960004722000103380001000004300010300015117000-1030007426000-
7756000494900010503000123750002747000-108000-575000850100086000<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. Nature of Business,
Basis of Presentation, and Liquidity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><p style="font: 10pt Times
New Roman, Times, Serif; margin: 0pt 0; text-align: left">Nature of business:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in;
text-align: left"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Longeveron was formed as a Delaware limited liability company on October 9,
2014, and was authorized to transact business in Florida on December 15, 2014. On February 12, 2021, Longeveron, LLC converted its corporate form (the "Corporate
Conversion") from a Delaware limited liability company (Longeveron, LLC) to a Delaware corporation, Longeveron Inc. (the "Company," "Longeveron" or "we," "us," or "our").
The Company is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company operates out of
its leased facilities in Miami, Florida.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company's product candidates are currently in development. There can be no assurance that the Company's research and development will be successfully
completed, that adequate protection for the Company's intellectual property will be obtained, that any products developed will obtain necessary government regulatory
approval or that any approved products will be commercially viable. Even if the Company's product development efforts are successful, it is uncertain when, if ever, the
Company will generate significant revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from,
among others, existing pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, partners and consultants,
</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying
interim condensed balance sheet as of June 30, 2024, and the condensed statements of operations, statements of comprehensive loss, stockholders' equity, and cash flows for
the three and six months ended June 30, 2024 and 2023, are unaudited. The unaudited condensed financial statements have been prepared according to the rules and
regulations of the Securities and Exchange Commission ("SEC") and, therefore, certain information and disclosures normally included in financial statements prepared in
accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") have been omitted. In the opinion of management, the accompanying
unaudited condensed financial statements for the periods presented reflect all adjustments which are normal and recurring, and necessary to fairly state the financial
position, results of operations, and cash flows of the Company. These unaudited condensed financial statements and notes should be read in conjunction with the audited
financial statements and notes thereto in the Company's 2023 Annual Report on Form 10-K filed with the SEC on February 27, 2024.</p><p style="font: 10pt Times New
Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Liquidity:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Since inception,
the Company has primarily been engaged in organizational activities, including raising capital, and research and development activities. The Company does not yet have a

The Company has been approved by the U.S. Food and Drug Administration ("FDA"), and has only generated revenues from grants, clinical trials and contract manufacturing.

The Company has not yet achieved profitable operations or generated positive cash flows from operations. The Company intends to continue its efforts to raise additional funds via equity financing, develop its intellectual property, and secure regulatory approvals to commercialize its products. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. Further, the Company's future operations are dependent on the success of the Company's efforts to raise additional capital, its research and commercialization efforts, regulatory approval, and, ultimately, the market acceptance of the Company's approved products, if any. These condensed financial statements do not include adjustments that might result from the outcome of these uncertainties.

The Company has incurred recurring losses from operations since its inception, including a net loss of \$7.5 million and \$10.3 million for the six months ended June 30, 2024 and 2023, respectively. In addition, as of June 30, 2024, the Company had an accumulated deficit of \$101.0 million. The Company expects to continue to generate operating losses in the foreseeable future.

As of June 30, 2024, the Company had cash and cash equivalents of \$12.4 million. The Company believes that its cash and cash equivalents as of June 30, 2024, together with \$15.3 million in gross cash proceeds from the July 2024 financing transactions (as described below), will enable it to fund its operating expenses and capital expenditure requirements through the fourth quarter of 2025.

The Company was incorporated under the laws of Delaware on March 26, 2021. On March 26, 2024, the Company effected a reverse stock split of the outstanding shares of its Class A common stock and Class B common stock on a one-for-ten (1:10) basis (the "Reverse Stock Split"). The Reverse Stock Split became effective at 11:59 p.m. Eastern Time on March 26, 2024 via a certificate of amendment to the Company's Certificate of Incorporation filed with the Secretary of State of the State of Delaware. At the effective time of the Reverse Stock Split, every ten shares of the Company's Class A common stock and Class B common stock, whether issued and outstanding or held by the Company as treasury stock, were automatically combined and converted (without any further act) into one fully paid and nonassessable share of Class A common stock or Class B common stock, respectively, subject to rounding up of fractional shares to the nearest whole number of shares resulting from the Reverse Stock Split without any change in the par value per share. All share, per share, option, warrant, equity award, and other derivative security numbers and exercise prices appearing in this Quarterly Report on Form 10-Q and the accompanying condensed financial statements have been adjusted to give effect to the Reverse Stock Split for all prior periods presented. However, the Company's annual, other periodic, and current reports, and all other information and documents incorporated by reference into this Quarterly Report on Form 10-Q that were filed prior to March 19, 2024, do not give effect to the Reverse Stock Split.

The presentation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and cash equivalents:

Accounting Standard Update ("ASU") 2023-09, "Improvements to Income Tax Disclosures". The amendments in this ASU change disclosure requirements for various items, including effective tax rate reconciliations and cash taxes paid. This ASU is effective for public companies for the financial reporting periods beginning on January 1, 2025, with early adoption permitted. We have not adopted ASU 2023-09 for our financial reporting period ending December 31, 2023, and will continue to evaluate early adoption for our financial reporting period ending December 31, 2024.

Cash and cash equivalents:

Marketable securities:

Marketable securities at June 30, 2024 and December 31, 2023 consisted of marketable fixed income securities, primarily corporate bonds which are categorized as available for sale securities and are thus marked to market and stated at fair value in accordance with ASC 820 - Fair Value Measurement. These investments are considered Level 1 and Level 2 investments within the ASC 820 fair value hierarchy. The fair value of Level 1 investments, including cash equivalents, money funds and U.S. government securities, are substantially based on quoted market prices in active markets. The fair value of corporate bonds is determined using standard market valuation methodologies, including discounted cash flows, matrix pricing and/or other similar techniques. The inputs to these valuation techniques include but are not limited to market interest rates, credit rating of the issuer or counterparty, industry sector of the issuer, coupon rate, call provisions, maturity, estimated duration and assumptions regarding liquidity and estimated future cash flows. In addition to bond characteristics, the valuation methodologies incorporate market data, such as actual trades completed, bids and actual dealer quotes, where such information is available. Accordingly, the estimated fair values are based on available market information and judgments about financial instruments categorized within Level 1 and Level 2 of the fair value hierarchy. Interest and dividends are recorded when earned. Realized gains and losses on investments are determined by specific identification and are recognized as incurred in the condensed statement of operations. Changes in net unrealized gains and losses are reported in other comprehensive loss and represent the change in the fair value of investment holdings during the reporting period. Changes in net unrealized losses were less than \$0.1 million for the three and six months ended June 30, 2024 and 2023, respectively.

Accounts and grants receivable:

Accounts and grants receivable include amounts due from customers, granting institutions and others. The amounts as of June 30, 2024, and December 31, 2023 are certain to be collected, and no amount has been recognized for expected credit losses. In addition, for the clinical trial revenue, most participants pay in advance of treatment. Advanced grant funds and prepayments for the clinical trial revenue are recorded to deferred revenue. Advance contract manufacturing payments are recorded to deferred revenue.

Accounts and grants receivable by source, as of (in thousands):

	June 30, 2024	December 31, 2023
National Institutes of Health - Grant	\$15.1	\$59.0
Total	\$15.1	\$59.0

Property and equipment:

Property and equipment, including improvements that extend the useful lives of related assets, are recorded at cost, while maintenance and repairs are charged to operations as incurred. Depreciation is calculated using the straight-line method based on the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the original term of the lease. Depreciation expense is recorded in the research and development line of the condensed statements of operations as the assets are primarily related to the Company's clinical programs.

Intangible assets:

Intangible assets include payments on license agreements with the Company's co-founder and Chief Scientific Officer ("CSO") and the University of Miami ("UM") (see Note 9) and legal costs incurred related to patents and trademarks. License agreements have been recorded at the value of cash consideration, common stock and membership units transferred to the respective parties when acquired.

Payments for license agreements are amortized using the straight-line method over the estimated term of the agreements, which range from 5-20 years. Patents are amortized over their estimated useful life, once issued. The Company considers trademarks to have an indefinite useful life and evaluates them for impairment on an annual basis. Amortization expense is recorded in the research and development line of the condensed statements of operations as the assets are primarily related to the Company's clinical programs.

Impairment of Long-Lived Assets:

The Company evaluates long-lived assets for impairment, including property and equipment and intangible assets, when events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. Upon the occurrence of a triggering event, the asset is reviewed to assess whether the estimated undiscounted cash flows expected from the use of the asset plus the residual value from the ultimate disposal exceeds the carrying value of the asset. If the carrying value exceeds the estimated recoverable amounts, the asset is written down to the estimated fair value. Any resulting impairment loss is reflected in the condensed statements of operations. Upon evaluation, management determined that there was no impairment of long-lived assets during the three and six months ended June 30, 2024 and 2023.

Deferred revenue:

The unearned portion of advanced grant funds and prepayments for clinical trial and contract manufacturing revenues, which will be recognized as revenue when the Company meets the respective performance obligations, has been presented as deferred revenue in the accompanying condensed balance sheets. For the six months ended June 30, 2024 and 2023, the Company recognized less than \$0.1 million, respectively, of funds that were previously classified as deferred revenue. Due to the MSCRF - Technology Development Corporation ("TEDCO") - grant Acute Respiratory Distress Syndrome ("ARDS") program being discontinued, \$0.4 million recorded as deferred revenue was reversed when the funds were returned to MSCRF - TEDCO. As of June 30, 2024 and December 31, 2023, the Company had \$0.4 million and \$0.5 million, respectively, recorded in deferred revenue on the condensed balance sheets.

Revenue recognition:

Option 0:

The Company recognizes revenue when performance obligations related to respective revenue streams are met.

For grant revenue, the Company considers the performance obligation met when the grant related expenses are incurred or supplies and materials are received. The Company is paid in tranches pursuant to terms of the related grant agreements, and then applies payments based on regular expense reimbursement submissions to grantors. There are no remaining performance obligations or variable consideration once grant expense reporting to the grantor is complete.

For clinical trial revenue, the Company considers the performance obligation met when the participant has received the treatment. The Company usually receives prepayment for these services or receives payment at the time the treatment is provided, and there are no remaining performance obligations or variable consideration once the participant receives the treatment.

For contract manufacturing revenue, the Company considers the performance obligation met when the contractual obligation and/or statement of work has been satisfied. Payment terms may vary depending on specific contract terms. There are no significant judgments affecting the determination of the amount and timing of revenue recognition.

Revenue by source	(in thousands)
Clinical trial revenue	\$287
Contract manufacturing	\$802
Total	\$1,089

The following table provides information about our deferred tax assets and liabilities as of June 30, 2024 and June 30, 2023.

Deferred tax asset/liability	June 30, 2024	June 30, 2023
Research and development costs capitalized	\$6.4 million	\$6.4 million
Charitable contributions	\$0.1 million	\$0.1 million
Net operating losses carryforwards	\$1.0 million	\$1.0 million
Other temporary differences	\$0.5 million	\$0.5 million
Total deferred tax assets	\$8.0 million	\$8.0 million
Valuation allowance	\$0.5 million	\$0.5 million
Total deferred tax assets, net of valuation allowance	\$7.5 million	\$7.5 million

We have recorded a valuation allowance against certain deferred tax assets if it is more likely than not that some portion of the deferred tax asset will not be realized. Our policy regarding the recording of such allowances is described below under "Taxation."

Taxation

The Company's operations are subject to various taxes in the United States and foreign jurisdictions. The Company records income taxes payable or receivable, plus any change during the period in deferred tax assets and liabilities. The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. In addition, a valuation allowance is established to reduce any deferred tax asset for which it is determined that it is more likely than not that some portion of the deferred tax asset will not be realized. The Company's tax provision was \$0 for the three and six months ended June 30, 2024 and 2023 due to net operating losses. The Company has not recorded any tax benefit for the net operating losses incurred due to the offset created by the Company's valuation allowance.

The Company benefits from uncertain tax positions that the Company has taken or expects to take on a tax return. In the unlikely event an uncertain tax position exists in which the Company could incur income taxes, the Company would evaluate whether there is a probability that the uncertain tax position taken would be sustained upon examination by a taxing authority. Reserves for uncertain tax positions would then be recorded if the Company determined it is probable that either a position would not be sustained upon examination, or a payment would have to be made to a taxing authority and the amount was reasonably estimable. As of June 30, 2024 and December 31, 2023, the Company does not believe it has any uncertain tax positions that would result in the Company having a liability to a taxing authority. It is the Company's policy to expense any interest and penalties associated with its tax obligations when they are probable and estimable.

Equity-based compensation

The Company accounts for equity-based compensation expense by the measurement and recognition of compensation expense for stock-based awards based on estimated fair values on the date of grant. The fair value of the stock options is estimated at the date of the grant using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires the input of highly subjective assumptions, the most significant of which are the expected share price volatility, the expected life of the stock option award, the risk-free rate of return, and dividends during the expected term. Because the option-pricing model is sensitive to changes in the input assumptions, different determinations of the required inputs may result in different fair value estimates of the stock options.

Neither the Company's stock options nor its restricted stock units ("RSUs") trade on an active market. Volatility is a measure of the amount by which a financial variable, such as a stock price, has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. Given the Company's limited historical data, the Company utilizes the average historical volatility of similar publicly traded companies that are in the same industry. The risk-free interest rate is the average U.S. treasury rate (having a term that most closely approximates the expected life of the option) for the period in which the stock option was granted. The expected life is the period of time that the stock options granted are expected to remain outstanding. Stock options granted have a maximum term of ten years. The Company has insufficient historical data to utilize in determining its expected life assumptions and, therefore, uses the simplified method for determining expected life.

Basis of presentation

The condensed financial statements of the Company were prepared in accordance with U.S. GAAP.

Certain reclassifications have been made to prior year condensed financial statements to conform to classifications used in the current year. These reclassifications had no impact on net loss, stockholders' equity or cash flows as previously reported.

Reverse Stock Split

On March 26, 2024, the Company effected a reverse stock split of the outstanding shares of its Class A common stock and Class B common stock on a one-for-10 (1:10) basis (the "Reverse Stock Split"). The Reverse Stock Split became effective at 11:59 p.m. Eastern Time on March 26, 2024 via a certificate of amendment to the Company's Certificate of Incorporation filed with the Secretary of State of the State of Delaware. At the effective time of the Reverse Stock Split, every 10 shares of the Company's Class A common stock and Class B common stock, whether issued and outstanding or held by the Company as treasury stock, were automatically combined and converted (without any further act) into one fully paid and nonassessable share of Class A common stock or Class B common stock, respectively, subject to rounding up of fractional shares to the nearest whole number of shares resulting from the Reverse Stock Split without any change in the par value per share. All share, per share, option, warrant, equity award, and other derivative security numbers and exercise prices appearing in this Quarterly Report on Form 10-Q and the accompanying condensed financial statements have been adjusted to give effect to the Reverse Stock Split for all prior periods presented. However, the Company's annual, other periodic, and current reports, and all other information and documents incorporated by reference into this Quarterly Report on Form 10-Q that were filed prior to March 19, 2024, do not give effect to the Reverse Stock Split.

Use of estimates

The preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Accounting Standard Updates

A variety of proposed or otherwise potential accounting standards are currently under consideration by standard-setting organizations and certain regulatory agencies. Because of the tentative and preliminary nature of such proposed standards, management has not yet determined the effect, if any, that the implementation of such proposed

standards would have on the Company's condensed financial statements.

In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-09, "Improvements to Income Tax Disclosures". The amendments in this ASU change disclosure requirements for various items, including effective tax rate reconciliations and cash taxes paid. This ASU is effective for public companies for the financial reporting periods beginning on January 1, 2025, with early adoption permitted. We have not adopted ASU 2023-09 for our financial reporting period ending December 31, 2023, and will continue to evaluate early adoption for our financial reporting period ending December 31, 2024.

Cash and cash equivalents: The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash.

Marketable securities: Marketable securities at June 30, 2024 and December 31, 2023 consisted of marketable fixed income securities, primarily corporate bonds which are categorized as available for sale securities and are thus marked to market and stated at fair value in accordance with ASC 820 Fair Value Measurement. These investments are considered Level 1 and Level 2 investments within the ASC 820 fair value hierarchy. The fair value of Level 1 investments, including cash equivalents, money funds and U.S. government securities, are substantially based on quoted market prices in active markets. The fair value of corporate bonds is determined using standard market valuation methodologies, including discounted cash flows, matrix pricing and/or other similar techniques. The inputs to these valuation techniques include but are not limited to market interest rates, credit rating of the issuer or counterparty, industry sector of the issuer, coupon rate, call provisions, maturity, estimated duration and assumptions regarding liquidity and estimated future cash flows. In addition to bond characteristics, the valuation methodologies incorporate market data, such as actual trades completed, bids and actual dealer quotes, where such information is available. Accordingly, the estimated fair values are based on available market information and judgments about financial instruments categorized within Level 1 and Level 2 of the fair value hierarchy. Interest and dividends are recorded when earned. Realized gains and losses on investments are determined by specific identification and are recognized as incurred in the condensed statement of operations. Changes in net unrealized gains and losses are reported in other comprehensive loss and represent the change in the fair value of investment holdings during the reporting period. Changes in net unrealized losses were less than \$0.1 million for the three and six months ended June 30, 2024 and 2023, respectively.

Accounts and grants receivable: Accounts and grants receivable include amounts due from customers, granting institutions and others. The amounts as of June 30, 2024, and December 31, 2023 are certain to be collected, and no amount has been recognized for expected credit losses. In addition, for the clinical trial revenue, most participants pay in advance of treatment. Advanced grant funds and prepayments for the clinical trial revenue are recorded to deferred revenue. Advance contract manufacturing payments are recorded to deferred revenue.

Accounts and grants receivable by source, as of (in thousands):

	June 30, 2024	December 31, 2023
NIH - grant	159	159
National Institutes of Health - Grant	15	15
Deferred offering costs	15,000	15,000
Property and equipment	15,000	15,000
Intangible assets	15,000	15,000
Revenue recognition	15,000	15,000

Property and equipment: Property and equipment, including improvements that extend the useful lives of related assets, are recorded at cost, while maintenance and repairs are charged to operations as incurred. Depreciation is calculated using the straight-line method based on the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the original term of the lease. Depreciation expense is recorded in the research and development line of the condensed statements of operations as the assets are primarily related to the Company's clinical programs.

Intangible assets: Intangible assets include payments on license agreements with the Company's co-founder and Chief Scientific Officer ("CSO") and the University of Miami ("UM") (see Note 9) and legal costs incurred related to patents and trademarks. License agreements have been recorded at the value of cash consideration, common stock and membership units transferred to the respective parties when acquired.

Payments for license agreements: Payments for license agreements are amortized using the straight-line method over the estimated term of the agreements, which range from 5-20 years. Patents are amortized over their estimated useful life, once issued. The Company considers trademarks to have an indefinite useful life and evaluates them for impairment on an annual basis. Amortization expense is recorded in the research and development line of the condensed statements of operations as the assets are primarily related to the Company's clinical programs.

Impairment of Long-Lived Assets: The Company evaluates long-lived assets for impairment, including property and equipment and intangible assets, when events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. Upon the occurrence of a triggering event, the asset is reviewed to assess whether the estimated undiscounted cash flows expected from the use of the asset plus the residual value from the ultimate disposal exceeds the carrying value of the asset. If the carrying value exceeds the estimated recoverable amounts, the asset is written down to the estimated fair value. Any resulting impairment loss is reflected in the condensed statements of operations. Upon evaluation, management determined that there was no impairment of long-lived assets during the three and six months ended June 30, 2024 and 2023.

Deferred revenue: The unearned portion of advanced grant funds and prepayments for clinical trial and contract manufacturing revenues, which will be recognized as revenue when the Company meets the respective performance obligations, has been presented as deferred revenue in the accompanying condensed balance sheets. For the six months ended June 30, 2024 and 2023, the Company recognized less than \$0.1 million, respectively, of funds that were previously classified as deferred revenue. Due to the MSCRF - Technology Development Corporation ("TEDCO") - grant Acute Respiratory Distress Syndrome ("ARDS") program being discontinued, \$0.4 million recorded as deferred revenue was reversed when the funds were returned to MSCRF - TEDCO. As of June 30, 2024 and December 31, 2023, the Company had \$0.4 million and \$0.5 million, respectively, recorded in deferred revenue on the condensed balance sheets.

Revenue recognition: The Company recognizes revenue when performance obligations related to respective revenue streams are met. For grant revenue, the Company considers the performance obligation met when the grant related expenses are incurred or supplies and materials are received. The Company is paid in tranches pursuant to terms of the related grant agreements, and then applies payments based on regular expense reimbursement submissions to grantors. There are no remaining performance obligations or variable consideration once grant expense reporting to the grantor is complete. For clinical trial revenue, the Company considers the performance obligation met when the participant has received the treatment. The Company usually receives prepayment for these services or receives payment at the time the treatment is provided, and there are no remaining performance obligations or variable consideration once the participant receives the treatment. For contract manufacturing revenue, the Company considers the performance obligation met when the contractual obligation and/or statement of work has been satisfied. Payment terms may vary depending on specific contract terms. There are no significant judgments affecting the determination of the amount and timing of revenue recognition.

Revenue by source (in thousands):

	June 30, 2024	December 31, 2023
NIH - grant	287	287
National Institutes of Health - Grant	217	217
Deferred offering costs	15,000	15,000
Property and equipment	15,000	15,000
Intangible assets	15,000	15,000
Revenue recognition	15,000	15,000

[illegible]

[illegible]

[illegible]

[illegible]

margin: Opt 0 Opt 22.65pt; text-indent: -22.65pt;>Future minimum payments under the operating leases as of June 30, 2024, are as follows (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: Opt 0 Opt 22.65pt; text-align: left; text-indent: -22.65pt;"></p><table cellpadding=“0” cellspacing=“0” border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;> <tr style=“vertical-align: bottom;”> <td style=“border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold;”>Years Ending December 31,</td><td style=“font-weight: bold; padding-bottom: 1.5pt;”></td><td colspan=“2” style=“font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;”>Amount</td><td style=“padding-bottom: 1.5pt; font-weight: bold;”></td></tr> <tr style=“vertical-align: bottom; background-color: rgb(204,238,255);”> <td style=“text-align: left; width: 88%;”>2024 (remaining six months)</td><td style=“width: 1%”></td><td style=“width: 1%; text-align: left;”>\$</td><td style=“width: 9%; text-align: right;”>341</td><td style=“width: 1%; text-align: left;”></td></tr> <tr style=“vertical-align: bottom;”> <td style=“text-align: left;”>2025</td><td></td><td style=“text-align: left;”></td><td style=“text-align: right;”>682</td><td style=“text-align: left;”></td></tr> <tr style=“vertical-align: bottom; background-color: rgb(204,238,255);”> <td style=“text-align: left;”>2026</td><td></td><td style=“text-align: left;”></td><td style=“text-align: right;”>682</td><td style=“text-align: left;”></td></tr> <tr style=“vertical-align: bottom;”> <td style=“text-align: left;”></td></tr> <tr style=“vertical-align: bottom;”> <td style=“padding-bottom: 1.5pt;”></td><td style=“padding-bottom: 1.5pt;”>2027</td><td style=“padding-bottom: 1.5pt;”></td><td style=“border-bottom: Black 1.5pt solid; text-align: left;”></td><td style=“border-bottom: Black 1.5pt solid; text-align: right;”>170</td><td style=“padding-bottom: 1.5pt;”></td></tr> <tr style=“vertical-align: top; background-color: rgb(204,238,255);”> <td style=“text-align: left; padding-bottom: 2.5pt;”>Present value of operating lease liability</td><td style=“padding-bottom: 2.5pt;”></td><td style=“border-bottom: Black 4pt double; text-align: left;”>\$</td><td style=“border-bottom: Black 4pt double; text-align: right;”>1,748</td><td style=“padding-bottom: 2.5pt; text-align: left;”></td></tr></table><p style=“font: 10pt Times New Roman, Times, Serif; margin: Opt 0 Opt 22.65pt; text-align: left; text-indent: -22.65pt;"></p><p style=“font: 10pt Times New Roman, Times, Serif; margin: Opt 0">During each of the three months ended June 30, 2024 and 2023, the Company incurred approximately \$0.2 million of total lease costs and for the six month periods ended June 30, 2024 and 2023, the Company incurred approximately \$0.3 million and \$0.2 million of total lease costs respectively, that are included in the general and administrative expenses in the condensed statements of operations.</p><p>1100000170000012000002000000Future minimum payments under the operating leases as of June 30, 2024, are as follows (in thousands):<table cellpadding=“0” cellspacing=“0” style=“border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;> <tr style=“vertical-align: bottom;”> <td style=“border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold;”>Years Ending December 31,</td><td style=“font-weight: bold; padding-bottom: 1.5pt;”></td><td colspan=“2” style=“font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;”>Amount</td><td style=“padding-bottom: 1.5pt; font-weight: bold;”></td></tr> <tr style=“vertical-align: bottom; background-color: rgb(204,238,255);”> <td style=“text-align: left; width: 88%;”>2024 (remaining six months)</td><td style=“width: 1%”></td><td style=“width: 1%; text-align: left;”>\$</td><td style=“width: 9%; text-align: right;”>341</td><td style=“width: 1%; text-align: left;”></td></tr> <tr style=“vertical-align: bottom;”> <td style=“text-align: left;”>2025</td><td></td><td style=“text-align: left;”></td><td style=“text-align: right;”>682</td><td style=“text-align: left;”></td></tr> <tr style=“vertical-align: bottom; background-color: rgb(204,238,255);”> <td style=“text-align: left;”>2026</td><td></td><td style=“text-align: left;”></td><td style=“text-align: right;”>682</td><td style=“text-align: left;”></td></tr> <tr style=“vertical-align: bottom;”> <td style=“text-align: left; padding-bottom: 1.5pt;”>2027</td><td style=“padding-bottom: 1.5pt;”></td><td style=“border-bottom: Black 1.5pt solid; text-align: left;”></td><td style=“border-bottom: Black 1.5pt solid; text-align: right;”>170</td><td style=“padding-bottom: 1.5pt; text-align: left;”></td></tr> <tr style=“vertical-align: top; background-color: rgb(204,238,255);”> <td style=“text-align: left; padding-bottom: 2.5pt;”>Present value of operating lease liability</td><td style=“padding-bottom: 2.5pt;”></td><td style=“border-bottom: Black 4pt double; text-align: left;”>\$</td><td style=“border-bottom: Black 4pt double; text-align: right;”>1,748</td><td style=“padding-bottom: 2.5pt; text-align: left;”></td></tr></table>34100068200068200017000018750001270001748000200000200000300000200000</p><p style=“font: 10pt Times New Roman, Times, Serif; margin: Opt 0">b>. Stockholders' Equity </p><p style=“font: 10pt Times New Roman, Times, Serif; margin: Opt 0">b>Class A Common Stock</p><p style=“font: 10pt Times New Roman, Times, Serif; margin: Opt 0">RSUs are taxable upon vesting based on the market value on the date of vesting. The Company is required to make mandatory tax withholding for the payment and satisfaction of income tax, social security tax, payroll tax, or payment on account of other tax related to withholding obligations that arise by reason of vesting of an RSU. The taxable income is calculated by multiplying the number of vested RSUs for each individual by the closing share price as of the vesting date and a tax liability is calculated based on each individual's tax bracket. The shares withheld are available for reissuance pursuant to the Company's Second Amended and Restated 2021 Incentive Award Plan (the "Equity Plan").</p><p style=“font: 10pt Times New Roman, Times, Serif; margin: Opt 0"></p><p style=“font: 10pt Times New Roman, Times, Serif; margin: Opt 0">During the six months ended June 30, 2024, no stock options were exercised for Class A common stock shares.</p><p style=“font: 10pt Times New Roman, Times, Serif; margin: Opt 0"></p><p style=“font: 10pt Times New Roman, Times, Serif; margin: Opt 0">b>Class B Common Stock</p><p style=“font: 10pt Times New Roman, Times, Serif; margin: Opt 0">Holders of Class A common stock generally have rights identical to holders of Class B common stock, except that holders of Class A common stock are entitled to one (1) vote per share and holders of Class B common stock are entitled to five (5) votes per share. The holders of Class B common stock may convert each share of Class B common stock into one share of Class A common stock at any time at the holder's option. Class B common stock is not publicly tradable.</p><p style=“font: 10pt Times New Roman, Times, Serif; margin: Opt 0"></p><p style=“font: 10pt Times New Roman, Times, Serif; margin: Opt 0">During the six months ended June 30, 2024, stockholders converted 1,555 shares of Class B common stock into 1,555 shares of Class A common stock.</p><p style=“font: 10pt Times New Roman, Times, Serif; margin: Opt 0"></p><p style=“font: 10pt Times New Roman, Times, Serif; margin: Opt 0">Warrants</p><p style=“font: 10pt Times New Roman, Times, Serif; margin: Opt 0">As part of the Company's initial public offering ("IPO"), the underwriter received warrants to purchase up to 10,640 shares of Class A common stock. The warrants are exercisable at any time and from time to time, in whole or in part, during the four and a half-year period commencing August 12, 2021, at a price of \$120.00 per share and the fair value of warrants was approximately \$0.5 million. During 2021, the underwriters assigned 9,576 of the warrants to its employees. As of June 30, 2024, 5,536 warrants remain outstanding.</p><p style=“font: 10pt Times New Roman, Times, Serif; margin: Opt 0"></p><p style=“font: 10pt Times New Roman, Times, Serif; margin: Opt 0">As part of the Company's 2021 private placement offering, the Company issued warrants to investors to purchase up to an aggregate of 116,935 shares of Class A common stock, equal to the number of shares of Class A common stock purchased by such investor in the offering, at an exercise price of \$175.00 per share, which were immediately exercisable, expire five years from the date of issuance and had certain downward pricing adjustment mechanisms, subject to a floor, as set forth in greater detail therein (the "Purchaser Warrants"). In addition, the Company granted the underwriters warrants, under similar terms, to purchase 4,679 shares of Class A common stock, at an exercise price of \$175.00 per share. On August 16, 2023, the Company announced its Stock Rights Offering, which triggered the downward pricing mechanism on the Purchaser Warrants, at which time these warrants were adjusted downward to an exercise price of \$52.50 for the period remaining through expiration. This resulted in a deemed dividend to common stockholders of approximately \$0.8 million for the change in the fair value of the warrants using a Black-Scholes pricing model.</p><p style=“font: 10pt Times New Roman, Times, Serif; margin: Opt 0"></p><p style=“font: 10pt Times New Roman, Times, Serif; margin: Opt 0">As part of an October 2023 registered direct offering, the Company issued Series A warrants and Series B warrants to purchase up to 242,425 and 242,425, respectively, shares of Class A common stock. Each series of warrants had an exercise price of \$16.50 per share, with the Series A warrants having a term of five and one-half years from the date of issuance, and the Series B warrants having a term of eighteen months from the date of issuance. Both the Series A and Series B warrants became exercisable as of December 26, 2023, following stockholder approval. In addition, the Company granted the placement agent warrants, under similar terms, to purchase 16,971 shares of Class A common stock, at an exercise price of \$20.625 per share. In April 2024, the Series A Warrants and Series B Warrants were amended to reduce the exercise price to \$2.35 per share . The Series A Warrants and Series B Warrants were subsequently exercised in full in April 2024.</p><p style=“font: 10pt Times

[illegible]

Number of Stock Options

204,238,255	88%	22,621	1%
204,238,255	88%	22,621	1%

Total stock options outstanding at June 30, 2024

204,238,255	88%	22,621	1%
204,238,255	88%	22,621	1%

Total stock options outstanding at December 31, 2023

204,238,255	88%	22,621	1%
204,238,255	88%	22,621	1%

Weighted Average Exercise Price

204,238,255	88%	22,621	1%
204,238,255	88%	22,621	1%

Outstanding at December 31, 2023

204,238,255	88%	22,621	1%
204,238,255	88%	22,621	1%

Options granted

204,238,255	88%	22,621	1%
204,238,255	88%	22,621	1%

Options expired/forfeited

204,238,255	88%	22,621	1%
204,238,255	88%	22,621	1%

Options exercised

204,238,255	88%	22,621	1%
204,238,255	88%	22,621	1%

Commitments and Contingencies

Master Services Agreements

As of June 30, 2024, the Company terminated its active master services agreements with third parties that were previously engaged to conduct its clinical trials and manage clinical research programs and clinical development services. This termination was due to the Company's decision to discontinue trial activities in Japan.

Consulting Services Agreement

On November 20, 2014, the Company entered into a ten-year consulting services agreement with Dr. Joshua Hare, its CSO. Under the agreement, the Company has agreed to pay the CSO \$265,000 annually. The compensation payments are for scientific knowledge, medical research, technical knowledge, skills, and abilities to be provided by the CSO to further develop the intellectual property rights assigned by the CSO to the Company. This agreement requires the CSO to also assign to the Company the exclusive right, title, and interest in any work product developed from his efforts during the term of this agreement. On November 16, 2022, the Company accounted for but had not issued 4,814 RSUs convertible to unregistered shares of Class A common stock, with an aggregate value of \$0.2 million as payment for accrued expenses under the consulting agreement with the CSO. These shares were issued on May 24, 2023. As of June 30, 2024 and December 31, 2023, the Company had accrued balances due to the CSO of approximately \$0.1 million and \$0.1 million, respectively, which are included in accrued expenses and an additional \$0.1 million and \$0.1 million, respectively, which are included in accounts payable in the accompanying condensed balance sheets.

Technology Services Agreement

On March 27, 2015, the Company entered into a technology services agreement with Optimal Networks, Inc. (a related company owned by Dr. Joshua Hare's brother-in-law) for use of information technology services. The technology services agreement was terminated as of April 14, 2023. As of June 30, 2024 and December 31, 2023, the Company owed \$0 pursuant to this agreement.

Exclusive Licensing Agreements

UM Agreement

On November 20, 2014, the Company entered into an Exclusive License Agreement with UM (the "UM License") for the use of certain Aging-related Frailty Mesenchymal Stem Cell ("MSC") technology rights developed by our CSO at UM. The UM License is a worldwide, exclusive license, with right to sublicense, with respect to any and all know-how specifically related to the development of the culture-expanded MSCs for Aging-related Frailty used at the Human-induced pluripotent stem cell-derived MSCs ("IMSCs"), all standard operating procedures used to create the IMSCs, and all data supporting isolation, culture, expansion, processing, cryopreservation and management of the IMSCs. The Company is required to pay UM (i) a license issue fee of \$5,000, (ii) a running royalty in an amount equal to three percent of annual net sales on products or services developed from the technology, payable on a country-by-country basis beginning on the date of first commercial sale through termination of the UM License Agreement, and which may be reduced to the extent we are required to pay royalties to a third party for the same product or process, (iii) escalating annual cash payments of up to \$50,000, subject to offset. The agreement extends for up to 20 years from the last date a product or process is commercialized from the technology and was amended in 2017 to modify certain milestone completion dates as detailed below. In 2021 the license fee was increased by an additional \$100,000, to defray patent costs. In addition, the Company issued 11,039 unregistered shares of Class A common stock to UM.

Milestone payment amendments shifted the triggering payments to three payments of \$500,000, to be paid within six months of: (a) the completion of the first Phase 3 clinical trial of the products (based upon the final data unblinding); (b) the receipt by the Company of approval for the first new drug application ("NDA"), biologics application ("BLA"), or other marketing or licensing application for the product; and (c) the first sale following product approval. "Approval" refers to product approval, licensure, or other marketing authorization by the U.S. Food and Drug Administration, or any successor agency. The amendments also provided for the Company's license of additional technology, to the extent not previously included in the UM License and granted the Company an exclusive option to obtain an exclusive license for (a) the HLHS investigational new drug application ("IND") with ckit+ cells; and (b) UMP-438 titled "Method of Determining Responsiveness to Cell Therapy in Dilated Cardiomyopathy."

The Company has the right to terminate the UM License upon 60 days' prior written notice, and either party has the right to terminate upon a breach of the UM License. To date, the Company has made payments totaling \$365,000 to UM, and as of June 30, 2024 and December 31, 2023, the Company had accrued \$40,000 and \$50,000 in milestone fees payable to UM, respectively and \$15,000 for the year ended December 31, 2023 for patent related reimbursements based on the estimated progress to date.

The Company also entered into an additional Exclusive License Agreement with UM, signed and effective as of July 18, 2024, for technology rights developed by our CSO at UM. This License is a worldwide, exclusive license, with right to sublicense, with respect to any and all know-how, SOPs, data and other all other rights related to UMP-144, entitled "A method to derive GHRHR+ cardiomyogenic cells from pluripotent stem cells (PSCs) for therapeutic and pharmacologic applications" and having inventors Joshua Hare and Konstantinos Chatzistergos. UM retained a non-exclusive, royalty-free, perpetual, irrevocable, worldwide right to practice, make, and use the Patent Rights or Technology for any non-profit purposes, including educational, and research purposes. Pursuant to the terms of the license agreement, Longeveron must pay to UM: (a) \$5,000 within 30 days of the Effective Date; and (b) reimbursement of \$21,307 within 90 days of the Effective Date for previously incurred patent expenses; and (c) an annual \$10,000 fee which is both creditable against other royalty payments for the applicable license year and is waived so long as Company is current on annual fee payments in accordance with the Exclusive License Agreement entered into November 20, 2014 between Company and UM. In addition to certain other royalty payments that would be due should the Company's sublicense of the technology result in revenue, Longeveron also agreed to the following additional milestones and payments: (c) \$150,000 upon completion of the first Phase 3 Clinical Trial; and (d) \$250,000 upon issuance of a biologics license application or new drug application based on the licensed technology. The Company has the right to terminate the new UM License for convenience upon 90 days' prior written notice, and both parties have additional termination rights for material breach of the agreement.

Other Royalty

Under the grant award agreement with the Alzheimer's Association, the Company may be required to make revenue sharing or distribution of revenue payments for products or inventions generated or resulting from this clinical trial program. The potential payments, although not currently defined, could result in a maximum payment of five times (5x) the award amount of \$3.0 million.

Contingencies - Legal

From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. As of June 30, 2024, the Company is not aware of any legal proceedings or material developments requiring disclosure.

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~Y(TKO7XQJ M7AGSS+XU2KM9L0%>=>Sf9N&HC&N\] ,#NAXU@M=N(X10U?> M3BVF#92-FR8W9?1INN1W[]@ MKNZOSO- 4%"E!"> &S06/L]/\$H4700M1,VNN>=Z\$JR+GXOH,H0N.PT.= UMP*W0\$ MF2.0^?N0P\$H;=C9LT^,86%WA(D6 4)X3/DD60(0)9G<[RQC20H381Y 4" M>7\$;R4WU?7/L1)O\$,@WJX0<3/-;+/-M\$B::NPWJ]/+ =<PCD.UK(1^+;?P+6 M=-ND>L42=O\$)RLB=-#++X%\$OCAUK,9=LTW.ZI,99/6L+7N;JLJ,JP=#\$5M M0ZR;OIE]FMIJ9E<5^V57HK8-2DFY38=>70#J?>1]9USG MC;OG#; 'H2/ M\$312,N2N8~23^3^?V57\$H\$?Z+>#),22^9><#>=3DPF?%;>B1D500KOG3S MZ?< (JV06) S\|IN4^:1OH^?8?E+G:0[DL='6T M8#%_1,0^N6VVRNR#8=-"B[4\$U 54B3\$=)H24V!SWQ@&0L%\$SOK\$%;J28*#)R M4:R<^~I~W:|";,|@V%JR(C5L! [MNL"UGTJ"/MS22IE7#N,N,'GH_QJR,<^TD MYI/V;D-RX%=-600YX"]=8D;,\$1FQ[PL,|IR\$43/L1.VVO<?>Q9C8K+<B&6! M5BR#<C?#7+>)(16V278F%GCZ%08H1,9,EDQ?Y12I? &F-B5LF(K3)<O&Q\$<_* M1NR\$SOHX9Q<#\$SDA\$+Y9=0%0T;[X9@ALF]\$3P/TWE@4<[P\$,,%GTINZO=I]=>D MQ?;ITV,>B8?J[72RP3&+&1.337Y2V90Q)M;,"2RF4,5;,,EA-DF)[8-BCE< M0IAM(L;LTJ];,|4BZ(7;BU M,|[(~1Y,S\$OH1760NC*@[QIB8=813]9D\$S;_*OQJ3\$%L'QORL,P2I?7>&8H9 M%VX%9IV~#KH/B0[BY];8MB1;C\$C8A,YL<2LT,Y);W6C1,CJEC8M8IR>=] MCO8H1W-FB0HFJ OT,S;+4<:D;\$_P/.VBNNJH5EX;- ZE248:MXW2IU VV? M]+WAJ]>'5D,- K+1_~!5!+ P04 " "L@ Y9?][I&J0! #&'P &@ 'AL M+UJR96QS+W=O)/[F/100D5\$ MJB1 %28/D<269Q#)[HE"\$8Y%08/F5-8(05?6)^~L[PE[=JR]0YYL^WSY+C? M? *BV932420EYNT;--UZZ#^C;Y7N[3D>UD82LYH'N< M9TY>3WZWJ1NM=HNTU,V -BG0_EE2:2D:TJ]=V6?>M; ,Q=SV=P^4@ M~?S>3Y;=\$_SV_2A-!~!~D";@<@R.H'.01Y_ (0);%"T R"906#;B'HMG10^ M0Y<0^ZAZ#^N\$S11FG\$DCK FTN1;~*P6!L(Q18D6PC,%D1,"069/L M%;\$6PCD\$J1;,"P6Q\$1(I;,%64PGT5M1;"36T<BN\WHIZ\$X">BGHK M@=>Z?>BN\WHIZ\$X">BGHK@=>Z?>BN\WHIZ&X\$>AGH;=>Z&=>AN\WJ;+*0VUO1 M(1#;4@<CT-M0;R0VUO10(1#;46GT-M1;R20VUO1 M(1#;1YO=1^H1ZT\$<COJ01Z,^KM\|H1ZT\$>COJ01Z1]J0[S\$N=4~1(H'<=4 M02.IWA_UCO^I=RGZ7J[U9?E]G1JW+! .@=&S&_EL6_0\$W>4,\$\$ENVH?W=W<@<M;.*HB\$J] MFT2) [7=?;_EL,GK;60\$35TU?IPL0K/C/E|0;7VJ; 4Q)<9<4,1=-F=7Y M4L^>B<%@R'+3!&!'|0UDLGH69Z587>|R:~J]5I0HFCRB>QJ]W\$-FN<=&NK M,M|3TKBRF^,7I? 4W<+4~"3B:T(S\]^>|KLFYJ]M 5+>+OPHNL MBVTJYL V(I^>+W&B1\$;E3D5)E 5<4GJK2=-> 51J^*M15_3F?*"TRP[|Z MORMS4+C#,G#IC?3PQIY?>8ZD?>VWL1^Y4)[Q&-B+~WUJ]U[V@450IR,V# MW+<[~"ZV_5L^J"/6,C_4O1\$,"1%"!E>?60@20Q1^<Z>,"I|QID^*T5_1^M%;\$Y?JD&PO=&AE;640=&AE;640Q+GAM;+1+ 0(4 Q0 (*R #EDVN@<QV@8 (I M 8 ^<@0T [X;]W;W&K&PO=VJR:W-H965T&UL4\$! A0#% @ K(. 65X,+S+I+ M P 7@X |,,"[X14^'AL+W=OE<3?,"#Q & @(\$#(>&PO=VJR:W-H965T&UL4\$! A0#M @ K(. 67 OTIS] P,|@L |@ M ("|"+, ^'AL+W=O&PO=VJR:W-H965T&UL4\$! A0# M%; @ K(. 692HJL|@P T1 |!@ ("I6'd^'AL+W=O M&UL M4\$! A0#% @ K(. 605_SL+!%<@ '\$ ID ("I4\$ M ^'AL+W=O&PO=VJR:W-H965T&UL4\$! A0#% @ MK(. 67BCK|6# P : @ ID ("!AV@ ^'AL+W=O&PO=VJR:W-H965T&UL4\$! A0#% @ K(. 66PO=VJR:W-H M965T&UL4\$! M A0#% @ K(. 60PT|T\$J] @ N < ID ("!EJ8^'AL M+W=O&PO=VJR:W-H965T&UL4\$! A0#% @ K(. M6;)'RUT^ P - < ID ("!TLO^'AL+W=O&PO=VJR:W-H965T&UL4\$! A0#% @ K(. 64H|<~^V @ V 4 M ID ("QLX^'AL+W=O&PO=VJR:W-H965T&UL4\$! A0#% @ K(. 69UXB|= 2 P 8PT ID M ("!4= @ ^'AL+W=O&PO=VJR:W-H965T M&UL4\$! A0# M%; @ K(. 619TBT/ P \$!D ID ("], ^'AL+W=O M&PO=VJR:W-H965T&UL4\$! A0#% @ K(. 6; &PO=VJR:W-H965T&UL4\$! A0#% @ K(. 6<39WGSa P @, ID M ("I8 H^'AL+W=O&PO M=VJR:W-H965T&UL4\$! A0#% @ K(. 65H4Y(6L -<0 < ID ("! M5@4! ^'AL+W=O&PO=VJR:W-H965T&UL4\$! A0# M @ K(. 64;^Y?; @ |@8 ID ("I2BL|^'AL+W=O&PO=VJR:W-H965T&UL4\$! A0#% @ K(. 62149X5) # 1IT ID M ("!G44! ^'AL+W=O&PO&PO7W)E;^O M=VJR:V)O;VLN>&UL+G)E;^02P\$"% 4 , "L@ Y9^F32ILH! ";^P M\$P @ \$770\$ 6T- O;G1E;G1P\$5EP9?=>+GAM;+!+108_/0 1^0 27P\$! end XML 68 Show.js IDEA: XBRL DOCUMENT //Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show=;};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&e.node.Name="TABLE")e=e.nextSibling;if(!e.node.Name="TABLE")([var ref=(window)?w.document:document).getElementById(r);if(ref)[e=ref.cloneNode(10);e.removeAttribute('id');a.parentNode.appendChild(e)] if(e.e.style.display='block';Show.LastAR=e);Show.hideAR=function() {Show.LastAR.style.display='none';Show.toggleNext=function(a){var e=a;while(e.e.Name!="DIV")e=e.nextSibling;if(!e.e.style){}else if(!e.e.style.display){}else{var d,p;if(e.e.style.display=="none")d='block';p='';}else{d='none';p='+'} e.e.style.display=d;if(a.textContent){a.textContent+=p+a.textContent.substring(1)}else{a.innerHTMLText+=p+a.innerHTMLText.substring(1)} } XML 69 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */Ref v2.2.0.24 */% DefRef Styles *.report table.authRefData { background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; }.report table.authRefData a { display: block; font-weight: bold; }.report table.authRefData p { margin-top: 0px; }.report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; }.report table.authRefData .hide a: hover { background-color: #2F4497; }.report table.authRefData .body { height: 150px; overflow: auto; width: 400px; }.report table.authRefData table { font-size: 1em; } /* Report Styles *.pl a, .pl a:visited { color: black; text-decoration: none; } /* table *.report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, sans-serif; margin-bottom: 2em; }.report hr { border: 1px solid #acf; } /* Top labels *.report th { background-color: #acf; color: black; font-weight: bold; text-align: center; }.report th: void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, sans-serif; text-align: left; }.report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ }.report td, .pl a { cursor: pointer; display: block; width: 200px; overflow: hidden; }.report td, .pl div a { width: 200px; }.report td, .pl a: hover { background-color: #fff; } /* Header rows... */.report tr, .tr { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */.report .rc { background-color: #f0f0f0; } /* Even rows... */.report .re, .report .reu { background-color: #def; }.report .reu td { border-bottom: 1px solid black; } /* Odd rows... */.report .ro, .report .rou { background-color: white; }.report .rou td { border-bottom: 1px solid black; }.report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker *.report .fn { white-space: nowrap; } /* styles for numeric types *.report .num, .report .nump { text-align: right; white-space: nowrap; }.report .nump { padding-left: 2em; }.report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types *.report .text { text-align: left; white-space: normal; }.report .text .big { margin-bottom: 1em; width: 17em; }.report .text .more { display: none; }.report .text .note { font-style: italic; font-weight: bold; }.report .text .small { width: 10em; }.report sup { font-style: italic; }.report .outerFootnotes { font-size: 1em; } XML 71 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html2582811true720false4 falsefalseR1.htm995100 - Document - CoverSheethttp://xbrl.sec.gov/dei/role/document/CoverCoverCover1 falsefalseR2.htm995301 - Statement - Condensed Balance SheetsSheethttp://www.LongeveronInc.com/role/ConsolidatedBalanceSheetCondensed Balance SheetsStatements2 falsefalseR3.htm995302 - Statement - Condensed Balance Sheets (Parentheticals)Sheethttp://www.LongeveronInc.com/role/ConsolidatedBalanceSheet_ParentheticalsCondensed Balance Sheets (Parentheticals)Statements3 falsefalseR4.htm995303 - Statement - Condensed Statements of Operations (Unaudited)Sheethttp://www.LongeveronInc.com/role/ConsolidatedIncomeStatementCondensed Statements of Operations (Unaudited)Statements4 falsefalseR5.htm995304 - Statement - Condensed Statements of Operations (Unaudited) (Parentheticals)Sheethttp://www.LongeveronInc.com/role/ConsolidatedIncomeStatement_ParentheticalsCondensed Statements of Operations (Unaudited) (Parentheticals)Statements5 falsefalseR6.htm995305 - Statement - Condensed Statements of Comprehensive Loss (Unaudited)Sheethttp://www.LongeveronInc.com/role/ConsolidatedComprehensiveIncomeCondensed Statements of Comprehensive Loss (Unaudited)Statements6 falsefalseR7.htm995306 - Statement - Condensed Statements of Stockholders??? Equity (Unaudited)Sheethttp://www.LongeveronInc.com/role/ShareholdersEquityType2or3Condensed Statements of Stockholders??? Equity (Unaudited)Statements7 falsefalseR8.htm995307 - Statement - Condensed Statements of Stockholders??? Equity (Unaudited) (Parentheticals)Sheethttp://www.LongeveronInc.com/role/ShareholdersEquityType2or3_ParentheticalsCondensed Statements of Stockholders??? Equity (Unaudited) (Parentheticals)Statements8 falsefalseR9.htm995308 - Statement - Condensed Statements of Cash Flows (Unaudited)Sheethttp://www.LongeveronInc.com/role/ConsolidatedCashFlowCondensed Statements of Cash Flows (Unaudited)Statements9 falsefalseR10.htm995309 - Disclosure - Nature of Business, Basis of Presentation, and LiquiditySheethttp://www.LongeveronInc.com/role/NatureofBusinessBasisofPresentationandLiquidityNature of Business, Basis of Presentation, and LiquidityNotes10 falsefalseR11.htm995310 - Disclosure - Summary of Significant Accounting PoliciesSheethttp://www.LongeveronInc.com/role/SummaryofSignificantAccountingPoliciesSummary of Significant Accounting PoliciesNotes11 falsefalseR12.htm995311 - Disclosure - Marketable SecuritiesSheethttp://www.LongeveronInc.com/role/MarketableSecuritiesMarketable SecuritiesNotes12 falsefalseR13.htm995312 - Disclosure - Property and Equipment, NetSheethttp://www.LongeveronInc.com/role/PropertyandEquipmentNetProperty and Equipment, NetNotes13 falsefalseR14.htm995313 - Disclosure - Intangible Assets, NetSheethttp://www.LongeveronInc.com/role/IntangibleAssetsNetIntangible Assets, NetNotes14 falsefalseR15.htm995314 - Disclosure - LeasesSheethttp://www.LongeveronInc.com/role/LeasesLeasesNotes15 falsefalseR16.htm995315 - Disclosure - Stockholders??? EquitySheethttp://www.LongeveronInc.com/role/StockholdersEquityStockholders??? EquityNotes16 falsefalseR17.htm995316 - Disclosure - Equity-Based CompensationSheethttp://www.LongeveronInc.com/role/EquityBasedCompensationEquity-Based CompensationNotes17 falsefalseR18.htm995317 - Disclosure - Commitments and ContingenciesSheethttp://www.LongeveronInc.com/role/CommitmentsandContingenciesCommitments and ContingenciesNotes18 falsefalseR19.htm995318 - Disclosure - Employee Benefits PlanSheethttp://www.LongeveronInc.com/role/EmployeeBenefitsPlanEmployee Benefits PlanNotes19 falsefalseR20.htm995319 - Disclosure - Loss Per ShareSheethttp://www.LongeveronInc.com/role/LossPerShareLoss Per ShareNotes20 falsefalseR21.htm995320 - Disclosure - Subsequent EventsSheethttp://www.LongeveronInc.com/role/SubsequentEventsSubsequent EventsNotes21 falsefalseR22.htm995410 - Disclosure - Pay vs Performance DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes22 falsefalseR23.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes23 falsefalseR24.htm996000 - Disclosure - Accounting Policies, by Policy (Policies)Sheethttp://www.LongeveronInc.com/role/AccountingPoliciesByPolicyAccounting Policies, by Policy (Policies) (Policies)Policieshttp://www.LongeveronInc.com/role/SummaryofSignificantAccountingPolicies24 falsefalseR25.htm996001 - Disclosure - Summary of Significant Accounting Policies (Tables)Sheethttp://www.LongeveronInc.com/role/SummaryofSignificantAccountingPoliciesTablesSummary of Significant Accounting Policies (Tables)Tableshttp://www.LongeveronInc.com/role/SummaryofSignificantAccountingPoliciesTables25 falsefalseR26.htm996002 - Disclosure - Marketable Securities (Tables)Sheethttp://www.LongeveronInc.com/role/MarketableSecuritiesTablesMarketable Securities (Tables)Tableshttp://www.LongeveronInc.com/role/MarketableSecurities26 falsefalseR27.htm996003 - Disclosure - Property and Equipment, Net (Tables)Sheethttp://www.LongeveronInc.com/role/PropertyandEquipmentNetTablesProperty and Equipment, Net (Tables)Tableshttp://www.LongeveronInc.com/role/PropertyandEquipmentNet27 falsefalseR28.htm996004 - Disclosure - Intangible Assets, Net (Tables)Sheethttp://www.LongeveronInc.com/role/IntangibleAssetsNetTablesIntangible Assets, Net (Tables)Tableshttp://www.LongeveronInc.com/role/IntangibleAssetsNet28 falsefalseR29.htm996005 - Disclosure - Leases (Tables)Sheethttp://www.LongeveronInc.com/role/LeasesTablesLeases (Tables)Tableshttp://www.LongeveronInc.com/role/Leases29 falsefalseR30.htm996006 - Disclosure - Equity-Based Compensation (Tables)Sheethttp://www.LongeveronInc.com/role/EquityBasedCompensationTablesEquity-Based Compensation (Tables)Tableshttp://www.LongeveronInc.com/role/EquityBasedCompensation30 falsefalseR31.htm996007 - Disclosure - Loss Per Share (Tables)Sheethttp://www.LongeveronInc.com/role/LossPerShareTablesLoss Per Share (Tables)Tableshttp://www.LongeveronInc.com/role/LossPerShare31 falsefalseR32.htm996008 - Disclosure - Nature of Business, Basis of Presentation, and Liquidity (Details)Sheethttp://www.LongeveronInc.com/role/NatureofBusinessBasisofPresentationandLiquidityDetailsNature of Business, Basis of Presentation, and Liquidity (Details)Detailshttp://www.LongeveronInc.com/role/NatureofBusinessBasisofPresentationandLiquidity32 falsefalseR33.htm996009 - Disclosure - Summary of Significant Accounting Policies (Details)Sheethttp://www.LongeveronInc.com/role/SummaryofSignificantAccountingPoliciesDetailsSummary of Significant Accounting Policies (Details)Detailshttp://www.LongeveronInc.com/role/SummaryofSignificantAccountingPoliciesTables33 falsefalseR34.htm996010 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Accounts and Grants ReceivableSheethttp://www.LongeveronInc.com/role/ScheduleofAccountsandGrantsReceivableTableSummary of Significant Accounting Policies (Details) - Schedule of Accounts and Grants ReceivableDetailshttp://www.LongeveronInc.com/role/SummaryofSignificantAccountingPoliciesTables34 falsefalseR35.htm996011 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of RevenueSheethttp://www.LongeveronInc.com/role/ScheduleofRevenueTableSummary of Significant Accounting Policies (Details) - Schedule of RevenueDetailshttp://www.LongeveronInc.com/role/SummaryofSignificantAccountingPoliciesTables35 falsefalseR36.htm996012 - Disclosure - Marketable Securities (Details)Sheethttp://www.LongeveronInc.com/role/MarketableSecuritiesDetailsMarketable Securities (Details)Detailshttp://www.LongeveronInc.com/role/MarketableSecuritiesTables36 falsefalseR37.htm996013 - Disclosure - Marketable Securities (Details) - Schedule of Marketable SecuritiesSheethttp://www.LongeveronInc.com/role/ScheduleofMarketableSecuritiesTableMarketable Securities (Details) - Schedule of Marketable SecuritiesDetailshttp://www.LongeveronInc.com/role/MarketableSecuritiesTables37 falsefalseR38.htm996014 - Disclosure - Property and Equipment, Net (Details)Sheethttp://www.LongeveronInc.com/role/PropertyandEquipmentNetDetailsProperty and Equipment, Net (Details)Detailshttp://www.LongeveronInc.com/role/PropertyandEquipmentNetTables38 falsefalseR39.htm996015 - Disclosure - Property and Equipment, Net (Details) - Schedule of Major Components of Property and EquipmentSheethttp://www.LongeveronInc.com/role/ScheduleofMajorComponentsofPropertyandEquipmentTableProperty and Equipment, Net (Details) - Schedule of Major Components of Property and EquipmentDetailshttp://www.LongeveronInc.com/role/PropertyandEquipmentNetTables39

falsefalseR40.htm996016 - Disclosure - Intangible Assets, Net (Details)Sheethttp://www.LongeveronInc.com/role/IntangibleAssetsNetDetailsIntangible Assets, Net (Details)Detailshttp://www.LongeveronInc.com/role/IntangibleAssetsNetTables40 falsefalseR41.htm996017 - Disclosure - Intangible Assets, Net (Details) - Schedule of Major Components of Intangible AssetsSheethttp://www.LongeveronInc.com/role/ScheduleofMajorComponentsofIntangibleAssetsTableIntangible Assets, Net (Details) - Schedule of Major Components of Intangible AssetsDetailshttp://www.LongeveronInc.com/role/IntangibleAssetsNetTables41 falsefalseR42.htm996018 - Disclosure - Intangible Assets, Net (Details) - Schedule of Future Amortization Expense for Intangible AssetsSheethttp://www.LongeveronInc.com/role/ScheduleofFutureAmortizationExpenseforIntangibleAssetsTableIntangible Assets, Net (Details) - Schedule of Future Amortization Expense for Intangible AssetsDetailshttp://www.LongeveronInc.com/role/IntangibleAssetsNetTables42 falsefalseR43.htm996019 - Disclosure - Leases (Details)Sheethttp://www.LongeveronInc.com/role/LeasesDetailsLeases (Details)Detailshttp://www.LongeveronInc.com/role/LeasesTables43 falsefalseR44.htm996020 - Disclosure - Leases (Details) - Schedule of Future Minimum Payments Under the Operating LeasesSheethttp://www.LongeveronInc.com/role/ScheduleofFutureMinimumPaymentsUndertheOperatingLeasesTableLeases (Details) - Schedule of Future Minimum Payments Under the Operating LeasesDetailshttp://www.LongeveronInc.com/role/LeasesTables44 falsefalseR45.htm996021 - Disclosure - Stockholders??? Equity (Details)Sheethttp://www.LongeveronInc.com/role/StockholdersEquityDetailsStockholders??? Equity (Details)Detailshttp://www.LongeveronInc.com/role/StockholdersEquity45 falsefalseR46.htm996022 - Disclosure - Equity-Based Compensation (Details)Sheethttp://www.LongeveronInc.com/role/EquityBasedCompensationDetailsEquity-Based Compensation (Details)Detailshttp://www.LongeveronInc.com/role/EquityBasedCompensationTables46 falsefalseR47.htm996023 - Disclosure - Equity-Based Compensation (Details) - Schedule of RSU ActivitySheethttp://www.LongeveronInc.com/role/ScheduleofRSUActivityTableEquity-Based Compensation (Details) - Schedule of RSU ActivityDetailshttp://www.LongeveronInc.com/role/EquityBasedCompensationTables47 falsefalseR48.htm996024 - Disclosure - Equity-Based Compensation (Details) - Schedule of Issued and Outstanding OptionsSheethttp://www.LongeveronInc.com/role/ScheduleofIssuedandOutstandingOptionsTableEquity-Based Compensation (Details) - Schedule of Issued and Outstanding OptionsDetailshttp://www.LongeveronInc.com/role/EquityBasedCompensationTables48 falsefalseR49.htm996025 - Disclosure - Equity-Based Compensation (Details) - Schedule of Stock Option ActivitySheethttp://www.LongeveronInc.com/role/ScheduleofStockOptionActivityTableEquity-Based Compensation (Details) - Schedule of Stock Option ActivityDetailshttp://www.LongeveronInc.com/role/EquityBasedCompensationTables49 falsefalseR50.htm996026 - Disclosure - Commitments and Contingencies (Details)Sheethttp://www.LongeveronInc.com/role/CommitmentsandContingenciesDetailsCommitments and Contingencies (Details)Detailshttp://www.LongeveronInc.com/role/CommitmentsandContingencies50 falsefalseR51.htm996027 - Disclosure - Employee Benefits Plan (Details)Sheethttp://www.LongeveronInc.com/role/EmployeeBenefitsPlanDetailsEmployee Benefits Plan (Details)Detailshttp://www.LongeveronInc.com/role/EmployeeBenefitsPlan51 falsefalseR52.htm996028 - Disclosure - Loss Per Share (Details) - Schedule of Diluted Net Loss per ShareSheethttp://www.LongeveronInc.com/role/ScheduleofDilutedNetLossperShareTableLoss Per Share (Details) - Schedule of Diluted Net Loss per ShareDetailshttp://www.LongeveronInc.com/role/LossPerShareTables52 falsefalseR53.htm996029 - Disclosure - Subsequent Events (Details)Sheethttp://www.LongeveronInc.com/role/SubsequentEvents53 falsefalseAll ReportsBookAll Reports ea0211041-10q_longeveron.htm1gvn-20240630.xsdlgvn-20240630.cal.xmllgvn-20240630.lab.xmllgvn-20240630.pre.xml image_001.jpgimage_002.jpgimage_003.jpg http://www.xbrl.org/2024http://xbrl.sec.gov/ecd/2024true JSON 74 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0211041-10q_longeveron.htm": { "nsprefix": "lgvn", "nsuri": "http://www.LongeveronInc.com/20240630", "dts": { "inline": { "local": { "ea0211041-10q_longeveron.htm" } }, "schema": { "local": { "lgvn-20240630.xsd" } }, "remote": { "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/1rr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/1rr/role/net-2009-12-16.xsd", "http://www.xbrl.org/1rr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-typex-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-typex-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024_def.xsd", "https://xbrl.sec.gov/dei/2024/lab.xsd", "https://xbrl.sec.gov/dei/2024_pre.xsd", "https://xbrl.sec.gov/dei/2024_def-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" } }, "calculationLink": { "local": { "lgvn-20240630.cal.xml" } }, "definitionLink": { "local": { "lgvn-20240630_def.xml" } }, "labelLink": { "local": { "lgvn-20240630.lab.xml" } }, "presentationLink": { "local": { "lgvn-20240630_pre.xml" } } }, "keyStandard": 252, "keyCustom": 29, "axisStandard": 21, "axisCustom": 0, "memberStandard": 35, "memberCustom": 29, "hidden": { "total": 271, "http://fasb.org/us-gaap/2024": 195, "http://www.LongeveronInc.com/20240630": 72, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 258, "entityCount": 1, "segmentCount": 72, "elementCount": 688, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 823, "http://xbrl.sec.gov/dei/2024": 32, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://xbrl.sec.gov/dei/role/document/Cover", "longName": "995100 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet", "longName": "995301 - Statement - Condensed Balance Sheets", "shortName": "Condensed Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true }, "uniqueAnchor": { "contextRef": "c4", "name": "us-gaap:MarketableSecuritiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "unique": true } }, "R3": { "role": "http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet_Parentheticals", "longName": "995302 - Statement - Condensed Balance Sheets (Parentheticals)", "shortName": "Condensed Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPershaires", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPershaires", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement", "longName": "995303 - Statement - Condensed Statements of Operations (Unaudited)", "shortName": "Condensed Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c21", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true }, "uniqueAnchor": { "contextRef": "c21", "name": "us-gaap:CostOfRevenue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "unique": true } }, "R5": { "role": "http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement_Parentheticals", "longName": "995304 - Statement - Condensed Statements of Operations (Unaudited) (Parentheticals)", "shortName": "Condensed Statements of Operations (Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": null, "uniqueAnchor": null }, "R6": { "role": "http://www.LongeveronInc.com/role/ConsolidatedComprehensiveIncome", "longName": "995305 - Statement - Condensed Statements of Comprehensive Loss (Unaudited)", "shortName": "Condensed Statements of Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c21", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true }, "uniqueAnchor": { "contextRef": "c21", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "unique": true } }, "R7": { "role": "http://www.LongeveronInc.com/role/ShareholdersEquityType2or3", "longName": "995306 - Statement - Condensed Statements of Stockholdersu2019 Equity (Unaudited)", "shortName": "Condensed Statements of Stockholdersu2019 Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c42", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true }, "uniqueAnchor": { "contextRef": "c49", "name": "lgvn:StockIssuesSuringPeriodClassACommonStockIssuedForRSUsVestedinShares", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "unique": true } }, "R8": { "role": "http://www.LongeveronInc.com/role/ShareholdersEquityType2or3_Parentheticals", "longName": "995307 - Statement - Condensed Statements of Stockholdersu2019 Equity (Unaudited) (Parentheticals)", "shortName": "Condensed Statements of Stockholdersu2019 Equity (Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c21", "name": "us-gaap:PaymentsOfStockIssuanceCosts", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c21", "name": "us-gaap:PaymentsOfStockIssuanceCosts", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.LongeveronInc.com/role/ConsolidatedCashFlow", "longName": "995308 - Statement - Condensed Statements of Cash Flows (Unaudited)", "shortName": "Condensed Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "unique": true } }, "R10": { "role": "http://www.LongeveronInc.com/role/NatureOfBusinessBasisOfPresentationandLiquidity", "longName": "995309 - Disclosure - Nature of Business, Basis of Presentation, and Liquidity", "shortName": "Nature of Business, Basis of Presentation, and Liquidity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.LongeveronInc.com/role/SummaryofSignificantAccountingPolicies", "longName": "995310 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.LongeveronInc.com/role/MarketableSecurities", "longName": "995311 - Disclosure - Marketable Securities", "shortName": "Marketable Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.LongeveronInc.com/role/PropertyandEquipmentNet", "longName": "995312 - Disclosure - Property and Equipment, Net", "shortName": "Property and Equipment, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-

gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.LongeveronInc.com/role/IntangibleAssetsNet", "longName": "995313 - Disclosure - Intangible Assets, Net", "shortName": "Intangible Assets, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.LongeveronInc.com/role/Leases", "longName": "995314 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.LongeveronInc.com/role/StockholdersEquity", "longName": "995315 - Disclosure - Stockholders'2019 Equity", "shortName": "Stockholders'2019 Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.LongeveronInc.com/role/EquityBasedCompensation", "longName": "995316 - Disclosure - Equity-Based Compensation", "shortName": "Equity-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.LongeveronInc.com/role/CommitmentsAndContingencies", "longName": "995317 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.LongeveronInc.com/role/EmployeeBenefitsPlan", "longName": "995318 - Disclosure - Employee Benefits Plan", "shortName": "Employee Benefits Plan", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.LongeveronInc.com/role/LossPerShare", "longName": "995319 - Disclosure - Loss Per Share", "shortName": "Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.LongeveronInc.com/role/SubsequentEvents", "longName": "995320 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.LongeveronInc.com/role/PayPerformanceDisclosure", "longName": "995321 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c21", "name": "us-gaap:NetIncomeLoss", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c21", "name": "us-gaap:NetIncomeLoss", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.LongeveronInc.com/role/InsiderTradingArrangements", "longName": "995322 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c21", "name": "us-gaap:InsiderTradingArrangementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c21", "name": "us-gaap:InsiderTradingArrangementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.LongeveronInc.com/role/AccountingPoliciesByPolicy", "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)", "shortName": "Accounting Policies, by Policy (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:BasisOfAccountingPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:BasisOfAccountingPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.LongeveronInc.com/role/SummaryOfSignificantAccountingPoliciesTables", "longName": "996001 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.LongeveronInc.com/role/MarketableSecuritiesTables", "longName": "996002 - Disclosure - Marketable Securities (Tables)", "shortName": "Marketable Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "

10q_longeveron.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.LongeveronInc.com/role/ScheduleofAccountsandGrantsReceivableTable", "longName": "996010 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Accounts and Grants Receivable", "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Accounts and Grants Receivable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true }, "uniqueAnchor": { "contextRef": "c92", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true }, "ix:continuation": "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "unique": true } }, "R35": { "role": "http://www.LongeveronInc.com/role/ScheduleofRevenueTable", "longName": "996011 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Revenue", "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c21", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true }, "uniqueAnchor": { "contextRef": "c96", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "unique": true } }, "R36": { "role": "http://www.LongeveronInc.com/role/MarketableSecuritiesDetails", "longName": "996012 - Disclosure - Marketable Securities (Details)", "shortName": "Marketable Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:AccruedInvestmentIncomeReceivable", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:AccruedInvestmentIncomeReceivable", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.LongeveronInc.com/role/ScheduleofMarketableSecuritiesTable", "longName": "996013 - Disclosure - Marketable Securities (Details) - Schedule of Marketable Securities", "shortName": "Marketable Securities (Details) - Schedule of Marketable Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:MarketableSecurities", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:MarketableSecurities", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.LongeveronInc.com/role/PropertyandEquipmentNetDetails", "longName": "996014 - Disclosure - Property and Equipment, Net (Details)", "shortName": "Property and Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c21", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c21", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.LongeveronInc.com/role/ScheduleofMajorComponentsofPropertyandEquipmentTable", "longName": "996015 - Disclosure - Property and Equipment, Net (Details) - Schedule of Major Components of Property and Equipment", "shortName": "Property and Equipment, Net (Details) - Schedule of Major Components of Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.LongeveronInc.com/role/IntangibleAssetsNetDetails", "longName": "996016 - Disclosure - Intangible Assets, Net (Details)", "shortName": "Intangible Assets, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c21", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c21", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.LongeveronInc.com/role/ScheduleofFutureAmortizationExpenseforIntangibleAssetsTable", "longName": "996017 - Disclosure - Intangible Assets, Net (Details) - Schedule of Future Amortization Expense for Intangible Assets", "shortName": "Intangible Assets, Net (Details) - Schedule of Future Amortization Expense for Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.LongeveronInc.com/role/ScheduleofFutureAmortizationExpenseforIntangibleAssetsTable", "longName": "996018 - Disclosure - Intangible Assets, Net (Details) - Schedule of Future Amortization Expense for Intangible Assets", "shortName": "Intangible Assets, Net (Details) - Schedule of Future Amortization Expense for Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.LongeveronInc.com/role/LeasesDetails", "longName": "996019 - Disclosure - Leases (Details)", "shortName": "Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c21", "name": "us-gaap:LeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.LongeveronInc.com/role/ScheduleofFutureMinimumPaymentsUndertheOperatingLeasesTable", "longName": "996020 - Disclosure - Leases (Details) - Schedule of Future Minimum Payments Under the Operating Leases", "shortName": "Leases (Details) - Schedule of Future Minimum Payments Under the Operating Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.LongeveronInc.com/role/StockholdersEquityDetails", "longName": "996021 - Disclosure - Stockholders' Equity (Details)", "shortName": "Stockholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c254", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.LongeveronInc.com/role/EquityBasedCompensationDetails", "longName": "996022 - Disclosure - Equity-Based Compensation (Details)", "shortName": "Equity-Based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.LongeveronInc.com/role/ScheduleofRSUActivityTable", "longName": "996023 - Disclosure - Equity-Based Compensation (Details) - Schedule of RSU Activity", "shortName": "Equity-Based Compensation (Details) - Schedule of RSU Activity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c207", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c208", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.LongeveronInc.com/role/ScheduleofIssuedandOutstandingOptionsTable", "longName": "996024 - Disclosure - Equity-Based Compensation (Details) - Schedule of Issued and Outstanding Options", "shortName": "Equity-Based Compensation (Details) - Schedule of Issued and Outstanding Options", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c209", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c211", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails", "longName": "996026 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c212", "name": "us-gaap:OtherExpenses", "unitRef": "usd", "xsiNil": "false",

"lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c212", "name": "us-gaap:OtherExpenses", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "R51": { "role": "http://www.LongeveronInc.com/role/EmployeeBenefitsPlanDetails", "longName": "996027 - Disclosure - Employee Benefits Plan (Details)", "shortName": "Employee Benefits Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c21", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c21", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.LongeveronInc.com/role/ScheduleofDilutedNetLossperShareTable", "longName": "996028 - Disclosure - Loss Per Share (Details) - Schedule of Diluted Net Loss per Share", "shortName": "Loss Per Share (Details) - Schedule of Diluted Net Loss per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.LongeveronInc.com/role/SubsequentEventsDetails", "longName": "996029 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "first": true, "uniqueAnchor": { "contextRef": "c253", "name": "us-gaap:ProceedsFromIssuanceOfDebt", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0211041-10q_longeveron.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesAndLoansReceivableLineItems", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofAccountsandGrantsReceivableTable"], "lang": { "en-us": { "role": { "label": "Schedule of Accounts and Grants Receivable [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r195", "r739"] }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofAccountsandGrantsReceivableTable"], "lang": { "en-us": { "role": { "label": "Receivable Type [Axis]", "documentation": "Information by type of receivable." } } }, "auth_ref": ["r51", "r57"] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r40", "r575"] }, "us-gaap_AccountsPayableOtherCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableOtherCurrentAndNoncurrent", "crdr": "credit", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Other", "documentation": "Amount of obligations incurred and payable classified as other." } } }, "auth_ref": ["r93"] }, "lgvn_AccountsReceivableFromCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "AccountsReceivableFromCustomersMember", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofAccountsandGrantsReceivableTable"], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable from customers [Member]", "label": "Accounts Receivable From Customers Member" } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet", "http://www.LongeveronInc.com/role/ScheduleofAccountsandGrantsReceivableTable"], "lang": { "en-us": { "role": { "terseLabel": "Accounts and grants receivable", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r737"] }, "us-gaap_AccruedIncomeReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedIncomeReceivableMember", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofMarketableSecuritiesTable"], "lang": { "en-us": { "role": { "terseLabel": "Accrued income [Member]", "label": "Accrued Income Receivable [Member]", "documentation": "Fees and other revenue recorded based on estimates or specific contractual terms as transactions occur or services are rendered, provided that persuasive evidence exists, the price to the customer is fixed or determinable and collectability is reasonably assured, which have not yet been received as of the balance sheet date." } } }, "auth_ref": [] }, "us-gaap_AccruedInvestmentIncomeReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedInvestmentIncomeReceivable", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/MarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest receivable related to marketable securities", "label": "Accrued Investment Income Receivable", "documentation": "Interest, dividends, rents, ancillary and other revenues earned but not yet received by the entity on its investments." } } }, "auth_ref": ["r91", "r416", "r717"] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r42"] }, "us-gaap_AccruedLiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate value", "label": "Accrued Liabilities, Fair Value Disclosure", "documentation": "Fair value portion of accrued expenses." } } }, "auth_ref": ["r42", "r770", "r771", "r781"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r14", "r15", "r58", "r128", "r412", "r438", "r439"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.LongeveronInc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Gain (Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r3", "r9", "r15", "r348", "r351", "r388", "r434", "r435", "r719", "r720", "r721", "r726", "r727", "r728", "r729"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r649"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r52", "r575", "r828"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.LongeveronInc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r449", "r726", "r727", "r728", "r729", "r769", "r831"] }, "dei_AdditionalSecurities462b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecurities462b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Additional Securities. 462(b)" } } }, "auth_ref": ["r705"] }, "dei_AdditionalSecurities462bFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecurities462bFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Additional Securities, 462(b), File Number" } } }, "auth_ref": ["r705"] }, "dei_AdditionalSecuritiesEffective413b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecuritiesEffective413b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Additional Securities Effective, 413(b)" } } }, "auth_ref": ["r703"] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AddressTypeDomain", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r662"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation;" } } }, "auth_ref": ["r662"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r662"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to PEO Compensation, Footnote" } } }, "auth_ref": ["r662"] }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities", "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used In) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "crdr": "credit", "presentation": ["http://www.LongeveronInc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Deemed dividend \u0026 2013 warrant inducement offers", "label": "Adjustments to Additional Paid in Capital, Other", "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC)." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri":

"http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": ["http://www.LongeveronInc.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "terseLabel": "Equity-based compensation", "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "terseLabel": "Class A common stock, issued for PSUs vested", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } }, "auth_ref": ["r10", "r81"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalStockSplit", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "terseLabel": "Reverse stock split rounding adjustment", "label": "Adjustments to Additional Paid in Capital, Stock Split", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately." } } }, "auth_ref": ["r10", "r81"] }, "ecd_AggtChngPnsnValInSummaryCompstnTblForApblBlyrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummaryCompstnTblForApblBlyrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r696"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r612", "r623", "r639", "r674"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r615", "r626", "r642", "r677"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r697"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r662"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r669"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r616", "r627", "r643", "r669", "r678", "r682", "r690"] }, "us-gaap_AllOtherCorporateBondsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllOtherCorporateBondsMember", "presentation": ["http://www.LongeveronInc.com/role/ScheduleOfMarketableSecuritiesTable", "lang": { "en-us": { "role": { "terseLabel": "Corporate bonds [Member]", "label": "Other Corporate Bonds [Member]", "documentation": "Investments in corporate fixed maturity debt securities classified as other." } } }, "auth_ref": ["r833"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r688"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/EquityBasedCompensationDetails", "lang": { "en-us": { "role": { "terseLabel": "Equity-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r311", "r320"] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/IntangibleAssetsNetDetails", "lang": { "en-us": { "role": { "terseLabel": "Amortization expense related to intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r7", "r206", "r212", "r551"] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": ["r619"] }, "Igvn_AnnualNetSalesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "AnnualNetSalesPercentage", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails", "lang": { "en-us": { "role": { "terseLabel": "Annual net sales percentage", "label": "Annual net sales percentage", "documentation": "Annual net sales percentage." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.LongeveronInc.com/role/ScheduleOfDilutedNetLossperShareTable", "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r175"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.LongeveronInc.com/role/ScheduleOfDilutedNetLossperShareTable", "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r23"] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.LongeveronInc.com/role/ScheduleOfDilutedNetLossperShareTable", "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r23"] }, "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": { "xbrltype": "dateOrAsapItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Approximate Date of Commencement of Proposed Sale to Public", "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet", "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r92", "r101", "r124", "r149", "r179", "r183", "r189", "r190", "r200", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r343", "r345", "r372", "r406", "r486", "r548", "r549", "r575", "r591", "r761", "r762", "r788"] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet", "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r118", "r129", "r149", "r200", "r226", "r227", "r228", "r229"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet", "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": ["r619"] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation", "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": ["r604", "r607", "r619"] }, "dei_AuditorLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLineItems", "lang": { "en-us": { "role": { "label": "Auditor [Line Items]" } } }, "auth_ref": [] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation", "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": ["r604", "r607", "r619"] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation", "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": ["r604", "r607", "r619"] }, "dei_AuditorOpinionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorOpinionTextBlock", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation", "lang": { "en-us": { "role": { "label": "Auditor Opinion [Text Block]" } } }, "auth_ref": ["r701"] }, "dei_AuditorTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation", "lang": { "en-us": { "role": { "label": "Auditor [Table]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r685"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r686"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r681"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r681"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r681"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r681"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r681"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType",

"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r681"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails", "http://www.LongeveronInc.com/role/EquityBasedCompensationDetails", "http://www.LongeveronInc.com/role/ScheduleofRSUActivityTable", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r281", "r282", "r283", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r305", "r306", "r307", "r308", "r309"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r684"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r683"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r682"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r682"] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.LongeveronInc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Basis of presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "lgvn_BiologicsLicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "BiologicsLicenseMember", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Biologics license [Member]", "label": "Biologics License Member" } } }, "auth_ref": [] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "BusinessContactMember", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": ["r607", "r619"] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": ["http://www.LongeveronInc.com/role/NatureofBusinessBasisOfPresentationandLiquidity"], "lang": { "en-us": { "role": { "terseLabel": "en-us", "role": { "label": "Nature of Business, Basis of Presentation, and Liquidity", "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": ["r39", "r73", "r74"] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/NatureofBusinessBasisOfPresentationandLiquidityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r104", "r409", "r460", "r481", "r575", "r591", "r714"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet", "http://www.LongeveronInc.com/role/NatureofBusinessBasisOfPresentationandLiquidityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r18", "r120", "r542"] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofMarketableSecuritiesTable"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": ["r120"] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": ["http://www.LongeveronInc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": ["r19"] }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "presentation": ["http://www.LongeveronInc.com/role/MarketableSecurities"], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities", "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]", "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)." } } }, "auth_ref": ["r740"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents at beginning of the period", "periodEndLabel": "Cash and cash equivalents at end of the period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r18", "r69", "r146"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedCashFlow": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "totalLabel": "Change in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r2", "r69"] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Supplement Disclosure of Non-cash Investing and Financing Activities", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r660"] }, "lgvn_ChiefScienceOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "ChiefScienceOfficerMember", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Chief Science Officer [Member]", "label": "Chief Science Officer Member" } } }, "auth_ref": [] }, "ecd_ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdVstInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdVstInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r657"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdVstInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdVstInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r655"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "lgvn_ClassACommonStockIssuedForRSUsVestedDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "ClassACommonStockIssuedForRSUsVestedDuringPeriod", "crdr": "credit", "presentation": ["http://www.LongeveronInc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Class A common stock, issued for RSUs vested", "documentation": "Class A common stock, issued for RSUs vested.", "label": "Class A Common Stock Issued For RSUs Vested During Period" } } }, "auth_ref": [] }, "lgvn_ClassACommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "ClassACommonStockWarrantsMember", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Class A common stock warrants [Member]", "label": "Class A Common Stock Warrants Member" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails", "http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet", "http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet_ParentDetails", "http://www.LongeveronInc.com/role/EquityBasedCompensationDetails", "http://www.LongeveronInc.com/role/ShareholdersEquityType2or3", "http://www.LongeveronInc.com/role/StockholdersEquityDetails", "http://www.LongeveronInc.com/role/SubsequentEventsDetails", "http://xbrl.sec.gov/dei/role/document/AuditInformation", "http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r115", "r125", "r126", "r127", "r149", "r168", "r169", "r172", "r174", "r181", "r182", "r200", "r226", "r228", "r229", "r230", "r233", "r234", "r237", "r238", "r241", "r244", "r251", "r372", "r443", "r444", "r445", "r446", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r461", "r473", "r495", "r512", "r528", "r529", "r530", "r531", "r532", "r713", "r724", "r730"] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Stockholdersu2019 Equity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r125", "r126", "r127", "r181", "r237", "r238", "r239", "r241", "r244", "r249", "r251", "r443", "r444", "r445", "r446", "r554", "r713", "r724"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails",

"http://www.LongeveronInc.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r30"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails", "http://www.LongeveronInc.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.LongeveronInc.com/role/EquityBasedCompensationDetails", "http://www.LongeveronInc.com/role/StockholdersEquityDetails", "http://www.LongeveronInc.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Warrants exercise price per share (in Dollars per share)", "verboseLabel": "Exercise price (in Dollars per share)", "netLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r252"] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Warrant purchase shares", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r252"] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails", "http://www.LongeveronInc.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of warrants outstanding", "verboseLabel": "Warrant shares", "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "lgnv_ClinicalTrialRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "ClinicalTrialRevenueMember", "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement", "http://www.LongeveronInc.com/role/ScheduleOfRevenueTable"], "lang": { "en-us": { "role": { "terseLabel": "Clinical trial revenue", "verboseLabel": "Clinical trial revenue [Member]", "label": "Clinical Trial Revenue Member" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r661"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r661"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 9)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r47", "r94", "r408", "r472"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingencies"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r79", "r220", "r221", "r534", "r756", "r758"] }, "lgnv_CommitmentsandContingenciesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "CommitmentsandContingenciesDetailsTable", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassAMember", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails", "http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet", "http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.LongeveronInc.com/role/ShareholdersEquityType2or3", "http://www.LongeveronInc.com/role/StockholdersEquityDetails", "http://www.LongeveronInc.com/role/SubsequentEventsDetails", "http://xbrl.sec.gov/dei/role/document/AuditInformation", "http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Class A Common Stock", "verboseLabel": "Class A", "netLabel": "Class A Common Stock [Member]", "label": "Class A common stock [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": ["r831"] }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassBMember", "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet", "http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.LongeveronInc.com/role/ShareholdersEquityType2or3", "http://www.LongeveronInc.com/role/StockholdersEquityDetails", "http://xbrl.sec.gov/dei/role/document/AuditInformation", "http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Class B Common Stock", "verboseLabel": "Class B common stock", "netLabel": "Class B", "label": "Class B Common Stock [Member]", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation." } } }, "auth_ref": ["r831"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.LongeveronInc.com/role/ShareholdersEquityType2or3", "http://www.LongeveronInc.com/role/StockholdersEquityDetails", "http://xbrl.sec.gov/dei/role/document/AuditInformation", "http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "verboseLabel": "Common Stock [Member]", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r581", "r582", "r583", "r585", "r586", "r587", "r588", "r726", "r727", "r729", "r769", "r827", "r831"] }, "us-gaap_CommonStockOtherSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockOtherSharesOutstanding", "presentation": ["http://www.LongeveronInc.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate shares", "label": "Common Stock, Other Shares, Outstanding", "documentation": "Number of shares of other common stock instruments held by shareholder, including, but not limited to, exchangeable shares." } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.LongeveronInc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in Dollars per share)", "verboseLabel": "Price per share (in Dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r50"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r50", "r473"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r50"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r10", "r50", "r473", "r492", "r831", "r832"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Common stock value", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r50", "r411", "r575"] }, "us-gaap_CommonStockVotingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockVotingRights", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock voting rights", "label": "Common Stock, Voting Rights", "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights." } } }, "auth_ref": ["r29"] }, "lgnv_CommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "CommonWarrantsMember", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common Warrants [Member]", "label": "Common Warrants Member" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r666"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r665"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r667"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r664"] }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "presentation": ["http://www.LongeveronInc.com/role/EmployeeBenefitsPlan"], "lang": { "en-us": { "role": { "terseLabel": "Employee Benefits Plan", "label": "Compensation and Employee Benefit Plans [Text Block]", "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans." } } }, "auth_ref": ["r83", "r84", "r85", "r86"] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Employee Benefits Plan [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedComprehensiveIncome": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedComprehensiveIncome"], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and

distributions to owners." } } }, "auth_ref": ["r16", "r134", "r136", "r141", "r403", "r421", "r422"] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofMajorComponentsofPropertyandEquipmentTable"], "lang": { "en-us": { "role": { "terseLabel": "Computer Equipment [Member]", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": ["http://www.LongeveronInc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Concentrations of credit risk", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": ["r38", "r107"] }, "dei_ContactPersonnelEmailAddress": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelEmailAddress", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contact Personnel Email Address", "documentation": "Email address of contact personnel." } } }, "auth_ref": [] }, "dei_ContactPersonnelFaxNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelFaxNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contact Personnel Fax Number", "documentation": "Fax Number of contact personnel." } } }, "auth_ref": ["r607"] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contained File Information, File Description", "documentation": "The description of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contained File Information, File Name", "documentation": "The name of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contained File Information, File Number", "documentation": "The SEC Document Number of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileType": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileType", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contained File Information, File Type", "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)." } } }, "auth_ref": [] }, "lgvn_ContractManufacturingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "ContractManufacturingMember", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofRevenueTable"], "lang": { "en-us": { "role": { "terseLabel": "Contract manufacturing [Member]", "label": "Contract Manufacturing Member" } } }, "auth_ref": [] }, "lgvn_ContractManufacturingRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "ContractManufacturingRevenueMember", "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Contract manufacturing revenue", "label": "Contract Manufacturing Revenue Member" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": ["http://www.LongeveronInc.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r254", "r255", "r266"] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": ["r254", "r255", "r266"] }, "us-gaap_ConversionOfStockAmountConverted1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockAmountConverted1", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "negatedLabel": "Conversion of Class B common stock for Class A common stock", "label": "Conversion of Stock, Amount Converted", "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \Part noncash\ refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r20", "r21", "r22"] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesConverted1", "presentation": ["http://www.LongeveronInc.com/role/ShareholdersEquityType2or3", "http://www.LongeveronInc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Conversion of Class B common stock for Class A common stock (in Shares)", "verboseLabel": "Stockholders shares converted", "label": "Conversion of Stock, Shares Converted", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \Part noncash\ refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r20", "r21", "r22"] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Cost of revenues", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": ["r60", "r149", "r200", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r372", "r548", "r761"] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear": { "xbrltype": "dateTimeItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear", "presentation": ["http://www.LongeveronInc.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expire date", "label": "Debt Conversion, Converted Instrument, Expiration or Due Date", "documentation": "Expiration, mandatory redemption, or due date, in YYYY-MM-DD format, of the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction." } } }, "auth_ref": ["r20", "r22"] }, "us-gaap_DebtInstrumentFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFeeAmount", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Initial fee paid", "label": "Debt Instrument, Fee Amount", "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument." } } }, "auth_ref": ["r44"] }, "lgvn_December2023OfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "December2023OfferingMember", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "December 2023 registered direct offering [Member]", "label": "December 2023 Offering Member" } } }, "auth_ref": [] }, "lgvn_DeemedDividendWarrantInducementOffers": { "xbrltype": "monetaryItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "DeemedDividendWarrantInducementOffers", "crdr": "debit", "calculation": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 2.0 }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedCashFlow", "http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Deemed dividend \u2013 2013 warrant inducement offers", "negatedLabel": "Deemed dividend \u2013 2013 warrant inducement offers", "documentation": "Represent the amount of deemed dividend warrant inducement offers." } } }, "auth_ref": [] }, "lgvn_DeferredOfferingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "DeferredOfferingCostsPolicyTextBlock", "presentation": ["http://www.LongeveronInc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Deferred offering costs", "label": "Deferred Offering Costs Policy Text Block" } } }, "auth_ref": [] }, "us-gaap_DeferredRevenueArrangementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueArrangementLineItems", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofRevenueTable"], "lang": { "en-us": { "role": { "label": "Schedule of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/EmployeeBenefitsPlanDetails"], "lang": { "en-us": { "role": { "terseLabel": "Company contributed amount", "label": "Defined Contribution Plan, Cost", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": ["r275"] }, "dei_DelayedOrContinuousOffering": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DelayedOrContinuousOffering", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Delayed or Continuous Offering" } } }, "auth_ref": ["r631", "r632", "r646"] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization, Nonproduction", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": ["r7", "r27"] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/PropertyandEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization expense", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r7", "r179", "r186", "r190", "r548", "r549"] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": ["http://www.LongeveronInc.com/role/EquityBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": ["r462", "r464", "r478", "r479", "r480", "r482", "r483", "r484", "r485", "r487", "r488", "r489", "r490", "r500", "r501", "r502", "r503", "r506", "r507", "r508", "r509", "r523", "r524", "r525", "r526", "r581", "r583", "r775", "r776", "r777", "r778", "r779", "r780", "r782", "r783"] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": ["http://www.LongeveronInc.com/role/EquityBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": ["r34", "r35", "r36", "r90", "r462", "r464", "r478", "r479", "r480", "r482", "r483", "r484", "r485", "r487", "r488", "r489", "r490", "r500", "r501", "r502", "r503", "r506", "r507", "r508", "r509", "r523", "r524", "r525", "r526", "r543", "r581", "r583", "r775", "r776", "r777", "r778", "r779", "r780", "r782", "r783"] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofRevenueTable"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r265", "r555", "r556", "r557", "r558", "r559", "r560", "r561"] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": ["http://www.LongeveronInc.com/role/SummaryofSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r764"] }, "us-

gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.LongeveronInc.com/role/EquityBasedCompensation"], "lang": { "en-us": { "role": { "terseLabel": "Equity-based compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r277", "r280", "r312", "r313", "r315", "r566"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Equity-Based Compensation [Abstract]" } } }, "auth_ref": [] }, "dei_DividendOrInterestReinvestmentPlanOnly": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DividendOrInterestReinvestmentPlanOnly", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Dividend or Interest Reinvestment Plan Only" } } }, "auth_ref": ["r631", "r632", "r646"] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other.'" } } }, "auth_ref": ["r607"] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": ["r604", "r607", "r619"] }, "dei_DocumentCopyrightInformation": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentCopyrightInformation", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Copyright Information", "documentation": "The copyright information for the document." } } }, "auth_ref": [] }, "dei_DocumentCreationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentCreationDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Creation Date", "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different." } } }, "auth_ref": [] }, "dei_DocumentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Description", "documentation": "The description of the document." } } }, "auth_ref": [] }, "dei_DocumentDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentDomain", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document [Domain]", "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards." } } }, "auth_ref": [] }, "dei_DocumentEffectiveDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentEffectiveDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Effective Date", "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases." } } }, "auth_ref": [] }, "dei_DocumentFinStmErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmErrorCorrectionFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": ["r604", "r607", "r619", "r670"] }, "dei_DocumentFinStmRestatementRecoveryAnalysisFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmRestatementRecoveryAnalysisFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Financial Statement Restatement Recovery Analysis [Flag]", "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to u00a7240.10D-1(b)."} } } }, "auth_ref": ["r604", "r607", "r619", "r670"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationDocumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationDocumentAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Information, Document [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTextBlock", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Information [Text Block]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Name", "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the <FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v103727.8k.txt.'" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r605"] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": ["r593"] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": ["r607"] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": ["r607"] }, "dei_DocumentSubtitle": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentSubtitle", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Subtitle", "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth.'" } } }, "auth_ref": [] }, "dei_DocumentSynopsis": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentSynopsis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Synopsis", "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period.'" } } }, "auth_ref": [] }, "dei_DocumentTitle": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTitle", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Title", "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report.'" } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r647"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other.'" } } }, "auth_ref": [] }, "dei_DocumentVersion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentVersion", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Version", "documentation": "The version identifier of the document." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": ["r596"] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PrpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "documentation": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": ["r659"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Loss Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Basic net loss per share (in Dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r142", "r155", "r156", "r157", "r158", "r159", "r160", "r165", "r168", "r172", "r173", "r174", "r178", "r339", "r342", "r355", "r356", "r404", "r423", "r545"] }, "us-gaap_EarningsPerShareBasicLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicLineItems", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofDilutedNetLossperShareTable"], "lang": { "en-us": { "role": { "label": "Schedule of Diluted Net Loss per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r168", "r169", "r172"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Diluted net loss per share", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r142", "r155", "r156", "r157", "r158", "r159", "r160", "r168", "r172", "r173", "r174", "r178", "r339", "r342", "r355", "r356", "r404", "r423", "r545"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.LongeveronInc.com/role/LossPerShare"], "lang": { "en-us": { "role": { "terseLabel": "Loss Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r164", "r176", "r177"] }, "dei_EffectiveAfter60Days486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveAfter60Days486a", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective after 60 Days, 486(a)" } } }, "auth_ref": ["r709"] }, "dei_EffectiveOnDate486a": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnDate486a", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"],

"lang": { "en-us": { "role": { "label": "Effective on Date, 486(a)" } } }, "auth_ref": ["r709"] }, "dei_EffectiveOnDate486b": { "xbrltype": "dateItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnDate486b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(b)" } } }, "auth_ref": ["r710"] }, "dei_EffectiveOnSetDate486a": { "xbrltype": "booleanItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnSetDate486a", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(a)" } } }, "auth_ref": ["r709"] }, "dei_EffectiveOnSetDate486b": { "xbrltype": "booleanItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnSetDate486b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(b)" } } }, "auth_ref": ["r710"] }, "dei_EffectiveUponFiling462e": { "xbrltype": "booleanItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveUponFiling462e", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective Upon Filing, 462(e)" } } }, "auth_ref": ["r708"] }, "dei_EffectiveUponFiling486b": { "xbrltype": "booleanItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveUponFiling486b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective upon Filing, 486(b)" } } }, "auth_ref": ["r710"] }, "dei_EffectiveWhenDeclaredSection8c": { "xbrltype": "booleanItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveWhenDeclaredSection8c", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective when Declared, Section 8(c)" } } }, "auth_ref": ["r712"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/EquityBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized equity-based compensation", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": ["r314"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://www.LongeveronInc.com/role/EquityBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized equity-based compensation term", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r314"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofDilutedNetLossperShareTable", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "verboseLabel": "Stock options [Member]", "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntitiesTable": { "xbrltype": "stringItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitiesTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityAccountingStandard": { "xbrltype": "stringItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAccountingStandard", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Accounting Standard", "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element." } } }, "auth_ref": [] }, "dei_EntityAddressAddressDescription": { "xbrltype": "stringItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Description", "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesAddressTypeAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityAddressesLineItems": { "xbrltype": "stringItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Addresses [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityAddressesTable": { "xbrltype": "stringItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Addresses [Table]", "documentation": "Container of address information for the entity" } } }, "auth_ref": ["r595"] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": ["r599"] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r595"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityContactPersonnelLineItems": { "xbrltype": "stringItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityContactPersonnelLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Contact Personnel [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails", "http://xbrl.sec.gov/dei/role/document/AuditInformation", "http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r595"] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": ["r711"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r595"] }, "dei_EntityHomeCountryISOCode": { "xbrltype": "countryCodeItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityHomeCountryISOCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Home Country ISO Code", "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element." } } }, "auth_ref": [] }, "dei_EntityIncorporationDateOffIncorporation": { "xbrltype": "dateItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationDateOffIncorporation", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, Date of Incorporation", "documentation": "Date when an entity was incorporated" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInformationLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [] }

"http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."} } }, "auth_ref": ["r700"] }, "dei_EntityInvCompanyType": { "xbrltype": "invCompanyType", "nsuri": "http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Inv Company Type", "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."} } }, "auth_ref": ["r699"] }, "dei_EntityLegalForm": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityLegalForm", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Legal Form", "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc." } } }, "auth_ref": [] }, "dei_EntityListingDepositoryReceiptRatio": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingDepositoryReceiptRatio", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Depository Receipt Ratio", "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5.'" } } }, "auth_ref": [] }, "dei_EntityListingDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Description", "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security." } } }, "auth_ref": [] }, "dei_EntityListingForeign": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingForeign", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Foreign", "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt." } } }, "auth_ref": [] }, "dei_EntityListingParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingParValuePerShare", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Par Value Per Share", "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01.'" } } }, "auth_ref": [] }, "dei_EntityListingPrimary": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingPrimary", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Primary", "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity." } } }, "auth_ref": [] }, "dei_EntityListingSecurityTradingCurrency": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingSecurityTradingCurrency", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Security Trading Currency", "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'" } } }, "auth_ref": [] }, "dei_EntityListingsExchangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsExchangeAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listings, Exchange [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityListingsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listings [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityListingsTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listings [Table]", "documentation": "Container for exchange listing information for an entity" } } }, "auth_ref": [] }, "dei_EntityNumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityNumberOfEmployees", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Number of Employees", "documentation": "Number of persons employed by the Entity" } } }, "auth_ref": [] }, "dei_EntityPhoneFaxNumbersLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPhoneFaxNumbersLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Phone Fax Numbers [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": ["r619"] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r595"] }, "dei_EntityReportingCurrencyISOCode": { "xbrltype": "currencyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityReportingCurrencyISOCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Reporting Currency ISO Code", "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD.'" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r595"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r595"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r595"] }, "dei_EntityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTextBlock", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity [Text Block]", "documentation": "Container to serve as parent of six Entity related Table concepts." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": ["r702"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r653"] }, "ecd_EqtyAwrdsAdjExclgValRprtdInSummaryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValRprtdInSummaryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r695"] }, "ecd_EqtyAwrdsAdjMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r695"] }, "ecd_EqtyAwrdsInSummaryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummaryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r695"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Stockholders'2019 Equity [Abstract]" } } }, "auth_ref": [] }, "lgvn_EquityBasedCompensationDetailsScheduleOfIssuedandOutstandingOptionsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "EquityBasedCompensationDetailsScheduleOfIssuedandOutstandingOptionsTable", "presentation": ["http://www.LongeveronInc.com/role/ScheduleOfIssuedandOutstandingOptionsTable"], "lang": { "en-us": { "role": { "label": "Equity-Based Compensation (Details) - Schedule of Issued and Outstanding Options [Table]" } } }, "auth_ref": [] }, "lgvn_EquityBasedCompensationDetailsScheduleofRSUActivityTable": { "xbrltype": "stringItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "EquityBasedCompensationDetailsScheduleofRSUActivityTable", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofRSUActivityTable"], "lang": { "en-us": { "role": { "label": "Equity-Based Compensation (Details) - Schedule of RSU Activity [Table]" } } }, "auth_ref": [] }, "lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofStockOptionActivityTable"], "lang": { "en-us": { "role": { "label": "Schedule of Stock Option Activity [Line Items]" } } }, "auth_ref": [] }, "lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityTable": { "xbrltype": "stringItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "EquityBasedCompensationDetailsScheduleofStockOptionActivityTable", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofStockOptionActivityTable"], "lang": { "en-us": { "role": { "label": "Equity-Based Compensation (Details) - Schedule of Stock Option Activity [Table]" } } }, "auth_ref": [] }, "lgvn_EquityBasedCompensationDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.LongeveronInc.com/role/EquityBasedCompensationDetails", "lang": { "en-us": { "role": { "label": "Equity-Based Compensation (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.LongeveronInc.com/role/ShareholdersEquityType2or3", "http://www.LongeveronInc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r10", "r116", "r138", "r139", "r140", "r150", "r151", "r152", "r154", "r159", "r161", "r163", "r180", "r201", "r202", "r219", "r253", "r333", "r334", "r336", "r337", "r338", "r340", "r341", "r342", "r347", "r348", "r349", "r350", "r351", "r352", "r354", "r373", "r374", "r375", "r376", "r377", "r378", "r380", "r382", "r388", "r420", "r434", "r435", "r436", "r449", "r512"] }, "us-gaap_EquitySecuritiesRestrictedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesRestrictedAbstract", "lang": { "en-us": { "role": { "label": "Equity Securities, Restricted [Abstract]" } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r663"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r612", "r623", "r639", "r674"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r609", "r620", "r636", "r671"] }, "us-gaap_ExcessStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ExcessStockSharesIssued", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Unregistered shares (in Shares)", "label": "Excess Stock, Shares Issued", "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders." } } }, "auth_ref": [] }, "dei_ExchangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ExchangeDomain", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Exchange [Domain]", "documentation": "The set of all exchanges. MIC exchange codes

are drawn from ISO 10383." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category." } } }, "auth_ref": ["r669"] }, "lgvn_ExerciseOfRemainingShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "ExerciseOfRemainingShares", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercise of remaining shares", "documentation": "Number of shares exercised.", "label": "Exercise Of Remaining Shares" } } }, "auth_ref": [] }, "dei_ExhibitsOnly462d": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ExhibitsOnly462d", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d)" } } }, "auth_ref": ["r707"] }, "dei_ExhibitsOnly462dFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ExhibitsOnly462dFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d), File Number" } } }, "auth_ref": ["r707"] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair value of warrants (in Dollars)", "label": "Fair Value Adjustment of Warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": ["r1", "r7"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": ["http://www.LongeveronInc.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": ["r362", "r363", "r364", "r365", "r366", "r367", "r370", "r569"] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": ["http://www.LongeveronInc.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": ["r362", "r363", "r364", "r365", "r366", "r367", "r370", "r569"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofMarketableSecuritiesTable"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r235", "r268", "r269", "r270", "r271", "r272", "r273", "r357", "r358", "r359", "r360", "r361", "r368", "r369", "r371", "r394", "r395", "r396", "r552", "r553", "r562", "r563", "r564", "r568", "r570"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofMarketableSecuritiesTable"], "lang": { "en-us": { "role": { "terseLabel": "Level 1 [Member]", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r235", "r268", "r273", "r358", "r369", "r394", "r562", "r563", "r564", "r568"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofMarketableSecuritiesTable"], "lang": { "en-us": { "role": { "terseLabel": "Level 2 [Member]", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r235", "r268", "r273", "r358", "r359", "r369", "r395", "r552", "r553", "r562", "r563", "r564", "r568"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofMarketableSecuritiesTable"], "lang": { "en-us": { "role": { "terseLabel": "Level 3 [Member]", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r235", "r268", "r269", "r270", "r271", "r272", "r273", "r358", "r359", "r360", "r361", "r369", "r396", "r552", "r553", "r562", "r563", "r564", "r568", "r570"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofMarketableSecuritiesTable"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r235", "r268", "r269", "r270", "r271", "r272", "r273", "r358", "r359", "r360", "r361", "r369", "r396", "r552", "r553", "r562", "r563", "r564", "r568"] }, "us-gaap_FiniteLivedIntangibleAssetsUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsUsefulLife", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofMajorComponentsofIntangibleAssetsTable"], "lang": { "en-us": { "role": { "terseLabel": "Useful Lives", "verboseLabel": "Intangible assets estimated useful life", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofMajorComponentsofIntangibleAssetsTable"], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r122", "r203", "r211", "r551"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": ["http://www.LongeveronInc.com/role/ScheduleofFutureAmortizationExpenseforIntangibleAssetsTable": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ScheduleofFutureAmortizationExpenseforIntangibleAssetsTable"], "lang": { "en-us": { "role": { "terseLabel": "2024 (remaining six months)", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r213", "r538", "r551"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": ["http://www.LongeveronInc.com/role/ScheduleofFutureAmortizationExpenseforIntangibleAssetsTable": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ScheduleofFutureAmortizationExpenseforIntangibleAssetsTable"], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r213", "r538", "r551"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "calculation": ["http://www.LongeveronInc.com/role/ScheduleofFutureAmortizationExpenseforIntangibleAssetsTable": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ScheduleofFutureAmortizationExpenseforIntangibleAssetsTable"], "lang": { "en-us": { "role": { "terseLabel": "2024 (remaining six months)", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": ["r834"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": ["http://www.LongeveronInc.com/role/ScheduleofFutureAmortizationExpenseforIntangibleAssetsTable": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ScheduleofFutureAmortizationExpenseforIntangibleAssetsTable"], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r213", "r538", "r551"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": ["http://www.LongeveronInc.com/role/ScheduleofFutureAmortizationExpenseforIntangibleAssetsTable": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ScheduleofFutureAmortizationExpenseforIntangibleAssetsTable"], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r213", "r538", "r551"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": ["http://www.LongeveronInc.com/role/ScheduleofFutureAmortizationExpenseforIntangibleAssetsTable": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ScheduleofFutureAmortizationExpenseforIntangibleAssetsTable"], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r213", "r538", "r551"] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofMajorComponentsofIntangibleAssetsTable"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r205", "r207", "r208", "r209", "r210", "r211", "r214", "r215", "r401", "r402", "r538"] }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Future Amortization Expense for Intangible Assets [Abstract]", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r203", "r211", "r402", "r551"] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofMajorComponentsofIntangibleAssetsTable"], "lang": { "en-us": { "role": { "label": "Schedule of Major Components of Intangible Assets [Line items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r205", "r211", "r214", "r215", "r217", "r401", "r538", "r551"] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofMajorComponentsofIntangibleAssetsTable"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r205", "r207", "r208", "r209", "r210", "r211", "r214", "r215", "r538"] }, "us-gaap_FiniteLivedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMember", "presentation": ["http://www.LongeveronInc.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets

```

"assets", "verboseLabel": "Finite-Lived Intangible Assets [Member]", "label": "Finite-Lived Intangible Assets [Member]", "documentation": "Assets, excluding financial assets, that lack physical substance, having a limited useful life." } } }, "auth_ref": [ ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "parentTag": "http://www.LongeveronInc.com/role/ScheduleOfFutureAmortizationExpenseForIntangibleAssetsTable", "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.LongeveronInc.com/role/ScheduleOfFutureAmortizationExpenseForIntangibleAssetsTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } }, "auth_ref": [ "r401", "r751" ] }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNetAbstract", "lang": { "en-us": { "role": { "label": "Intangible Assets, Net [Abstract]" } } }, "auth_ref": [ ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r616", "r627", "r643", "r678" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r616", "r627", "r643", "r678" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r616", "r627", "r643", "r678" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r616", "r627", "r643", "r678" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r616", "r627", "r643", "r678" ] }, "dei_FormerAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "FormerAddressMember", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Former Address [Member]", "documentation": "Former address for entity" } } }, "auth_ref": [ "r606", "r630" ] }, "dei_FormerFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "FormerFiscalYearEndDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Former Fiscal Year End Date", "documentation": "Former end date of previous fiscal years" } } }, "auth_ref": [ ] }, "ecd_FrValAsOfPrYrEndOfEqtyAwrdsGrntdInPrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrYrEndOfEqtyAwrdsGrntdInPrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r658" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.LongeveronInc.com/role/ScheduleOfMajorComponentsOfPropertyAndEquipmentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture Lab Equipment [Member]", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [ ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "parentTag": "http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r63", "r497" ] }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": [ "http://www.LongeveronInc.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }, "auth_ref": [ "r742", "r743" ] }, "lgnv_GrantRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "GrantRevenueMember", "presentation": [ "http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Grant revenue", "label": "Grant Revenue Member" } } }, "auth_ref": [ ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "parentTag": "http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r59", "r60", "r100", "r149", "r200", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r372", "r547", "r548", "r731", "r732", "r733", "r734", "r735", "r761" ] }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IPOMember", "presentation": [ "http://www.LongeveronInc.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Public offering [Member]", "label": "IPO [Member]", "documentation": "First sale of stock by a private company to the public." } } }, "auth_ref": [ ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r604", "r607", "r619" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://www.LongeveronInc.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of Long-Lived Assets", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r70", "r78" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [ ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://www.LongeveronInc.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax provision", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r103", "r113", "r162", "r163", "r179", "r187", "r190", "r327", "r328", "r335", "r424", "r567" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.LongeveronInc.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r137", "r325", "r326", "r329", "r330", "r331", "r332", "r442" ] }, "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsAndOtherReceivables", "crdr": "debit", "calculation": { "parentTag": "http://www.LongeveronInc.com/role/ConsolidatedCashFlow", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.LongeveronInc.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts and grants receivable", "label": "Increase (Decrease) in Accounts and Other Receivables", "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "parentTag": "http://www.LongeveronInc.com/role/ConsolidatedCashFlow", "weight": 1.0, "order": 4.0 } }, "presentation
```

"presentation": ["http://www.LongeveronInc.com/role/ConsolidatedCashFlow", "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r6"]], "Igvn_IncurredTerms": { "xbrltype": "durationItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "IncurredTerms", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Incurred term", "documentation": "Incurred terms.", "label": "Incurred Terms" } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedLicenseAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedLicenseAgreements", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "License agreement amount", "label": "Indefinite-Lived License Agreements", "documentation": "Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the capitalized costs to acquire rights under a license arrangement (for example, to sell specified products in a specified territory) having an indefinite period of benefit." } } }, "auth_ref": ["r715", "r753"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual.", "auth_ref": ["r616", "r627", "r643", "r669", "r678", "r682", "r690"] } } }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements." } } }, "auth_ref": ["r688"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures.", "auth_ref": ["r608", "r694"] } } }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r608", "r694"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": ["http://www.LongeveronInc.com/role/IntangibleAssetsNet"], "lang": { "en-us": { "role": { "label": "Intangible assets, net", "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": ["r204", "r216", "r218", "r537", "r538"] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet"], "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "presentation": ["http://www.LongeveronInc.com/role/ScheduleofMajorComponentsofIntangibleAssetsTable"], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "verboseLabel": "Total", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": ["r205", "r751", "r753"] }, "dei_InvestmentCompanyActFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyActFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Investment Company Act File Number" } } }, "auth_ref": ["r632", "r633", "r634", "r635"] }, "dei_InvestmentCompanyActRegistration": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyActRegistration", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Investment Company Act Registration" } } }, "auth_ref": ["r648"] }, "us-gaap_InvestmentCompanyExcessExpenseReimbursable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentCompanyExcessExpenseReimbursable", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Reimbursement", "label": "Investment Company, Reimbursable Excess Expense", "documentation": "Amount of carryover of excess expense potentially reimbursable to adviser but not recorded as liability by investment company." } } }, "auth_ref": ["r448"] }, "dei_InvestmentCompanyRegistrationAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyRegistrationAmendment", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment" } } }, "auth_ref": ["r648"] }, "dei_InvestmentCompanyRegistrationAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyRegistrationAmendmentNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment Number" } } }, "auth_ref": ["r648"] }, "Igvn_JulyOfferingPlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "JulyOfferingPlacementMember", "presentation": ["http://www.LongeveronInc.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "July Offering Placement [Member]", "label": "July Offering Placement Member" } } }, "auth_ref": [] }, "Igvn_JulyOrdinaryCoursePlacementAgentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "JulyOrdinaryCoursePlacementAgentMember", "presentation": ["http://www.LongeveronInc.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "July Ordinary Course Placement Agent [Member]", "label": "July Ordinary Course Placement Agent Member" } } }, "auth_ref": [] }, "Igvn_JulyPrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "JulyPrivatePlacementMember", "presentation": ["http://www.LongeveronInc.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "July Private Placement [Member]", "label": "July Private Placement Member" } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lease costs", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": ["r385", "r574"] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofMajorComponentsofPropertyandEquipmentTable"], "lang": { "en-us": { "role": { "terseLabel": "Leasehold Improvements [Member]", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": ["r77", "r387"] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "auth_ref": [] }, "Igvn_LeasesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "LeasesDetailsTable", "presentation": ["http://www.LongeveronInc.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "label": "Leases (Details) [Table]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails", "http://xbrl.sec.gov/dei/role/document/AuditInformation", "http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_LegalEntityIdentifier": { "xbrltype": "legalEntityIdentifierItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityIdentifier", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Legal Entity Identifier", "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI." } } }, "auth_ref": ["r592"] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://www.LongeveronInc.com/role/LeasesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum Payments under the Operating Leases", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r785"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": ["http://www.LongeveronInc.com/role/ScheduleofFutureMinimumPaymentsUndertheOperatingLeasesTable"], "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": ["http://www.LongeveronInc.com/role/ScheduleofFutureMinimumPaymentsUndertheOperatingLeasesTable"], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r386"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": ["http://www.LongeveronInc.com/role/ScheduleofFutureMinimumPaymentsUndertheOperatingLeasesTable"], "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 }, "presentation": ["http://www.LongeveronInc.com/role/ScheduleofFutureMinimumPaymentsUndertheOperatingLeasesTable"], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r386"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": ["http://www.LongeveronInc.com/role/ScheduleofFutureMinimumPaymentsUndertheOperatingLeasesTable"], "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 }, "presentation": ["http://www.LongeveronInc.com/role/ScheduleofFutureMinimumPaymentsUndertheOperatingLeasesTable"], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r386"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": ["http://www.LongeveronInc.com/role/ScheduleofFutureMinimumPaymentsUndertheOperatingLeasesTable"], "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 }, "presentation": ["http://www.LongeveronInc.com/role/ScheduleofFutureMinimumPaymentsUndertheOperatingLeasesTable"], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r386"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOffFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOffFiscalYear", "crdr": "credit", "calculation": ["http://www.LongeveronInc.com/role/ScheduleofFutureMinimumPaymentsUndertheOperatingLeasesTable"], "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 }, "presentation": ["http://www.LongeveronInc.com/role/ScheduleofFutureMinimumPaymentsUndertheOperatingLeasesTable"], "lang": { "en-us": { "role": { "terseLabel": "2024 (remaining six months)", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r785"] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofFutureMinimumPaymentsUndertheOperatingLeasesTable"], "lang": { "en-us": { "role": { "terseLabel": "Less: Interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r386"] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": ["http://www.LongeveronInc.com/role/Leases"], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": ["r381"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet"], "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount

of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } , "auth_ref": ["r13", "r41", "r42", "r43", "r45", "r46", "r47", "r48", "r149", "r200", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r344", "r345", "r372", "r471", "r546", "r591", "r761", "r788", "r789"] } , "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } } , "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u002019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } } , "auth_ref": ["r56", "r95", "r414", "r575", "r725", "r741", "r784"] } , "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } , "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } } , "auth_ref": ["r43", "r119", "r149", "r200", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r344", "r345", "r346", "r372", "r575", "r761", "r788", "r789"] } , "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } } , "auth_ref": [] } , "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } , "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "Total long-term liabilities", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } } , "auth_ref": ["r13", "r45", "r46", "r47", "r48", "r149", "r200", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r344", "r345", "r346", "r372", "r761", "r788", "r789"] } , "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Long-term liabilities:", "label": "Liabilities, Noncurrent [Abstract]" } } } , "auth_ref": [] } , "us-gaap_LicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicenseMember", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "License [Member]", "verboseLabel": "UM License [Member]", "label": "License [Member]", "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark." } } } , "auth_ref": ["r765"] } , "us-gaap_LicensingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicensingAgreementsMember", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofMajorComponentsofIntangibleAssetsTable"], "lang": { "en-us": { "role": { "terseLabel": "License agreements [Member]", "label": "Licensing Agreements [Member]", "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory." } } } , "auth_ref": ["r33", "r324", "r744", "r745", "r746", "r747", "r748", "r749", "r751", "r753", "r754", "r755", "r768"] } , "us-gaap_LoanRestructuringTrialModificationsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoanRestructuringTrialModificationsAmount", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Completion of trial", "label": "Loan Restructuring, Trial Modifications, Amount", "documentation": "Amount of financing receivable modified on trial basis." } } } , "auth_ref": ["r102"] } , "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } } , "auth_ref": [] } , "lgvn_IgvnLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "LongeveronMember", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Longeveron [Member]", "label": "Longeveron Member" } } } , "auth_ref": [] } , "us-gaap_MarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecurities", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofMarketableSecuritiesTable"], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities", "label": "Marketable Securities", "documentation": "Amount of investment in marketable security." } } } , "auth_ref": ["r96", "r716"] } , "us-gaap_MarketableSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Marketable Securities [Abstract]" } } } , "auth_ref": [] } , "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } , "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities", "label": "Marketable Securities, Current", "documentation": "Amount of investment in marketable security, classified as current." } } } , "auth_ref": ["r716"] } , "lgvn_MarketableSecuritiesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "MarketableSecuritiesDetailsTable", "presentation": ["http://www.LongeveronInc.com/role/MarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Marketable Securities (Details) [Table]" } } } , "auth_ref": [] } , "us-gaap_MarketableSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesLineItems", "presentation": ["http://www.LongeveronInc.com/role/MarketableSecuritiesDetails", "http://www.LongeveronInc.com/role/ScheduleofMarketableSecuritiesTable"], "lang": { "en-us": { "role": { "label": "Schedule of Marketable Securities [Line Items]", "terseLabel": "Marketable Securities [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth_ref": [] } , "us-gaap_MarketableSecuritiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesPolicy", "presentation": ["http://www.LongeveronInc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities", "label": "Marketable Securities, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment classified as marketable security." } } } , "auth_ref": ["r37"] } , "us-gaap_MarketableSecuritiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesTable", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofMarketableSecuritiesTable"], "lang": { "en-us": { "role": { "label": "Disclosure of information about investment in marketable security." } } } , "auth_ref": [] } , "us-gaap_MarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesTextBlock", "presentation": ["http://www.LongeveronInc.com/role/MarketableSecuritiesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Marketable Securities", "label": "Marketable Securities [Table Text Block]", "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets." } } } , "auth_ref": [] } , "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } , "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Interest earned on marketable securities", "label": "Marketable Security, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in marketable security." } } } , "auth_ref": ["r65"] } , "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.LongeveronInc.com/role/EquityBasedCompensationDetails", "http://www.LongeveronInc.com/role/LeasesDetails", "http://www.LongeveronInc.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum [Member]", "label": "Maximum [Member]" } } } , "auth_ref": ["r222", "r223", "r224", "r225", "r276", "r321", "r361", "r399", "r432", "r433", "r440", "r463", "r464", "r519", "r520", "r521", "r522", "r527", "r535", "r536", "r550", "r554", "r565", "r570", "r571", "r572", "r577", "r763", "r790", "r791", "r792", "r793", "r794", "r795"] } , "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } } , "auth_ref": ["r661"] } , "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } } , "auth_ref": ["r661"] } , "lgvn_MilestoneFeesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "MilestoneFeesPayable", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Milestone fees payable", "documentation": "Milestone fees Payable." } } } , "auth_ref": [] } , "lgvn_MilestoneOfTriggeringPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "MilestoneOfTriggeringPayments", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Milestone payment", "documentation": "Amount of milestone of triggering payments." } } } , "auth_ref": [] } , "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.LongeveronInc.com/role/EquityBasedCompensationDetails", "http://www.LongeveronInc.com/role/LeasesDetails", "http://www.LongeveronInc.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "label": "Minimum [Member]" } } } , "auth_ref": ["r222", "r223", "r224", "r225", "r276", "r321", "r361", "r399", "r432", "r433", "r440", "r463", "r464", "r519", "r520", "r521", "r522", "r527", "r535", "r536", "r550", "r554", "r565", "r570", "r571", "r572", "r577", "r763", "r790", "r791", "r792", "r793", "r794", "r795"] } , "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } } , "auth_ref": ["r681"] } , "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofMarketableSecuritiesTable"], "lang": { "en-us": { "role": { "terseLabel": "Money market funds [Member]", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } } , "auth_ref": ["r766"] } , "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } } , "auth_ref": ["r689"] } , "dei_NameChangeEventDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventDateAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Name Change Event Date [Axis]", "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type." } } } , "auth_ref": [] } , "dei_NameChangeEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Name Change Event [Line Items]", "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table." } } } , "auth_ref": [] } , "dei_NameChangeEventTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Name Change Event [Table]", "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period." } } } , "auth_ref": [] } , "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } } , "auth_ref": ["r662"] } , "lgvn_NationalInstitutesOfHealthGrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "NationalInstitutesOfHealthGrantMember", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofAccountsandGrantsReceivableTable", "http://www.LongeveronInc.com/role/ScheduleofRevenueTable"], "lang": { "en-us": { "role": { "terseLabel": "National Institutes of Health \u00202013 Grant [Member]", "verboseLabel": "NIH - grant [Member]", "label": "National Institutes Of Health Grant Member" } } } , "auth_ref": [] } , "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } , "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } } , "auth_ref": ["r145"] } , "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

```
"CashFlowsFromFinancingActivitiesAbstract": { "http://www.LongeveronInc.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [ ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.LongeveronInc.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r145" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.LongeveronInc.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [ ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.LongeveronInc.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r69", "r70", "r72" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.LongeveronInc.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [ ] }, "us-gaap_NetIncomeLoss": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 1.0 }, "http://www.LongeveronInc.com/role/ConsolidatedComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.LongeveronInc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "presentation": [ "http://www.LongeveronInc.com/role/ConsolidatedCashFlow", "http://www.LongeveronInc.com/role/ConsolidatedComprehensiveIncome", "http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement", "http://www.LongeveronInc.com/role/NatureOfBusinessBasisOfPresentationandLiquidityDetails", "http://www.LongeveronInc.com/role/ShareholdersEquityType2or3", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "verboseLabel": "Net loss", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r61", "r72", "r97", "r117", "r133", "r135", "r140", "r149", "r153", "r155", "r156", "r157", "r158", "r159", "r162", "r163", "r170", "r200", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r339", "r342", "r356", "r372", "r419", "r494", "r510", "r511", "r589", "r761" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to common stockholders", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r143", "r155", "r156", "r157", "r158", "r165", "r166", "r171", "r174", "r342" ] }, "lgvn_NetSalesOfSubLicensees": { "xbrlType": "percentItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "NetSalesOfSubLicensees", "presentation": [ "http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net sales of sub licensees percentage", "documentation": "Net sales of sub licensees.", "label": "Net Sales Of Sub Licensees" } } }, "auth_ref": [ ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.LongeveronInc.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Standard Updates", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [ ] }, "dei_NewEffectiveDateForPreviousFiling": { "xbrlType": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NewEffectiveDateForPreviousFiling", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "New Effective Date for Previous Filing" } } }, "auth_ref": [ "r632", "r633", "r634", "r635" ] }, "dei_NoSubstantiveChanges462c": { "xbrlType": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoSubstantiveChanges462c", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c)" } } }, "auth_ref": [ "r706" ] }, "dei_NoSubstantiveChanges462cFileNumber": { "xbrlType": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoSubstantiveChanges462cFileNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c), File Number" } } }, "auth_ref": [ "r706" ] }, "dei_NoTradingSymbolFlag": { "xbrlType": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [ ] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r661" ] }, "ecd_NonNeosMember": { "xbrlType": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r616", "r627", "r643", "r669", "r678" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrlType": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r652" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrlType": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r651" ] }, "ecd_NonPeoNeoMember": { "xbrlType": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r669" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrlType": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r689" ] }, "lgvn_NonRule10b51ArrModifiedFlag": { "xbrlType": "booleanItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "NonRule10b51ArrModifiedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b51 Arr Modified Flag", "label": "Non Rule 10b51 Arr Modified Flag" } } }, "auth_ref": [ ] }, "ecd_NonRule10b51ArrTrmndFlag": { "xbrlType": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r689" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 }, "presentation": [ "http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income, net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r66" ] }, "us-gaap_NoteWarrantMember": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoteWarrantMember
```

"r383"] }, "us-gaap_OperatingLeasedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasedAssetsLineItems", "presentation": ["http://www.LongeveronInc.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "label": "Leases [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOffFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOffFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Nature of Business, Basis of Presentation, and Liquidity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesNoncurrent", "crdr": "credit", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Other Accrued Liabilities, Noncurrent", "documentation": "Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r46"] }, "dei_OtherAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherAddressMember", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Other Address [Member]", "documentation": "Other address for entity" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet", { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r123"] }, "us-gaap_OtherCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash payment", "label": "Other Cash Equivalents, at Carrying Value", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates, classified as other. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsLineItems", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "calculation": ["http://www.LongeveronInc.com/role/ConsolidatedComprehensiveIncome", { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedComprehensiveIncome"], "lang": { "en-us": { "role": { "terseLabel": "Net unrealized (loss) gain on available-for-sale securities", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": ["r130", "r131", "r132", "r420"] }, "lgvn_OtherComprehensiveLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "OtherComprehensiveLossAbstract", "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedComprehensiveIncome"], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive loss", "label": "Other Comprehensive Loss Abstract" } } }, "auth_ref": [] }, "us-gaap_OtherExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherExpenses", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expenditures amount", "label": "Other Expenses", "documentation": "Amount of expense classified as other." } } }, "auth_ref": ["r63", "r64"] }, "us-gaap_OtherGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/EquityBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "General and administrative expenses", "label": "Other General and Administrative Expense", "documentation": "Amount of general and administrative expense classified as other." } } }, "auth_ref": ["r63", "r830"] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndExpensesAbstract", "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Other income and (expenses)", "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet", { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r46"] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": ["http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement", { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Other income, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r67"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r661"] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "Item 17 or Item 18 specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": ["r607"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r614", "r625", "r641", "r676"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r617", "r628", "r644", "r679"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r617", "r628", "r644", "r679"] }, "dei_ParentEntityLegalName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ParentEntityLegalName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Parent Entity Legal Name", "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity" } } }, "auth_ref": [] }, "us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PartnersCapitalAccountUnitsSoldInPublicOffering", "presentation": ["http://www.LongeveronInc.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Public offering shares", "label": "Partners' Capital Account, Units, Sold in Public Offering", "documentation": "The number of units sold in a public offering of each class of partners' capital account. Units represent shares of ownership of the general, limited, and preferred partners." } } }, "auth_ref": ["r81", "r82"] }, "us-gaap_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PatentsMember", "presentation": ["http://www.LongeveronInc.com/role/ScheduleOfMajorComponentsofIntangibleAssetsTable"], "lang": { "en-us": { "role": { "terseLabel": "Patent costs [Member]", "label": "Patents [Member]", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": ["r89", "r744", "r745", "r746", "r747", "r749", "r751", "r754", "r755"] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r650"] }, "lgvn_PaymentPerWarrant": { "xbrltype": "perShareItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "PaymentPerWarrant", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Payment per warrant (in Dollars per share)", "label": "Payment per warrant", "documentation": "Payment per warrant." } } }, "auth_ref": [] }, "us-gaap_PaymentsForFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForFees", "crdr": "credit", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Payments to UM", "label": "Payments for Other Fees", "documentation": "Amount of cash outflow for fees classified as other." } } }, "auth_ref": ["r5"] }, "lgvn_PaymentsForTaxesOnRSUsVested": { "xbrltype": "monetaryItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "PaymentsForTaxesOnRSUsVested", "crdr": "credit", "calculation": ["http://www.LongeveronInc.com/role/ConsolidatedCashFlow", { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Payments for taxes on RSUs vested", "documentation": "Payments for taxes on RSUs vested", "label": "Payments For Taxes On RSUs Vested" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": ["http://www.LongeveronInc.com/role/ShareholdersEquityType2or3_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Class A common stock issued in public offering, net of issuance costs", "label": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": ["r17"] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": ["http://www.LongeveronInc.com/role/ConsolidatedCashFlow", { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Acquisition of intangible assets", "label": "Payments to Acquire Intangible Assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": ["r68"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": ["http://www.LongeveronInc.com/role/ConsolidatedCashFlow", { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Acquisition of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r68"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r660"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r660"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r652"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r669"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r662"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r651"] }, "lgvn_PercentageOfAggregateNumberOfShares": { "xbrltype": "percentItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "PercentageOfAggregateNumberOfShares", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails", "http://www.LongeveronInc.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of aggregate number of shares", "documentation": "Percentage of aggregate number of shares.", "label": "Percentage Of Aggregate Number Of Shares" } } }, "auth_ref": [] }, "us-gaap_PhantomShareUnitsPSUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PhantomShareUnitsPSUsMember" }

"PhantomShareUnitsPSUsMember", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofDilutedNetLossperShareTable"], "lang": { "en-us": { "role": { "terseLabel": "PSUs [Member]", "label": "Phantom Share Units (PSUs) [Member]", "documentation": "Share-based payment arrangement awarded as phantom share or unit." } } }, "auth_ref": [] }, { "dei_PhoneFaxNumberDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PhoneFaxNumberDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Phone Fax Number Description", "documentation": "Description of Phone or Fax Number" } } }, "auth_ref": [] }, { "lgvn_PlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "PlacementAgentWarrantsMember", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Placement agent warrants [Member]", "label": "Placement Agent Warrants Member" } } }, "auth_ref": [] }, { "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r653"] }, { "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r698"] }, { "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r652"] }, { "dei_PostEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PostEffectiveAmendment", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment" } } }, "auth_ref": ["r593"] }, { "dei_PostEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PostEffectiveAmendmentNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective." } } }, "auth_ref": ["r593"] }, { "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": ["r600"] }, { "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": ["r602"] }, { "dei_PreEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreEffectiveAmendment", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment" } } }, "auth_ref": ["r593"] }, { "dei_PreEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreEffectiveAmendmentNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective." } } }, "auth_ref": ["r593"] }, { "lgvn_PreFundedWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "PreFundedWarrantMember", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Pre Funded Warrant [Member]", "label": "Pre Funded Warrant Member" } } }, "auth_ref": [] }, { "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in Dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r49", "r237"] }, { "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r49", "r473"] }, { "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r49", "r237"] }, { "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r49", "r473", "r492", "r831", "r832"] }, { "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, \$0.001 par value per share, 5,000,000 shares authorized, no shares issued and outstanding at June 30, 2024, and December 31, 2023.", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r49", "r410", "r575"] }, { "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r718"] }, { "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDebtNetOfIssuanceCosts", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds (in Dollars)", "label": "Proceeds from Debt, Net of Issuance Costs", "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination." } } }, "auth_ref": ["r144"] }, { "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the issuance of common stock, net of issuance cost", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r4"] }, { "us-gaap_ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Deemed dividend to common stockholders (in Dollars)", "label": "Proceeds from Issuance of Common Stock, Dividend Reinvestment Plan", "documentation": "Amount of cash inflow from capital contributions to an entity associated with a dividend reinvestment plan." } } }, "auth_ref": ["r722"] }, { "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate gross (in Dollars)", "label": "Proceeds from Issuance of Debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": ["r723"] }, { "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from warrants exercised, net of issuance cost", "label": "Proceeds from Issuance of Warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": ["r4"] }, { "us-gaap_ProceedsFromLicenseFeesReceived": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLicenseFeesReceived", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "License fee", "label": "Proceeds from License Fees Received", "documentation": "Cash received from licensees for license fees during the current period." } } }, "auth_ref": ["r71"] }, { "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the sale of marketable securities", "label": "Proceeds from Sale and Maturity of Marketable Securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, { "lgvn_ProceedsFromStockSubscriptionReceivable": { "xbrltype": "monetaryItem", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "ProceedsFromStockSubscriptionReceivable", "crdr": "debit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from stock subscription receivable", "label": "Amount of proceeds from stock subscription receivable." } } }, "auth_ref": [] }, { "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares issuable (in Dollars)", "label": "Proceeds from Warrant Exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": ["r722"] }, { "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails", "http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement", "http://www.LongeveronInc.com/role/ScheduleofRevenueTable"], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": ["r191", "r400", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r541", "r555", "r576", "r577", "r578", "r579", "r580", "r759", "r760", "r764", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826"] }, { "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails", "http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement", "http://www.LongeveronInc.com/role/ScheduleofRevenueTable"], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": ["r191", "r400", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r541", "r555", "r576", "r577", "r578", "r579", "r580", "r759", "r760", "r764", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826"] }, { "us-gaap_ProfessionalFees": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfessionalFees", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Professional fees", "label": "Professional Fees", "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer." } } }, "auth_ref": ["r548", "r589", "r829", "r830"] }, { "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofMajorComponentsofPropertyandEquipmentTable"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r8", "r387"] }, { "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock" }

"PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": ["http://www.LongeveronInc.com/role/PropertyandEquipmentNet"], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r76", "r108", "r111", "r112"] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.LongeveronInc.com/role/ScheduleofMajorComponentsofPropertyandEquipmentTable": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ScheduleofMajorComponentsofPropertyandEquipmentTable"], "lang": { "en-us": { "role": { "terseLabel": "Total Property and Equipment", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r77", "r121", "r418"] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofMajorComponentsofPropertyandEquipmentTable"], "lang": { "en-us": { "role": { "label": "Schedule of Major Components of Property and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r387"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.LongeveronInc.com/role/ScheduleofMajorComponentsofPropertyandEquipmentTable": { "parentTag": null, "weight": null, "order": null, "root": true } } }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet", "http://www.LongeveronInc.com/role/ScheduleofMajorComponentsofPropertyandEquipmentTable"], "lang": { "en-us": { "role": { "totalLabel": "Property and equipment, net", "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r8", "r387", "r405", "r418", "r575"] }, "us-gaap_PropertyPlantAndEquipmentNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNetAbstract", "lang": { "en-us": { "role": { "label": "Property and Equipment, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentOtherAccumulatedDepreciation", "crdr": "credit", "calculation": { "http://www.LongeveronInc.com/role/ScheduleofMajorComponentsofPropertyandEquipmentTable": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ScheduleofMajorComponentsofPropertyandEquipmentTable"], "lang": { "en-us": { "role": { "terseLabel": "Less accumulated depreciation and amortization", "label": "Property, Plant and Equipment, Other, Accumulated Depreciation", "documentation": "Amount of accumulated depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": ["http://www.LongeveronInc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r8", "r108", "r111", "r417"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://www.LongeveronInc.com/role/PropertyandEquipmentNetTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Major Components of Property and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": ["r8"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofMajorComponentsofPropertyandEquipmentTable"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r77", "r387"] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofMajorComponentsofPropertyandEquipmentTable"], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment, Useful Lives", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in PnYnMnDtNnHnMnS format, for example, P1Y5M13D represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r650"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r650"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.LongeveronInc.com/role/EquityBasedCompensationDetails", "http://www.LongeveronInc.com/role/LeasesDetails", "http://www.LongeveronInc.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r222", "r223", "r224", "r225", "r267", "r276", "r306", "r307", "r308", "r321", "r361", "r397", "r398", "r399", "r432", "r433", "r440", "r463", "r464", "r519", "r520", "r521", "r522", "r527", "r535", "r536", "r550", "r554", "r565", "r570", "r571", "r572", "r573", "r577", "r583", "r575", "r763", "r773", "r791", "r792", "r793", "r794", "r795"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.LongeveronInc.com/role/EquityBasedCompensationDetails", "http://www.LongeveronInc.com/role/LeasesDetails", "http://www.LongeveronInc.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r222", "r223", "r224", "r225", "r267", "r276", "r306", "r307", "r308", "r321", "r361", "r397", "r398", "r399", "r432", "r433", "r440", "r463", "r464", "r519", "r520", "r521", "r522", "r527", "r535", "r536", "r550", "r554", "r565", "r570", "r571", "r572", "r573", "r577", "r583", "r575", "r763", "r773", "r791", "r792", "r793", "r794", "r795"] }, "us-gaap_ReceivableTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivableTypeDomain", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofAccountsandGrantsReceivableTable"], "lang": { "en-us": { "role": { "label": "Receivable [Domain]", "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates." } } }, "auth_ref": ["r51", "r57"] }, "us-gaap_ReceivablesFromStockholderMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesFromStockholderMember", "presentation": ["http://www.LongeveronInc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Subscription Receivable", "label": "Receivables from Stockholder [Member]", "documentation": "Category of equity that is due from owners or affiliates of the reporting entity (including due from officers or directors) resulting from the sale of stock before the cash payment is received." } } }, "auth_ref": [] }, "us-gaap_ReceivablesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesPolicyTextBlock", "presentation": ["http://www.LongeveronInc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Accounts and grants receivable", "label": "Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable." } } }, "auth_ref": ["r196", "r197", "r198", "r199", "r738"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r609", "r620", "r636", "r671"] }, "dei_RegistrationStatementAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "RegistrationStatementAmendmentNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Registration Statement Amendment Number", "documentation": "Amendment number to registration statement under the Investment Company Act of 1940." } } }, "auth_ref": ["r593"] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r194", "r274", "r389", "r390", "r407", "r415", "r466", "r467", "r468", "r469", "r470", "r491", "r493", "r518"] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": ["http://www.LongeveronInc.com/role/EquityBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": ["r389", "r390", "r787"] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": ["http://www.LongeveronInc.com/role/EquityBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r194", "r274", "r389", "r390", "r407", "r415", "r466", "r467", "r468", "r469", "r470", "r491", "r493", "r518", "r787"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r323", "r538", "r548", "r796"] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": ["http://www.LongeveronInc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Research and development expense", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": ["r322"] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r610", "r621", "r637", "r672"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r611", "r622", "r638", "r673"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require recovery" } } }, "auth_ref": ["r618", "r629"] }

"r645", "r680"] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": ["http://www.LongeveronInc.com/role/ScheduleOfMarketableSecuritiesTable"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r120"] }, "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsItemsLineItems", "presentation": ["http://www.LongeveronInc.com/role/ScheduleOfRSUActivityTable"], "lang": { "en-us": { "role": { "label": "Schedule of RSU Activity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r797"] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://www.LongeveronInc.com/role/EquityBasedCompensationDetails", "http://www.LongeveronInc.com/role/ScheduleOfDilutedNetLossPerShareTable", "http://www.LongeveronInc.com/role/ScheduleOfRSUActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units (RSUs) [Member]", "verboseLabel": "RSUs [Member]", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet", "http://www.LongeveronInc.com/role/NatureOfBusinessBasisOfPresentationandLiquidityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r53", "r81", "r413", "r437", "r439", "r447", "r474", "r575"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.LongeveronInc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r116", "r150", "r151", "r152", "r154", "r159", "r161", "r163", "r201", "r202", "r219", "r333", "r334", "r336", "r337", "r338", "r340", "r341", "r342", "r347", "r349", "r350", "r352", "r354", "r380", "r382", "r434", "r436", "r449", "r831"] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement", "http://www.LongeveronInc.com/role/ScheduleOfRevenueTable"], "lang": { "en-us": { "role": { "terseLabel": "Total revenues", "verboseLabel": "Total revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": ["r98", "r99", "r179", "r184", "r185", "r188", "r190", "r191", "r192", "r193", "r264", "r265", "r400"] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": ["http://www.LongeveronInc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": ["r114", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r540"] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": ["http://www.LongeveronInc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognition", "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": ["r496", "r540", "r544"] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "lgvn_ReverseStockSplitPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "ReverseStockSplitPolicyTextBlock", "presentation": ["http://www.LongeveronInc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Reverse Stock Split", "documentation": "Disclosure of Reverse Stock Split." }, "label": "Reverse Stock Split Policy Text Block" } } }, "auth_ref": [] }, "us-gaap_RoyaltyExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyExpense", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Annual royalty fee", "label": "Royalty Expense", "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property." } } }, "auth_ref": ["r62"] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r689"] }, "lgvn_Rule10b51ArrModifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "Rule10b51ArrModifiedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arr Modified Flag" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrTrmmtdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmmtdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r689"] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Company value amount", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails", "http://www.LongeveronInc.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares issued (in Shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "lgvn_ScheduleOfAccountsAndGrantsReceivableAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "ScheduleOfAccountsAndGrantsReceivableAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Accounts And Grants Receivable Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "presentation": ["http://www.LongeveronInc.com/role/ScheduleOfAccountsAndGrantsReceivableTable"], "lang": { "en-us": { "role": { "label": "Accounts and Financing Receivables [Table]", "documentation": "Disclosure of information about accounts and financing receivables. Includes, but is not limited to, amount of receivable and allowance for credit loss." } } }, "auth_ref": ["r51", "r57", "r195", "r739"] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": ["http://www.LongeveronInc.com/role/SummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts and Grants Receivable", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": ["r51", "r57"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.LongeveronInc.com/role/ScheduleOfDilutedNetLossPerShareTable"], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r23"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.LongeveronInc.com/role/LossPerShareTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Diluted Net Loss Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r23"] }, "lgvn_ScheduleOfDilutedNetLossPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "ScheduleOfDilutedNetLossPerShareAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Diluted Net Loss Per Share Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": ["http://www.LongeveronInc.com/role/ScheduleOfMajorComponentsOfIntangibleAssetsTable"], "lang": { "en-us": { "role": { "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": ["r205", "r211", "r214", "r215", "r217", "r401", "r538", "r551"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": ["http://www.LongeveronInc.com/role/IntangibleAssetsNetTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Major Components of Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": ["r551", "r750"] }, "lgvn_ScheduleOfIssuedAndOutstandingOptionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "ScheduleOfIssuedAndOutstandingOptionsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Issued And Outstanding Options Abstract" } } }, "auth_ref": [] }, "lgvn_ScheduleOfMajorComponentsOfIntangibleAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "ScheduleOfMajorComponentsOfIntangibleAssetsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Major Components Of Intangible Assets Abstract" } } }, "auth_ref": [] }, "lgvn_ScheduleOfMajorComponentsOfPropertyAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "ScheduleOfMajorComponentsOfPropertyAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Major Components Of Property And Equipment Abstract" } } }, "auth_ref": [] }, "lgvn_ScheduleOfMarketableSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "ScheduleOfMarketableSecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Marketable Securities Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": ["http://www.LongeveronInc.com/role/ScheduleOfMajorComponentsOfPropertyAndEquipmentTable"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": ["r8", "r387"] }, "lgvn_ScheduleOfRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "ScheduleOfRevenueAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Revenue Abstract" } } }, "auth_ref": [] }, "lgvn_ScheduleOfRsuActivityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "ScheduleOfRsuActivityAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Rsu Activity Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock", "presentation": [

"http://www.LongeveronInc.com/role/EquityBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Issued and Outstanding Options", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]", "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r88"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.LongeveronInc.com/role/EquityBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r11", "r12", "r87"] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": ["http://www.LongeveronInc.com/role/EquityBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of RSU Activity", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "Igvn_ScheduleOfStockOptionActivityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "ScheduleOfStockOptionActivityAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Stock Option Activity Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": ["http://www.LongeveronInc.com/role/IntangibleAssetsNetTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Amortization Expense for Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": ["r551", "r752"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r594"] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": ["r598"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r597"] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": ["r603"] }, "Igvn_SeriesAAndSeriesBWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "SeriesAAndSeriesBWarrantsMember", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Series A and Series B Warrants [Member]", "label": "Series A and Series B Warrants Member" } } }, "auth_ref": [] }, "us-gaap_SeriesAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesAMember", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Series A warrants [Member]", "label": "Series A [Member]", "documentation": "A classification of auction market preferred securities that may have different rights to other classifications of auction market preferred securities, for example Series B." } } }, "auth_ref": [] }, "us-gaap_SeriesBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesBMember", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Series B warrants [Member]", "label": "Series B [Member]", "documentation": "A classification of auction market preferred securities that may have different rights to other classifications of auction market preferred securities, for example Series A." } } }, "auth_ref": [] }, "Igvn_SeriesBWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "SeriesBWarrantsMember", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Series B Warrants [Member]", "label": "Series BWarrants Member" } } }, "auth_ref": [] }, "Igvn_SeriesCUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "SeriesCUnitsMember", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Series C Units [Member]", "label": "Series CUnits Member" } } }, "auth_ref": [] }, "Igvn_SeriesCWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "SeriesCWarrantsMember", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Series C warrants [Member]", "label": "Series CWarrants Member" } } }, "auth_ref": [] }, "Igvn_SeriesDWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "SeriesDWarrantsMember", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Series D Warrants [Member]", "label": "Series DWarrants Member" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.LongeveronInc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Equity-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r6"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofRSUActivityTable"], "lang": { "en-us": { "role": { "negatedLabel": "RSU expired/forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r296"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofRSUActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "RSU granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). } } }, "auth_ref": ["r296"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://www.LongeveronInc.com/role/EquityBasedCompensationDetails"], "lang": { "en-us": { "role": { "negatedLabel": "RSUs vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r297"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://www.LongeveronInc.com/role/EquityBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r307"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://www.LongeveronInc.com/role/EquityBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r308"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.LongeveronInc.com/role/EquityBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Equity-Based Compensation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r278", "r279", "r281", "r282", "r283", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r305", "r306", "r307", "r308", "r309"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofStockOptionActivityTable"], "lang": { "en-us": { "role": { "negatedLabel": "Number of Stock Options, Options expired/forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": ["r767"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofStockOptionActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "Number of Stock Options, Options granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r289"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "calculation": { "http://www.LongeveronInc.com/role/ScheduleofIssuedandOutstandingOptionsTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.LongeveronInc.com/role/EquityBasedCompensationDetails", "http://www.LongeveronInc.com/role/ScheduleofIssuedandOutstandingOptionsTable", "http://www.LongeveronInc.com/role/ScheduleofStockOptionActivityTable"], "lang": { "en-us": { "role": { "totalLabel": "Total stock options outstanding", "periodStartLabel": "Number of Stock Options, Outstanding at Beginning", "periodEndLabel": "Number of Stock Options, Outstanding at ending", "terseLabel": "Stock option issued and outstanding (in Shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r285", "r286"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.LongeveronInc.com/role/EquityBasedCompensationDetails", "http://www.LongeveronInc.com/role/ScheduleofStockOptionActivityTable",

"http://www.LongeveronInc.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Exercise Price, Outstanding at Beginning", "periodEndLabel": "Weighted Average Exercise Price, Outstanding at ending", "terseLabel": "Exercise price (in Dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r285", "r286"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "calculation": { "http://www.LongeveronInc.com/role/ScheduleOfIssuedandOutstandingOptionsTable": { "parentTag": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ScheduleOfIssuedandOutstandingOptionsTable"], "lang": { "en-us": { "role": { "terseLabel": "Stock options vested (based on ratable vesting)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r301"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": ["http://www.LongeveronInc.com/role/EquityBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share percentage", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum", "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock." } } }, "auth_ref": [] }, "lgvn_ShareBasedCompensationArrangementByShareBasedPaymentStockOptionExpirationTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentStockOptionExpirationTerm", "presentation": ["http://www.LongeveronInc.com/role/EquityBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock option expiration term", "documentation": "Period of expiration of stock options.", "label": "Share Based Compensation Arrangement By Share Based Payment Stock Option Expiration Term" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardTypeAndPlanNameDomain", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails", "http://www.LongeveronInc.com/role/EquityBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r281", "r282", "r283", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r305", "r306", "r307", "r308", "r309"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.LongeveronInc.com/role/ScheduleOfStockOptionActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price, Options exercised", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r290"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.LongeveronInc.com/role/ScheduleOfStockOptionActivityTable"], "lang": { "en-us": { "role": { "negatedLabel": "Weighted Average Exercise Price, Options expired/forfeited", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r291"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.LongeveronInc.com/role/ScheduleOfStockOptionActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price, Options granted", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r289"] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": ["http://www.LongeveronInc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Equity-based compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": ["r277", "r284", "r303", "r304", "r305", "r306", "r309", "r316", "r317", "r318", "r319"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "presentation": ["http://www.LongeveronInc.com/role/ScheduleOfIssuedandOutstandingOptionsTable"], "lang": { "en-us": { "role": { "label": "Schedule of Issued and Outstanding Options [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "lgvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRSUsVested": { "xbrltype": "sharesItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "SharebasedCompensationArrangementByShareBasedPaymentAwardOptionsRSUsVested", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Issued RSUs shares (in Shares)", "documentation": "Number of option right of use vested.", "label": "Sharebased Compensation Arrangement By Share Based Payment Award Options RSUs Vested" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Award amount", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount", "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement." } } }, "auth_ref": ["r310"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://www.LongeveronInc.com/role/EquityBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected life", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r305"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.LongeveronInc.com/role/EquityBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock options exercisable term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r31"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "calculation": { "http://www.LongeveronInc.com/role/ScheduleOfIssuedandOutstandingOptionsTable": { "parentTag": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.LongeveronInc.com/role/ScheduleOfIssuedandOutstandingOptionsTable"], "lang": { "en-us": { "role": { "terseLabel": "Stock options unvested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares", "documentation": "Number of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.LongeveronInc.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Options granted maximum term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r88"] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssued", "presentation": ["http://www.LongeveronInc.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share issued", "label": "Shares, Issued", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": ["r10"] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://www.LongeveronInc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in Shares)", "periodEndLabel": "Balance (in Shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.LongeveronInc.com/role/SummaryofSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r73", "r147"] }, "us-gaap_SoftwareDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SoftwareDevelopmentMember", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofMajorComponentsofPropertyandEquipmentTable"], "lang": { "en-us": { "role": { "terseLabel": "Software Website [Member]", "label": "Software Development [Member]", "documentation": "Internally developed software for sale, licensing or long-term internal use." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": ["r601"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails", "http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet", "http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.LongeveronInc.com/role/EquityBasedCompensationDetails", "http://www.LongeveronInc.com/role/ShareholdersEquityType2or3", "http://www.LongeveronInc.com/role/StockholdersEquityDetails", "http://www.LongeveronInc.com/role/SubsequentEventsDetails", "http://xbrl.sec.gov/dei/role/document/AuditInformation", "http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r115", "r125", "r126", "r127", "r149", "r168", "r169", "r172", "r174", "r181", "r182", "r200", "r226", "r228", "r229", "r230", "r233", "r234", "r237", "r238", "r241", "r244", "r251", "r372", "r443", "r444", "r445", "r446", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r461", "r473", "r495", "r512", "r528", "r529", "r530", "r531", "r532", "r713", "r724", "r730"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.LongeveronInc.com/role/ShareholdersEquityType2or3",

`"http://www.LongeveronInc.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r10", "r50", "r54", "r55", "r116", "r138", "r139", "r140", "r150", "r151", "r152", "r154", "r159", "r161", "r163", "r180", "r201", "r202", "r219", "r253", "r333", "r334", "r336", "r337", "r338", "r340", "r341", "r342", "r347", "r348", "r349", "r350", "r351", "r352", "r354", "r373", "r374", "r375", "r376", "r377", "r378", "r380", "r382", "r388", "r420", "r434", "r435", "r436", "r449", "r512"], "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet",
"http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement",
"http://www.LongeveronInc.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r150", "r151", "r152", "r180", "r382", "r400", "r441", "r461", "r465", "r466", "r467", "r468", "r469", "r470", "r473", "r476", "r477", "r478", "r479", "r480", "r482", "r483", "r484", "r485", "r487", "r488", "r489", "r490", "r491", "r493", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r512", "r584"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet", "http://www.LongeveronInc.com/role/ConsolidatedBalanceSheet_Parentheticals",
"http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement", "http://www.LongeveronInc.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r150", "r151", "r152", "r180", "r194", "r382", "r400", "r441", "r461", "r465", "r466", "r467", "r468", "r469", "r470", "r473", "r476", "r477", "r478", "r479", "r480", "r482", "r483", "r484", "r485", "r487", "r488", "r489", "r490", "r491", "r493", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r512", "r584"] }, "ecd_StkPrCOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrCOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/rold/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r613", "r624", "r640", "r675"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/rold/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "lgvn_StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested": { "xbrltype": "monetaryItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested", "crdr": "credit", "presentation": ["http://www.LongeveronInc.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "terseLabel": "Class A common stock, held for taxes on RSUs vested", "documentation": "Class A common stock, held for taxes on RSUs vested.", "label": "Stock Issued During Period Class A Common Stock Held For Taxes On RSUs Vested" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "presentation": ["http://www.LongeveronInc.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "terseLabel": "Conversion of Units into Class A and B common stock (in Shares)", "label": "Stock Issued During Period, Shares, Conversion of Units", "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "auth_ref": ["r10", "r29", "r49", "r50", "r81"] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.LongeveronInc.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "terseLabel": "Class A common stock issued in public offering, net of issuance cost of $1,145 (in Shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r10", "r49", "r50", "r81", "r443", "r512", "r529"] }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesOther", "presentation": ["http://www.LongeveronInc.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "terseLabel": "Class A common stock, held for taxes on PSUs vested (in Shares)", "label": "Stock Issued During Period, Shares, Other", "documentation": "Number of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "presentation": ["http://www.LongeveronInc.com/role/ShareholdersEquityType2or3", "http://www.LongeveronInc.com/role/SubsequentEventsDetails", "lang": { "en-us": { "role": { "terseLabel": "Reverse stock split rounding adjustment (in Shares)", "verboseLabel": "Reverse stock split", "label": "Stock Issued During Period, Shares, Reverse Stock Splits", "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split." } } }, "auth_ref": ["r10"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.LongeveronInc.com/role/ScheduleofStockOptionActivityTable", "http://www.LongeveronInc.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "terseLabel": "Class A common stock issue for warrants exercised, net of issuance cost of $1,359 (in Shares)", "verboseLabel": "Number of Stock Options, Options exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r10", "r49", "r50", "r81", "r290"] }, "lgvn_StockIssuedDuringPeriodUnrealizedLossAttributableToChangeInMarketValueOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "StockIssuedDuringPeriodUnrealizedLossAttributableToChangeInMarketValueOfAvailableForSaleSecurities", "crdr": "credit", "presentation": ["http://www.LongeveronInc.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain attributable to change in market value of available for sale investments", "documentation": "Represent the amount of unrealized loss attributable to change in market value of available-for-sale securities.", "label": "Stock Issued During Period Unrealized Loss Attributable To Change In Market Value Of Available For Sale Securities" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "crdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "terseLabel": "Conversion of Units into Class A and B common stock", "label": "Stock Issued During Period, Value, Conversion of Units", "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "auth_ref": ["r10", "r50", "r54", "r55", "r81"] }, "lgvn_StockIssuedDuringPeriodValueForWarrantsExercisedNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "StockIssuedDuringPeriodValueForWarrantsExercisedNetOfIssuanceCosts", "crdr": "credit", "presentation": ["http://www.LongeveronInc.com/role/ShareholdersEquityType2or3_Parentheticals", "lang": { "en-us": { "role": { "terseLabel": "Class A common stock issued for warrants exercised, net of issuance costs", "documentation": "Amount of common stock issued for warrants exercised, net of issuance costs.", "label": "Stock Issued During Period Value For Warrants Exercised Net Of Issuance Costs" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://www.LongeveronInc.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "terseLabel": "Class A common stock issued in public offering, net of issuance cost of $1,145", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r10", "r49", "r50", "r81", "r449", "r`

cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital. } } } , "auth_ref": ["r28", "r49", "r50", "r54", "r517"] } , "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": ["http://www.LongeveronInc.com/role/SubsequentEventsDetails"] , "lang": { "en-us": { "role": { "label": "Subsequent Events [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } } , "auth_ref": ["r379", "r392"] } , "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://www.LongeveronInc.com/role/SubsequentEventsDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Member]", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } } , "auth_ref": ["r379", "r392"] } , "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://www.LongeveronInc.com/role/SubsequentEventsDetails"] , "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } } , "auth_ref": ["r379", "r392"] } , "us-gaap_SubsequentEventDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventDomain", "presentation": ["http://www.LongeveronInc.com/role/SubsequentEventsDetails"] , "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } } , "auth_ref": ["r379", "r392"] } , "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } } , "auth_ref": [] , "lgvn_SubsequentEventsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "SubsequentEventsDetailsTable", "presentation": ["http://www.LongeveronInc.com/role/SubsequentEventsDetails"] , "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Table]" } } } , "auth_ref": [] } , "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://www.LongeveronInc.com/role/SubsequentEvents"] , "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } } , "auth_ref": ["r391", "r393"] } , "us-gaap_SubsidarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails", "http://www.LongeveronInc.com/role/SubsequentEventsDetails"] , "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } } , "auth_ref": [] } , "lgvn_SummaryOfSignificantAccountingPoliciesDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "SummaryOfSignificantAccountingPoliciesDetailsLineItems", "presentation": ["http://www.LongeveronInc.com/role/SummaryOfSignificantAccountingPoliciesDetails"] , "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies [Line Items]" } } } , "auth_ref": [] } , "lgvn_SummaryOfSignificantAccountingPoliciesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "SummaryOfSignificantAccountingPoliciesDetailsTable", "presentation": ["http://www.LongeveronInc.com/role/SummaryOfSignificantAccountingPoliciesDetails"] , "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) [Table]" } } } , "auth_ref": [] } , "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } } , "auth_ref": ["r668"] } , "lgvn_TechnologyServicesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "TechnologyServicesAgreementMember", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Technology Services Agreement [Member]", "label": "Technology Services Agreement Member" } } } , "auth_ref": [] } , "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment", "cdr": "debit", "presentation": ["http://www.LongeveronInc.com/role/ShareholdersEquityType2or3"] , "lang": { "en-us": { "role": { "terseLabel": "Class A common stock, held for taxes on PSUs vested", "label": "Temporary Equity, Accretion to Redemption Value, Adjustment", "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders." } } } , "auth_ref": [] } , "lgvn_TermsOfAgreement": { "xbrltype": "durationItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "TermsOfAgreement", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Agreement term", "documentation": "Terms of agreement." , "label": "Terms Of Agreement" } } } , "auth_ref": [] } , "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"] , "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } } , "auth_ref": ["r736", "r786"] } , "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"] , "lang": { "en-us": { "role": { "label": "Title and Position [Domain]" } } } , "auth_ref": [] } , "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } } , "auth_ref": ["r660"] } , "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } } , "auth_ref": ["r667"] } , "us-gaap_TrademarksMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TrademarksMember", "presentation": ["http://www.LongeveronInc.com/role/ScheduleOfMajorComponentsOfIntangibleAssetsTable"] , "lang": { "en-us": { "role": { "terseLabel": "Trademark costs [Member]", "label": "Trademarks [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style." } } } , "auth_ref": ["r32", "r551", "r744", "r745", "r746", "r747", "r748", "r749", "r751", "r753", "r754", "r755"] } , "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] , "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement" } } } , "auth_ref": ["r688"] } , "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] , "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } } , "auth_ref": ["r690"] } , "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } } , "auth_ref": [] } , "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] , "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } } , "auth_ref": ["r691"] } , "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] , "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } } , "auth_ref": ["r692"] } , "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] , "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } } , "auth_ref": ["r692"] } , "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] , "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } } , "auth_ref": ["r690"] } , "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] , "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } } , "auth_ref": ["r690"] } , "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] , "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } } , "auth_ref": ["r693"] } , "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] , "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } } , "auth_ref": ["r691"] } , "lgvn_TwoThousandAndTwentyOnePIPEOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "TwoThousandAndTwentyOnePIPEOfferingMember", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails"] , "lang": { "en-us": { "role": { "terseLabel": "2021 private placement offering [Member]", "verboseLabel": "2021 PIPE Offering [Member]", "label": "Two Thousand Twenty One PIPEOffering Member" } } } , "auth_ref": [] } , "lgvn_UMAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "UMAgreementsMember", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"] , "lang": { "en-us": { "role": { "terseLabel": "UM Agreements [Member]", "label": "UMAgreements Member" } } } , "auth_ref": [] } , "lgvn_UnderwritersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "UnderwritersMember", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Underwriters [Member]", "label": "Underwriters Member" } } } , "auth_ref": [] } , "lgvn_UnderwritersWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "UnderwritersWarrantsMember", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Underwriters Warrants [Member]", "label": "Underwriters Warrants Member" } } } , "auth_ref": [] } , "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"] , "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } } , "auth_ref": ["r687"] } , "us-gaap_UnrealizedGainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrealizedGainLossOnInvestments", "cdr": "credit", "presentation": ["http://www.LongeveronInc.com/role/SummaryOfSignificantAccountingPoliciesDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Net unrealized losses", "label": "Unrealized Gain (Loss) on Investments", "documentation": "Amount of unrealized gain (loss) on investment." } } } , "auth_ref": ["r7"] } , "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.LongeveronInc.com/role/AccountingPoliciesByPolicy"] , "lang": { "en-us": { "role": { "terseLabel": "Use of estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } } , "auth_ref": ["r24", "r25", "r26", "r105", "r106", "r109", "r110"] } , "us-gaap_ValuationTechniqueAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueAxis", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails"] , "lang": { "en-us": { "role": { "label": "Valuation Approach and Technique [Axis]", "documentation": "Information by valuation approach and technique." } } } , "auth_ref": ["r359", "r360", "r570", "r774"] } , "us-gaap_ValuationTechniqueConsensusPricingModelMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueConsensusPricingModelMember", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Black-Scholes pricing model [Member]", "label": "Valuation Technique, Consensus Pricing Model [Member]", "documentation": "Valuation technique combining analyst price estimates." } } } , "auth_ref": ["r570", "r772", "r773", "r774"] } , "us-gaap_ValuationTechniqueDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueDomain", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails"] , "lang": { "en-us": { "role": { "label": "Valuation Approach and Technique [Domain]", "documentation": "Valuation approach and technique." } } } , "auth_ref": ["r359", "r360", "r570", "r774"] } , "lgvn_VestingOfRSUsAndPSUsIntoClassACommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "VestingOfRSUsAndPSUsIntoClassACommonStock", "cdr": "credit", "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedCashFlow"] , "lang": { "en-us": { "role": { "terseLabel": "Vesting of RSUs and PSUs into Class A common stock", "documentation": "Amount of vesting of RSU and PSUs into class A common stock." , "label": "Vesting Of RSUs And PSUs Into Class ACommon Stock" } } } , "auth_ref": [] } , "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } } , "auth_ref": ["r656"] } , "us-gaap_WarrantExercisePriceIncrease": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantExercisePriceIncrease", "presentation": ["http://www.LongeveronInc.com/role/SubsequentEventsDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Exercise price (in Dollars per share)", "label": "Warrant, Exercise Price, Increase", "documentation": "Per share increase in exercise price of

antidilution provision." } } } , "auth_ref": ["r252"] } , "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": ["http://www.LongeveronInc.com/role/ScheduleOfDilutedNetLossesShareTable", "http://www.LongeveronInc.com/role/StockholdersEquityDetails", "http://www.LongeveronInc.com/role/SubsequentEventsDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Warrants [Member]", "verboseLabel": "Warrant [Member]", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } } , "auth_ref": ["r581", "r582", "r583", "r586", "r587", "r588"] } , "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Warrant term", "label": "Warrants and Rights Outstanding, Term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } } , "auth_ref": ["r772", "r773", "r774"] } , "lgvn_WarrantsToPurchase": { "xbrltype": "sharesItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "WarrantsToPurchase", "presentation": ["http://www.LongeveronInc.com/role/StockholdersEquityDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Warrants to purchase", "documentation": "Warrants to purchase." , "label": "Warrants To Purchase" } } } , "auth_ref": [] } , "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOFSharesOutstandingBasic", "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement_Parenticals"] , "lang": { "en-us": { "role": { "terseLabel": "Diluted weighted average common shares outstanding", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } } , "auth_ref": ["r167", "r174"] } , "us-gaap_WeightedAverageNumberOFSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOFSharesOutstandingBasic", "presentation": ["http://www.LongeveronInc.com/role/ConsolidatedIncomeStatement"] , "lang": { "en-us": { "role": { "terseLabel": "Basic weighted average common shares outstanding (in Shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } } , "auth_ref": ["r165", "r174"] } , "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } } , "auth_ref": ["r704"] } , "ecd_YrEndFrValOfEqtyAwrdGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } } , "auth_ref": ["r654"] } , "lgvn_firstPhase3ClinicalTrialMember": { "xbrltype": "domainItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "firstPhase3ClinicalTrialMember", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"] , "lang": { "en-us": { "role": { "terseLabel": "first Phase 3 Clinical Trial [Member]", "label": "first Phase3 Clinical Trial Member" } } } , "auth_ref": [] } , "lgvn_licenseAgreementTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.LongeveronInc.com/20240630", "localname": "licenseAgreementTerm", "presentation": ["http://www.LongeveronInc.com/role/CommitmentsandContingenciesDetails"] , "lang": { "en-us": { "role": { "terseLabel": "License agreement term", "documentation": "license agreement term." , "label": "License Agreement Term" } } } , "auth_ref": [] } , "std_ref": ["r0"] , "role": { "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4" } , "r1": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13" } , "r2": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" } , "r3": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" } , "r4": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" } , "r5": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" } , "r6": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" } , "r7": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" } , "r8": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" } , "r9": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" } , "r10": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481122/505-10-50-2" } , "r11": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" } , "r12": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" } , "r13": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" } , "r14": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" } , "r15": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" } , "r16": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" } , "r17": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" } , "r18": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" } , "r19": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph":

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Subparagraph: "(b)", **Publisher:** "FASB", **URI:** "<https://asc.fasb.org/1943274/2147479777/606-10-55-91>", **r557:** { **"role":** "<http://www.xbrl.org/2003/role/exampleRef>", **"Topic":** "606", **"SubTopic":** "10", **"Name":** "Accounting Standards Codification", **"Section":** "55", **"Paragraph":** "91", **"Publisher":** "FASB", **"URI":** "<https://asc.fasb.org/1943274/2147479777/606-10-55-91>", **r558:** { **"role":** "<http://www.xbrl.org/2003/role/exampleRef>", **"Topic":** "606", **"SubTopic":** "10", **"Name":** "Accounting Standards Codification", **"Section":** "55", **"Paragraph":** "91", **"Publisher":** "FASB", **"URI":** "<https://asc.fasb.org/1943274/2147479777/606-10-55-91>", **r559:** { **"role":** "<http://www.xbrl.org/2003/role/exampleRef>", **"Topic":** "606", **"SubTopic":** "10", **"Name":** "Accounting Standards Codification", **"Section":** "55", **"Paragraph":** "91", **"Publisher":** "FASB", **"URI":** "<https://asc.fasb.org/1943274/2147479777/606-10-55-91>", **r560:** { **"role":** "<http://www.xbrl.org/2003/role/exampleRef>", **"Topic":** "606", **"SubTopic":** "10", **"Name":** "Accounting Standards Codification", **"Section":** "55", **"Paragraph":** "91", **"Publisher":** "FASB", **"URI":** "<https://asc.fasb.org/1943274/2147479777/606-10-55-91>", **r561:** { **"role":** "<http://www.xbrl.org/2003/role/exampleRef>", **"Topic":** "606", **"SubTopic":** "10", **"Name":** "Accounting Standards Codification", **"Section":** "55", **"Paragraph":** "91", **"Publisher":** "FASB", **"URI":** "<https://asc.fasb.org/1943274/2147479777/606-10-55-91>", **r562:** { **"role":** "<http://www.xbrl.org/2003/role/exampleRef>", **"Topic":** "715", **"SubTopic":** "20", **"Name":** "Accounting Standards Codification", **"Section":** "55", **"Paragraph":** "17", **"Publisher":** "FASB", **"URI":** "<https://asc.fasb.org/1943274/2147480482/715-20-55-17>", **r565:** { **"role":** "<http://www.xbrl.org/2003/role/exampleRef>", **"Topic":** "715", **"SubTopic":** "80", **"Name":** "Accounting Standards Codification", **"Section":** "55", **"Paragraph":** "8", **"Publisher":** "FASB", **"URI":** "<https://asc.fasb.org/1943274/2147480547/715-80-55-8>", **r566:** { **"role":** "<http://www.xbrl.org/2003/role/exampleRef>", **"Topic":** "718", **"SubTopic":** "10", **"Name":** "Accounting Standards Codification", **"Section":** "50", **"Paragraph":** "2", **"Publisher":** "FASB", **"URI":** "<https://asc.fasb.org/1943274/2147480429/718-10-50-2>", **r567:** { **"role":** "<http://www.xbrl.org/2003/role/exampleRef>", **"Topic":** "740", **"SubTopic":** "10", **"Name":** "Accounting Standards Codification", **"Section":** "55", **"Paragraph":** "231", **"Publisher":** "FASB", **"URI":** "<https://asc.fasb.org/1943274/2147482663/740-10-55-231>", **r568:** { **"role":** "<http://www.xbrl.org/2003/role/exampleRef>", **"Topic":** "820", **"SubTopic":** "10", **"Name":** "Accounting Standards Codification", **"Section":** "55", **"Paragraph":** "100", **"Publisher":** "FASB", **"URI":** "<https://asc.fasb.org/1943274/2147482078/820-10-55-100>", **r569:** { **"role":** "<http://www.xbrl.org/2003/role/exampleRef>", **"Topic":** "820", **"SubTopic":** "10", **"Name":** "Accounting Standards Codification", **"Section":** "55", **"Paragraph":** "101", **"Publisher":** "FASB", **"URI":** "<https://asc.fasb.org/1943274/2147482078/820-10-55-101>", **r570:** { **"role":** "<http://www.xbrl.org/2003/role/exampleRef>", **"Topic":** "820", **"SubTopic":** "10", **"Name":** "Accounting Standards Codification", **"Section":** "55", **"Paragraph":** "103", **"Publisher":** "FASB", **"URI":** "<https://asc.fasb.org/1943274/2147482078/820-10-55-103>", **r571:** { **"role":** "<http://www.xbrl.org/2003/role/exampleRef>", **"Topic":** "820", **"SubTopic":** "10", **"Name":** "Accounting Standards Codification", **"Section":** "55", **"Paragraph":** "107", **"Publisher":** "FASB", **"URI":** "<https://asc.fasb.org/1943274/2147482078/820-10-55-107>", **r572:** { **"role":** "<http://www.xbrl.org/2003/role/exampleRef>", **"Topic":** "820", **"SubTopic":** "10", **"Name":** "Accounting Standards Codification", **"Section":** "55", **"Paragraph":** "107", **"Publisher":** "FASB", **"URI":** "<https://asc.fasb.org/1943274/2147482078/820-10-55-107>", **r573:** { **"role":** "<http://www.xbrl.org/2003/role/exampleRef>", **"Topic":** "820", **"SubTopic":** "10", **"Name":** "Accounting Standards Codification", **"Section":** "55", **"Paragraph":** "107", **"Publisher":** "FASB", **"URI":** "<https://asc.fasb.org/1943274/2147482078/820-10-55-107>", **r574:** { **"role":** "<http://www.xbrl.org/2003/role/exampleRef>", **"Topic":** "842", **"SubTopic":** "20", **"Name":** "Accounting Standards Codification", **"Section":** "55", **"Paragraph":** "53", **"Publisher":** "FASB", **"URI":** "<https://asc.fasb.org/1943274/2147479589/842-20-55-53>", **r575:** { **"role":** "<http://www.xbrl.org/2003/role/exampleRef>", **"Topic":** "852", **"SubTopic":** "10", **"Name":** "Accounting Standards Codification", **"Section":** "55", **"Paragraph":** "10", **"Publisher":** "FASB", **"URI":** "<https://asc.fasb.org/1943274/2147481372/852-10-55-10>", **r576:** { **"role":** "[http://www.xbrl.org/2003/role/example](http://www.xbrl.org/2003/role/exampleRef)

[illegible]

[illegible]

[illegible]

1PIJD *Q3UJ*VE6Q1J3\$ M!)^1=NTDJIYD#1^~^W17W8.S 0VT>T6,K5-ZJ1JJD)+=3EO-ZCPMS<Q^7Y>LYM(C M155^O+...R7,4X-7F!*3XI+>31C0R5?W1_78F&4Y-V^T4DQFV%,^4R1JIG AHY6VD,M.D>=>USX9VW/J3,B,LA0EJ?^OY*9=8H/,?4Y4IVZR1*Q>Q> BK^J^10FO M&OH^>,YO%P=HW4H-HJ@K1&0K0T1^Y136QQM*^V.VVWHJ,N.>+BKN=A;EZ&,\$.SN MK&J<J8P,QJ&SYJUSVCYS AKIK,G.XI=XJ:JSXXVIM+M+LYCHIB[MLC,LE>F,X:S15-89%MMB^12YR^CHG_<3Q#>1AA^OK^R+X\$G^?PNTJ,6 M8 Z=ZKQK5%^U9=419?Y\$Y%W#A,1&J; (PMK1J3 A_&X) T:XH(VX6G/UW M2,16KPKPJ21SOH79,4LR_~M^0/91%5MHSB6H,j,1%12>Z94(4,6X MC1N^OBK^PNTJ[SMTX<4<@?Q083Q9XX76^EVP,=#IRTS50,JTU,1J07A^/2G+^/I MM4&SVJF;N71DA5QSA,*^23->C2/&^/AXM-^CL@&1PX26MW081MIPOM?U=Y&:5K^X1Q\$S.RV&%;\$^A1G61\$J:5:MAF(^I M^* MC;?#>@XD^ETJ^A^MS^Y+>^IYLJY2E5>W:6Y/JW9MT^ [W61M-F5F713B3HVSQW M^@N1J(TOLPQ3%FISF<^B1^GO_YW,55B^?7^SMPIY\$;WBW&[U3 MD,1E.LBY=K:YB3 L>X+UTZ@,T161@:XIG^M^4FC+>^AMLJ8/[GGJ&U0;^ZKOG# MLNU;C977 VHS+>+G^T^~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~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~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~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

P7:01.M.8U)I=GSD/L=L=7422GPM+97&L01)RXJ IQ^=WSI>3\$KZ.2%I MiG...4RAE"MYUX.8HM7;,\$4)I(35V<,"A%,<I-VL@I=1%*9T=A;A7X3Z;.&Z MYX#<.<K&A5FE;ZNZS@UXI<F=GTZMD@1%IURJE^5VQC=E9Q2.GKBR2T(K M<=1&P. 0.PX 1&F=)IEVV>7&AZK3F5? 9G/7K9J@I:6=>=1YXKJ3A&9M+ "16 MM:(6YX"1#>+>P% PJV?<C&.JAMZ2+EMUI>=NZ9I>Q>?@8&L&#SUB=QO 1 MP2+6;.<X%9.SNAP&1^PS GT<7? 079B1.60 WJ&M+M/D3?74-0?>ONCKM1 MIFB-
X4S.5%8/FIEE4&KRIC&3GFT>GNF42.A.WIHR&S6B\$>V/AM9&P/ M2(DBG# 11PH8MF873Z\$P?IFZ^>21G&8.QOBI4&PSO8F2FB NQ32391; .VU%#K@IRJ6I9A1+; .J
MG<C1IHCUMBSM<@J6N4N>3ZVEYD(.\$>L+7\$B+VAQ^LN1&0/U E/27&H&XX M9EMR850SN;PQ/26W&(TQ S0+NF?&SLY=B^"K<C0.4CZV L/0/2?3K@J1I04I3R2
M^E#73Q:K14EBK(A.C-307I63.3ZOBZ-F.E.EDS)"HIL"1@DO;PL/EY(9T% MZ^=DX2/4OL12L%OR1<MFOR&QT55Q;./<C?291GR/SP/3P2 D=50/<S/OMI M7^<^>VE3ZU
MV^H4\$<EFZ11-17 .>J>O^PYZD26^I38+AH4XZ^L>ZS95+SWIMWP1+T)TF-IBANSYR=V-57F2. MB T<0SNO183RWF6 CX5I075D10.4\$+&#<S<K-
MB^N^P(O)IX:141^1#1&IPM>=0I(AWS.SU 1%YN1."1^2Y(X-H-E:A6G M%9&S&#>21J^HNOIRMB10M0SHT @PMWY(<36;=NBK1"1L0^?PTT2I2BIH65 FF
MOI^NCR>>7X>G1:Q%>WYS="4I..141+^>73GR<=1^KZYI(C&#NUIJ?5"O)TJ5+H1\$KNGYO/IEIRJ>OSO&A6 MKD78C6&8Y<UMWEVWY9G8^VY2W@>J)D2
>X9I0NGR=CESP+&W3..QC..NH6U M<1.QIJO6<^IIR-06Q^W">I> /MSU(1^>+)&A 1F\$1^1) LOWOW:W\$CA< MACN9N<CFSS7^J+.<?73&X@<UZI2DME+ON
ZONCV18KARX8RYE<IK39HU:NM M6R\$ 7V/35^LRI&5G 5&IW+&%(U/<^> X:1.2\$=;YY7GDL1I%=<KJ MY0I>0.#" OPY%Q2>4B=>I>OM^FEVIZ=E93RTB=O6M:F-M-
SCCMI.TLE.NY/O: MR=OWANA+3.1MTOIXMM^NJVF>3>3?>P7+IB.FE2/U/MJVVU7>7^>KWC EC-M-@1/6=D>3Z?&1O<X^NKKDR74P/ SI/4+F<^<S<#AGI(A8I) (?7D^19
MKKE8E?GYIV&2& XQ^N3@ HYI=)NOISUVOAK6B1QIB>0/ CLV:W5>20 M+JVVLL S2L^KWCKE:9^>PKZD27+>=I9)I9.G?>+T6I&Z6>=2BASV5M M^CC4I=I/457YVC&I4PM..>J2B8\$=7J>I.F8F9 -C= APLPM=18?>K8 M07R.IMB=V^ED7EIM^L138&L+1EPA Q8I^3+> M+J44R(%%@I6I<0.1I1EV9&8)W ^RPE<H7CI MB
B^A4TK&S1AMQ07E1C11^?K8XYBAXB3+NU00< GW2Y^+&K/E8IM6 7#F(I 1.WL+>+BG+4X8Q
ME3\$&5&XAO.NXVC&K^94QOI((I13E.6^XNM@K)8R561LZ2DM.K5T6+&^W15I=ZA.MPW2?>I7HXMZ=WM^WM?>N1008WM2^*+&E=J LEL2.S^W:W>:4N7FGZ&UXI
M2OC9D41XVFR.6FI. =9>5>OJAR?I>ZDWOX2^92SM^10VYGR41X.7IOM.MN?2^I?U#N(9ST29, MO9Y9^IR^?1=8(8W1^USOJH5VJ+&QU7I8?V17P8A1%&1SYX9PG)T-O^ M
LH9>9KXFDI4XB9&FU> .>7&9I8>H^OU+T7VZBVJUL @.80Y2A51S 0/6 M1 7^F%Z4I<#JL P6 OC 1#3ITVYOSH^NF14%\$V42P1Y&Y1>+>O? M1%+?C^%13A..\$+>+
7UB.XYC(OA) X'K09S. HXMA.A7UI^S V1&+&%(SIC^F M9I2?14IY JCVI):1.1Z<K1=CBPP2.8-6WU:8?I^?78I0I2-2VUOW1=%% MTZ>EY66I A1BDS>P92H3QFS>\$ &IQN >X>2-8
R00\$=E^YJNM+J1LY&G^L M<B+D>=>LAA<L^F)DP>?>OE^ARQFZL.K'DO>6EZ4+> 6XDPHUE/KJ7 M/EJF&I07M ^>ARP2&WYIA8I=E3+&^&X^7XN>Z0S077^3NXOU8UP1C
M6&G7XMKH/G3&8.2G>5>1GY8HGXV014&#>M&5Y&LJF 91L#2DOAZT^S M^*@BNTN1S6=9^UFP>=DV12I^?6\$&N)EW%&@>YHG+P861^CL5C 60B72Y0X M11%>?77I0?
P=IK5^GT1A2^JD^ORE&WSI.ZGXG R.^EY#<^E:7I4<1 MGRV.YIYV7J.S.IQDW(O=I)SHX^?<#9>.<^>3S%&0IUYX^8?8PH^ 2I&M0:VG71A>:(<S^%6MD1I1TEN.0R-
S2QOZCACOF=>2Y94 13&J^LP7&A<O+3>+<C 7#1.MXIBOF&O&F09/K3@GQ MZ5CW(K)H&X^&8> J A 60GH(O)EHSIXUF8749^3.3% J<5) MHP5M.3-T2H(8F5F7YTW AX+<-
Z%>?>171BB(GI&I4W&BV^T)4XQ<=TD) M/QM=M>GH>0-IGQ^I16IR3I<@P7A.1#L: TF.M.YC 1P6C(O) MR4HHD+&S.P(XH^<4X^I42I1<3-62H^>#>+&: A^*#>B^Q YSV:GL^?B M
C 40(GEXZV.WD8.X2WGV2^V9>99GHV+^Y36^ZLSS1JL. M66B8<1.3#^Q2G&A.41 A ^AP5I8V10Y^Y<K^&EBQV^OAP^1L^?Q<1 M.XP,K+&^&X^&DJO4 0^GY^?<
TY^0Z.JH27EZ^YV 1I.P.2^%<F&U.C 6-LX8:DX1&Z(I&P8 MB.L>K.SE=Q%&I&ZL M&FZM=O38J1^W42 YGR.BJ+XYUUD+O^F^C=>=I10^SR V3OF 0K3I9I^L.D+&S.W.@.B)&(<M
M+04X3M>0^S1^S=0<^>N^TWI^IYX1.9FA.WI 13I^05%<H^>6.:O=>S=I.H. MCI2LE%&1%?>K<+>50S MPM^13SI0CP^7QO" =YHM^?6G3I^AD^<4^*30.RCC6D<^D-H
^6G3G&W:3T&O8I@+1^>^N^M)6EC10D^4I@X7U@.I1Q @MHIYMAE0N1(2)<(<3I^>=IUXW&S^3>+>04GG^S:6C&YF.Z3(CWV-N2V5.
M^*^Q&.&I&X^P(030@&8&E.^DC/^M^?I^G>FT^@/687I4>0H. ^74FDE+&W. MVH)KDK^X.V.ILTD&^>TDR=>+Y.9M:IMZ=.T@Y>L@7REOV1JFX^I1Y7RY5CFI/787&
KYE+&^SPWST7B.M<5&PCS21&LVK M5B^BBMR^MOA<5^L9I^L^Y.1.K10^I:3SY2F59YF2^>CVM1?H&SIX&H^
M9^N3^239Y0T10^600QD@<?E174EIH34Y9.#^S=1LSD99I6<^>M^YF968M MT2^YI-M^WNJBK^*3M1%ZN>?>^0I E:7NJ.4 PP(I@QS&:SOIIAKDR/@ M2P2C1?
H5<212QCOVYX/HTCW4.WB2P1.YI 9.(CM 19IUY=S<=&I. M^S^SHRESH<+&.SHI5P1WA-(5B?IWA/O#)>#^W#<3^ /2R^=16 HLOM4KX2R> .MIYU9XT52IQCI650M^
R^TXFF%<#^Y^ELR@ M/80I+3^IDGT2SE2IM. 3I\$ 18IYX^>V1Y7KN^1=S PLMW9/R 6I3VPIVM^ILSGS32I>+&
MKE.18M6I06C9PM8IH^E#>+&E:ES^N76:RSIJ^6RXE+^YE3@P2+>2B.IHG&#&^%MIDPI1<.<C>Y>L@B^P1ZS6-1^>SG DK2NO&N@DO/I?D?>U5Y M1UBN=JX@*8-
W21DIU1PQ 2^A@>?I=1<98>1 M^R&9P)PM+A>O1^9&K.M:POL5U^PMG&WAP) @=H^M^>SLD B7N^3KQ 0Y4CH>+&^/DAO&9HJEME+&I1X420I100D+&I ZSUG
M.O3+&^OCMA4I 1839.S8I8J>Y>E\$>B7>=WM.Z4G^V1.4I RZ1P0E9# M^&

